WorldWideScience

Sample records for accelerator-based bnct facility

  1. Accelerator-based BNCT.

    Science.gov (United States)

    Kreiner, A J; Baldo, M; Bergueiro, J R; Cartelli, D; Castell, W; Thatar Vento, V; Gomez Asoia, J; Mercuri, D; Padulo, J; Suarez Sandin, J C; Erhardt, J; Kesque, J M; Valda, A A; Debray, M E; Somacal, H R; Igarzabal, M; Minsky, D M; Herrera, M S; Capoulat, M E; Gonzalez, S J; del Grosso, M F; Gagetti, L; Suarez Anzorena, M; Gun, M; Carranza, O

    2014-06-01

    The activity in accelerator development for accelerator-based BNCT (AB-BNCT) both worldwide and in Argentina is described. Projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators are briefly presented. In particular, the present status and recent progress of the Argentine project will be reviewed. The topics will cover: intense ion sources, accelerator tubes, transport of intense beams, beam diagnostics, the (9)Be(d,n) reaction as a possible neutron source, Beam Shaping Assemblies (BSA), a treatment room, and treatment planning in realistic cases. © 2013 Elsevier Ltd. All rights reserved.

  2. Development of an accelerator-based BNCT facility at the Berkeley Lab

    International Nuclear Information System (INIS)

    Ludewigt, B.A.; Bleuel, D.; Chu, W.T.; Donahue, R.J.; Kwan, J.; Reginato, L.L.; Wells, R.P.

    1998-01-01

    An accelerator-based BNCT facility is under construction at the Berkeley Lab. An electrostatic-quadrupole (ESQ) accelerator is under development for the production of neutrons via the 7 Li(p,n) 7 Be reaction at proton energies between 2.3 and 2.5 MeV. A novel type of power supply, an air-core coupled transformer power supply, is being built for the acceleration of beam currents exceeding 50 mA. A metallic lithium target has been developed for handling such high beam currents. Moderator, reflector and neutron beam delimiter have extensively been modeled and designs have been identified which produce epithermal neutron spectra sharply peaked between 10 and 20 keV. These. neutron beams are predicted to deliver significantly higher doses to deep seated brain tumors, up to 50% more near the midline of the brain than is possible with currently available reactor beams. The accelerator neutron source will be suitable for future installation at hospitals

  3. An accelerator-based Boron Neutron Capture Therapy (BNCT) facility based on the 7Li(p,n)7Be

    Science.gov (United States)

    Musacchio González, Elizabeth; Martín Hernández, Guido

    2017-09-01

    BNCT (Boron Neutron Capture Therapy) is a therapeutic modality used to irradiate tumors cells previously loaded with the stable isotope 10B, with thermal or epithermal neutrons. This technique is capable of delivering a high dose to the tumor cells while the healthy surrounding tissue receive a much lower dose depending on the 10B biodistribution. In this study, therapeutic gain and tumor dose per target power, as parameters to evaluate the treatment quality, were calculated. The common neutron-producing reaction 7Li(p,n)7Be for accelerator-based BNCT, having a reaction threshold of 1880.4 keV, was considered as the primary source of neutrons. Energies near the reaction threshold for deep-seated brain tumors were employed. These calculations were performed with the Monte Carlo N-Particle (MCNP) code. A simple but effective beam shaping assembly (BSA) was calculated producing a high therapeutic gain compared to previously proposed facilities with the same nuclear reaction.

  4. Present status of Accelerator-Based BNCT.

    Science.gov (United States)

    Kreiner, Andres Juan; Bergueiro, Javier; Cartelli, Daniel; Baldo, Matias; Castell, Walter; Asoia, Javier Gomez; Padulo, Javier; Suárez Sandín, Juan Carlos; Igarzabal, Marcelo; Erhardt, Julian; Mercuri, Daniel; Valda, Alejandro A; Minsky, Daniel M; Debray, Mario E; Somacal, Hector R; Capoulat, María Eugenia; Herrera, María S; Del Grosso, Mariela F; Gagetti, Leonardo; Anzorena, Manuel Suarez; Canepa, Nicolas; Real, Nicolas; Gun, Marcelo; Tacca, Hernán

    2016-01-01

    This work aims at giving an updated report of the worldwide status of Accelerator-Based BNCT (AB-BNCT). There is a generalized perception that the availability of accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of BNCT. Accordingly, in recent years a significant effort has started to develop such machines. A variety of possible charged-particle induced nuclear reactions and the characteristics of the resulting neutron spectra are discussed along with the worldwide activity in suitable accelerator development. Endothermic (7)Li(p,n)(7)Be and (9)Be(p,n)(9)B and exothermic (9)Be(d,n)(10)B are compared. In addition to having much better thermo-mechanical properties than Li, Be as a target leads to stable products. This is a significant advantage for a hospital-based facility. (9)Be(p,n)(9)B needs at least 4-5 MeV bombarding energy to have a sufficient yield, while (9)Be(d,n)(10)B can be utilized at about 1.4 MeV, implying the smallest possible accelerator. This reaction operating with a thin target can produce a sufficiently soft spectrum to be viable for AB-BNCT. The machines considered are electrostatic single ended or tandem accelerators or radiofrequency quadrupoles plus drift tube Linacs. (7)Li(p,n)(7)Be provides one of the best solutions for the production of epithermal neutron beams for deep-seated tumors. However, a Li-based target poses significant technological challenges. Hence, Be has been considered as an alternative target, both in combination with (p,n) and (d,n) reactions. (9)Be(d,n)(10)B at 1.4 MeV, with a thin target has been shown to be a realistic option for the treatment of deep-seated lesions.

  5. Present status of accelerator-based BNCT: Focus on developments in Argentina

    International Nuclear Information System (INIS)

    Cartelli, D.; Capoulat, M.E.; Bergueiro, J.; Gagetti, L.; Suárez Anzorena, M.; Grosso, M.F. del; Baldo, M.; Castell, W.; Padulo, J.; Suárez Sandín, J.C.; Igarzabal, M.; Erhardt, J.; Mercuri, D.

    2015-01-01

    In this work we provide some information on the present status of accelerator-based BNCT (AB-BNCT) worldwide and subsequently concentrate on the recent accelerator technology developments in Argentina. - Highlights: • The current status of projects and associated facilities for AB-BNCT worldwide is shown. • Only low (few MeV) energy accelerators are included. • The recent progress of the Argentine AB-BNCT program is described.

  6. Shielding design of a treatment room for an accelerator-based epithermal neutron irradiation facility for BNCT

    International Nuclear Information System (INIS)

    Evans, J.F.; Blue, T.E.

    1996-01-01

    Protecting the facility personnel and the general public from radiation exposure is a primary safety concern of an accelerator-based epithermal neutron irradiation facility. This work makes an attempt at answering the questions open-quotes How much?close quotes and open-quotes What kind?close quotes of shielding will meet the occupational limits of such a facility. Shielding effectiveness is compared for ordinary and barytes concretes in combination with and without borated polyethylene. A calculational model was developed of a treatment room, patient open-quotes scatterer,close quotes and the epithermal neutron beam. The Monte Carlo code, MCNP, was used to compute the total effective dose equivalent rates at specific points of interest outside of the treatment room. A conservative occupational effective dose rate limit of 0.01 mSv h -1 was the guideline for this study. Conservative Monte Carlo calculations show that constructing the treatment room walls with 1.5 m of ordinary concrete, 1.2 m of barytes concrete, 1.0 m of ordinary concrete preceded by 10 cm of 5% boron-polyethylene, or 0.8 m of barytes concrete preceded by 10 cm of 5% boron-polyethylene will adequately protect facility personnel. 20 refs., 8 figs., 2 tabs

  7. Treatment planning capability assessment of a beam shaping assembly for accelerator-based BNCT.

    Science.gov (United States)

    Herrera, M S; González, S J; Burlon, A A; Minsky, D M; Kreiner, A J

    2011-12-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) a theoretical study was performed to assess the treatment planning capability of different configurations of an optimized beam shaping assembly for such a facility. In particular this study aims at evaluating treatment plans for a clinical case of Glioblastoma. Copyright © 2011 Elsevier Ltd. All rights reserved.

  8. Treatment planning capability assessment of a beam shaping assembly for accelerator-based BNCT

    International Nuclear Information System (INIS)

    Herrera, M.S.; González, S.J.; Burlon, A.A.; Minsky, D.M.; Kreiner, A.J.

    2011-01-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) a theoretical study was performed to assess the treatment planning capability of different configurations of an optimized beam shaping assembly for such a facility. In particular this study aims at evaluating treatment plans for a clinical case of Glioblastoma.

  9. A Tandem-electrostatic-quadrupole for accelerator-based BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Kwan, J.W.; Burlon, A.A.; Di Paolo, H.; Henestroza, E.; Minsky, D.M.; Valda, A.A.; Debray, M.E.; Somacal, H.

    2007-01-01

    A project to develop a Tandem-electrostatic-quadrupole (TESQ) accelerator for accelerator-based boron neutron capture therapy (AB-BNCT) is described. A folded Tandem, with 1.25 MV terminal voltage, combined with an electrostatic quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p, n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p, n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT

  10. Tandem-ESQ for accelerator-based BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Burlon, A.A.; Di Paolo, H.; Minsky, D.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Kwan, J.W.; Henestroza, E.

    2006-01-01

    A project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) is described. A folded tandem, with 1.25 MV terminal voltage, combined with an ElectroStatic Quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the '7Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. (author)

  11. Spectrum shaping of accelerator-based neutron beams for BNCT

    CERN Document Server

    Montagnini, B; Esposito, J; Giusti, V; Mattioda, F; Varone, R

    2002-01-01

    We describe Monte Carlo simulations of three facilities for the production of epithermal neutrons for Boron Neutron Capture Therapy (BNCT) and examine general aspects and problems of designing the spectrum-shaping assemblies to be used with these neutron sources. The first facility is based on an accelerator-driven low-power subcritical reactor, operating as a neutron amplifier. The other two facilities have no amplifier and rely entirely on their primary sources, a D-T fusion reaction device and a conventional 2.5 MeV proton accelerator with a Li target, respectively.

  12. Spectrum shaping assessment of accelerator-based fusion neutron sources to be used in BNCT treatment

    Science.gov (United States)

    Cerullo, N.; Esposito, J.; Daquino, G. G.

    2004-01-01

    Monte Carlo modelling of an irradiation facility, for boron neutron capture therapy (BNCT) application, using a set of advanced type, accelerator based, 3H(d,n) 4He (D-T) fusion neutron source device is presented. Some general issues concerning the design of a proper irradiation beam shaping assembly, based on very hard energy neutron source spectrum, are reviewed. The facility here proposed, which represents an interesting solution compared to the much more investigated Li or Be based accelerator driven neutron source could fulfil all the medical and safety requirements to be used by an hospital environment.

  13. Characterisation of an accelerator-based neutron source for BNCT versus beam energy

    CERN Document Server

    Agosteo, S; D'Errico, F; Nath, R; Tinti, R

    2002-01-01

    Neutron capture in sup 1 sup 0 B produces energetic alpha particles that have a high linear energy transfer in tissue. This results in higher cell killing and a higher relative biological effectiveness compared to photons. Using suitably designed boron compounds which preferentially localize in cancerous cells instead of healthy tissues, boron neutron capture therapy (BNCT) has the potential of providing a higher tumor cure rate within minimal toxicity to normal tissues. This clinical approach requires a thermal neutron source, generally a nuclear reactor, with a fluence rate sufficient to deliver tumorcidal doses within a reasonable treatment time (minutes). Thermal neutrons do not penetrate deeply in tissue, therefore BNCT is limited to lesions which are either superficial or otherwise accessible. In this work, we investigate the feasibility of an accelerator-based thermal neutron source for the BNCT of skin melanomas. The source was designed via MCNP Monte Carlo simulations of the thermalization of a fast ...

  14. Analysis of accelerator based neutron spectra for BNCT using proton recoil spectroscopy

    International Nuclear Information System (INIS)

    Wielopolski, L.; Ludewig, H.; Powell, J.R.; Raparia, D.; Alessi, J.G.; Lowenstein, D.I.

    1998-01-01

    Boron Neutron Capture Therapy (BNCT) is a promising binary treatment modality for high-grade primary brain tumors (glioblastoma multiforme, GM) and other cancers. BNCT employs a boron-10 containing compound that preferentially accumulates in the cancer cells in the brain. Upon neutron capture by 10 B energetic alpha particles and triton released at the absorption site kill the cancer cell. In order to gain penetration depth in the brain Fairchild proposed, for this purpose, the use of energetic epithermal neutrons at about 10 keV. Phase I/II clinical trials of BNCT for GM are underway at the Brookhaven Medical Research Reactor (BMRR) and at the MIT Reactor, using these nuclear reactors as the source for epithermal neutrons. In light of the limitations of new reactor installations, e.g. cost, safety and licensing, and limited capability for modulating the reactor based neutron beam energy spectra alternative neutron sources are being contemplated for wider implementation of this modality in a hospital environment. For example, accelerator based neutron sources offer the possibility of tailoring the neutron beams, in terms of improved depth-dose distributions, to the individual and offer, with relative ease, the capability of modifying the neutron beam energy and port size. In previous work new concepts for compact accelerator/target configuration were published. In this work, using the Van de Graaff accelerator the authors have explored different materials for filtering and reflecting neutron beams produced by irradiating a thick Li target with 1.8 to 2.5 MeV proton beams. However, since the yield and the maximum neutron energy emerging from the Li-7(p,n)Be-7 reaction increase with increase in the proton beam energy, there is a need for optimization of the proton energy versus filter and shielding requirements to obtain the desired epithermal neutron beam. The MCNP-4A computer code was used for the initial design studies that were verified with benchmark experiments

  15. Beam shaping assembly optimization for (7)Li(p,n)(7)Be accelerator based BNCT.

    Science.gov (United States)

    Minsky, D M; Kreiner, A J

    2014-06-01

    Within the framework of accelerator-based BNCT, a project to develop a folded Tandem-ElectroStatic-Quadrupole accelerator is under way at the Atomic Energy Commission of Argentina. The proposed accelerator is conceived to deliver a proton beam of 30mA at about 2.5MeV. In this work we explore a Beam Shaping Assembly (BSA) design based on the (7)Li(p,n)(7)Be neutron production reaction to obtain neutron beams to treat deep seated tumors. © 2013 Elsevier Ltd. All rights reserved.

  16. Characterisation of an accelerator-based neutron source for BNCT versus beam energy

    Science.gov (United States)

    Agosteo, S.; Curzio, G.; d'Errico, F.; Nath, R.; Tinti, R.

    2002-01-01

    Neutron capture in 10B produces energetic alpha particles that have a high linear energy transfer in tissue. This results in higher cell killing and a higher relative biological effectiveness compared to photons. Using suitably designed boron compounds which preferentially localize in cancerous cells instead of healthy tissues, boron neutron capture therapy (BNCT) has the potential of providing a higher tumor cure rate within minimal toxicity to normal tissues. This clinical approach requires a thermal neutron source, generally a nuclear reactor, with a fluence rate sufficient to deliver tumorcidal doses within a reasonable treatment time (minutes). Thermal neutrons do not penetrate deeply in tissue, therefore BNCT is limited to lesions which are either superficial or otherwise accessible. In this work, we investigate the feasibility of an accelerator-based thermal neutron source for the BNCT of skin melanomas. The source was designed via MCNP Monte Carlo simulations of the thermalization of a fast neutron beam, generated by 7 MeV deuterons impinging on a thick target of beryllium. The neutron field was characterized at several deuteron energies (3.0-6.5 MeV) in an experimental structure installed at the Van De Graaff accelerator of the Laboratori Nazionali di Legnaro, in Italy. Thermal and epithermal neutron fluences were measured with activation techniques and fast neutron spectra were determined with superheated drop detectors (SDD). These neutron spectrometry and dosimetry studies indicated that the fast neutron dose is unacceptably high in the current design. Modifications to the current design to overcome this problem are presented.

  17. High neutronic efficiency, low current targets for accelerator-based BNCT applications

    International Nuclear Information System (INIS)

    Powell, J.R.; Ludewig, H.; Todosow, M.

    1998-01-01

    The neutronic efficiency of target/filters for accelerator-based BNCT applications is measured by the proton current required to achieve a desirable neutron current at the treatment port (10 9 n/cm 2 /s). In this paper the authors describe two possible targeyt/filter concepts wihch minimize the required current. Both concepts are based on the Li-7 (p,n)Be-7 reaction. Targets that operate near the threshold energy generate neutrons that are close tothe desired energy for BNCT treatment. Thus, the filter can be extremely thin (∼ 5 cm iron). However, this approach has an extremely low neutron yield (n/p ∼ 1.0(-6)), thus requiring a high proton current. The proposed solutino is to design a target consisting of multiple extremely thin targets (proton energy loss per target ∼ 10 keV), and re-accelerate the protons between each target. Targets operating at ihgher proton energies (∼ 2.5 MeV) have a much higher yield (n/p ∼ 1.0(-4)). However, at these energies the maximum neutron energy is approximately 800 keV, and thus a neutron filter is required to degrade the average neutron energy to the range of interest for BNCT (10--20 keV). A neutron filter consisting of fluorine compounds and iron has been investigated for this case. Typically a proton current of approximately 5 mA is required to generate the desired neutron current at the treatment port. The efficiency of these filter designs can be further increased by incorporating neutron reflectors that are co-axial with the neutron source. These reflectors are made of materials which have high scattering cross sections in the range 0.1--1.0 MeV

  18. Design of a BNCT facility at HANARO

    International Nuclear Information System (INIS)

    Jun, Byung Jin; Lee, Byung Chul

    1998-01-01

    Based on the feasibility study of the BNCT at HANARO, it was confirmed that only thermal BNCT is possible at the IR beam tube if appropriate filtering system be installed. Medical doctors in Korea Cancer Center Hospital agreed that the thermal BNCT facility would be worthwhile for the BNCT technology development in Korea as well as superficial cancer treatment. For the thermal BNCT to be effective, the thermal neutron flux should be high enough for patient treatment during relatively short time and also the fast neutron and gamma-ray fluxes should be as low as possible. In this point of view, the following design requirements are set up: 1) thermal neutron flux at the irradiation position should be higher than 3x10 9 n/cm 2 -sec, 2) ratio of the fast neutrons and gamma-rays to the thermal neutrons should be minimized, and 3) patient treatment should be possible without interrupt to the reactor operation. To minimize the fast neutrons and gamma-rays with the required thermal neutrons at the irradiation position, a radiation filter consisting of single crystals of silicon and bismuth at liquid nitrogen temperature is designed. For the shielding purpose around the irradiation position, polyethylene, lead, LiF, etc., are appropriately arranged around the radiation filter. A water shutter in front of the radiation filter is adopted so as to avoid interrupt to the reactor operation. At present, detail design of the radiation filter is ongoing. Cooling capabilities of the filter will be tested through a mockup experiment. Dose rate distributions around the radiation filter and a prompt gamma-ray activation analysis system for the analyses of boron content in the biological samples are under design. The construction of this facility will be started from next year if it is permitted from the regulatory body this year. Some other future works exist and are described in the paper. (author)

  19. Fission reactor based epithermal neutron irradiation facilities for routine clinical application in BNCT-Hatanaka memorial lecture

    International Nuclear Information System (INIS)

    Harling, Otto K.

    2009-01-01

    Based on experience gained in the recent clinical studies at MIT/Harvard, the desirable characteristics of epithermal neutron irradiation facilities for eventual routine clinical BNCT are suggested. A discussion of two approaches to using fission reactors for epithermal neutron BNCT is provided. This is followed by specific suggestions for the performance and features needed for high throughput clinical BNCT. An example of a current state-of-the-art, reactor based facility, suited for routine clinical use is discussed. Some comments are provided on the current status of reactor versus accelerator based epithermal neutron sources for BNCT. This paper concludes with a summary and a few personal observations on BNCT by the author.

  20. Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Castell, W.; Di Paolo, H.; Baldo, M.; Bergueiro, J.

    2011-01-01

    We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas.

  1. Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Kreiner, A J; Castell, W; Di Paolo, H; Baldo, M; Bergueiro, J; Burlon, A A; Cartelli, D; Vento, V Thatar; Kesque, J M; Erhardt, J; Ilardo, J C; Valda, A A; Debray, M E; Somacal, H R; Sandin, J C Suarez; Igarzabal, M; Huck, H; Estrada, L; Repetto, M; Obligado, M; Padulo, J; Minsky, D M; Herrera, M; Gonzalez, S J; Capoulat, M E

    2011-12-01

    We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the (7)Li(p,n)(7)Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas. Copyright © 2011 Elsevier Ltd. All rights reserved.

  2. Accelerator based-boron neutron capture therapy (BNCT)-clinical QA and QC

    International Nuclear Information System (INIS)

    Suzuki, Minoru; Tanaka, Hiroki; Sakurai, Yoshinori; Yong, Liu; Kashino, Genro; Kinashi, Yuko; Masunaga, Shinichiro; Ono, Koji; Maruhashi, Akira

    2009-01-01

    Alpha-particle and recoil Li atom yielded by the reaction ( 10 B, n), due to their high LET properties, efficiently and specifically kill the cancer cell that has incorporated the boron. Efficacy of this boron neutron capture therapy (BNCT) has been demonstrated mainly in the treatment of recurrent head/neck and malignant brain cancers in Kyoto University Research Reactor Institute (KUR). As the clinical trial of BNCT is to start from 2009 based on an accelerator (not on the Reactor), this paper describes the tentative outline of the standard operation procedure of BNCT for its quality assurance (QA) and quality control (QC) along the flow of its clinical practice. Personnel concerned in the practice involve the attending physician, multiple physicians in charge of BNCT, medical physicists, nurses and reactor stuff. The flow order of the actual BNCT is as follows: Pre-therapeutic evaluation mainly including informed consent and confirmation of the prescription; Therapeutic planning including setting of therapy volume, and of irradiation axes followed by meeting for stuffs' agreement, decision of irradiating field in the irradiation room leading to final decision of the axis, CT for the planning, decision of the final therapeutic plan according to Japan Atomic Energy Agency-Computational Dosimetry System (JCDS) and meeting of all related personnel for the final confirmation of therapeutic plan; and BNCT including the transport of patient to KUR, dripping of boronophenylalanine, setting up of the patient on the machine, blood sampling for pharmacokinetics, boron level measurement for decision of irradiating time, switch on/off of the accelerator, confirmation of patient's movement in the irradiated field after the neutron irradiation, blood sampling for confirmation of the boron level, and patient's leave from the room. The QA/QC check is principally to be conducted with the two-person rule. The purpose of the clinical trial is to establish the usefulness of BNCT

  3. Electrostatic design and beam transport for a folded tandem electrostatic quadrupole accelerator facility for accelerator-based boron neutron capture therapy

    International Nuclear Information System (INIS)

    Thatar Vento, V.; Bergueiro, J.; Cartelli, D.; Valda, A.A.; Kreiner, A.J.

    2011-01-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), we discuss here the electrostatic design of the machine, including the accelerator tubes with electrostatic quadrupoles and the simulations for the transport and acceleration of a high intensity beam.

  4. Introducing BNCT treatment in new treatment facilities

    International Nuclear Information System (INIS)

    Gabel, D.

    2001-01-01

    The physical and radiobiological studies that should be performed before the initiation of BNCT are discussed. The need for dose-escalation versus response studies in large animal models is questioned. These studies are time consuming, expensive and legally difficult in some countries and may be dispensable. (author)

  5. Design of a beam shaping assembly for an accelerator-based BNCT system

    International Nuclear Information System (INIS)

    Stichelbaut, F.; Forton, E.; Jongen, Y.

    2006-01-01

    A complete BNCT system based on a high-intensity proton accelerator is developed by the IBA company. The neutron beam is produced via the 7 Li(p,n) 7 Be reaction using a solid lithium target. The neutron energy spectrum is tailored with a beam shaping assembly surrounding the target. This device is the object of an extensive R and D project and is fully designed with the Monte Carlo simulation code MCNPX. The emphasis is put on the treatment quality, notably the radiation dose at the skin level, and the achievable neutron flux. (author)

  6. Characterisation of the TAPIRO BNCT epithermal facility

    Energy Technology Data Exchange (ETDEWEB)

    Burn, K. W. [FIS-NUC, ENEA, Via Martiri di Montesole 4, Bologna (Italy); Colli, V. [Dept. of Physics of Univ., INFN, Via Celoria 16, I-20133 Milano (Italy); Curzio, G.; D' Errico, F. [DIMNP, Univ. of Pisa, Via Diotisalvi 2, I-56126 Pisa (Italy); Gambarini, G. [Dept. of Physics of Univ., INFN, Via Celoria 16, I-20133 Milano (Italy); Rosi, G. [FIS-ION, ENEA, Casaccia, Via Anguillarese 301, I-00060 Santa Maria di Galeria, Roma (Italy); Scolari, L. [Dept. of Physics of Univ., INFN, Via Celoria 16, I-20133 Milano (Italy)

    2004-07-01

    A collimated epithermal beam for boron neutron capture therapy (BNCT) research has been designed and built at the TAPIRO fast research reactor. A complete experimental characterisation of the radiation field in the irradiation chamber has been performed, to verify agreement with IAEA requirements. Slow neutron fluxes have been measured by means of an activation technique and with thermoluminescent detectors (TLDs). The fast neutron dose has been determined with gel dosemeters, while the fast neutron spectrum has been acquired by means of a neutron spectrometer based on superheated drop detectors. The gamma-dose has been measured with gel dosemeters and TLDs. For an independent verification of the experimental results, fluxes, doses and neutron spectra have been calculated with Monte Carlo simulations using the codes MCNP4B and MCNPX 2.1.5 with the direct statistical approach (DSA). The results obtained confirm that the epithermal beams achievable at TAPIRO are of suitable quality for BNCT purposes. (authors)

  7. BNL ACCELERATOR-BASED RADIOBIOLOGY FACILITIES

    International Nuclear Information System (INIS)

    LOWENSTEIN, D.I.

    2000-01-01

    For the past several years, the Alternating Gradient Synchrotron (AGS) at Brookhaven National Laboratory (USA) has provided ions of iron, silicon and gold, at energies from 600 MeV/nucleon to 10 GeV/nucleon, for the US National Aeronautics and Space Administration (NASA) radiobiology research program. NASA has recently funded the construction of a new dedicated ion facility, the Booster Applications Facility (BAF). The Booster synchrotron will supply ion beams ranging from protons to gold, in an energy range from 40--3,000 MeV/nucleon with maximum beam intensities of 10 10 to 10 11 ions per pulse. The BAF Project is described and the future AGS and BAF operation plans are presented

  8. Characterisation of the TAPIRO BNCT thermal facility

    Energy Technology Data Exchange (ETDEWEB)

    Rosi, G. [ENEA FIS-ION, CR Casaccia, Via Anguillarese 301, I-00060 Roma (Italy); Gambarini, G.; Colli, V.; Gay, S.; Scolari, L. [Dept. of Physics, Univ. of Milan, INFN, Via Celoria 16, I-20133 Milano (Italy); Fiorani, O.; Perrone, A. [ENEA FIS-ION, CR Casaccia, Via Anguillarese 301, I-00060 Roma (Italy); Nava, E. [ENEA FIS-NUC, Via Martiri di Monte Sole 4, I-40129 Bologna (Italy); Fasolo, F.; Visca, L.; Zanini, A. [INFN, Via Pietro Giuria 1, I-10125 Torino (Italy)

    2004-07-01

    Dosimetry and spectrometry measurements have been carried out in the thermal column of the research fast reactor RSV-TAPIRO (ENEA-Casaccia, Rome) in order to investigate its suitability for irradiation of cells or mice, with a view to research in the interests of boron neutron capture therapy (BNCT). The thermal column consists of a graphite moderator (40 cm thick) containing a lead shield (13 cm thick) in order to shield reactor background. The irradiation volume, inside this structure, has cubic shape (18 x 18 x 18 cm{sup 3}). Besides measurements of fluence and dose rates in air or in phantom performed with thermoluminescence dosemeters (TLDs) and using the activation technique, dose and fluence profiles have been generated using a method based on gel dosemeters analysed with optical imaging. To check the consistency of the results, spectrometry measurements in the same irradiation volume have been performed by means of bubble detectors. (authors)

  9. Tandem electrostatic accelerators for BNCT

    International Nuclear Information System (INIS)

    Ma, J.C.

    1994-01-01

    The development of boron neutron capture therapy (BNCT) into a viable therapeutic modality will depend, in part, on the availability of suitable neutron sources compatible with installation in a hospital environment. Low-energy accelerator-based intense neutron sources, using electrostatic or radio frequency quadrupole proton accelerators have been suggested for this purpose and are underdevelopment at several laboratories. New advances in tandem electrostatic accelerator technology now allow acceleration of the multi-milliampere proton beams required to produce therapeutic neutron fluxes for BNCT. The relatively compact size, low weight and high power efficiency of these machines make them particularly attractive for installation in a clinical or research facility. The authors will describe the limitations on ion beam current and available neutron flux from tandem accelerators relative to the requirements for BNCT research and therapy. Preliminary designs and shielding requirements for a tandern accelerator-based BNCT research facility will also be presented

  10. Development of a Tandem-ElectroStatic-Quadrupole accelerator facility for Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Thatar Vento, V.; Levinas, P.; Bergueiro, J.; Burlon, A.A.; Di Paolo, H.; Kesque, J.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Minsky, D.M.; Estrada, L.; Hazarabedian, A.; Johann, F.; Suarez Sandin, J.C.; Castell, W.; Davidson, J.; Davidson, M.; Repetto, M.; Obligado, M.; Nery, J.P.; Huck, H.; Igarzabal, M.; Fernandez Salares, A.

    2008-01-01

    There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). An ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.4-2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.20-1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is one of the technologically simplest and cheapest solutions for optimized AB-BNCT. At present there is no BNCT facility in the world with the characteristics presented in this work. For the accelerator, results on its design, construction and beam transport calculations are discussed. Taking into account the peculiarities of the expected irradiation field, the project also considers a specific study of the treatment room. This study aims at the design of the treatment room emphasizing aspects related to patient, personnel and public radiation protection; dose monitoring; patient positioning and room construction. The design considers both thermal (for the treatment of shallow tumors) and epithermal (for deep-seated tumors) neutron beams entering the room through a port connected to the accelerator via a moderation and neutron beam shaping assembly. Preliminary results of dose calculations for the treatment room design, using the MCNP program, are presented

  11. Electrostatic design and beam transport for a folded tandem electrostatic quadrupole accelerator facility for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Vento, V Thatar; Bergueiro, J; Cartelli, D; Valda, A A; Kreiner, A J

    2011-12-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), we discuss here the electrostatic design of the machine, including the accelerator tubes with electrostatic quadrupoles and the simulations for the transport and acceleration of a high intensity beam. Copyright © 2011 Elsevier Ltd. All rights reserved.

  12. Development of a tandem-electrostatic-quadrupole accelerator facility for BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Thatar Vento, V.; Levinas, P.; Bergueiro, J.; Di Paolo, H.; Burlon, A.A.; Kesque, J.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Minsky, D.M.

    2009-01-01

    In this work we describe the present status of an ongoing project to develop a tandem-electrostatic-quadrupole (TESQ) accelerator facility for accelerator-based (AB) BNCT at the Atomic Energy Commission of Argentina in Buenos Aires. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. An electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. The machine being designed and constructed is a folded TESQ with a high-voltage terminal at 1.2 MV intended to work in air. Such a machine is conceptually shown to be capable of transporting and accelerating a 30 mA proton beam to 2.4 MeV. The general geometric layout, its associated electrostatic fields, and the acceleration tube are simulated using a 3D finite element procedure. The design and construction of the ESQ modules is discussed and their electrostatic fields are investigated. Beam transport calculations through the accelerator are briefly mentioned. Likewise, work related to neutron production targets, strippers, beam shaping assembly and patient treatment room is briefly described.

  13. Development of a tandem-electrostatic-quadrupole accelerator facility for BNCT.

    Science.gov (United States)

    Kreiner, A J; Thatar Vento, V; Levinas, P; Bergueiro, J; Di Paolo, H; Burlon, A A; Kesque, J M; Valda, A A; Debray, M E; Somacal, H R; Minsky, D M; Estrada, L; Hazarabedian, A; Johann, F; Suarez Sandin, J C; Castell, W; Davidson, J; Davidson, M; Giboudot, Y; Repetto, M; Obligado, M; Nery, J P; Huck, H; Igarzabal, M; Fernandez Salares, A

    2009-07-01

    In this work we describe the present status of an ongoing project to develop a tandem-electrostatic-quadrupole (TESQ) accelerator facility for accelerator-based (AB) BNCT at the Atomic Energy Commission of Argentina in Buenos Aires. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the (7)Li(p,n)(7)Be reaction slightly beyond its resonance at 2.25 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the (7)Li(p,n)(7)Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. An electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. The machine being designed and constructed is a folded TESQ with a high-voltage terminal at 1.2 MV intended to work in air. Such a machine is conceptually shown to be capable of transporting and accelerating a 30 mA proton beam to 2.4 MeV. The general geometric layout, its associated electrostatic fields, and the acceleration tube are simulated using a 3D finite element procedure. The design and construction of the ESQ modules is discussed and their electrostatic fields are investigated. Beam transport calculations through the accelerator are briefly mentioned. Likewise, work related to neutron production targets, strippers, beam shaping assembly and patient treatment room is briefly described.

  14. Experimental and Simulated Characterization of a Beam Shaping Assembly for Accelerator- Based Boron Neutron Capture Therapy (AB-BNCT)

    International Nuclear Information System (INIS)

    Burlon, Alejandro A.; Valda, Alejandro A.; Girola, Santiago; Minsky, Daniel M.; Kreiner, Andres J.

    2010-01-01

    In the frame of the construction of a Tandem Electrostatic Quadrupole Accelerator facility devoted to the Accelerator-Based Boron Neutron Capture Therapy, a Beam Shaping Assembly has been characterized by means of Monte-Carlo simulations and measurements. The neutrons were generated via the 7 Li(p, n) 7 Be reaction by irradiating a thick LiF target with a 2.3 MeV proton beam delivered by the TANDAR accelerator at CNEA. The emerging neutron flux was measured by means of activation foils while the beam quality and directionality was evaluated by means of Monte Carlo simulations. The parameters show compliance with those suggested by IAEA. Finally, an improvement adding a beam collimator has been evaluated.

  15. Demonstration of the importance of a dedicated neutron beam monitoring system for BNCT facility

    International Nuclear Information System (INIS)

    Chao, Der-Sheng; Liu, Yuan-Hao; Jiang, Shiang-Huei

    2016-01-01

    The neutron beam monitoring system is indispensable to BNCT facility in order to achieve an accurate patient dose delivery. The neutron beam monitoring of a reactor-based BNCT (RB-BNCT) facility can be implemented through the instrumentation and control system of a reactor provided that the reactor power level remains constant during reactor operation. However, since the neutron flux in reactor core is highly correlative to complicated reactor kinetics resulting from such as fuel depletion, poison production, and control blade movement, some extent of variation may occur in the spatial distribution of neutron flux in reactor core. Therefore, a dedicated neutron beam monitoring system is needed to be installed in the vicinity of the beam path close to the beam exit of the RB-BNCT facility, where it can measure the BNCT beam intensity as closely as possible and be free from the influence of the objects present around the beam exit. In this study, in order to demonstrate the importance of a dedicated BNCT neutron beam monitoring system, the signals originating from the two in-core neutron detectors installed at THOR were extracted and compared with the three dedicated neutron beam monitors of the THOR BNCT facility. The correlation of the readings between the in-core neutron detectors and the BNCT neutron beam monitors was established to evaluate the improvable quality of the beam intensity measurement inferred by the in-core neutron detectors. In 29 sampled intervals within 16 days of measurement, the fluctuations in the mean value of the normalized ratios between readings of the three BNCT neutron beam monitors lay within 0.2%. However, the normalized ratios of readings of the two in-core neutron detectors to one of the BNCT neutron beam monitors show great fluctuations of 5.9% and 17.5%, respectively. - Highlights: • Two in-core neutron detectors and three BNCT neutron beam monitors were compared. • BNCT neutron beam monitors improve the stability in neutron

  16. Feasibility study to develop BNCT facility at the Indonesian research reactor

    International Nuclear Information System (INIS)

    Hastowo, H.

    2001-01-01

    A survey on the Indonesian research reactors and its supporting facilities has been done in order to check the possibility to install BNCT facility. Oncologists from several hospitals have been informing about the BNCT treatment for tumours and they give a positive response to support utilisation of the BNCT facility. Several aspects required to support the BNCT treatment have also been identified and related activities on that matter soon will be initiated. The interim result in our survey indicated that utilisation of the 30 MW Multipurpose reactor would not be possible from the technical point of view. Further study will be concentrated on the TRIGA reactor and an epithermal neutron beam facility at the thermal column of this reactor will be designed for further work. (author)

  17. Commissioning of accelerator based boron neutron capture therapy system

    International Nuclear Information System (INIS)

    Nakamura, S.; Wakita, A.; Okamoto, H.; Igaki, H.; Itami, J.; Ito, M.; Abe, Y.; Imahori, Y.

    2017-01-01

    Boron neutron capture therapy (BNCT) is a treatment method using a nuclear reaction of 10 B(n, α) 7 Li. BNCT can be deposited the energy to a tumor since the 10 B which has a higher cross-section to a neutron is high is concentrated on the tumor. It is different from conventional radiation therapies that BNCT expects higher treatment effect to radiation resistant tumors since the generated alpha and lithium particles have higher radiological biological effectiveness. In general, BNCT has been performed in research nuclear reactor. Thus, BNCT is not widely applied in a clinical use. According to recent development of accelerator-based boron neutron capture therapy system, the system has an adequate flux of neutrons. Therefore, National Cancer Canter Hospital, Tokyo, Japan is planning to install accelerator based BNCT system. Protons with 2.5 MeV are irradiated to a lithium target system to generate neutrons. As a result, thermal load of the target is 50 kW since current of the protons is 20.0 mA. Additionally, when the accelerator-based BNCT system is installed in a hospital, the facility size is disadvantage in term of neutron measurements. Therefore, the commissioning of the BNCT system is being performed carefully. In this article, we report about the commissioning. (author)

  18. Investigation of development and management of treatment planning systems for BNCT at foreign facilities

    International Nuclear Information System (INIS)

    2001-03-01

    A new computational dosimetry system for BNCT: JCDS is developed by JAERI in order to carry out BNCT with epithermal neutron beam at present. The development and management situation of computational dosimetry system, which are developed and are used in BNCT facilities in foreign countries, were investigated in order to accurately grasp functions necessary for preparation of the treatment planning and its future subjects. In present state, 'SERA', which are developed by Idaho National Engineering and Environmental Laboratory (INEEL), is used in many BNCT facilities. Followings are necessary for development and management of the treatment planning system. (1) Reliability confirmation of system performance by verification as comparison examination of calculated value with actual experimental measured value. (2) Confirmation systems such as periodic maintenance for retention of the system quality. (3) The improvement system, which always considered relative merits and demerits with other computational dosimetry system. (4) The development of integrated system with patient setting. (author)

  19. The Idaho Power Burst Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program overview

    International Nuclear Information System (INIS)

    Dorn, R.V. III; Griebenow, M.L.; Ackermann, A.L.; Miller, L.G.; Miller, D.L.; Wheeler, F.J.; Bradshaw, K.M.; Wessol, D.E.; Harker, Y.D.; Nigg, D.W.; Randolph, P.D.; Bauer, W.F.; Gavin, P.R.; Richards, T.L.

    1992-01-01

    The Power Burst Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program has been funded since 1988 to evaluate brain tumor treatment using Na 2 B 12 H 11 SH (borocaptate sodium or BSH) and epithermal neutrons. The PBF/BNCT Program pursues this goal as a comprehensive, multidisciplinary, multiorganizational endeavor applying modern program management techniques. The initial focus was to: (1) establish a representative large animal model and (2) develop the generic analytical and measurement capabilities require to control treatment repeatability and determine critical treatment parameters independent of tumor type and body location. This paper will identify the PBF/BNCT Program elements and summarize the status of some of the developed capabilities

  20. Accelerator based research facility as an inter university centre

    International Nuclear Information System (INIS)

    Mehta, G.K.

    1995-01-01

    15 UD pelletron has been operating as a user facility from July 1991. It is being utilised by a large number of universities and other institutions for research in basic Nuclear Physics, Materials Science, Atomic Physics, Radiobiology and Radiation Chemistry. There is an on-going programme for augmenting the accelerator facilities by injecting Pelletron beams into superconducting linear accelerator modules. Superconducting niobium resonator is being developed in Argonne National Laboratory as a joint collaborative effort. All other things such as cryostats, rf instrumentation, cryogenic distribution system, computer control etc are being done indigenously. Research facilities, augmentation plans and the research being conducted by the universities in various disciplines are described. (author)

  1. Future directions of accelerator-based NP and HEP facilities

    Energy Technology Data Exchange (ETDEWEB)

    Roser, T.

    2011-07-24

    Progress in particle and nuclear physics has been closely connected to the progress in accelerator technologies - a connection that is highly beneficial to both fields. This paper presents a review of the present and future facilities and accelerator technologies that will push the frontiers of high-energy particle interactions and high intensity secondary particle beams.

  2. Optimization of the irradiation beam in the BNCT research facility at IEA-R1 reactor

    International Nuclear Information System (INIS)

    Castro, Vinicius Alexandre de

    2014-01-01

    Boron Neutron Capture Therapy (BNCT) is a radiotherapeutic technique for the treatment of some types of cancer whose useful energy comes from a nuclear reaction that occurs when thermal neutron impinges upon a Boron-10 atom. In Brazil there is a research facility built along the beam hole number 3 of the IEA-R1 research reactor at IPEN, which was designed to perform BNCT research experiments. For a good performance of the technique, the irradiation beam should be mostly composed of thermal neutrons with a minimum as possible gamma and above thermal neutron components. This work aims to monitor and evaluate the irradiation beam on the sample irradiation position through the use of activation detectors (activation foils) and also to propose, through simulation using the radiation transport code, MCNP, new sets of moderators and filters which shall deliver better irradiation fields at the irradiation sample position In this work, a simulation methodology, based on a MCNP card, known as wwg (weight window generation) was studied, and the neutron energy spectrum has been experimentally discriminated at 5 energy ranges by using a new set o activation foils. It also has been concluded that the BNCT research facility has the required thermal neutron flux to perform studies in the area and it has a great potential for improvement for tailoring the irradiation field. (author)

  3. Radiation field characterization of a BNCT research facility using Monte Carlo Method - Code MCNP-4B

    International Nuclear Information System (INIS)

    Hernandes, Antonio Carlos

    2002-01-01

    Boron Neutron Capture Therapy - BNCT- is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an AmBe neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these BNCT studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluency Ν Τ = 1,35x10 8 n/cm 2 , a fast neutron dose of 5,86x -1 0 Gy/Ν Τ and a gamma ray dose of 8,30x -14 Gy/Ν Τ . (author)

  4. Towards the final BSA modeling for the accelerator-driven BNCT facility at INFN LNL

    Energy Technology Data Exchange (ETDEWEB)

    Ceballos, C. [Centro de Aplicaciones Tecnlogicas y Desarrollo Nuclear, 5ta y30, Miramar, Playa, Ciudad Habana (Cuba); Esposito, J., E-mail: juan.esposito@lnl.infn.it [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Agosteo, S. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Colautti, P.; Conte, V.; Moro, D. [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Pola, A. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy)

    2011-12-15

    Some remarkable advances have been made in the last years on the SPES-BNCT project of the Istituto Nazionale di Fisica Nucleare (INFN) towards the development of the accelerator-driven thermal neutron beam facility at the Legnaro National Laboratories (LNL), aimed at the BNCT experimental treatment of extended skin melanoma. The compact neutron source will be produced via the {sup 9}Be(p,xn) reactions using the 5 MeV, 30 mA beam driven by the RFQ accelerator, whose modules construction has been recently completed, into a thick beryllium target prototype already available. The Beam Shaping Assembly (BSA) final modeling, using both neutron converter and the new, detailed, Be(p,xn) neutron yield spectra at 5 MeV energy recently measured at the CN Van de Graaff accelerator at LNL, is summarized here.

  5. The BNCT facility at the HFR Petten: Quality assurance for reactor facilities in clinical trials

    International Nuclear Information System (INIS)

    Moss, R.; Watkins, P.; Vroegindeweij, C.; Stecher-Rasmussen, F.; Huiskamp, R.; Ravensberg, K.; Appelman, K.; Sauerwein, W.; Hideghety, K.; Gabel, D.

    2001-01-01

    The first clinical trial in Europe of Boron Neutron Capture Therapy (BNCT) for the treatment of glioblastoma was opened in July 1997. The trial is a Phase I study with the principal aim to establish the maximum tolerated radiation dose and the dose limiting toxicity under defined conditions. It is the first time that a clinical application could be realised on a completely multi-national scale. The treatment takes place at the High Flux Reactor (HFR) in Petten, the Netherlands, is operated by an international team of experts under the leadership of a German radiotherapist, and treats patients coming from different European countries. It has therefore been necessary to create a very specialised organisation and contractual structure with the support of administrations from different countries, who had to find and adapt solutions within existing laws that had never foreseen such a situation. Furthermore, the treatment does not take place in an hospital environment and even more so, the facility is at a nuclear research reactor. Hence, special efforts were made on quality assurance, in order that the set-up at the facility and the personnel involved complied, as closely as possible, with similar practices in conventional radiotherapy departments. (author)

  6. Quality assurance for BNCT at nuclear facilities. A necessary burden or the unavoidable seal of approval

    International Nuclear Information System (INIS)

    Moss, R.; Morrissey, J.; Sauerwein, W.; Hideghety, K.; Rassow, J.; Stecher-Rasmussen, F.

    2000-01-01

    The BNCT clinical trial at the HFR Petten is performed on a completely multi-national basis. The irradiation facility is located in one country (The Netherlands), is operated by an international team of experts under the leadership of a radiotherapist from another country (Germany) and treats patients coming from different European countries. In gaining the necessary approval, it became apparent, especially in the many discussions with the (Dutch) Health authorities that Quality Assurance (QA) would be and is a critical aspect. This is even more so, in the case of BNCT, where it was not only a (relatively) new experimental treatment (in 1996/97) about to be performed for the first time in Europe, but it was to be performed in a non-hospital environment and furthermore in a nuclear research reactor. It was necessary therefore to comply, as closely as possible, with similarly accepted practices in conventional radiotherapy. Despite QA being a sometimes burdensome task, this paper nevertheless raises the issue as to whether it is necessary or whether it is the seal of approval for BNCT as an acceptable mode of treatment in mainstream radiotherapy. (author)

  7. Radiation field characterization of a BNCT research facility using Monte Carlo method - code MCNP-4B

    International Nuclear Information System (INIS)

    Hernandez, Antonio Carlos

    2002-01-01

    Boron Neutron Capture Therapy - BNCT - is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an Am Be neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these Becton studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluencyN T = 1,35x10 8 n/cm , a fast neutron dose of 5,86x10 -10 Gy/N T and a gamma ray dose of 8,30x10 -14 Gy/N T . (author)

  8. Calculation of fluence rate distributions in a pre design clinical facility for BNCT at the LFR

    International Nuclear Information System (INIS)

    Peeters, T.T.J.M.; Freudenreich, W.E.

    1995-12-01

    In a previous study [1], it was demonstrated that the creation of a thermal neutron facility for clinical BNCT in the LFR is feasible. Monte Carlo calculations had shown that the neutron fluence rates and gamma dose rates at the detector position of a model representing a first outline of a clinical facility met all requirements that are necessary for clinical BNCT. In order to gain more information about the neutron fluence rates at several positions, a second step is required. Calculations have been performed for the free beam and for a tumour bearing phantom at 5 cm and 10 cm distance from the irradiation window. Due to thermalization and back scattering, the thermal fluence rates in the tumour at 5 and 10 cm distance from the bismuth shield appeared to be approximately twice as high as the thermal fluence rates in the free beam at the corresponding positions of 5 to 6 cm and 10 to 11 cm from the irradiation window. (orig.)

  9. Improvements at the biological shielding of BNCT research facility in the IEA-R1 reactor

    International Nuclear Information System (INIS)

    Souza, Gregorio Soares de

    2011-01-01

    The technique of neutron capture in boron is a promising technique in cancer treatment, it uses the high LET particles from the reaction 10 B (n, α) 7 Li to destroy cancer cells.The development of this technique began in the mid-'50s and even today it is the object of study and research in various centers around the world, Brazil has built a facility that aims to conduct research in BNCT, this facility is located next to irradiation channel number three at the research nuclear reactor IEA-R1 and has a biological shielding designed to meet the radiation protection standards. This biological shielding was developed to allow them to conduct experiments with the reactor at maximum power, so it is not necessary to turn on and off the reactor to irradiate samples. However, when the channel is opened for experiments the background radiation in the experiments salon increases and this background variation makes it impossible to perform measurements in a neutron diffraction research that utilizes the irradiation channel number six. This study aims to further improve the shielding in order to minimize the variation of background making it possible to perform the research facility in BNCT without interfering with the action of the research group of the irradiation channel number six. To reach this purpose, the code MCNP5, dosimeters and activation detectors were used to plan improvements in the biological shielding. It was calculated with the help of the code an improvement that can reduce the average heat flow in 71.2% ± 13 and verified experimentally a mean reduce of 70 ± 9% in dose due to thermal neutrons. (author)

  10. Proceedings of neutron irradiation technical meeting on BNCT

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2000-10-01

    The 'Neutron Irradiation Technical Meeting for Boron Neutron Capture Therapy (BNCT)' was held on March 13, 2000 at Tokai Research Establishment. The Meeting is aimed to introduce the neutron beam facility for medical irradiation at JRR-4 to Japanese researchers widely, as well as providing an opportunity for young researchers, engineers, medical representatives such surgeons and doctors of pharmacology to present their research activities and to exchange valuable information. JAERI researcher presented the performance and the irradiation technology in the JRR-4 neutron beam facility, while external researchers made various and beneficial presentations containing such accelerator-based BNCT, spectrum-shifter, biological effect, pharmacological development and so on. In this meeting, a special lecture titled 'The Dawn of BNCT and Its Development.' was given by MD, Prof. Takashi Minobe, an executive director of Japan Foundation for Emergency Medicine. The 11 of the presented papers are indexed individually. (J.P.N.)

  11. Proceedings of neutron irradiation technical meeting on BNCT

    International Nuclear Information System (INIS)

    2000-10-01

    The 'Neutron Irradiation Technical Meeting for Boron Neutron Capture Therapy (BNCT)' was held on March 13, 2000 at Tokai Research Establishment. The Meeting is aimed to introduce the neutron beam facility for medical irradiation at JRR-4 to Japanese researchers widely, as well as providing an opportunity for young researchers, engineers, medical representatives such surgeons and doctors of pharmacology to present their research activities and to exchange valuable information. JAERI researcher presented the performance and the irradiation technology in the JRR-4 neutron beam facility, while external researchers made various and beneficial presentations containing such accelerator-based BNCT, spectrum-shifter, biological effect, pharmacological development and so on. In this meeting, a special lecture titled 'The Dawn of BNCT and Its Development.' was given by MD, Prof. Takashi Minobe, an executive director of Japan Foundation for Emergency Medicine. The 11 of the presented papers are indexed individually. (J.P.N.)

  12. PBF/BNCT [power burst facility/boron neutron capture therapy] program for cancer treatment

    International Nuclear Information System (INIS)

    Dorn, R.V. III.

    1989-06-01

    Highlights of the PBF/BNCT Program during June include progress within the areas of gross boron analysis in tissue, blood, and urine; analytical methodologies development for BSH (sodium borocaptate) purity determination; boron microscopic (subcellular) analytical development; noninvasive boron quantification determination; dosimetry; and analytical radiation transport and interaction modeling for BNCT

  13. Development of breast cancer irradiation technique for BNCT at JRR-4

    International Nuclear Information System (INIS)

    Nakamura, Takemi; Horiguchi, Hironori; Arai, Masaji; Yanagie, Hironobu

    2014-06-01

    In the Department of Research Reactor and Tandem Accelerator, developments of irradiation technique with application enlargement for breast cancer on BNCT have been performed in the second medium term plans. We compiled this report about the technological development to solve several problems with the irradiation of breast cancer in the medical irradiation facility of JRR-4. In the present study, design fabrication of a collimator for breast cancer, dose evaluation analysis by clinical model, investigation of dose enhancement at deeper region and investigation of fixing method for breast cancer irradiation were studied. By these evaluation results, we verified that the developed breast cancer irradiation technique can be applied to BNCT medical irradiation of JRR-4. These results are expected to be able to contribute to breast cancer irradiation techniques of other reactor-based BNCT and future accelerator-based BNCT. (author)

  14. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    Pozzi, E. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)], E-mail: epozzi@cnea.gov.ar; Nigg, D.W. [Idaho National Laboratory, Idaho Falls (United States); Miller, M.; Thorp, S.I. [Instrumentation and Control Department, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Zarza, L.; Estryk, G. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Monti Hughes, A.; Molinari, A.J.; Garabalino, M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Quintana, J. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Trivillin, V.A.; Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)

    2009-07-15

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10{sup 9} n cm{sup -2} s{sup -1} and the fast neutron flux was 2.5x10{sup 6} n cm{sup -2} s{sup -1}, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in {sup 6}Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  15. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    International Nuclear Information System (INIS)

    Pozzi, E.; Nigg, D.W.; Miller, M.; Thorp, S.I.; Heber, E.M.; Zarza, L.; Estryk, G.; Monti Hughes, A.; Molinari, A.J.; Garabalino, M.; Itoiz, M.E.; Aromando, R.F.; Quintana, J.; Trivillin, V.A.; Schwint, A.E.

    2009-01-01

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10 9 n cm -2 s -1 and the fast neutron flux was 2.5x10 6 n cm -2 s -1 , indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in 6 Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  16. Dosimetric study of varying aperture-surface distance at the Finnish BNCT facility

    International Nuclear Information System (INIS)

    Uusi-Simola, Jouni; Seppaelae, Tiina; Nieminen, Katja; Kotiluoto, Petri; Seren, Tom; Auterinen, Iiro; Kortesniemi, Mika; Savolainen, Sauli

    2006-01-01

    Comparison of experimental and calculated dosimetric values in a water phantom was performed at the Finnish BNCT facility at the FiR 1 research reactor. The purpose was to study the effect of changing aperture to surface distance (ASD) to radiation dose and to verify the accuracy of the treatment planning and to provide data for comparison of the methods. A magnesium ionisation chamber flushed with argon gas was used to measure absorbed photon dose rate. Diluted manganese (Mn) and gold (Au) foils and Mn wires were used to determine Mn and Au activation reaction rates. Computer simulations with both SERA and MCNP programs were used to independently calculate the corresponding values. Photon dose and activation reaction rate depth profiles at beam central axis an axial profiles at 2.5 and 6 cm depths were measured and calculated for 11 and 14 and 17 cm diameter apertures. Depth profiles for activation reaction rates were determined for the clinically used 11 and 14 cm diameter apertures for 0, 5, and 10 cm ASD. In addition, the optional 17 cm beam was characterised at 0 and 5 cm ASD. The beam intensity decreases by approximately 20% and 40% when ASD is increased to 5 cm or 10 cm, respectively. The shape of the 55 Mn activation reaction rate depth profile and photon depth radial profile did not vary more than 5% for the 14 cm beam when the ASD was increased from 0 cm to 10 cm. (author)

  17. Development of an anthropomorfic simulator for simulation and measurements of neutron dose and flux the facility for BNCT studies

    International Nuclear Information System (INIS)

    Muniz, Rafael Oliveira Rondon

    2010-01-01

    IPEN facility for researches in BNCT (Boron Neutron Capture Therapy) uses IEA-R1 reactor's irradiation channel number 3, where there is a mixed radiation field - neutrons and gamma. The researches in progress require the radiation fields, in the position of the irradiation of sample, to have in its composition maximized thermal neutrons component and minimized, fast and epithermal neutron flux and gamma radiation. This work was developed with the objective of evaluating whether the present radiation field in the facility is suitable for BNCT researches. In order to achieve this objective, a methodology for the dosimetry of thermal neutrons and gamma radiation in mixed fields of high doses, which was not available in IPEN, was implemented in the Center of Nuclear Engineering of IPEN, by using thermoluminescent dosimeters - TLDs 400, 600 and 700. For the measurements of thermal and epithermal neutron flux, activation detectors of gold were used applying the cadmium ratio technique. A cylindrical phantom composed by acrylic discs was developed and tested in the facility and the DOT 3.5. computational code was used in order to obtain theoretical values of neutron flux and the dose along phantom. In the position corresponding to about half the length of the cylinder of the phantom, the following values were obtained: thermal neutron flux (2,52 ± 0,06).10 8 n/cm 2 s, epithermal neutron flux (6,17 ± 0,26).10 7 .10 6 n/cm 2 s, absorbed dose due to thermal neutrons (4,2 ± 1,8)Gy and (10,1 ± 1,3)Gy due to gamma radiation. The obtained values show that the fluxes of thermal and epithermal neutrons flux are appropriate for studies in BNCT, however, the dose due to gamma radiation is high, indicating that the facility should be improved. (author)

  18. Clinical requirements and accelerator concepts for BNCT

    International Nuclear Information System (INIS)

    Ludewigt, B.A.; Bleuel, D.L.; Chu, W.T.; Donahue, R.J.; Kwan, J.; Leung, K.N.; Reginato, L.L.; Wells, R.P.

    1997-05-01

    Accelerator-based neutron sources are an attractive alternative to nuclear reactors for providing epithermal neutron beams for Boron Neutron Capture Therapy. Based on clinical requirements and neutronics modeling the use of proton and deuteron induced reactions in 7 Li and 9 Be targets has been compared. Excellent epithermal neutron beams can be produced via the 7 Li(p,n) 7 Be reaction at proton energies of ∼2.5 MeV. An electrostatic quadrupole accelerator and a lithium target, which can deliver and handle 2.5 MeV protons at beam currents up to 50 mA, are under development for an accelerator-based BNCT facility at the Lawrence Berkeley National Laboratory

  19. Development of cancer therapy facility of HANARO and medical research in BNCT; development of the technique for boron concentration analysis

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Hee Dong; Byun, Soo Hyun; Sun, Gwang Min; Kim, Suk Kwon; Kim, In Jung; Park, Chang Su [Seoul National University, Seoul (Korea)

    2002-03-01

    Objective and Necessity of the Project- Development of a boron concentration analysis facility used for BNCT. - Development of the technique for boron concentration analysis. Contents and Scopes of the Project - Construction of the boron concentration analysis facility based on PGAA. Estimation of the neutron beam characteristics. -Establishment of the technique for the boron concentration analysis. - Estimation of the reliability for the boron analysis. Results of the Project -Installation of the boron concentration analysis facility at Hanaro. - Neutron beam characteristics are the sample position (neutron flux : 7.9 x 10{sup 7} n/cm{sup 2}s, Cd-ratio : 266) Technique for the boron concentration analysis. - Boron detection sensitivity and limit (detection sensitivity : 2, 131 cps/mg-B, detection limit : 67 ng for 10,000 sec). 63 refs., 37 figs., 13 tabs. (Author)

  20. MCNP study for epithermal neutron irradiation of an isolated liver at the Finnish BNCT facility.

    Science.gov (United States)

    Kotiluoto, P; Auterinen, I

    2004-11-01

    A successful boron neutron capture treatment (BNCT) of a patient with multiple liver metastases has been first given in Italy, by placing the removed organ into the thermal neutron column of the Triga research reactor of the University of Pavia. In Finland, FiR 1 Triga reactor with an epithermal neutron beam well suited for BNCT has been extensively used to irradiate patients with brain tumors such as glioblastoma and recently also head and neck tumors. In this work we have studied by MCNP Monte Carlo simulations, whether it would be beneficial to treat an isolated liver with epithermal neutrons instead of thermal ones. The results show, that the epithermal field penetrates deeper into the liver and creates a build-up distribution of the boron dose. Our results strongly encourage further studying of irradiation arrangement of an isolated liver with epithermal neutron fields.

  1. Physical and biological dosimetry at the RA-3 facility for small animal irradiation: preliminary BNCT studies in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Pozzi, Emiliano; Miller, Marcelo; Thorp, Silvia I.; Heber, Elisa M.; Trivillin, Veronica A.; Zarza, Leandro; Estryk, Guillermo; Schwint, Amanda E.; Nigg, David W.

    2007-01-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality based on the capture reaction that occurs between thermal neutrons and boron-10 atoms that accumulate selectively in tumor tissue, emitting high linear energy transfer (LET), short range (5-9 microns) particles (alpha y 7 Li). Thus, BNCT would potentially target tumor tissue selectively, sparing normal tissue. Herein we evaluated the feasibility of treating experimental oral mucosa tumors with BNCT at RA-3 (CAE) employing the hamster cheek pouch oral cancer model and characterized the irradiation field at the RA-3 facility. We evaluated the therapeutic effect on tumor of BNCT mediated by BPA in the hamster cheek pouch oral cancer model and the potential radio toxic effects in normal tissue. We evidenced a moderate biological response in tumor, with no radio toxic effects in normal tissue following irradiations with no shielding for the animal body. Given the sub-optimal therapeutic response, we designed and built a 6 Li 2 CO 3 shielding for the body of the animal to increase the irradiation dose to tumor, without exceeding normal tissue radio tolerance. The measured absolute magnitude of thermal neutron flux and the characterization of the beam with and without the shielding in place, suggest that the irradiation facility in the thermal column of RA-3 would afford an excellent platform to perform BNCT studies in vitro and in vivo in small experimental animals. The present findings must be confirmed and extended by performing in vivo BNCT radiobiological studies in small experimental animals, employing the shielding device for the animal body. (author) [es

  2. INEL BNCT Program

    International Nuclear Information System (INIS)

    Ackermann, A.L.; Dorn, R.V. III.

    1991-03-01

    This Bulletin presents a summary of accomplishments and highlights in the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program for March 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, a milestone summary, and animal data charts

  3. INEL BNCT Program

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-08-01

    This Bulletin presents a summary of accomplishments and highlights in the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for August 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  4. Collimator and shielding design for boron neutron capture therapy (BNCT) facility at TRIGA MARK II reactor

    International Nuclear Information System (INIS)

    Mohd Rafi Mohd Solleh; Abdul Aziz Tajuddin; Abdul Aziz Mohamed; Eid Mahmoud Eid Abdel Munem; Mohamad Hairie Rabir; Julia Abdul Karim; Yoshiaki, Kiyanagi

    2011-01-01

    The geometry of reactor core, thermal column, collimator and shielding system for BNCT application of TRIGA MARK II Reactor were simulated with MCNP5 code. Neutron particle lethargy and dose were calculated with MCNPX code. Neutron flux in a sample located at the end of collimator after normalized to measured value (Eid Mahmoud Eid Abdel Munem, 2007) at 1 MW power was 1.06 x 10 8 n/ cm 2 / s. According to IAEA (2001) flux of 1.00 x 10 9 n/ cm 2 / s requires three hours of treatment. Few modifications were needed to get higher flux. (Author)

  5. Ion Beam Facilities at the National Centre for Accelerator based Research using a 3 MV Pelletron Accelerator

    Science.gov (United States)

    Trivedi, T.; Patel, Shiv P.; Chandra, P.; Bajpai, P. K.

    A 3.0 MV (Pelletron 9 SDH 4, NEC, USA) low energy ion accelerator has been recently installed as the National Centre for Accelerator based Research (NCAR) at the Department of Pure & Applied Physics, Guru Ghasidas Vishwavidyalaya, Bilaspur, India. The facility is aimed to carried out interdisciplinary researches using ion beams with high current TORVIS (for H, He ions) and SNICS (for heavy ions) ion sources. The facility includes two dedicated beam lines, one for ion beam analysis (IBA) and other for ion implantation/ irradiation corresponding to switching magnet at +20 and -10 degree, respectively. Ions with 60 kV energy are injected into the accelerator tank where after stripping positively charged ions are accelerated up to 29 MeV for Au. The installed ion beam analysis techniques include RBS, PIXE, ERDA and channelling.

  6. IFMIF [International Fusion Materials Irradiation Facility], an accelerator-based neutron source for fusion components irradiation testing: Materials testing capabilities

    International Nuclear Information System (INIS)

    Mann, F.M.

    1988-08-01

    The International Fusion Materials Irradiation Facility (IFMIF) is proposed as an advanced accelerator-based neutron source for high-flux irradiation testing of large-sized fusion reactor components. The facility would require only small extensions to existing accelerator and target technology originally developed for the Fusion Materials Irradiation Test (FMIT) facility. At the extended facility, neutrons would be produced by a 0.1-A beam of 35-MeV deuterons incident upon a liquid lithium target. The volume available for high-flux (>10/sup 15/ n/cm/sup 2/-s) testing in IFMITF would be over a liter, a factor of about three larger than in the FMIT facility. This is because the effective beam current of 35-MeV deuterons on target can be increased by a factor of ten to 1A or more. Such an increase can be accomplished by funneling beams of deuterium ions from the radio-frequency quadruple into a linear accelerator and by taking advantage of recent developments in accelerator technology. Multiple beams and large total current allow great variety in available testing. For example, multiple simultaneous experiments, and great flexibility in tailoring spatial distributions of flux and spectra can be achieved. 5 refs., 2 figs., 1 tab

  7. Beta Beams: an accelerator based facility to explore Neutrino oscillation physics

    CERN Document Server

    Wildner, E; Hansen, C; De Melo Mendonca, T; Stora, T; Payet, J; Chance, A; Zorin, V; Izotov, I; Rasin, S; Sidorov, A; Skalyga, V; De Angelis, G; Prete, G; Cinausero, M; Kravchuk, VL; Gramegna, F; Marchi, T; Collazuol, G; De Rosa, G; Delbar, T; Loiselet, M; Keutgen, T; Mitrofanov, S; Lamy, T; Latrasse, L; Marie-Jeanne, M; Sortais, P; Thuillier, T; Debray, F; Trophime, C; Hass, M; Hirsh, T; Berkovits, D; Stahl, A

    2011-01-01

    The discovery that the neutrino changes flavor as it travels through space has implications for the Standard Model of particle physics (SM)[1]. To know the contribution of neutrinos to the SM, needs precise measurements of the parameters governing the neutrino oscillations. This will require a high intensity beam-based neutrino oscillation facility. The EURONu Design Study will review three currently accepted methods of realizing this facility (the so-called Super-Beams, Beta Beams and Neutrino Factories) and perform a cost assessment that, coupled with the physics performance, will give means to the European research authorities to make a decision on the layout and construction of the future European neutrino oscillation facility. ”Beta Beams” produce collimated pure electron neutrino and antineutrino beams by accelerating beta active ions to high energies and letting them decay in a race-track shaped storage ring. EURONu Beta Beams are based on CERNs infrastructure and the fact that some of the already ...

  8. Accelerator-based research facility of UGC as an inter-university centre

    International Nuclear Information System (INIS)

    Mehta, G.K.

    1994-01-01

    A 15-UD Pelletron has been operating as a users facility from July 1991. It is being utilised by a large number of universities and other institutions for research in basic nuclear physics, materials science, atomic physics, radiobiology and radiation chemistry. There is an on-going programme for augmenting the accelerator facilities by injecting Pelletron beams into superconducting linear accelerator modules. Superconducting niobium resonators are being developed at Argonne National Laboratory as a joint collaborative effort. All other things such as cryostat, rf-instrumentation, cryogene distribution system, computer control etc. are being done indigenously. Research possibilities are described. (author). 6 refs., 4 figs

  9. Neutron flux and gamma dose measurement in the BNCT irradiation facility at the TRIGA reactor of the University of Pavia

    Science.gov (United States)

    Bortolussi, S.; Protti, N.; Ferrari, M.; Postuma, I.; Fatemi, S.; Prata, M.; Ballarini, F.; Carante, M. P.; Farias, R.; González, S. J.; Marrale, M.; Gallo, S.; Bartolotta, A.; Iacoviello, G.; Nigg, D.; Altieri, S.

    2018-01-01

    University of Pavia is equipped with a TRIGA Mark II research nuclear reactor, operating at a maximum steady state power of 250 kW. It has been used for many years to support Boron Neutron Capture Therapy (BNCT) research. An irradiation facility was constructed inside the thermal column of the reactor to produce a sufficient thermal neutron flux with low epithermal and fast neutron components, and low gamma dose. In this irradiation position, the liver of two patients affected by hepatic metastases from colon carcinoma were irradiated after borated drug administration. The facility is currently used for cell cultures and small animal irradiation. Measurements campaigns have been carried out, aimed at characterizing the neutron spectrum and the gamma dose component. The neutron spectrum has been measured by means of multifoil neutron activation spectrometry and a least squares unfolding algorithm; gamma dose was measured using alanine dosimeters. Results show that in a reference position the thermal neutron flux is (1.20 ± 0.03) ×1010 cm-2 s-1 when the reactor is working at the maximum power of 250 kW, with the epithermal and fast components, respectively, 2 and 3 orders of magnitude lower than the thermal component. The ratio of the gamma dose with respect to the thermal neutron fluence is 1.2 ×10-13 Gy/(n/cm2).

  10. Initial Experimental Verification of the Neutron Beam Modeling for the LBNL BNCT Facility

    International Nuclear Information System (INIS)

    Bleuel, D.L.; Chu, W.T.; Donahue, R.J.; Ludewigt, B.A.; McDonald, R.J.; Smith, A.R.; Stone, N.A.; Vuji, J.

    1999-01-01

    In preparation for future clinical BNCT trials, neutron production via the 7Li(p,n) reaction as well as subsequent moderation to produce epithermal neutrons have been studied. Proper design of a moderator and filter assembly is crucial in producing an optimal epithermal neutron spectrum for brain tumor treatments. Based on in-phantom figures-of-merit,desirable assemblies have been identified. Experiments were performed at the Lawrence Berkeley National Laboratory's 88-inch cyclotron to characterize epithermal neutron beams created using several microampere of 2.5 MeV protons on a lithium target. The neutron moderating assembly consisted of Al/AlF3 and Teflon, with a lead reflector to produce an epithermal spectrum strongly peaked at 10-20 keV. The thermal neutron fluence was measured as a function of depth in a cubic lucite head phantom by neutron activation in gold foils. Portions of the neutron spectrum were measured by in-air activation of six cadmium-covered materials (Au, Mn, In, Cu, Co, W) with high epithermal neutron absorption resonances. The results are reasonably reproduced in Monte Carlo computational models, confirming their validity

  11. Demonstration of a high-intensity neutron source based on a liquid-lithium target for Accelerator based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Halfon, S; Arenshtam, A; Kijel, D; Paul, M; Weissman, L; Berkovits, D; Eliyahu, I; Feinberg, G; Kreisel, A; Mardor, I; Shimel, G; Shor, A; Silverman, I; Tessler, M

    2015-12-01

    A free surface liquid-lithium jet target is operating routinely at Soreq Applied Research Accelerator Facility (SARAF), bombarded with a ~1.91 MeV, ~1.2 mA continuous-wave narrow proton beam. The experiments demonstrate the liquid lithium target (LiLiT) capability to constitute an intense source of epithermal neutrons, for Accelerator based Boron Neutron Capture Therapy (BNCT). The target dissipates extremely high ion beam power densities (>3 kW/cm(2), >0.5 MW/cm(3)) for long periods of time, while maintaining stable conditions and localized residual activity. LiLiT generates ~3×10(10) n/s, which is more than one order of magnitude larger than conventional (7)Li(p,n)-based near threshold neutron sources. A shield and moderator assembly for BNCT, with LiLiT irradiated with protons at 1.91 MeV, was designed based on Monte Carlo (MCNP) simulations of BNCT-doses produced in a phantom. According to these simulations it was found that a ~15 mA near threshold proton current will apply the therapeutic doses in ~1h treatment duration. According to our present results, such high current beams can be dissipated in a liquid-lithium target, hence the target design is readily applicable for accelerator-based BNCT. Copyright © 2015 Elsevier Ltd. All rights reserved.

  12. Progress in neutron beam development at the HFR Petten (feasibility study for a BNCT facility)

    International Nuclear Information System (INIS)

    Constantine, G.; Moss, R.L.; Watkins, P.R.D.; Perks, C.A.; Delafield, H.J.; Ross, D.; Voorbraak, W.P.; Paardekooper, A.; Freudenreich, W.E.; Stecher-Rasmussen, F.

    1990-08-01

    Boron Neutron Capture Therapy, using intermediate energy neutrons to achieve the deep penetration essential for treating brain tumours, can be implemented with a filtered reactor neutron beam. This is designed to minimize the mean energy of the neutrons to keep proton recoil damage to the scalp within normal tissue tolerance limits whilst delivering the required thermal neutron fluence to the tumour over a reasonably short period. This can only be realized in conjunction with a high power density reactor. At the Joint Research Centre Petten an optimized neutron filter is currently being built for installation into the HB11 beam tube of the High Flux Reactor HFR. Part of the development leading to this design has been an extensive study of broad spectrum, filtered beam performance on the HB7 beam tube facility. A wide range of calculations was performed using the Monte Carlo code, MCPN, supported by validation experiments in which several filter configuration incorporating aluminium, sulphur, liquid argon, titanium and cadmium were installed for low power measurements of the neutron fluence rate, neutron spectra and beam gamma-ray contamination. The measurements were carried out within a successful European collaboration. Evaluations were made of the reactor core edge and unfiltered beam spectra, for comparison with MCNP calculations. Multi-foil activation methods and also gamma dose determination in the filtered beam using thermo-luminescent detectors were performed by the ECN. The Harwell/ Birmingham University collaborators undertook the neutron spectrum measurements in the filtered beam. proton recoil spectrometry was used above 30 keV, combined with a multi-sphere and BF 3 chamber response modification technique. Subsequent spectrum adjustment was carried out with the SENSAK code. The agreement between the calculated and measured spectra has given confidence in the reactor and filter modelling methods used to design the HB11 therapy facility. (author). 12 refs

  13. A shielding design for an accelerator-based neutron source for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Hawk, A.E.; Blue, T.E. E-mail: blue.1@osu.edu; Woollard, J.E

    2004-11-01

    Research in boron neutron capture therapy (BNCT) at The Ohio State University Nuclear Engineering Department has been primarily focused on delivering a high quality neutron field for use in BNCT using an accelerator-based neutron source (ABNS). An ABNS for BNCT is composed of a proton accelerator, a high-energy beam transport system, a {sup 7}Li target, a target heat removal system (HRS), a moderator assembly, and a treatment room. The intent of this paper is to demonstrate the advantages of a shielded moderator assembly design, in terms of material requirements necessary to adequately protect radiation personnel located outside a treatment room for BNCT, over an unshielded moderator assembly design.

  14. INEL BNCT Research Program annual report 1994

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1995-11-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included

  15. First clinical results from the EORTC phase I Trial ''postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility''

    International Nuclear Information System (INIS)

    Sauerwein, W.; Hideghety, K.; Rassow, J.; Devries, M.J.; Goetz, C.; Paquis, P.; Grochulla, F.; Wolbers, J.G.; Haselsberger, K.; Turowski, B.; Moss, R.L.; Stecher-Rasmussen, F.; Touw, D.; Wiestler, O.D.; Frankhauser, H.; Gabel, D.

    2001-01-01

    Based on the pre-clinical work of the European Collaboration on Boron Neutron Capture Therapy a study protocol was prepared in 1995 to initiate Boron Neutron Capture Therapy (BNCT) in patients at the High Flux Reactor (HFR) in Petten. Bio-distribution and pharmacokinetics data of the boron drug Na 2 B 12 H 11 SH (BSH) as well as the radiobiological effects of BNCT with BSH in healthy brain tissue of dogs were considered in designing the strategy for this clinical Phase I trial. The primary goal of the radiation dose escalation study is the investigation of possible adverse events due to BNCT; i.e. to establish the dose limiting toxicity and the maximal tolerated dose. The treatment is delivered in 4 fractions at a defined average boron concentration in blood. Cohorts of 10 patients are treated per dose group. The starting dose was set at 80% of the dose at which neurological symptoms occurred in preclinical dog experiments following a single fraction. After an observation period of at least 6 months, the dose is increased by 10% for the next cohort if less then three severe side effects related to the treatment occurred. The results of the first cohort are presented here. The evaluated dose level can be considered safe. (author)

  16. First clinical results from the EORTC phase I Trial ''postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility''

    Energy Technology Data Exchange (ETDEWEB)

    Sauerwein, W; Hideghety, K; Rassow, J [Department of Radiotherapy, University of Essen (Germany); Devries, M J [NDDO Oncology, Amsterdam (Netherlands); Goetz, C [Neurochirurgische Klinik, Klinikum Grosshadern Muenchen, Munich (Germany); Paquis, P [Dept. de Neurochirurgie, Hopital Pasteur, Nice (France); Grochulla, F [Klinik fuer Neurochirurgie, Zentralkrankenhaus Bremen (Germany); Wolbers, J G [Department of Neurosurgery, University Hospital ' ' Vrije Universiteit' ' , Amsterdam (Netherlands); Haselsberger, K [Klinik fuer Neurochirurgie, Karl-Franzens-Universitaet, Graz (Austria); Turowski, B [Institut fuer Neuroradiologie, Johann-Wolfgang-von-Goethe-Universitaet, Frankfurt (Germany); Moss, R L [HFR Unit, Joint Research Centre, European Commission, Petten (Netherlands); Stecher-Rasmussen, F [Nuclear Research and Consultancy Group NRG, Petten (Netherlands); Touw, D [Pharmacy, University/Academic Hospital ' ' Vrije Universiteit' ' , Amsterdam (Netherlands); Wiestler, O D [Department of Neuropathology, German Brain Tumour Reference Centre, Universitaetsklinikum Bonn (Germany); Frankhauser, H [Service de Neurochirurgie CHUV, Lausanne (Switzerland); Gabel, D [Chemistry Department, University of Bremen (Germany)

    2001-05-01

    Based on the pre-clinical work of the European Collaboration on Boron Neutron Capture Therapy a study protocol was prepared in 1995 to initiate Boron Neutron Capture Therapy (BNCT) in patients at the High Flux Reactor (HFR) in Petten. Bio-distribution and pharmacokinetics data of the boron drug Na{sub 2}B{sub 12}H{sub 11}SH (BSH) as well as the radiobiological effects of BNCT with BSH in healthy brain tissue of dogs were considered in designing the strategy for this clinical Phase I trial. The primary goal of the radiation dose escalation study is the investigation of possible adverse events due to BNCT; i.e. to establish the dose limiting toxicity and the maximal tolerated dose. The treatment is delivered in 4 fractions at a defined average boron concentration in blood. Cohorts of 10 patients are treated per dose group. The starting dose was set at 80% of the dose at which neurological symptoms occurred in preclinical dog experiments following a single fraction. After an observation period of at least 6 months, the dose is increased by 10% for the next cohort if less then three severe side effects related to the treatment occurred. The results of the first cohort are presented here. The evaluated dose level can be considered safe. (author)

  17. Accelerator Based Neutron Beams for Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Yanch, Jacquelyn C.

    2003-01-01

    The DOE-funded accelerator BNCT program at the Massachusetts Institute of Technology has resulted in the only operating accelerator-based epithermal neutron beam facility capable of generating significant dose rates in the world. With five separate beamlines and two different epithermal neutron beam assemblies installed, we are currently capable of treating patients with rheumatoid arthritis in less than 15 minutes (knee joints) or 4 minutes (finger joints) or irradiating patients with shallow brain tumors to a healthy tissue dose of 12.6 Gy in 3.6 hours. The accelerator, designed by Newton scientific Incorporated, is located in dedicated laboratory space that MIT renovated specifically for this project. The Laboratory for Accelerator Beam Applications consists of an accelerator room, a control room, a shielded radiation vault, and additional laboratory space nearby. In addition to the design, construction and characterization of the tandem electrostatic accelerator, this program also resulted in other significant accomplishments. Assemblies for generating epithermal neutron beams were designed, constructed and experimentally evaluated using mixed-field dosimetry techniques. Strategies for target construction and target cooling were implemented and tested. We demonstrated that the method of submerged jet impingement using water as the coolant is capable of handling power densities of up to 6 x 10(sup 7) W/m(sup 2) with heat transfer coefficients of 10(sup 6)W/m(sup 2)-K. Experiments with the liquid metal gallium demonstrated its superiority compared with water with little effect on the neutronic properties of the epithermal beam. Monoenergetic proton beams generated using the accelerator were used to evaluate proton RBE as a function of LET and demonstrated a maximum RBE at approximately 30-40 keV/um, a finding consistent with results published by other researchers. We also developed an experimental approach to biological intercomparison of epithermal beams and

  18. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Bergueiro, J.; Igarzabal, M.; Suarez Sandin, J.C.; Somacal, H.R.; Thatar Vento, V.; Huck, H.; Valda, A.A.; Repetto, M.

    2011-01-01

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes.

  19. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Bergueiro, J. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Buenos Aires (Argentina); Igarzabal, M.; Suarez Sandin, J.C. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina); Somacal, H.R. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Thatar Vento, V. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Buenos Aires (Argentina); Huck, H.; Valda, A.A. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Repetto, M. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)

    2011-12-15

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes.

  20. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Bergueiro, J; Igarzabal, M; Sandin, J C Suarez; Somacal, H R; Vento, V Thatar; Huck, H; Valda, A A; Repetto, M; Kreiner, A J

    2011-12-01

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes. Copyright © 2011 Elsevier Ltd. All rights reserved.

  1. Employment of MCNP in the study of TLDS 600 and 700 seeking the implementation of radiation beam characterization of BNCT facility at IEA-R1

    International Nuclear Information System (INIS)

    Cavalieri, Tassio Antonio

    2013-01-01

    Boron Neutron Capture Therapy, BNCT, is a bimodal radiotherapy procedure for cancer treatment. Its useful energy comes from a nuclear reaction driven by impinging thermal neutron upon Boron 10 atoms. A BNCT research facility has been constructed in IPEN at the IEA-R1 reactor, to develop studies in this area. One of its prime experimental parameter is the beam dosimetry which is nowadays made by using activation foils, for neutron measurements, and TLD 400, for gamma dosimetry. For mixed field dosimetry, the International Commission on Radiation Units and Measurements, ICRU, recommends the use of pair of detectors with distinct responses to the field components. The TLD 600/ TLD 700 pair meets this criteria, as the amount of 6 Li, a nuclide with high thermal neutron cross section, greatly differs in their composition. This work presents a series of experiments and simulations performed in order to implement the mixed field dosimetry based on the use of TLD 600/TLD 700 pair. It also intended to compare this mixed field dosimetric methodology to the one so far used by the BNCT research group of IPEN. The response of all TLDs were studied under irradiations in different irradiation fields and simulations, underwent by MCNP, were run in order to evaluate the dose contribution from each field component. Series of repeated irradiations under pure gamma field and mixed field neutron/gamma field showed differences in the TLD individual responses which led to the adoption of a Normalization Factor. It has allowed to overcome TLD selection. TLD responses due to different field components and spectra were studied. It has shown to be possible to evaluate the relative gamma/neutron fluxes from the relative responses observed in the two Regions of Interest, ROIs, from TLD 600 and TLD 700. It has also been possible to observe the TLD 700 response to neutron, which leads to a gamma dose overestimation when one follows the ICRU recommended mixed field dosimetric procedure. Dose

  2. An epithermal neutron source for BNCT based on an ESQ-accelerator

    International Nuclear Information System (INIS)

    Ludewigt, B.A.; Chu, W.T.; Donahue, R.J.; Kwan, J.; Phillips, T.L.; Reginato, L.L.; Wells, R.P.

    1997-07-01

    An accelerator-based BNCT facility is under development at the Lawrence Berkeley National Laboratory. Neutrons will be produced via the 7 Li(p,n) reaction at proton energies of about 2.5 MeV with subsequent moderation and filtering for shaping epithermal neutron beams for BNCT. Moderator, filter, and shielding assemblies have been modeled using MCNP. Head-phantom dose distributions have been calculated using the treatment planning software BNCT RTPE. The simulation studies have shown that a proton beam current of ∼ 20 mA is required to deliver high quality brain treatments in about 40 minutes. The results also indicate that significantly higher doses can be delivered to deep-seated tumors in comparison to the Brookhaven Medical Research Reactor beam. An electrostatic quadrupole (ESQ) accelerator is ideally suited to provide the high beam currents desired. A novel power supply utilizing the air-coupled transformer concept is under development. It will enable the ESQ-accelerator to deliver proton beam currents exceeding 50 mA. A lithium target has been designed which consists of a thin layer of lithium on an aluminum backing. Closely spaced, narrow coolant passages cut into the aluminum allow the removal of a 50kW heat-load by convective water cooling. The system under development is suitable for hospital installation and has the potential for providing neutron beams superior to reactor sources

  3. Tandem-ESQ for Accelerator-Based BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Kwan, J.W.; Burlon, A.A.; Di Paolo, H.; Henestroza, E.; Minsky, D.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.

    2006-01-01

    A new ultrahigh-resolution photoemission electron microscope called PEEM3 is being developed and built at the Advanced Light Source (ALS). An electron mirror combined with a much-simplified magnetic dipole separator is to be used to provide simultaneous correction of spherical and chromatic aberrations. It is installed on an elliptically polarized undulator (EPU) beamline, and will be operated with very high spatial resolution and high flux to study the composition, structure, electric and magnetic properties of complex materials. The instrument has been designed and is described. The instrumental hardware is being deployed in 2 phases. The first phase is the deployment of a standard PEEM type microscope consisting of the standard linear array of electrostatic electron lenses. The second phase will be the installation of the aberration corrected upgrade to improve resolution and throughput. This paper describes progress as the instrument enters the commissioning part of the first phase

  4. Monte Carlo simulation of neutron irradiation facility developed for accelerator based in vivo neutron activation measurements in human hand bones

    International Nuclear Information System (INIS)

    Aslam; Prestwich, W.V.; McNeill, F.E.; Waker, A.J.

    2006-01-01

    The neutron irradiation facility developed at the McMaster University 3 MV Van de Graaff accelerator was employed to assess in vivo elemental content of aluminum and manganese in human hands. These measurements were carried out to monitor the long-term exposure of these potentially toxic trace elements through hand bone levels. The dose equivalent delivered to a patient during irradiation procedure is the limiting factor for IVNAA measurements. This article describes a method to estimate the average radiation dose equivalent delivered to the patient's hand during irradiation. The computational method described in this work augments the dose measurements carried out earlier [Arnold et al., 2002. Med. Phys. 29(11), 2718-2724]. This method employs the Monte Carlo simulation of hand irradiation facility using MCNP4B. Based on the estimated dose equivalents received by the patient hand, the proposed irradiation procedure for the IVNAA measurement of manganese in human hands [Arnold et al., 2002. Med. Phys. 29(11), 2718-2724] with normal (1 ppm) and elevated manganese content can be carried out with a reasonably low dose of 31 mSv to the hand. Sixty-three percent of the total dose equivalent is delivered by non-useful fast group (>10 keV); the filtration of this neutron group from the beam will further decrease the dose equivalent to the patient's hand

  5. Current status of accelerator-based boron neutron capture therapy

    International Nuclear Information System (INIS)

    Kreiner, A. J.; Bergueiro, J.; Di Paolo, H.; Castell, W.; Vento, V. Thatar; Cartelli, D.; Kesque, J.M.; Valda, A.A.; Ilardo, J.C.; Baldo, M.; Erhardt, J.; Debray, M.E.; Somacal, H.R.; Estrada, L.; Sandin, J.C. Suarez; Igarzabal, M.; Huck, H.; Padulo, J.; Minsky, D.M.

    2011-01-01

    The direct use of proton and heavy ion beams for radiotherapy is a well established cancer treatment modality, which is becoming increasingly widespread due to its clear advantages over conventional photon-based treatments. This strategy is suitable when the tumor is spatially well localized. Also the use of neutrons has a long tradition. Here Boron Neutron Capture Therapy (BNCT) stands out, though on a much smaller scale, being a second-generation promising alternative for tumors which are diffuse and infiltrating. On this sector, so far only nuclear reactors have been used as neutron sources. In this paper we describe the current situation worldwide as far as the use of accelerator-based neutron sources for BNCT is concerned (so-called Accelerator-Based (AB)-BNCT). In particular we discuss the present status of an ongoing project to develop a folded Tandem-ElectroStatic-Quadrupole (TESQ) accelerator at the Atomic Energy Commission of Argentina. The project goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams to perform BNCT for deep-seated tumors in less than an hour. (author)

  6. An Accelerator Neutron Source for BNCT

    International Nuclear Information System (INIS)

    Blue, Thomas E.

    2006-01-01

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were (1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, (2) that the patient treatment time be reasonable, (3) that the proton current required to treat patients in reasonable times be technologically achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally (4) that the treatment be safe for the patients

  7. An Accelerator Neutron Source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Blue, Thomas, E

    2006-03-14

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were 1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, 2) that the patient treatment time be reasonable, 3) that the proton current required to treat patients in reasonable times be technologially achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally 4) that the treatment be safe for the patients.

  8. The studsvik BNCT project: structure and the proposed protocols

    International Nuclear Information System (INIS)

    Capala, J.; Stenstam, B.H.; Skoeld, K.; Henriksson, R.; Salford, L.; Carlsson, J.

    2000-01-01

    The BNCT facility at Studsvik is now ready for clinical trials. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of all major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia and to assure the quality of the research. Proposed clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, initially, will involve two protocols: Protocol no.1. BNCT for glioblastoma patients who have not received any therapy other than surgery (including stereotactic biopsy only). Protocol no.2. BNCT as a palliative treatment for patients with recurrent glioblastoma following conventional therapies or BNCT. In both protocols, BPA, administered by a 6 hour i.v. infusion, will be used as the boron delivery agent. (author)

  9. BNCT Technology Development on HANARO Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Chun, Ki Jung; Park, Kyung Bae; Whang, Seung Ryul; Kim, Myong Seop

    2007-06-15

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented.

  10. BNCT Technology Development on HANARO Reactor

    International Nuclear Information System (INIS)

    Chun, Ki Jung; Park, Kyung Bae; Whang, Seung Ryul; Kim, Myong Seop

    2007-06-01

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented

  11. INEL BNCT Program: Volume 5, No. 9

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-01-01

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  12. INEL BNCT Research Program annual report 1994

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1995-11-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included. Selected papers have been indexed separately for inclusion in the Energy Science and Technology Database.

  13. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

    Science.gov (United States)

    Blue, Thomas E; Yanch, Jacquelyn C

    2003-01-01

    This paper reviews the development of low-energy light ion accelerator-based neutron sources (ABNSs) for the treatment of brain tumors through an intact scalp and skull using boron neutron capture therapy (BNCT). A major advantage of an ABNS for BNCT over reactor-based neutron sources is the potential for siting within a hospital. Consequently, light-ion accelerators that are injectors to larger machines in high-energy physics facilities are not considered. An ABNS for BNCT is composed of: (1) the accelerator hardware for producing a high current charged particle beam, (2) an appropriate neutron-producing target and target heat removal system (HRS), and (3) a moderator/reflector assembly to render the flux energy spectrum of neutrons produced in the target suitable for patient irradiation. As a consequence of the efforts of researchers throughout the world, progress has been made on the design, manufacture, and testing of these three major components. Although an ABNS facility has not yet been built that has optimally assembled these three components, the feasibility of clinically useful ABNSs has been clearly established. Both electrostatic and radio frequency linear accelerators of reasonable cost (approximately 1.5 M dollars) appear to be capable of producing charged particle beams, with combinations of accelerated particle energy (a few MeV) and beam currents (approximately 10 mA) that are suitable for a hospital-based ABNS for BNCT. The specific accelerator performance requirements depend upon the charged particle reaction by which neutrons are produced in the target and the clinical requirements for neutron field quality and intensity. The accelerator performance requirements are more demanding for beryllium than for lithium as a target. However, beryllium targets are more easily cooled. The accelerator performance requirements are also more demanding for greater neutron field quality and intensity. Target HRSs that are based on submerged-jet impingement and

  14. Dose estimation of the THOR BNCT treatment room

    International Nuclear Information System (INIS)

    Hsu, F.Y.; Liu, H.M.; Yu, C.C.; Huang, Y.H.; Tsai, H.N.

    2006-01-01

    BNCT beam of Tsing Hua Open-pool Reactor (THOR) was designed and constructed since 1998. A treatment room for the newly modified THOR BNCT beam was constructed for the next clinical-stage trials in 2004. Dose distribution in a patient (or a phantom) is important as irradiated with the BNCT beam. The dose distributions for different type of radiations such as neutron and photons in the treatment room are strongly becoming the index or reference of success for a BNCT facility. An ART head phantom was placed in front of the THOR BNCT beam port and was irradiated. In each section of the head phantom, numbers of small holes are inside and separated uniformly. Dual detector: TLD-600 and TLD-700 chips were placed inside these holes within the phantom to distinct doses of neutron and photon. Besides, Dual-TLD chips were latticed placed in the horizontal plane of beam central axis, in the treatment room to estimate the spatial dose distribution of neutron and photon. Gold foils were assisted in TLD dose calibrations. Neutron and photon dose distributions in phantom and spatial dose distributions in the THOR BNCT treatment room were both estimated in this work. Testing and improvement in THOR BNCT beam were continuative during these years. Results of this work could be the reference and be helpful for the further clinical trials in nearly future. (author)

  15. New EORTC clinical trials for BNCT

    International Nuclear Information System (INIS)

    Hideghety, K.; Moss, R.; Vries, M. de

    2000-01-01

    Due to ethical reasons, a separated optimization of the two components of BNCT in the frame of clinical investigations can only be performed applying the whole binary system. The ongoing trial at HFR (High Flux Reactor Petten) has proven the feasibility of BNCT under defined conditions. On that basis the European Commission supported a comprehensive research project on boron imaging including three further clinical studies. In the first trial the boron uptake related to the blood boron concentration and surrounding normal tissue in various solid tumours will be examined using BSH (Sodiumborocaptate), BPA (Boronophenylalanine) or both in order to explore tumour entities, which may gain benefit from BNCT. The major objectives of the second trial are to define the maximum tolerated single and cumulative dose, and the dose limiting toxicity of BSH. The third clinical trial, a phase II study is designed to evaluate the anti-tumour effect of fractionated BNCT at the Petten treatment facility against cerebral metastasis of malignant melanoma using BPA. (author)

  16. BNCT-RTPE: BNCT radiation treatment planning environment

    International Nuclear Information System (INIS)

    Wessol, D.E.; Wheeler, F.J.; Babcock, R.S.

    1995-01-01

    Several improvements have been developed for the BNCT radiation treatment planning environment (BNCT-Rtpe) during 1994. These improvements have been incorporated into Version 1.0 of BNCT-Rtpe which is currently installed at the INEL, BNL, Japanese Research Center (JRC), and Finland's Technical Research Center. Platforms supported by this software include Hewlett-Packard (HP), SUN, International Business Machines (IBM), and Silicon Graphics Incorporated (SGI). A draft version of the BNCT-Rtpe user manual is available. Version 1.1 of BNCT-Rtpe is scheduled for release in March 1995. It is anticipated that Version 2.x of BNCT-Rtpe, which includes the nonproprietary NURBS library and data structures, will be released in September 1995

  17. Requirements for BNCT at a nuclear research reactor. Results from a BNCT workshop organized by the European Commission in Prague, November 2005

    International Nuclear Information System (INIS)

    Moss, Ray; Sauerwein, Wolfgang; Wittig, Andrea; Burian, Jiri

    2006-01-01

    As part of the European Commission's Enlargement and Integration Action (E and IA), which is intended to improve exchange and relationship within the extended European Union (EU), a Workshop was organized in Prague in November 2005. The purpose of the workshop was to present and discuss technical and organisational requirements in setting up a BNCT facility at a research reactor. Topics included: treatment of a patient by BNCT; organisational aspects and regulatory affairs; BNCT from the nuclear perspective and BNCT from the clinician's perspective. Presentations were given by BNCT experts in their particular field, whilst eleven different national nuclear research centres from the New Member States and Accession Countries, interested in developing a BNCT programme, presented the status of their preparations. The conclusions of the Workshop were that an early and close collaboration between nuclear and medical groups is the basis for BNCT, that a local effort to build a BNCT facility should be supported by a national research programme including basic and clinical science and that the JRC and its partners are ready to support national initiatives within the EU and candidate countries. (author)

  18. Employment of MCNP in the study of TLDS 600 and 700 seeking the implementation of radiation beam characterization of BNCT facility at IEA-R1; Emprego do MCNP no estudo dos TLDS 600 e 700 visando a implementacao da caracterizacao do feixe de irradiacao da instalacao de BNCT do IEA-R1

    Energy Technology Data Exchange (ETDEWEB)

    Cavalieri, Tassio Antonio

    2013-07-01

    Boron Neutron Capture Therapy, BNCT, is a bimodal radiotherapy procedure for cancer treatment. Its useful energy comes from a nuclear reaction driven by impinging thermal neutron upon Boron 10 atoms. A BNCT research facility has been constructed in IPEN at the IEA-R1 reactor, to develop studies in this area. One of its prime experimental parameter is the beam dosimetry which is nowadays made by using activation foils, for neutron measurements, and TLD 400, for gamma dosimetry. For mixed field dosimetry, the International Commission on Radiation Units and Measurements, ICRU, recommends the use of pair of detectors with distinct responses to the field components. The TLD 600/ TLD 700 pair meets this criteria, as the amount of {sup 6}Li, a nuclide with high thermal neutron cross section, greatly differs in their composition. This work presents a series of experiments and simulations performed in order to implement the mixed field dosimetry based on the use of TLD 600/TLD 700 pair. It also intended to compare this mixed field dosimetric methodology to the one so far used by the BNCT research group of IPEN. The response of all TLDs were studied under irradiations in different irradiation fields and simulations, underwent by MCNP, were run in order to evaluate the dose contribution from each field component. Series of repeated irradiations under pure gamma field and mixed field neutron/gamma field showed differences in the TLD individual responses which led to the adoption of a Normalization Factor. It has allowed to overcome TLD selection. TLD responses due to different field components and spectra were studied. It has shown to be possible to evaluate the relative gamma/neutron fluxes from the relative responses observed in the two Regions of Interest, ROIs, from TLD 600 and TLD 700. It has also been possible to observe the TLD 700 response to neutron, which leads to a gamma dose overestimation when one follows the ICRU recommended mixed field dosimetric procedure. Dose

  19. SERA -- An advanced treatment planning system for neutron therapy and BNCT

    International Nuclear Information System (INIS)

    Nigg, D.W.; Wemple, C.A.; Wessol, D.E.; Wheeler, F.J.; Albright, C.; Cohen, M.; Frandsen, M.; Harkin, G.; Rossmeier, M.

    1999-01-01

    Detailed treatment planning calculations on a patient-specific basis are required for boron neutron capture therapy (BNCT). Two integrated treatment planning systems developed specifically for BNCT have been in clinical use in the United States over the past few years. The MacNCTPLAN BNCT treatment planning system is used in the clinical BNCT trials that are underway at the Massachusetts Institute of Technology. A second system, BNCT rtpe (BNCT radiation therapy planning environment), developed independently by the Idaho national Engineering and Environmental Laboratory (INEEL) in collaboration with Montana State University (MSU), is used for treatment planning in the current series of BNCT clinical trials for glioblastoma at Brookhaven National Laboratory (BNL). This latter system is also licensed for use at several other BNCT research facilities worldwide. Although the currently available BNCT planning systems have served their purpose well, they suffer from somewhat long computation times (2 to 3 CPU-hours or more per field) relative to standard photon therapy planning software. This is largely due to the need for explicit three-dimensional solutions to the relevant transport equations. The simplifying approximations that work well for photon transport computations are not generally applicable to neutron transport computations. Greater computational speeds for BNCT treatment planning must therefore generally be achieved through the application of improved numerical techniques rather than by simplification of the governing equations. Recent efforts at INEEL and MSU have been directed toward this goal. This has resulted in a new paradigm for this type of calculation and the subsequent creation of the new simulation environment for radiotherapy applications (SERA) treatment planning system for BNCT. SERA is currently in initial clinical testing in connection with the trials at BNL, and it is expected to replace the present BNCT rtpe system upon general release

  20. High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases

    Energy Technology Data Exchange (ETDEWEB)

    Halfon, S. [Soreq NRC, Yavne 81800 (Israel); Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel)], E-mail: halfon@phys.huji.ac.il; Paul, M. [Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel); Steinberg, D. [Biofilm Laboratory, Institute of Dental Sciences, Faculty of Dentistry, Hebrew University-Hadassah (Israel); Nagler, A.; Arenshtam, A.; Kijel, D. [Soreq NRC, Yavne 81800 (Israel); Polacheck, I. [Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center (Israel); Srebnik, M. [Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Hebrew University, Jerusalem 91120 (Israel)

    2009-07-15

    A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction {sup 7}Li(p,n){sup 7}Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.

  1. Additive effect of BPA and Gd-DTPA for application in accelerator-based neutron source

    International Nuclear Information System (INIS)

    Yoshida, F.; Yamamoto, T.; Nakai, K.; Zaboronok, A.; Matsumura, A.

    2015-01-01

    Because of its fast metabolism gadolinium as a commercial drug was not considered to be suitable for neutron capture therapy. We studied additive effect of gadolinium and boron co-administration using colony forming assay. As a result, the survival of tumor cells with additional 5 ppm of Gd-DTPA decreased to 1/10 compared to the cells with boron only. Using gadolinium to increase the effect of BNCT instead of additional X-ray irradiation might be beneficial, as such combination complies with the short-time irradiation regimen at the accelerator-based neutron source. - Highlights: • Gd-DTPA is widely clinically used as a contrast medium for MRI. • Shift to an accelerator-based neutron source is advantageous for gadolinium NCT. • Boron–gadolinium NCT effects on tumor cell lines were significant. • Additional administration of Gd-DTPA might enhance the effect of BPA–BNCT.

  2. BNCT Project at the J. Stefan TRIGA Reactor

    International Nuclear Information System (INIS)

    Glumac, B.; Maucec, M.; Jeraj, R.; Kodeli, I.

    1994-01-01

    Contribution presents condensed description of the BNCT method, as one of the most promising methods of cancer radio therapy in the future. Certain planned research activities considering realization of BNCT project in Slovenia are also shown. Modelling of irradiation facility as well as mathematical simulation of neutron and photon transport are completely performed by Monte Carlo computer simulation, and for that reason some basic characteristics and capabilities of MCNP4A computer code are also presented. Finally, some results obtained up to this time are presented. (author)

  3. INEL BNCT Program: Volume 5, No. 9. Bulletin, September 1991

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. [ed.

    1991-12-31

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory`s (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  4. High-power liquid-lithium target prototype for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Bisyakoev, M; Eliyahu, I; Feinberg, G; Hazenshprung, N; Kijel, D; Nagler, A; Silverman, I

    2011-12-01

    A prototype of a compact Liquid-Lithium Target (LiLiT), which will possibly constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals, was built. The LiLiT setup is presently being commissioned at Soreq Nuclear Research Center (SNRC). The liquid-lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power generated using a high-intensity proton beam (>10 kW), necessary for sufficient neutron flux. In off-line circulation tests, the liquid-lithium loop generated a stable lithium jet at high velocity, on a concave supporting wall; the concept will first be tested using a high-power electron beam impinging on the lithium jet. High intensity proton beam irradiation (1.91-2.5 MeV, 2-4 mA) will take place at Soreq Applied Research Accelerator Facility (SARAF) superconducting linear accelerator currently in construction at SNRC. Radiological risks due to the (7)Be produced in the reaction were studied and will be handled through a proper design, including a cold trap and appropriate shielding. A moderator/reflector assembly is planned according to a Monte Carlo simulation, to create a neutron spectrum and intensity maximally effective to the treatment and to reduce prompt gamma radiation dose risks. Copyright © 2011 Elsevier Ltd. All rights reserved.

  5. Research of accelerator-based neutron source for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Li Changkai; Ma Yingjie; Tang Xiaobin; Xie Qin; Geng Changran; Chen Da

    2013-01-01

    Background: 7 Li (p, n) reaction of high neutron yield and low threshold energy has become one of the most important neutron generating reactions for Accelerator-based Boron Neutron Capture Therapy (BNCT). Purpose Focuses on neutron yield and spectrum characteristics of this kind of neutron generating reaction which serves as an accelerator-based neutron source and moderates the high energy neutron beams to meet BNCT requirements. Methods: The yield and energy spectrum of neutrons generated by accelerator-based 7 Li(p, n) reaction with incident proton energy from 1.9 MeV to 3.0 MeV are researched using the Monte Carlo code-MCNPX2.5.0. And the energy and angular distribution of differential neutron yield by 2.5-MeV incident proton are also given in this part. In the following part, the character of epithermal neutron beam generated by 2.5-MeV incident protons is moderated by a new-designed moderator. Results: Energy spectra of neutrons generated by accelerator-based 7 Li(p, n) reaction with incident proton energy from 1.9 MeV to 3.0 MeV are got through the simulation and calculation. The best moderator thickness is got through comparison. Conclusions: Neutron beam produced by accelerator-based 7 Li(p, n) reaction, with the bombarding beam of 10 mA and the energy of 2.5 MeV, can meet the requirement of BNCT well after being moderated. (authors)

  6. Preliminary energy-filtering neutron imaging with time-of-flight method on PKUNIFTY: A compact accelerator based neutron imaging facility at Peking University

    Energy Technology Data Exchange (ETDEWEB)

    Wang, Hu; Zou, Yubin, E-mail: zouyubin@pku.edu.cn; Wen, Weiwei; Lu, Yuanrong; Guo, Zhiyu

    2016-07-01

    Peking University Neutron Imaging Facility (PKUNIFTY) works on an accelerator–based neutron source with a repetition period of 10 ms and pulse duration of 0.4 ms, which has a rather low Cd ratio. To improve the effective Cd ratio and thus improve the detection capability of the facility, energy-filtering neutron imaging was realized with the intensified CCD camera and time-of-flight (TOF) method. Time structure of the pulsed neutron source was firstly simulated with Geant4, and the simulation result was evaluated with experiment. Both simulation and experiment results indicated that fast neutrons and epithermal neutrons were concentrated in the first 0.8 ms of each pulse period; meanwhile in the period of 0.8–2.0 ms only thermal neutrons existed. Based on this result, neutron images with and without energy filtering were acquired respectively, and it showed that detection capability of PKUNIFTY was improved with setting the exposure interval as 0.8–2.0 ms, especially for materials with strong moderating capability.

  7. Accelerator-based pulsed cold neutron source

    International Nuclear Information System (INIS)

    Inoue, Kazuhiko; Iwasa, Hirokatsu; Kiyanagi, Yoshiaki

    1979-01-01

    An accelerator-based pulsed cold neutron source was constructed. The accelerator is a 35 MeV electron linear accelerator with 1 kW average beam power. The cold neutron beam intensity at a specimen is equivalent to that of a research reactor of 10 14 n/cm 2 .s thermal flux in the case of the quasi-elastic neutron scattering measurements. In spite of some limitations to the universal uses, it has been demonstrated by this facility that the modest capacity accelerator-based pulsed cold neutron source is a highly efficient cold neutron source with low capital investment. Design philosophy, construction details, performance and some operational experiences are described. (author)

  8. BNCT of canine osteosarcoma

    International Nuclear Information System (INIS)

    Mitin, V.N.; Kulakov, V.N.; Khokhlov, V.F.

    2006-01-01

    A dog was diagnosed with osteosarcoma (8x6x5cm) in the right wing of ilium by radiography, radionuclide scintigraphy and histological study of biopsy material. The treatment plan was as follows: γ-therapy in combination with chemotherapy; prevention of hematogenous pulmonary metastases by the transfusion of 130 ml of allogenic marrow from a healthy donor; administration of 11.4g 10 B-boronphenylalanine into the right iliac artery; resection of the right iliac wing with the osteosarcoma lesion; neutron irradiation (MEPhI Reactor) of the bone fragment (dose on healthy osteocytes - 15±4 Gy (W), on tumor - 50±9 Gy (W); reimplantation and fixation of the fragment; three courses of adjuvant chemotherapy. The doses were determined in full-scale calculations of the reactor radiation fields with a model of the bone under the code RADUGA. The 10 B concentration (μg/g) in the bone was: normal tissue - 9±3, tumor - 28±5. In 24 hours post operation the dog was able to walk using the treated limb, and 6 months later it moved freely. The patient has been under observation for 30 months. The results of the research demonstrate complete cure. The use of similar treatment plans improves the therapeutic efficiency of BNCT. (author)

  9. Qualitative safety analysis in accelerator based systems

    International Nuclear Information System (INIS)

    Sarkar, P.K.; Chowdhury, Lekha M.

    2006-01-01

    In recent developments connected to high energy and high current accelerators, the accelerator driven systems (ADS) and the Radioactive Ion Beam (RIB) facilities come in the forefront of application. For medical and industrial applications high current accelerators often need to be located in populated areas. These facilities pose significant radiological hazard during their operation and accidental situations. We have done a qualitative evaluation of radiological safety analysis using the probabilistic safety analysis (PSA) methods for accelerator-based systems. The major contribution to hazard comes from a target rupture scenario in both ADS and RIB facilities. Other significant contributors to hazard in the facilities are also discussed using fault tree and event tree methodologies. (author)

  10. INEL BNCT research program: Annual report, 1995

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1996-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented

  11. INEL BNCT research program: Annual report, 1995

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1996-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented.

  12. Study of a neutron producing target via the 7Li(p,n)7Be reaction near its energy threshold for BNCT (boron neutron capture therapy)

    International Nuclear Information System (INIS)

    Burlon, Alejandro; Kreiner, Andres J.; Debray, Mario E.; Stoliar, Pablo; Kesque, Jose M.; Naab, Fabian; Ozafran, Mabel J.; Schuff, Juan; Vazquez, Monica; Caraballo, Maria E.; Valda, Alejandro; Somacal, Hector; Davidson, Miguel; Davidson, Jorge

    2000-01-01

    In the framework of Accelerator Based BNCT (AB-BNCT) the 7 Li(p,n) 7 Be reaction near its energy threshold is one of the most promising. In this work a thick LiF target irradiated with a proton beam was studied as a neutron source. The 1.88-2.0 MeV proton beam was produced by the tandem accelerator TANDAR at CNEA's facilities in Buenos Aires. A water-filled phantom, containing a boron sample was irradiated with the resulting neutron beam. The boron neutron capture reaction produces a 0.478 MeV gamma ray in 94 % of the cases. The neutron yield was monitored by detecting this gamma ray using a germanium detector with an 'anti-Compton' shield. Moreover, the thermal neutron flux was evaluated at different depths inside the phantom using bare and Cd-covered gold foils. A maximum neutron thermal flux of 1.4 x 10 8 1/(cm 2 -s-mA) was obtained at 4.2 cm from the phantom surface. (author)

  13. The BNCT project in the Czech Republic

    International Nuclear Information System (INIS)

    Burian, J.; Marek, M.; Rataj, J.; Honova, H.; Petruzelka, L.; Prokes, K.; Tovarys, F.; Dbaly, V.; Honzatko, J.; Tomandl, I.

    2000-01-01

    The start of clinical trials is expected before NCT Osaka 2000. The experiences from different part of project are presented. The BNCT facility at LVR-15 reactor of NRI consists of epithermal neutron beam with improved construction (6.98 x 10 8 /cm 2 s with acceptable background of fast neutrons and gammas) and irradiation and control rooms equipped by appropriate devices. Internationally-recognized software MacNCTPLAN is utilized for computational dosimetry and treatment planning. In the part of protocol the following parameters have been assessed: patient selection, BSH dosage, fractionation, starting dose, dose escalation steps. At the LVR-15, at horizontal channel, a prompt gamma ray analysis (PGRA) system has been developed and is operated for BNCT purposes. Some human blood samples were analyzed and compared with classical ICP method. During the process of licensing the experience was obtained, some notes are discussed in the paper. The first results were received for the study of biological effect of the LVR source for small animal model. (author)

  14. Improvement of neutron irradiation field of research reactors for BNCT

    International Nuclear Information System (INIS)

    Aizawa, Otohiko

    1992-01-01

    The modification of research reactors for an improvement of the irradiation field for BNCT has been investigated in comparison with the field characteristics of the 'old' configuration at the Musashi reactor. The new point of this study is that the evaluation has been done by using an arrangement including both the facility structure and a whole-body phantom, and also by considering the whole-body absorbed dose. (author)

  15. An accelerator based steady state neutron source

    International Nuclear Information System (INIS)

    Burke, R.J.; Johnson, D.L.

    1985-01-01

    Using high current, c.w. linear accelerator technology, a spallation neutron source can achieve much higher average intensities than existing or proposed pulsed spallation sources. With about 100 mA of 300 MeV protons or deuterons, the Accelerator Based Neutron Research Facility (ABNR) would initially achieve the 10 16 n/cm 2 .s thermal flux goal of the advanced steady state neutron source, and upgrading could provide higher steady state fluxes. The relatively low ion energy compared to other spallation sources has an important impact on R and D requirements as well as capital cost, for which a range of $300-450M is estimated by comparison to other accelerator-based neutron source facilities. The source is similar to a reactor source in most respects. It has some higher energy neutrons but fewer gamma rays, and the moderator region is free of many of the design constraints of a reactor, which helps to implement sources for various neutron energy spectra, many beam tubes, etc. With the development of multi-beam concept and the basis for currents greater than 100 mA that is assumed in the R and D plan, the ABNR would serve many additional uses, such as fusion materials development, production of proton-rich isotopes, and other energy and defense program needs

  16. Mock-up experiment at Birmingham University for BNCT project of Osaka University – Neutron flux measurement with gold foil

    International Nuclear Information System (INIS)

    Tamaki, S.; Sakai, M.; Yoshihashi, S.; Manabe, M.; Zushi, N.; Murata, I.; Hoashi, E.; Kato, I.; Kuri, S.; Oshiro, S.; Nagasaki, M.; Horiike, H.

    2015-01-01

    Mock-up experiment for development of accelerator based neutron source for Osaka University BNCT project was carried out at Birmingham University, UK. In this paper, spatial distribution of neutron flux intensity was evaluated by foil activation method. Validity of the design code system was confirmed by comparing measured gold foil activities with calculations. As a result, it was found that the epi-thermal neutron beam was well collimated by our neutron moderator assembly. Also, the design accuracy was evaluated to have less than 20% error. - Highlights: • Accelerator based neutron source for BNCT is being developed in Osaka University. • Mock-up experiment was carried out at Birmingham University, UK. • Neutronics performance of our assembly was evaluated from gold foil activation. • Gold foil activation was determined by using HPGe detectors. • Validity of the neutronics design code system was confirmed.

  17. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Mitchell, Hannah E. [Georgia Inst. of Technology, Atlanta, GA (United States)

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 107 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF3 composite and a stacked Al/Teflon design) at various incident electron energies.

  18. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Mitchell, H.E.

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 10 7 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF 3 composite and a stacked Al/Teflon design) at various incident electron energies

  19. Simulation study of accelerator based quasi-mono-energetic epithermal neutron beams for BNCT.

    Science.gov (United States)

    Adib, M; Habib, N; Bashter, I I; El-Mesiry, M S; Mansy, M S

    2016-01-01

    Filtered neutron techniques were applied to produce quasi-mono-energetic neutron beams in the energy range of 1.5-7.5 keV at the accelerator port using the generated neutron spectrum from a Li (p, n) Be reaction. A simulation study was performed to characterize the filter components and transmitted beam lines. The feature of the filtered beams is detailed in terms of optimal thickness of the primary and additive components. A computer code named "QMNB-AS" was developed to carry out the required calculations. The filtered neutron beams had high purity and intensity with low contamination from the accompanying thermal, fast neutrons and γ-rays. Copyright © 2015 Elsevier Ltd. All rights reserved.

  20. Quality control procedure of the BNCT patient dose determination

    International Nuclear Information System (INIS)

    Bjugg, H.; Kortesniemi, M.; Seppaelae, T.; Karila, J.; Perkioe, J.; Ryynaenen, P.; Savolainen, S.; Auterinen, I.; Kotiluoto, P.; Seren, T.

    2000-01-01

    The concepts used at the Finnish BNCT facility for the patient dose quality assurance are introduced here. Dose planning images are obtained using a MR scanner with MRI sensitive markers. The dose distribution is computed with BNCT Rtpe. The program and the beam (DORT) model used have been verified with measurements and validated with MCNP calculations in phantoms. Dosimetric intercomparison has been done between FiR 1 and BMRR BNCT beams. The FiR 1 beam has been characterised also by visiting teams. Before every patient irradiation the relationship between beam monitor pulse rate and neutron fluence rate in the beam is checked by activation measurements. Cross-hair lasers used in the patient positioning are checked for spatial drift prior to each treatment. Kinetic models used to estimate the time-behaviour of blood boron concentration have been verified using independent patient sample data to assess and verify the performance of the applications. Quality control guides have been developed for each step in the patient irradiation. (author)

  1. First clinical results on the finnish study on BPA-mediated BNCT in glioblastoma

    International Nuclear Information System (INIS)

    Kankaanranta, L.; Seppaelae, T.; Kallio, M.

    2000-01-01

    An open phase I dose-escalation boron neutron capture therapy (BNCT) study on glioblastoma multiforme (GBM) was initiated at the BNCT facility FiR 1, Espoo, Finland, in May 1999. The aim of the study is to investigate the safety of boronophenylalanine (BPA)-mediated BNCT. Ten GBM patients were treated with a 2-field treatment plan using one fraction. BPA-F was used as the 10 B carrier infused as a fructose solution 290 mg BPA/kg over 2-hours prior to irradiation with epithermal neutrons. Average doses to the normal brain, contrast enhancing tumour, and the target ranged from 3.0 to 5.6 Gy (W), from 35.1 to 66.7 Gy (W), and from 29.6 to 53.6 Gy (W), respectively. BNCT was associated with acceptable toxicity. The median follow-up is 9 months (range, 3 to 16 months) post diagnosis in July 2000. Seven of the 10 patients have recurrent or persistent GBM, and the median time to progression is 8 months. Only one patient has died, and the estimated 1-year overall survival is 86%. Five of the recurrent tumours were treated with external beam photon radiation therapy to the total dose of 30-40 Gy with few acute side-effects. These preliminary findings suggest that acute toxicity of BPA-mediated BNCT is acceptable when average brain doses of 5.6 Gy (W) or less are used. The followup time is too short to evaluate survival, but the estimated 1-year survival of 86% achieved with BNCT followed by conventional photon irradiation at the time of tumour progression is encouraging and emphasises the need of further investigation of BPA-mediated BNCT. (author)

  2. BNCT with linac, feasibility study

    International Nuclear Information System (INIS)

    Alfuraih, A.; Ma, A.; Spyrou, N.M.; Awotwi-Pratt, Joseph

    2006-01-01

    High energy photon beams from Medical Linear Accelerators (linacs) which are used in radiotherapy produce undesirable neutrons, beside the clinically useful electron and photon beams. Neutrons are produced from the photonuclear reaction (γ,n) of high energy photons with high Z-materials which compose the accelerator head. In this paper the possible use of these undesirable neutrons for BNCT is investigated, making use of high energy linacs already installed in hospitals, primarily for high energy electron and photon therapy and applying them in the context of BNCT. The photoneutron components emitted by the accelerator is the source for Monte Carlo simulations of the interactions that take place within the head of a voxel-based phantom. The neutron flux across the phantom head is calculated using different moderator arrangements and different techniques in the aim of increasing the thermal neutron flux at the targeted site. Also, we shall test different configurations of the linac head to maximize the exposure of high-Z materials to the photon beam, including the removal of the flattening filter, so as to boost the photoneutron production in the linac head. Experimental work will be conducted in hospitals to validate the Monte Carlo simulations. To make use of linacs for BNCT will be advantageous in the sense that the setting in a hospital department is much more acceptable by the public than a reactor installation. This will mean less complications regarding patient positioning and movement with respect to the beams, additional patient transportation and management will be more cost effective. (author)

  3. Proposed Brookhaven accelerator-based neutron generator

    International Nuclear Information System (INIS)

    Grand, P.; Batchelor, K.; Chasman, R.; Rheaume, R.

    1976-01-01

    The d-Li Neutron Source concept, which includes a high-current dueteron linac, is an outgrowth of attempts made to use the BNL, 200-MeV proton linac BLIP facility to do radiation damage studies. It included a 100 mA, 30-MeV deuteron linear accelerator and a fast-flowing liquid lithium jet as the target. The latest design is not very different, except that the current is now 200 mA and the linac energy has been raised to 35 MeV. Both parameters, were changed to optimize the effectiveness of the facility with respect to flux, experimental volume and match to 14 MeV neutron-radiation-damage effects. The proposed Brookhaven Accelerator-based Neutron Generator is described with particular emphasis on the linear accelerator. The proposed facility is a practical and efficient way of producing the intense, high energy neutron beams needed for CTR material studies. The accelerator and liquid-metal technologies are well proven, state-of-the-art technologies. The fact that no new technology is required guarantees the possibility of meeting construction schedules, and more importantly, guarantees a high level of operational reliability

  4. Implementation of BNCT treatment planning procedures

    International Nuclear Information System (INIS)

    Capala, J.; Ma, R.; Diaz, A.Z.; Chanana, A.D.; Coderre, J.A.

    2001-01-01

    Estimation of radiation doses delivered during boron neutron capture therapy (BNCT) requires combining data on spatial distribution of both the thermal neutron fluence and the 10 B concentration, as well as the relative biological effectiveness of various radiation dose components in the tumor and normal tissues. Using the treatment planning system created at Idaho National Engineering and Environmental Laboratory and the procedures we had developed for clinical trials, we were able to optimize the treatment position, safely deliver the prescribed BNCT doses, and carry out retrospective analyses and reviews. In this paper we describe the BNCT treatment planning process and its implementation in the ongoing dose escalation trials at Brookhaven National Laboratory. (author)

  5. Quality management in BNCT at a nuclear research reactor

    Energy Technology Data Exchange (ETDEWEB)

    Sauerwein, Wolfgang, E-mail: w.sauerwein@uni-due.de [NCTeam, Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen (Germany); Moss, Raymond [ESE Unit, Institute for Energy, Joint Research Centre, European Commission, Westerduinweg 3, P.O. Box 2 NL-1755ZG Petten (Netherlands); Stecher-Rasmussen, Finn [NCT Physics, Nassaulaan 12, 1815GK Alkmaar (Netherlands); Rassow, Juergen [NCTeam, Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen (Germany); Wittig, Andrea [Department of Radiotherapy and Radiation Oncology, University Hospital Marburg, Philipps-University Marburg, Baldingerstrasse, 35043 Marburg (Germany)

    2011-12-15

    Each medical intervention must be performed respecting Health Protection directives, with special attention to Quality Assurance (QA) and Quality Control (QC). This is the basis of safe and reliable treatments. BNCT must apply QA programs as required for performance and safety in (conventional) radiotherapy facilities, including regular testing of performance characteristics (QC). Furthermore, the well-established Quality Management (QM) system of the nuclear reactor used has to be followed. Organization of these complex QM procedures is offered by the international standard ISO 9001:2008.

  6. Clinical results of BNCT for malignant meningiomas

    International Nuclear Information System (INIS)

    Miyatake, Shin-ichi; Tamura, Yoji; Kawabata, Shinji

    2006-01-01

    Malignant meningiomas is difficult pathology to be controlled as well as GBM. Since June of 2005, we applied BNCT for 7 cases of malignancy related meningiomas with 13 times neutron irradiation. Five were anaplastic, one was atypical meningiomas and one was sarcoma transformed from meningioma with cervical lymph node metastasis. All cases were introduced after repetitive surgeries and XRT or SRS. Follow-up images were available for 6 cases with observation duration between 2 to 9 months. We applied F-BPA-PET before BNCT in 6 out of 7 cases. One case was received methionine-PET. Five out of 6 cases who received BPA-PET study showed good BPA uptake more than 3 of T/N ratio. One atypical meningiomas cases showed 2.0 of T/N ratio. Original tumor sizes were between 9.2 to 92.7 ml. Two out of 5 anaplastic meningiomas showed CR and all six cases showed radiographic improvements. Clinical symptoms before BNCT such as hemiparesis and facial pain were improved after BNCT, except one case. An huge atypical meningiomas which arisen from tentorium and extended bilateral occipital lobes and brain stem, visual problems were worsened after repetitive BNCT with increase of peritumoral edema. Malignant meningiomas are seemed to be good candidate for BNCT. (author)

  7. Radiation protection in BNCT patients

    International Nuclear Information System (INIS)

    Blaumann, Hernan R.; Scharnichia, E.; Levanon, I.; Fernandez, C.; Facchini, Guillermo; Longhino, J.; Calzetta, Osvaldo; Pereira, M.

    2008-01-01

    Full text: Boron Neutron Capture Therapy (BNCT) is a technique that selectively targets cancer cells while sparing normal tissues by virtue of the differential uptake of a 10 B carrier compound in tumor. The National Atomic Energy Commission (CNEA) and the Oncology Institute 'Angel H. Roffo' (IOAR) began a BNCT programme in 2003 for treating cutaneous skin melanomas in extremities. The neutron beam used is the hyperthermal one developed at the RA-6 Reactor of the Bariloche Atomic Centre (CAB). The prescribed dose is delivered in one fraction and therefore patient positioning and knowledge of the dose received by normal tissue are crucial. 10 irradiations have been done since 2003, all of them in legs and feet and the dose prescription was determined by the maximum tolerable skin dose. Due to the characteristics of this treatment the patient body might be exposed not only to the primary beam but also to the secondary photon beam produced by neutron capture at the target itself. Thus a patient radiation-monitoring plan was implemented in order to evaluate the gamma dose delivered to sensible organs of each patient. An acrylic water-filled whole body phantom was used for preliminary gamma dose and thermal neutron flux measurements at positions related to patient's body sensible organs considering tentative patient positions. The beam port shielding was, in this way, optimized. TLD-700 and Manganese foils were used for gamma and thermal neutron detection. The TLD-700 thermal neutron response was previously evaluated by using the in-phantom beam dosimetry characterization. In-vivo dosimetry with TLD is routinely implemented in order to evaluate gamma dose to sensible organs of each patient. These organs are chosen depending on its distance from the zone to be irradiated and its radio-sensibility. All TLDs have been positioned well outside the irradiation field. Maximum gamma dose received outside the radiation field in healthy tissues was well below tolerance dose for

  8. Accelerator-based neutrino oscillation searches

    International Nuclear Information System (INIS)

    Whitehouse, D.A.; Rameika, R.; Stanton, N.

    1993-01-01

    This paper attempts to summarize the neutrino oscillation section of the Workshop on Future Directions in Particle and Nuclear Physics at Multi-GeV Hadron Beam Facilities. There were very lively discussions about the merits of the different oscillation channels, experiments, and facilities, but we believe a substantial consensus emerged. First, the next decade is one of great potential for discovery in neutrino physics, but it is also one of great peril. The possibility that neutrino oscillations explain the solar neutrino and atmospheric neutrino experiments, and the indirect evidence that Hot Dark Matter (HDM) in the form of light neutrinos might make up 30% of the mass of the universe, point to areas where accelerator-based experiments could play a crucial role in piecing together the puzzle. At the same time, the field faces a very uncertain future. The LSND experiment at LAMPF is the only funded neutrino oscillation experiment in the United States and it is threatened by the abrupt shutdown of LAMPF proposed for fiscal 1994. The future of neutrino physics at the Brookhaven National Laboratory AGS depends the continuation of High Energy Physics (HEP) funding after the RHIC startup. Most proposed neutrino oscillation searches at Fermilab depend on the completion of the Main Injector project and on the construction of a new neutrino beamline, which is uncertain at this point. The proposed KAON facility at TRIUMF would provide a neutrino beam similar to that at the AGS but with a much increase intensity. The future of KAON is also uncertain. Despite the difficult obstacles present, there is a real possibility that we are on the verge of understanding the masses and mixings of the neutrinos. The physics importance of such a discovery can not be overstated. The current experimental status and future possibilities are discussed below

  9. Accelerator based neutron source for neutron capture therapy

    International Nuclear Information System (INIS)

    Salimov, R.; Bayanov, B.; Belchenko, Yu.; Belov, V.; Davydenko, V.; Donin, A.; Dranichnikov, A.; Ivanov, A.; Kandaurov, I; Kraynov, G.; Krivenko, A.; Kudryavtsev, A.; Kursanov, N.; Savkin, V.; Shirokov, V.; Sorokin, I.; Taskaev, S.; Tiunov, M.

    2004-01-01

    Full text: The Budker Institute of Nuclear Physics (Novosibirsk) and the Institute of Physics and Power Engineering (Obninsk) have proposed an accelerator based neutron source for neutron capture and fast neutron therapy for hospital. Innovative approach is based upon vacuum insulation tandem accelerator (VITA) and near threshold 7 Li(p,n) 7 Be neutron generation. Pilot accelerator based neutron source for neutron capture therapy is under construction now at the Budker Institute of Nuclear Physics, Novosibirsk, Russia. In the present report, the pilot facility design is presented and discussed. Design features of facility components are discussed. Results of experiments and simulations are presented. Complete experimental tests are planned by the end of the year 2005

  10. Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system

    Science.gov (United States)

    NAKAMURA, Satoshi; IMAMICHI, Shoji; MASUMOTO, Kazuyoshi; ITO, Masashi; WAKITA, Akihisa; OKAMOTO, Hiroyuki; NISHIOKA, Shie; IIJIMA, Kotaro; KOBAYASHI, Kazuma; ABE, Yoshihisa; IGAKI, Hiroshi; KURITA, Kazuyoshi; NISHIO, Teiji; MASUTANI, Mitsuko; ITAMI, Jun

    2017-01-01

    This study aimed to evaluate the residual radioactivity in mice induced by neutron irradiation with an accelerator-based boron neutron capture therapy (BNCT) system using a solid Li target. The radionuclides and their activities were evaluated using a high-purity germanium (HP-Ge) detector. The saturated radioactivity of the irradiated mouse was estimated to assess the radiation protection needs for using the accelerator-based BNCT system. 24Na, 38Cl, 80mBr, 82Br, 56Mn, and 42K were identified, and their saturated radioactivities were (1.4 ± 0.1) × 102, (2.2 ± 0.1) × 101, (3.4 ± 0.4) × 102, 2.8 ± 0.1, 8.0 ± 0.1, and (3.8 ± 0.1) × 101 Bq/g/mA, respectively. The 24Na activation rate at a given neutron fluence was found to be consistent with the value reported from nuclear-reactor-based BNCT experiments. The induced activity of each nuclide can be estimated by entering the saturated activity of each nuclide, sample mass, irradiation time, and proton current into the derived activation equation in our accelerator-based BNCT system. PMID:29225308

  11. Accelerator-Based Boron Neutron Capture Therapy and the Development of a Dedicated Tandem-Electrostatic-Quadrupole

    International Nuclear Information System (INIS)

    Kreiner, A. J.; Di Paolo, H.; Burlon, A. A.; Valda, A. A.; Debray, M. E.; Somacal, H. R.; Minsky, D. M.; Kesque, J. M.; Giboudot, Y.; Levinas, P.; Fraiman, M.; Romeo, V.

    2007-01-01

    There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). Progress on an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. A 30 mA proton beam of 2.5 MeV are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. The first design and construction of an ESQ module is discussed and its electrostatic fields are investigated theoretically and experimentally. Also new beam transport calculations through the accelerator are presented

  12. BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, Hiroaki

    2006-01-01

    BSH-based intra-operative BNCT as an initial treatment underwent in 4 children with malignant brain tumors since 1998. There were 2 glioblastomas, one primitive neuroectodermal tumor (PNET) and one anaplastic ependymoma patient. They included two children under 3-year-old. All GBM patients were died of CSF dissemination without tumor regrowth in the primary site. Another PNET and anaplastic ependymoma patients are still alive without tumor recurrence. We can consider BNCT is optimal treatment modality for malignant brain tumor in children. (author)

  13. Radiobiology studies for the evaluation of epithermal neutron beams used for BNCT

    International Nuclear Information System (INIS)

    Green, S.; Jones, B.; Mill, A.J.

    2006-01-01

    This paper outlines our plans for a study to establish the radiobiological effectiveness of the various mixes of radiation components present in an epithermal neutron beam designed for BNCT and to incorporate these data into clinical protocols for the treatment of malignant glioma. This is a description of work which is funded and just now beginning in Birmingham so no results can be presented. Our project will involve a combination of experimental measurements carried out in Birmingham and in Boston and mathematical modelling carried out in Birmingham. Despite all the extant in-vitro and in-vivo work, there is no widely accepted method to determine biological effect by accounting for variations in beam component mix, dose rate and treatment fractionation for disparate from the various BNCT centres. The objectives of this study are: To develop a cell-based radiobiology protocol to provide essential data on safety and efficacy of beams for Boron Neutron Capture Therapy (BNCT) in advance of clinical trials. To exploit the facilities at Massachusetts Institute of Technology for variable dose-rate epithermal irradiations to validate the above protocol. To develop mathematical models of this radiobiological system that can be used to inform decisions on dose selection, fractionation schedules, BNCT use as supplementary boosts or for re-treatment of recurrent cancers. To provide fundamental data relevant to the understanding of the radiobiology of simultaneous mixed high-and low-LET radiations over a clinically relevant dose-range. (author)

  14. High-power electron beam tests of a liquid-lithium target and characterization study of (7)Li(p,n) near-threshold neutrons for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Cohen, D; Eliyahu, I; Kijel, D; Mardor, I; Silverman, I

    2014-06-01

    A compact Liquid-Lithium Target (LiLiT) was built and tested with a high-power electron gun at Soreq Nuclear Research Center (SNRC). The target is intended to demonstrate liquid-lithium target capabilities to constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals. The lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power >5kW generated by high-intensity proton beams, necessary for sufficient therapeutic neutron flux. In preliminary experiments liquid lithium was flown through the target loop and generated a stable jet on the concave supporting wall. Electron beam irradiation demonstrated that the liquid-lithium target can dissipate electron power densities of more than 4kW/cm(2) and volumetric power density around 2MW/cm(3) at a lithium flow of ~4m/s, while maintaining stable temperature and vacuum conditions. These power densities correspond to a narrow (σ=~2mm) 1.91MeV, 3mA proton beam. A high-intensity proton beam irradiation (1.91-2.5MeV, 2mA) is being commissioned at the SARAF (Soreq Applied Research Accelerator Facility) superconducting linear accelerator. In order to determine the conditions of LiLiT proton irradiation for BNCT and to tailor the neutron energy spectrum, a characterization of near threshold (~1.91MeV) (7)Li(p,n) neutrons is in progress based on Monte-Carlo (MCNP and Geant4) simulation and on low-intensity experiments with solid LiF targets. In-phantom dosimetry measurements are performed using special designed dosimeters based on CR-39 track detectors. © 2013 Elsevier Ltd. All rights reserved.

  15. Medical set-up of boron neutron capture therapy (BNCT) for malignant glioma at the Japan research reactor (JRR)-4

    International Nuclear Information System (INIS)

    Yamamoto, T.; Matsumura, A.; Nose, T.; Shibata, Y.; Nakai, K.; Sakurai, F.; Kishi, T.; Kumada, H.; Yamamoto, K.; Torii, Y.

    2001-01-01

    The University of Tsukuba project for boron neutron capture therapy (BNCT) was initiated at the Japan Atomic Energy Research Institute (JAERI) in 1992. The clinical study for BNCT began at the Japan Research Reactor (JRR)-2 of the JAERI in November 1995. By the end of 1998, a new medical irradiation facility had been installed in JRR-4 of that included a new medical treatment room and patient-monitoring area adjacent to the irradiation room. The medical treatment room was built to reflect a hospital-type operation room that includes an operating table with a carbon head frame, anesthesia apparatus with several cardiopulmonary monitors, etc. Following craniotomy in the treatment room, a patient under anesthesia is transported into the irradiation room for BNCT. The boron concentration in tissue is measured with prompt gamma ray analysis (PGA) and simultaneously by inductively coupled plasma atomic emission spectroscopy (ICP-AES) methods. For the immediate pre- and post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of the JAERI. The long term follow-up is done at the University of Tsukuba Hospital. Epithermal neutron beam also became available at the new JRR-4. By changing the thickness and/or the configuration of heavy water, a cadmium plate, and a graphite reflector, the JRR-4 provides a variety of neutron beams, including three typical beams (Epithermal mode and Thermal modes I and II). Intraoperative BNCT using the thermal beam is planned to study at the beginning of the clinical trial. The ongoing development of the JAERI Computational Dosimetry System (JCDS) and radiobiological studies have focused in the application of the epithermal beam for BNCT. After obtaining these basic data, we are planning to use the epithermal beam for intraoperative BNCT. (author)

  16. Reprint of Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

    International Nuclear Information System (INIS)

    Gadan, M.A.; González, S.J.; Batalla, M.; Olivera, M.S.; Policastro, L.; Sztejnberg, M.L.

    2015-01-01

    In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research. - Highlights: • A new proposal of BNCT for HER2+ breast cancer treatment is introduced. • The proposal considers development of immunoliposomes as boron carrier nanovehicles. • Locoregional recurrences after treatment were identified as candidates for initial BNCT studies. • First analysis show acceptable neutron flux distributions provided by RA-6 BNCT facility.

  17. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, H.

    2011-01-01

    The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment. - Highlights: ► In this study, we evaluate the clinical outcome of boron neutron capture therapy (BNCT) for malignant brain tumors. ► We have treated 23 glioblastoma (GBM) patients with BNCT without any additional chemotherapy. ► Clinical results of BNCT in patients with GBM are superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.

  18. Proceedings of the specialists' meeting on accelerator-based transmutation

    International Nuclear Information System (INIS)

    Wenger, H.U.

    1992-09-01

    The meeting was organised under the auspices of OECD Nuclear Agency's International Information Exchange Programme on Actinide and Fission Product Partitioning and Transmutation. In the original announcement for the meeting the following sessions were proposed: 1) Concepts of accelerator-based transmutation systems, 2) Nuclear design problems of accelerator-based transmutation systems with emphasis on target facilities and their interfaces with accelerators, 3) Data and methods for nuclear design of accelerator-based transmutation systems, 4) Related cross-section measurements and integral experiments, 5) Identification of discrepancies and gaps and discussion of desirable R+D and benchmark activities. Due to the large number of papers submitted it was necessary to split session 2 into two parts and to reassign some papers in order to balance the sessions more evenly. No papers were submitted for session 5 and this was replaced by a summary and general discussion session. These proceedings contain all 30 papers in the order they were presented at the meeting. They are copies of the duplication-ready versions given to us during or shortly after the meeting. In the Table of Contents, the papers are listed together with the name of the presenter. (author) figs., tabs., refs

  19. Use of accelerator based neutron sources

    International Nuclear Information System (INIS)

    2000-05-01

    With the objective of discussing new requirements related to the use of accelerator based neutron generators an Advisory Group meeting was held in October 1998 in Vienna. This meeting was devoted to the specific field of the utilization of accelerator based neutron generators. This TECDOC reports on the technical discussions and presentations that took place at this meeting and reflects the current status of neutron generators. The 14 MeV neutron generators manufactured originally for neutron activation analysis are utilised also for nuclear structure and reaction studies, nuclear data acquisition, radiation effects and damage studies, fusion related studies, neutron radiography

  20. Development of beryllium-based neutron target system with three-layer structure for accelerator-based neutron source for boron neutron capture therapy.

    Science.gov (United States)

    Kumada, Hiroaki; Kurihara, Toshikazu; Yoshioka, Masakazu; Kobayashi, Hitoshi; Matsumoto, Hiroshi; Sugano, Tomei; Sakurai, Hideyuki; Sakae, Takeji; Matsumura, Akira

    2015-12-01

    The iBNCT project team with University of Tsukuba is developing an accelerator-based neutron source. Regarding neutron target material, our project has applied beryllium. To deal with large heat load and blistering of the target system, we developed a three-layer structure for the target system that includes a blistering mitigation material between the beryllium used as the neutron generator and the copper heat sink. The three materials were bonded through diffusion bonding using a hot isostatic pressing method. Based on several verifications, our project chose palladium as the intermediate layer. A prototype of the neutron target system was produced. We will verify that sufficient neutrons for BNCT treatment are generated by the device in the near future. Copyright © 2015 Elsevier Ltd. All rights reserved.

  1. Bioimaging of cells and tissues using accelerator-based sources.

    Science.gov (United States)

    Petibois, Cyril; Cestelli Guidi, Mariangela

    2008-07-01

    A variety of techniques exist that provide chemical information in the form of a spatially resolved image: electron microprobe analysis, nuclear microprobe analysis, synchrotron radiation microprobe analysis, secondary ion mass spectrometry, and confocal fluorescence microscopy. Linear (LINAC) and circular (synchrotrons) particle accelerators have been constructed worldwide to provide to the scientific community unprecedented analytical performances. Now, these facilities match at least one of the three analytical features required for the biological field: (1) a sufficient spatial resolution for single cell (pros and cons of the most popular techniques that have been implemented on accelerator-based sources to address analytical issues on biological specimens.

  2. 'Sequential' Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    International Nuclear Information System (INIS)

    Molinari, Ana J.; Pozzi, Emiliano C.C.; Hughes, Andrea Monti; Heber, Elisa M.; Garabalino, Marcela A.; Thorp, Silvia I.; Miller, Marcelo; Itoiz, Maria E.; Aromando, Romina F.; Nigg, David W.; Quintana, Jorge; Santa Cruz, Gustavo A.; Trivillin, Veronica A.; Schwint, Amanda E.

    2011-01-01

    In the present study we evaluated the therapeutic effect and/or potential radiotoxicity of the novel 'Tandem' Boron Neutron Capture Therapy (T-BNCT) for the treatment of oral cancer in the hamster cheek pouch model at RA-3 Nuclear Reactor. Two groups of animals were treated with 'Tandem BNCT', i.e. BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (T-24h-BNCT) or 48 h (T-48h-BNCT) later. A total tumor dose-matched single application of BNCT mediated by BPA and GB-10 administered jointly ((BPA + GB-10)-BNCT) was administered to an additional group of animals. At 28 days post-treatment, T-24h-BNCT and T-48h-BNCT induced, respectively, overall tumor control (OTC) of 95% and 91%, with no statistically significant differences between protocols. Tumor response for the single application of (BPA + GB-10)-BNCT was 75%, significantly lower than for T-BNCT. The T-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47% and 60% of the animals respectively. No normal tissue radiotoxicity was associated to tumor control for any of the protocols. 'Tandem' BNCT enhances tumor control in oral cancer and reduces or, at worst, does not increase, mucositis in dose-limiting precancerous tissue.

  3. 9Be(d,n)10B-based neutron sources for BNCT

    International Nuclear Information System (INIS)

    Capoulat, M.E.; Herrera, M.S.; Minsky, D.M.; González, S.J.; Kreiner, A.J.

    2014-01-01

    In the frame of accelerator-based BNCT, the 9 Be(d,n) 10 B reaction was investigated as a possible source of epithermal neutrons. In order to determine the configuration in terms of bombarding energy, target thickness and Beam Shaping Assembly (BSA) design that results in the best possible beam quality, a systematic optimization study was carried out. From this study, the optimal configuration resulted in tumor doses ≥40 Gy-Eq, with a maximum value of 51 Gy-Eq at a depth of about 2.7 cm, in a 60 min treatment. The optimal configuration was considered for the treatment planning assessment of a real Glioblastoma Multiforme case. From this, the resulted dose performances were comparable to those obtained with an optimized 7 Li(p,n)-based neutron source, under identical conditions and subjected to the same clinical protocol. - Highlights: • Study of the 9 Be(d,n) 10 B reaction as a source of epithermal neutrons for BNCT. • Evaluation of the optimal configuration of target thickness, deuteron energy and BSA design. • Computational dose assessment for brain tumor treatments using the MCNP code. • Treatment planning assessment of a particular clinical Glioblastoma Multiforme case. • Dose performances were comparable to those obtained with an optimized 7 Li(p,n)-based source

  4. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Emiliano C. C. Pozzi; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Silvia I. Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz; Veronica A. Trivillin; Amanda E. Schwint

    2011-04-01

    In the present study we evaluated the therapeutic effect and/or potential radiotoxicity of the novel “Tandem” Boron Neutron Capture Therapy (T-BNCT) for the treatment of oral cancer in the hamster cheek pouch model at RA-3 Nuclear Reactor. Two groups of animals were treated with “Tandem BNCT”, i.e. BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (T-24h-BNCT) or 48 h (T-48h-BNCT) later. A total tumor dose-matched single application of BNCT mediated by BPA and GB-10 administered jointly [(BPA + GB-10)-BNCT] was administered to an additional group of animals. At 28 days post-treatment, T-24h-BNCT and T-48h-BNCT induced, respectively, overall tumor control (OTC) of 95% and 91%, with no statistically significant differences between protocols. Tumor response for the single application of (BPA + GB-10)-BNCT was 75%, significantly lower than for T-BNCT. The T-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47% and 60% of the animals respectively. No normal tissue radiotoxicity was associated to tumor control for any of the protocols. “Tandem” BNCT enhances tumor control in oral cancer and reduces or, at worst, does not increase, mucositis in dose-limiting precancerous tissue.

  5. Radiation transport calculation methods in BNCT

    International Nuclear Information System (INIS)

    Koivunoro, H.; Seppaelae, T.; Savolainen, S.

    2000-01-01

    Boron neutron capture therapy (BNCT) is used as a radiotherapy for malignant brain tumours. Radiation dose distribution is necessary to determine individually for each patient. Radiation transport and dose distribution calculations in BNCT are more complicated than in conventional radiotherapy. Total dose in BNCT consists of several different dose components. The most important dose component for tumour control is therapeutic boron dose D B . The other dose components are gamma dose D g , incident fast neutron dose D f ast n and nitrogen dose D N . Total dose is a weighted sum of the dose components. Calculation of neutron and photon flux is a complex problem and requires numerical methods, i.e. deterministic or stochastic simulation methods. Deterministic methods are based on the numerical solution of Boltzmann transport equation. Such are discrete ordinates (SN) and spherical harmonics (PN) methods. The stochastic simulation method for calculation of radiation transport is known as Monte Carlo method. In the deterministic methods the spatial geometry is partitioned into mesh elements. In SN method angular integrals of the transport equation are replaced with weighted sums over a set of discrete angular directions. Flux is calculated iteratively for all these mesh elements and for each discrete direction. Discrete ordinates transport codes used in the dosimetric calculations are ANISN, DORT and TORT. In PN method a Legendre expansion for angular flux is used instead of discrete direction fluxes, land the angular dependency comes a property of vector function space itself. Thus, only spatial iterations are required for resulting equations. A novel radiation transport code based on PN method and tree-multigrid technique (TMG) has been developed at VTT (Technical Research Centre of Finland). Monte Carlo method solves the radiation transport by randomly selecting neutrons and photons from a prespecified boundary source and following the histories of selected particles

  6. Liquid Li based neutron source for BNCT and science application

    International Nuclear Information System (INIS)

    Horiike, H.; Murata, I.; Iida, T.; Yoshihashi, S.; Hoashi, E.; Kato, I.; Hashimoto, N.; Kuri, S.; Oshiro, S.

    2015-01-01

    Liquid lithium (Li) is a candidate material for a target of intense neutron source, heat transfer medium in space engines and charges stripper. For a medical application of BNCT, epithermal neutrons with least energetic neutrons and γ-ray are required so as to avoid unnecessary doses to a patient. This is enabled by lithium target irradiated by protons at 2.5 MeV range, with utilizing the threshold reaction of "7Li(p,n)"7Be at 1.88 MeV. In the system, protons at 2.5 MeV penetrate into Li layer by 0.25 mm with dissipating heat load near the surface. To handle it, thin film flow of high velocity is important for stable operation. For the proton accelerator, electrostatic type of the Schnkel or the tandem is planned to be employed. Neutrons generated at 0.6 MeV are gently moderated to epithermal energy while suppressing accompanying γ-ray minimum by the dedicated moderator assembly. - Highlights: • Liquid lithium (Li) is a candidate material for a target of intense neutron source. • An accelerator based neutron source with p-liquid Li target for boron neutron capture therapy is under development in Osaka University, Japan. • In our system, the harmful radiation dose due to rays and fast neutrons will be suppressed very low. • The system performance are very promising as a state of art cancer treatment system. • The project is planned as a joint undertaking between industries and Osaka University.

  7. FiR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

    International Nuclear Information System (INIS)

    Auterinen, I.; Salmenhaara, S.E.J. . Author

    2004-01-01

    The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT), but FiR 1 has also an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics etc. with isotope production and activation analysis services. In the 1990's a BNCT treatment facility was built at the FiR 1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material Fluental TM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality after a major renovation of the whole reactor building in 1997. Recently the lithiated polyethylene neutron shielding of the beam aperture was modified to ease the positioning of the patient close to the beam aperture. Increasing the reactor power to 500 kW would allow positioning of the patient further away from the beam aperture. Possibilities to accomplish a safety analysis for this is currently under considerations. Over thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. Currently three clinical trial protocols for tumours in the brain as well as in the head and neck region are recruiting patients. (author)

  8. An accelerator neutron source for BNCT. Technical progress report, 1 June 1993--31 May 1994

    International Nuclear Information System (INIS)

    Blue, T.E.; Vafai, K.

    1994-02-01

    This is the progress report for the project entitled, ''An Accelerator Neutron Source for BNCT.'' The progress report is for the period from July 1, 1993 to date. The overall objective of our research project is to develop an Accelerator Epithermal Neutron Irradiation Facility (AENIF) for Boron Neutron Capture Therapy (BNCT). The AENIF consists of a 2.5 MeV high current proton accelerator, a lithium target to produce source neutrons, and a moderator/reflector assembly to obtain from the energetic source neutrons an epithermal neutron field suitable for BNCT treatments. Our project goals are to develop the non-accelerator components of the AENIF, and to specifically include in our development: (1) design, numerical simulation, and experimental verification of a target assembly which is capable of removing 75 kW of beam power; (2) re-optimization of the moderator assembly design based on in-phantom dose assessments using neutron spectra calculated in phantom and an energy-dependent neutron Relative Biological Effectiveness (RBE); (3) construction of a prototype moderator assembly and confirmation of its design by measurements; (4) design of the shielding of the accelerator and treatment rooms for an AENIF; and (5) design of a high energy beam transport system which is compatible with the shielding design and the thermal-hydraulic design

  9. Optimization of beam shaping assembly based on D-T neutron generator and dose evaluation for BNCT

    Science.gov (United States)

    Naeem, Hamza; Chen, Chaobin; Zheng, Huaqing; Song, Jing

    2017-04-01

    The feasibility of developing an epithermal neutron beam for a boron neutron capture therapy (BNCT) facility based on a high intensity D-T fusion neutron generator (HINEG) and using the Monte Carlo code SuperMC (Super Monte Carlo simulation program for nuclear and radiation process) is proposed in this study. The Monte Carlo code SuperMC is used to determine and optimize the final configuration of the beam shaping assembly (BSA). The optimal BSA design in a cylindrical geometry which consists of a natural uranium sphere (14 cm) as a neutron multiplier, AlF3 and TiF3 as moderators (20 cm each), Cd (1 mm) as a thermal neutron filter, Bi (5 cm) as a gamma shield, and Pb as a reflector and collimator to guide neutrons towards the exit window. The epithermal neutron beam flux of the proposed model is 5.73 × 109 n/cm2s, and other dosimetric parameters for the BNCT reported by IAEA-TECDOC-1223 have been verified. The phantom dose analysis shows that the designed BSA is accurate, efficient and suitable for BNCT applications. Thus, the Monte Carlo code SuperMC is concluded to be capable of simulating the BSA and the dose calculation for BNCT, and high epithermal flux can be achieved using proposed BSA.

  10. INEL BNCT Research Program annual report, 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-05-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database.

  11. Carborane-containing metalloporphyrins for BNCT

    International Nuclear Information System (INIS)

    Miura, Michiko; Joel, D.D.; Nawrocky, M.M.; Micca, P.L.

    1996-01-01

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of 10 B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 μg B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses

  12. Clinical practice in BNCT to the brain

    International Nuclear Information System (INIS)

    Nakagawa, Y.

    2001-01-01

    Our concept of Boron Neutron Capture Therapy (BNCT) is to selectively destroy tumour cells using the high LET particles yielded from the 10B(n,α)7Li reactions. The effort of clinical investigators has concentrated on how to escalate the radiation dose at the target point. BNCT in Japan combines thermal neutrons and BSH (Na 2 B 12 H 11 SH). The radiation dose is determined by the neutron fluence at the target point and the boron concentration in the tumour tissue. According to the recent analysis, the ratio of boron concentration (BSH) in tumour tissue and blood is nearly stable at around 1.2 to 1.69. Escalation of the radiation dose was carried out by means of improving the penetration of the thermal neutron beam. Since 1968, 175 patients with glioblastoma (n=83), anaplastic astrocytoma (n=44), low grade astrocytoma (n=16) or other types of tumour (n=32) were treated by BNCT at 5 reactors (HTR n=13, JRR-3 n=1, MulTR n=98, KUR n=30, JRR-2 n=33). The retrospective analysis revealed that the important factors related to the clinical results and QOL of the patients were minimum tumour volume radiation dose, more than 18Gy of physical dose and maximum vascular radiation dose (less than 15Gy) in the normal cortex. We have planned several trials to escalate the target radiation dose. One trial makes use of a cavity in the cortex following debulking surgery of the tumour tissue to improve neutron penetration. The other trial is introduction of epithermal neutron. KUR and JRR-4 were reconstructed and developed to be able to irradiate using epithermal neutrons. The new combination of surgical procedure and irradiation using epithermal neutrons should remarkably improve the target volume dose compared to the radiation dose treated by thermal neutrons. (author)

  13. Carborane-containing metalloporphyrins for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Joel, D.D.; Nawrocky, M.M.; Micca, P.L. [and others

    1996-12-31

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of {sup 10}B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 {mu}g B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses.

  14. INEL BNCT Research Program annual report, 1992

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1993-05-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database

  15. Accelerator-based cold neutron sources and their cooling system

    International Nuclear Information System (INIS)

    Inoue, Kazuhiko; Yanai, Masayoshi; Ishikawa, Yoshikazu.

    1985-01-01

    We have developed and installed two accelerator-based cold neutron sources within a electron linac at Hokkaido University and a proton synchrotoron at National Laboratory for High Energy Physics. Solid methane at 20K was adopted as the cold moderator. The methane condensing heat exchangers attached directly to the moderator chambers were cooled by helium gas, which was kept cooled in refrigerators and circulated by ventilation fans. Two cold neutron sources have operated smoothly and safely for the past several years. In this paper we describe some of the results obtained in the preliminary experiments by using a modest capacity refrigerator, the design philosophy of the cooling system for the pulsed cold neutron sources, and outline of two facilities. (author)

  16. American brain tumor patients treated with BNCT in Japan

    International Nuclear Information System (INIS)

    Laramore, G.E.; Griffin, B.R.; Spence, A.

    1995-01-01

    The purpose of this work is to establish and maintain a database for patients from the United States who have received BNCT in Japan for malignant gliomas of the brain. This database will serve as a resource for the DOE to aid in decisions relating to BNCT research in the United States, as well as assisting the design and implementation of clinical trials of BNCT for brain cancer patients in this country. The database will also serve as an information resource for patients with brain tumors and their families who are considering this form of therapy

  17. Design of experiment existing parameter physics for supporting of Boron Neutron Capture Therapy (BNCT) method a t the piercing radial beam port of Kartini research reactor

    International Nuclear Information System (INIS)

    Indry Septiana Novitasari; Yosaphat Sumardi; Widarto

    2014-01-01

    The experiment existing parameters physics for supporting of in vivo and in vitro test facility of Boron Neutron Capture Therapy (BNCT) preliminary study at the piercing radial beam port has been done. The existing experiments is needed for determining that the parameter physics is fulfill the BNCT method requirement. To realize the existing experiment have been done by design analysis, methodology, calculation method and some procedure related with radiation safety analysis and environment. Preparation for existing experiment physics such as foil detector of Gold (Au) should be irradiated for 30 minute, irradiation instrument and procedure related with the experiment for radiation safety. (author)

  18. Accelerator based atomic physics experiments: an overview

    International Nuclear Information System (INIS)

    Moak, C.D.

    1976-01-01

    Atomic Physics research with beams from accelerators has continued to expand and the number of papers and articles at meetings and in journals reflects a steadily increasing interest and an increasing support from various funding agencies. An attempt will be made to point out where interdisciplinary benefits have occurred, and where applications of the new results to engineering problems are expected. Drawing from material which will be discussed in the conference, a list of the most active areas of research is presented. Accelerator based atomic physics brings together techniques from many areas, including chemistry, astronomy and astrophysics, nuclear physics, solid state physics and engineering. An example is the use of crystal channeling to sort some of the phenomena of ordinary heavy ion stopping powers. This tool has helped us to reach a better understanding of stopping mechanisms with the result that now we have established a better base for predicting energy losses of heavy ions in various materials

  19. Biodistribution of Boron compounds in an experimental model of liver metastases for Boron Neutron Capture (BNCT) Studies

    International Nuclear Information System (INIS)

    Garabalino, Marcela A.; Monti Hughes, Andrea; Molinari, Ana J.; Heber, Elisa M.; Pozzi, Emiliano C.C.; Itoiz, Maria E.; Trivillin, Veronica A.; Schwint, Amanda E.; Nievas, Susana; Aromando, Romina F.

    2009-01-01

    + iv; BPA 46.5 mg 10 B/kg ip + GB-10 20 mg 10 B/kg iv; BPA 31 mg 10 B/kg ip; BPA 31 mg 10 B/kg iv + ip; BPA 31 mg 10 B/kg ip + GB-10 34.5 mg 10 B/kg iv. Conclusions: Boron concentration values in tumor and normal tissues in the liver metastases model reveal the feasibility of reaching therapeutic BNCT doses in tumor without exceeding radio-tolerance in normal tissue at the thermal neutron facility at RA-3. (author)

  20. Biological dosimetry studies for boron neutron capture therapy at the RA-1 research reactor facility

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Castillo, Jorge

    2004-01-01

    Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminescent dosimeters to characterize the BNCT facility developed at the RA-1 research reactor operated by the National Atomic Energy Commission in Buenos Aires. Biological dosimetry was performed employing the hamster cheek pouch oral cancer model previously validated for BNCT studies by our group. Results indicate that the RA-1 neutron source produces useful dose rates for BNCT studies but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications. (author)

  1. Epithermal neutron beam for BNCT research at the Washington State University TRIGA research reactor

    International Nuclear Information System (INIS)

    Nigg, D.W.; Venhuizen, J.R.; Wheeler, F.J.; Wemple, C.A.; Tripard, G.E.; Gavin, P.R.

    2000-01-01

    A new epithermal-neutron beam facility for BNCT (Boron Neutron Capture Therapy) research and boronated agent screening in animal models is in the final stages of construction at Washington State University (WSU). A key distinguishing feature of the design is the incorporation of a new, high-efficiency, neutron moderating and filtering material, Fluental, developed by the Technical Research Centre of Finland. An additional key feature is the provision for adjustable filter-moderator thickness to systematically explore the radiobiological consequences of increasing the fast-neutron contamination above the nominal value associated with the baseline system. (author)

  2. A case of astrocytoma, 19 year history after BNCT

    International Nuclear Information System (INIS)

    Kamano, Shuji

    2006-01-01

    A 39-year-old man had received Boron Neutron Capture Therapy (BNCT) in 1987 for a Grade II Astrocytoma. He gradually exacerbated and received a second operation in 1994. The mass taken in the second operation is almost competent with radiation necrosis. Following that, he shows no signs of recurrence. Currently, he has returned to full time employment in physical labor. This case suggests effectiveness of BNCT for rather low-grade astrocytomas. (author)

  3. A core laboratory offering full evaluation of new boron compounds. A service to the BNCT community

    International Nuclear Information System (INIS)

    Zamenhof, R.G.; Patel, H.; Palmer, M.R.; Lin, H.C.; Busse, P.M.; Harling, O.; Binns, P.J.; Riley, K.J.; Bernard, J.

    2000-01-01

    A joint project by the Beth Israel Deaconess Medical Center at Harvard Medical School and The Nuclear Reactor Laboratory of the Massachusetts Institute of Technology is proposed which would provide a core laboratory for the evaluation of new boron compounds. Federal agency funding has been applied for to support such a facility. The facility's evaluation of candidate boron compounds will include: quantitative cellular boron uptake; cell survival curve analysis (using a thermal neutron beam); small or large animal pharmacokinetic analysis; macro- and micro boron distribution analysis using high-resolution autoradiography, prompt gamma analysis and ICP-AES; small or large animal in vivo tumor control studies (using thermal or epithermal neutron beams); and pharmacological in vivo toxicity evaluation. The laboratory will include small and large animal surgical facilities and resources for additional boron compound chemistry as required by the evaluation procedure. This facility will be open to the BNCT research community. (author)

  4. Research activities related to accelerator-based transmutation at PSI

    International Nuclear Information System (INIS)

    Wydler, P.

    1993-01-01

    Transmutation of actinides and fission products using reactors and other types of nuclear systems may play a role in future waste management schemes. Possible advantages of separation and transmutation are: volume reductions, the re-use of materials, the avoidance of a cumulative risk, and limiting the duration of the risk. With its experience in reactor physics, accelerator-based physics, and the development of the SINQ spallation neutron source, PSI is in a good position to perform basic theoretical and experimental studies relating to the accelerator-based transmutation of actinides. Theoretical studies at PSI have been concentrated, so far, on systems in which protons are used directly to transmute actinides. With such systems and appropriate recycling schemes, the studies showed that considerable reduction factors for long-term toxicity can be obtained. With the aim of solving some specific data and method problems related to these types of systems, a programme of differential and integral measurements at the PSI ring accelerator has been initiated. In a first phase of this programme, thin samples of actinides will be irradiated with 590 MeV protons, using an existing irradiation facility. The generated spallation and fission products will be analysed using different experimental techniques, and the results will be compared with theoretical predictions based on high-energy nucleon-meson transport calculations. The principal motivation for these experiments is to resolve discrepancies observed between calculations based on different high-energy fission models. In a second phase of the programme, it is proposed to study the neutronic behaviour of multiplying target-blanket assemblies with the help of zero-power experiments set up at a separate, dedicated beam line of the accelerator. (author) 3 figs., 2 tabs., 8 refs

  5. Accelerator-based neutrino oscillation searches

    International Nuclear Information System (INIS)

    Whitehouse, D.; Rameika, G.

    1993-01-01

    This paper attempts to summarize the neutrino oscillation section of the Workshop on Future Directions in Particle and Nuclear Physics at Multi-GeV Hadron Beam Facilities. There were very lively discussions about the merits of the different oscillation channels, experiments, and facilities, but the authors believe a substantial consensus emerged

  6. First accelerator-based physics of 2014

    CERN Multimedia

    Katarina Anthony

    2014-01-01

    Experiments in the East Area received their first beams from the PS this week. Theirs is CERN's first accelerator-based physics since LS1 began last year.   For the East Area, the PS performs a so-called slow extraction, where beam is extracted during many revolution periods (the time it take for particles to go around the PS, ~2.1 μs). The yellow line shows the circulating beam current in the PS, decreasing slowly during the slow extraction, which lasts 350 ms. The green line is the measured proton intensity in the transfer line toward the East Area target. Although LHC physics is still far away, we can now confirm that the injectors are producing physics! In the East Area - the experimental area behind the PS - the T9 and T10 beam lines are providing beams for physics. These beam lines serve experiments such as AIDA - which looks at new detector solutions for future accelerators - and the ALICE Inner Tracking System - which tests components for the ALICE experiment. &qu...

  7. Development of lithium target for accelerator based neutron capture therapy

    International Nuclear Information System (INIS)

    Taskaev, Sergey; Bayanov, Boris; Belov, Victor; Zhoorov, Eugene

    2006-01-01

    Pilot innovative accelerator based neutron source for neutron capture therapy of cancer is now of the threshold of its operation at the BINP, Russia. One of the main elements of the facility is lithium target producing neutrons via threshold 7 Li(p,n) 7 Be reaction at 25 kW proton beam with energies 1.915 MeV or 2.5 MeV. The main problems of lithium target were determined to be: 7 Be radioactive isotope activation keeping lithium layer solid, presence of photons due to proton inelastic scattering on lithium nuclei, and radiation blistering. The results of thermal test of target prototype were presented as previous NCT Congress. It becomes clear that water is preferable for cooling the target, and that lithium target 10 cm in diameter is able to run before melting. In the present report, the conception of optimal target is proposed: thin metal disk 10 cm in diameter easy for detaching, with evaporated thin layer of pure lithium from the side of proton beam exposure, its back being intensively cooled with turbulent water flow to maintain lithium layer solid. Design of the target for the neutron source constructed at BINP is shown. The results of investigation of radiation blistering and lithium layer are presented. Target unit of facility is under construction now, and obtaining neutrons is expected in nearest future. (author)

  8. Comparison and analysis of BNCT radiation dose between gold wire and JCDS measurement

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, Hiroaki

    2006-01-01

    We compared and evaluated boron neutron capture therapy (BNCT) radiation dose between gold wire measurement and JAERI Computational Dosimetry System (JCDS). Gold wire analysis demonstrates the actual BNCT dose though it dose not reflect the real the maximum and minimum dose in tumor tissue. We can conclude that JCDS is precise and high-reliable dose planning system for BNCT. (author)

  9. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: An experimental study that supports a potential new application of BNCT

    International Nuclear Information System (INIS)

    Monti Hughes, A.; Heber, E.M.; Pozzi, E.; Nigg, D.W.; Calzetta, O.; Blaumann, H.; Longhino, J.; Nievas, S.I.; Aromando, R.F.; Itoiz, M.E.; Trivillin, V.A.; Schwint, A.E.

    2009-01-01

    We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na 2 10 B 10 H 10 ) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.

  10. Proposal for an accelerator-based neutron generator

    International Nuclear Information System (INIS)

    Grand, P.

    1975-07-01

    An Accelerator-based Neutron Generator is described that consists of a 30-MeV deuteron linear accelerator using a flowing liquid lithium target. With a continuous deuteron current of 100 milliamperes, a source intensity of more than 10 16 neutrons per second will be produced. The neutrons will be emitted in a roughly collimated beam. The proposed facility can be divided into two areas: the 30-MeV linear accelerator and the multiple-target experimental area. The 30-MeV accelerator will consist of eight rf accelerating cavities in a single vacuum tank, each cavity being powered by its own rf power amplifier operating at 50 MHz. To shield the beam bunches from the rf field when it is in the decelerating direction, 66 ''drift tubes'' will be included; the drift-tube structures will include quadrupole magnets which will keep the beam focused. The accelerator will produce a continuous beam of 100 milliamperes. Beam power will thus be 3.0 megawatts; total power including rf losses in the accelerating cavities will be 4.5 megawatts. The injectors for the linear accelerator will be two 500-kV dc accelerators, one for injection of D + ions and the other for D - ions. They can be used simultaneously or one can serve as a spare in case of breakdown or maintenance of the other. (U.S.)

  11. Cyclotron Development and Technical Aspects on Accelerator Based Laboratory Development

    International Nuclear Information System (INIS)

    Sunarhadijoso

    2000-01-01

    BATAN is planning to establish an accelerator-based laboratory at P3TM Yogyakarta as an effort in the development and use of accelerator technology for improving industrial performance and public welfare. This paper reviews several aspects of cyclotron technology and describes the combination of a linear accelerator - cyclotron system as an alternative to be considered in the planing of the laboratory. The progress of cyclotron technology is discussed covering three generations, i.e. conventional cyclotron, synchrocyclotron and AVF cyclotron generations. The planning should not consider the accelerator application for radioisotope production because it is established in Serpong with the existing negative ion cyclotron. The proposed facility at P3TM may comprise two linear accelerators coupled with a positive ion cyclotron of synchrocyclotron generation. In fact, the attachment of the synchrocyclotron unit is flexible and it can be installed subsequently if the higher energy particle beam, which can not be produced by the linear accelerators, is extremely needed. Some technical aspects related to ion beam application, building construction and infrastructure, human resources, and specification of function test are discussed for additional information in the implementation of the planning. (author)

  12. In vitro studies of the cellular response to boron neutron capture therapy (BNCT) in thyroid carcinoma

    International Nuclear Information System (INIS)

    Rodriguez, C; Carpano, M; Perona, M; Thorp, S; Curotto, P; Pozzi, E; Casal, M; Juvenal, G; Pisarev, M; Dagrosa, A

    2012-01-01

    Background: Previously, we have started to study the mechanisms of DNA damage and repair induced by BNCT in thyroid carcinoma some years ago. We have shown different genotoxic patterns for tumor cells irradiated with gamma rays, neutrons alone or neutrons plus different compounds, boronophenylalanine (BPA) or α, β - dihydroxyethyl)-deutero-porphyrin IX (BOPP). In the present study we analyzed the expression of Ku70, Rad51 and Rad54 components of non homologous end-joing (NHEJ) and homologous recombination repair (HRR) pathways, respectively, induced by BNCT in human cells of thyroid carcinoma. Methods: A human cell line of follicular thyroid carcinoma (WRO) in exponential growth phase was distributed into the following groups: 1) Gamma Radiation, 2) Radiation with neutrons beam (NCT), 3) Radiation with n th in presence of BPA (BNCT). A control group for each treatment was added. The cells were irradiated in the thermal column facility of the RA-3 reactor (flux= 1.10 10 n/cm 2 sec) or with a source of 60 Co. The irradiations were performed during different lapses in order to obtain a total physical dose of 3 Gy (±10%). The mRNA expressions of Ku70, Rad 51 and Rad 54 were analysed by reverse transcription-polymerase chain reaction (RT-PCR) at different times post irradiation (2, 4, 6, 24 and 48 h). DNA damage was evaluated by immunofluorescence using an antibody against the phosphorylation of histone H2AX, which indicates double strand breaks in the DNA. Results: The expression of Rad51 increased at 2 h post-irradiation and it lasted until 6 h only in the neutron and neutron + BPA groups (p<0.05). Rad54 showed an up-regulation from 2 to 24 h in both groups irradiated with the neutron beam (with and without BPA) (p<0.05). On the other hand, Ku70 mRNA did not show a modification of its expression in the irradiated groups respect to the control group. Conclusion: these results would indicate an activation of the HRR pathway in the thyroid carcinoma cells treated by

  13. INEEL BNCT Research Program Annual Report, CY-2000

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, James Robert

    2001-03-01

    This report is a summary of the activities conducted in conjunction with the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 2000. Applications of supportive research and development, as well as technology deployment in the fields of chemistry, radiation physics and dosimetry, neutron source design and demonstration, and support the Department of Energy’s (DOE) National BNCT Program goals are the goals of this Program. Contributions from the individual contributors about their projects are included, specifically described are the following, chemistry: analysis of biological samples and an infrared blood-boron analyzer, and physics: progress in the patient treatment planning software, measurement of neutron spectra for the Argentina RA-6 reactor, and recalculation of the Finnish research reactor FiR 1 neutron spectra, BNCT accelerator technology, and modification to the research reactor at Washington State University for an epithermal-neutron beam.

  14. Protocols for BNCT of glioblastoma multiforme at Brookhaven: Practical considerations

    Energy Technology Data Exchange (ETDEWEB)

    Chanana, A.D.; Coderre, J.A.; Joel, D.D.; Slatkin, D.N.

    1996-12-31

    In this report we discuss some issues considered in selecting initial protocols for boron neutron capture therapy (BNCT) of human glioblastoma multiforme. First the tolerance of normal tissues, especially the brain, to the radiation field. Radiation doses limits were based on results with human and animal exposures. Estimates of tumor control doses were based on the results of single-fraction photon therapy and single fraction BNCT both in humans and experimental animals. Of the two boron compounds (BSH and BPA), BPA was chosen since a FDA-sanctioned protocol for distribution in humans was in effect at the time the first BNCT protocols were written and therapy studies in experimental animals had shown it to be more effective than BSH.

  15. Cyclotron-based neutron source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Mitsumoto, T.; Yajima, S.; Tsutsui, H.; Ogasawara, T.; Fujita, K. [Sumitomo Heavy Industries, Ltd (Japan); Tanaka, H.; Sakurai, Y.; Maruhashi, A. [Kyoto University Research Reactor Institute (Japan)

    2013-04-19

    Kyoto University Research Reactor Institute (KURRI) and Sumitomo Heavy Industries, Ltd. (SHI) have developed a cyclotron-based neutron source for Boron Neutron Capture Therapy (BNCT). It was installed at KURRI in Osaka prefecture. The neutron source consists of a proton cyclotron named HM-30, a beam transport system and an irradiation and treatment system. In the cyclotron, H- ions are accelerated and extracted as 30 MeV proton beams of 1 mA. The proton beams is transported to the neutron production target made by a beryllium plate. Emitted neutrons are moderated by lead, iron, aluminum and calcium fluoride. The aperture diameter of neutron collimator is in the range from 100 mm to 250 mm. The peak neutron flux in the water phantom is 1.8 Multiplication-Sign 109 neutrons/cm{sup 2}/sec at 20 mm from the surface at 1 mA proton beam. The neutron source have been stably operated for 3 years with 30 kW proton beam. Various pre-clinical tests including animal tests have been done by using the cyclotron-based neutron source with {sup 10}B-p-Borono-phenylalanine. Clinical trials of malignant brain tumors will be started in this year.

  16. Conceptual Design of a Clinical BNCT Beam in an Adjacent Dry Cell of the Jozef Stefan Institute TRIGA Reactor

    International Nuclear Information System (INIS)

    Maucec, Marko

    2000-01-01

    The MCNP4B Monte Carlo transport code is used in a feasibility study of the epithermal neutron boron neutron capture therapy facility in the thermalizing column of the 250-kW TRIGA Mark II reactor at the Jozef Stefan Institute (JSI). To boost the epithermal neutron flux at the reference irradiation point, the efficiency of a fission plate with almost 1.5 kg of 20% enriched uranium and 2.3 kW of thermal power is investigated. With the same purpose in mind, the TRIGA reactor core setup is optimized, and standard fresh fuel elements are concentrated partly in the outermost ring of the core. Further, a detailed parametric study of the materials and dimensions for all the relevant parts of the irradiation facility is carried out. Some of the standard epithermal neutron filter/moderator materials, as well as 'pressed-only' low-density Al 2 O 3 and AlF 3 , are considered. The proposed version of the BNCT facility, with PbF 2 as the epithermal neutron filter/moderator, provides an epithermal neutron flux of ∼1.1 x 10 9 n/cm 2 .s, thus enabling patient irradiation times of nfast /φ epi -13 Gy.cm 2 /n and [overdot]D γ /φ epi -13 Gy.cm 2 /n), the in-air performances of the proposed beam are comparable to all existing epithermal BNCT facilities. The design presents an equally efficient alternative to the BNCT beams in TRIGA reactor thermal columns that are more commonly applied. The cavity of the dry cell, a former JSI TRIGA reactor spent-fuel storage facility, adjacent to the thermalizing column, could rather easily be rearranged into a suitable patient treatment room, which would substantially decrease the overall developmental costs

  17. Feasibility of the utilization of BNCT in the fast neutron therapy beam at Fermilab

    International Nuclear Information System (INIS)

    Langen, Katja; Lennox, Arlene J.; Kroc, Thomas K.; DeLuca, Paul M. Jr.

    2000-01-01

    The Neutron Therapy Facility at Fermilab has treated cancer patients since 1976. Since then more than 2,300 patients have been treated and a wealth of clinical information accumulated. The therapeutic neutron beam at Fermilab is produced by bombarding a beryllium target with 66 MeV protons. The resulting continuous neutron spectrum ranges from thermal to 66 MeV in neutron energy. It is clear that this spectrum is not well suited for the treatment of tumors with boron neutron capture therapy (BNCT) only However, since this spectrum contains thermal and epithermal components the authors are investigating whether BNCT can be used in this beam to boost the tumor dose. There are clinical scenarios in which a selective tumor dose boost of 10 - 15% could be clinically significant. For these cases the principal treatment would still be fast neutron therapy but a tumor boost could be used either to deliver a higher dose to the tumor tissue or to reduce the dose to the normal healthy tissue while maintaining the absorbed dose level in the tumor tissue

  18. Monte Carlo simulation to study the doses in an accelerator BNCT treatment

    International Nuclear Information System (INIS)

    Burlon, Alejandro A.; Valda, Alejandro A.; Somacal, Hector R.; Kreiner, Andres J.; Minsky, Daniel M.

    2003-01-01

    In this work the 7 Li(p, n) 7 Be reaction has been studied as a neutron source for accelerator-based BNCT (Boron Neutron Capture Therapy). In order to optimize the design of the neutron production target and the beam shaping assembly, extensive MCNP simulations have been performed. These simulations include a thick Li metal target, a whole-body phantom, a moderator-reflector assembly (Al/AlF 3 as moderator and graphite as reflector) and the treatment room. The doses were evaluated for two proton bombarding energies of 1.92 MeV (near to the threshold of the reaction) and 2.3 MeV (near to the resonance of the reaction) and for three Al/ALF 3 moderator thicknesses (18, 26 and 34 cm). To assess the doses, a comparison using a Tumor Control Probability (TCP) model was done. In a second instance, the effect of the specific skin radiosensitivity (an RBE of 2.5 for the 10 B(n,α) 7 Li reaction) and a 10 B uptake of 17 ppm was considered for the scalp. Finally, the simulations show the advantage of irradiating with near-resonance-energy protons (2.3 MeV) because of the high neutron yield at this energy, leading to the lowest treatment times. Moreover, the 26 cm Al/AlF 3 moderator has shown the best performance among the studied cases. (author)

  19. Reactor - and accelerator-based filtered beams

    International Nuclear Information System (INIS)

    Mill, A.J.; Harvey, J.R.

    1980-01-01

    The neutrons produced in high flux nuclear reactors and in accelerator, induced fission and spallation reactions, represent the most intense sources of neutrons available for research. However, the neutrons from these sources are not monoenergetic, covering the broad range extending from 10 -3 eV up to 10 7 eV or so. In order to make quantitative measurements of the effects of neutrons and their dependence on neutron energy it is desirable to have mono-energetic neutron sources. The paper describes briefly methods of obtaining mono-energetic neutrons and different methods of filtration. This is followed by more detailed discussion of neutron window filters and a summary of the filtered beam facilities using this technique. The review concludes with a discussion of the main applications of filtered beams and their present and future importance

  20. Boron Neutron Capture Therapty (BNCT) in an Oral Precancer Model: Therapeutic Benefits and Potential Toxicity of a Double Application of BNCT with a Six-Week Interval

    Energy Technology Data Exchange (ETDEWEB)

    Andrea Monti Hughes; Emiliano C.C. Pozzi; Elisa M. Heber; Silvia Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; Ana J. Molinari; Marcela A. Garabalino; David W. Nigg; Veronica A. Trivillin; Amanda E. Schwint

    2011-11-01

    Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10 + BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB- 10 + BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10 + BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.

  1. Specific contributions of the Dutch progamme ''RAS'' towards accelerator-based transmutation

    International Nuclear Information System (INIS)

    Abrahams, K.; Franken, W.M.P.; Bultman, J.H.; Heil, J.A.; Koning, A.J.

    1994-09-01

    Accelerator-based transmutation is being studied by ECN within its general nuclear waste transmutation programme RAS. In this paper the following contributions are presented: (1) Evaluation of cross sections at intermediate energies, within an international frame given by NEA, (2) Cell calculations on the equilibration of transuranium actinides in thermal molten-salt transmuters, (3) Irradiation facilities at the European research reactor HFR in Petten, which have been constructed with the purpose to demonstrate and investigate the transmutation of waste in a high neutron flux, (4) Studies of accelerator-based neutron generating systems to transmute neptunium and technetium, (5) Comparison of several systems on the basis of criteria for successful nuclear waste-management. (orig.)

  2. In vivo BNCT in experimental and spontaneous tumors at RA-1 reactor

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Nigg, David W.

    2003-01-01

    Within the search for new applications of Boron Neutron Capture Therapy (BNCT) and the basic research oriented towards the study of BNCT radiobiology to optimize its therapeutic gain, we previously proposed and validated the hamster cheek pouch oral cancer model and showed, for the first time, the success of BNCT to treat oral cancer in an experimental model. The staff of the Ra-1 Reactor (Constituyentes Atomic Center) adapted the thermal beam and physical set-up to perform in vivo BNCT of superficial tumors in small animals. We preformed a preliminary characterization of the thermal beam, performed beam only irradiation of normal and tumor bearing hamsters and in vivo BNCT of experimental oral squamous cell carcinomas in hamsters mediated by boron phenylalanine (BPA) and GB-10 (Na 2 10 B 10 H 10 ). Having demonstrated the absence of radio toxic effects in healthy tissue and a therapeutic effect of in vivo BNCT in hamster cheek pouch tumors employing the Ra-1 thermal beam, we performed a feasibility study of the treatment by BNCT of 3 terminal cases of spontaneous head and neck squamous cell carcinoma in cats following the corresponding biodistribution studies. This was the first treatment of spontaneous tumors by BNCT in our country and the first treatment by BNCT in cats worldwide. This preclinical study in terminal cases showed significant tumor control by BNCT with no damage to normal tissue. (author)

  3. An update on the clinical trial of BNCT at the BMRR

    International Nuclear Information System (INIS)

    Ma, R.; Capala, J.; Chanana, A.D.; Coderre, J.A.; Diaz, A.Z.

    1999-01-01

    Boron neutron capture therapy (BNCT) was proposed more than six decades ago. It is a binary treatment modality that requires selective delivery of a 10 B-labeled compound to a tumor and slow neutron irradiation of the tumor-bearing tissues. In order to improve the penetration of the neutron beam, an epithermal neutron beam was developed at the Brookhaven Medical Research Reactor (BMRR). This epithermal neutron beam can deliver relatively high thermal neutron fluence at depth without severe skin damage. Boronophenylalanine-fructose (BPA-F), a nontoxic boron carrier, was found to preferentially accumulate in tumor cells following intravenous infusion in patients with GBM. In preclinical BNCT studies in rats bearing 9L gliosarcoma, BPA-mediated BNCT was shown to be more efficacious than photon irradiation. In 1994, improvements in the neutron beam and in the understanding of the radiobiology of BPA-mediated BNCT led to the initiation of BNCT trials for human GBM at BMRR using BPA-F and epithermal neutrons. The primary objective of the phase I/II clinical trial of BPA-mediated BNCT at BMRR is to evaluate the safety of the BPA-F-mediated BNCT using epithermal neutrons in patients with GBM at a series of escalating BNCT doses. An incidental objective is to evaluate the therapeutic effectiveness of BNCT at each dose level. For each dose escalation group, the average brain dose (ABD) is escalated, as well as the minimum tumor dose. In summary, the BNCT procedure employed in the phase I/II clinical trial of BPA-F-mediated BNCT for GBM at BNL was found to be safe in all patients. The palliation afforded by a single session of BNCT compares favorably with palliation provided by fractionated photon therapy and adjuvant chemotherapy. If no evidence of radiation-induced brain toxicity is found in the current protocol, BNCT radiation dose will be further escalated

  4. Boron Neutron Capture Therapy at the TRIGA Mark II of Pavia, Italy - The BNCT of the diffuse tumours

    Energy Technology Data Exchange (ETDEWEB)

    Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Gadan, M.A. [University of Pavia (Italy); INFN - National Institute for Nuclear Physics, of Pavia (Italy)

    2008-10-29

    The selectivity based on the B distribution rather than on the irradiation field makes Boron neutron Capture Therapy (BNCT) a valid option for the treatment of the disseminated tumours. As the range of the high LET particles is shorter than a cell diameter, the normal cells around the tumour are not damaged by the reactions occurring in the tumoral cells. PAVIA 2001: first treatment of multiple hepatic metastases from colon ca by BNCT and auto-transplantation technique: TAOrMINA project. The liver was extracted after BPA infusion, irradiated in the Thermal Column of the Pavia TRIGA Mark II reactor, and re-implanted in the patient. Two patients were treated, demonstrating the feasibility of the therapy and the efficacy in destroying the tumoral nodules sparing the healthy tissues. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research are presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. The dose distribution in the thorax are simulated using MCNP and the anthropomorphic model ADAM. To have a good thermal flux distribution inside the lung epithermal neutrons must be used, which thermalize crossing the first tissue layers. Thermal neutrons do not penetrate and the obtained uniformity is poor. In the future, the construction of a PGNAA facility using a horizontal channel of the TRIGA Mark II is planned. With this method the B concentration can be measured also in liquid samples (blood, urine) and

  5. SPES-BNCT Project Beam Shaping Assembly. State of the Art

    International Nuclear Information System (INIS)

    Ceballos Sanchez, Cesar

    2007-01-01

    The SPES-BNCT project will exploit the intense proton beam provided by the RFQ (30mA, 5MeV), currently under construction at LNL, to yield a neutron source using the 9 Be(p,xn) nuclear reaction. The goal is to setup an accelerator-driven, thermal neutron beam facility, aimed at the Boron Neutron Capture experimental treatment of extended shallow skin melanoma. The neutron energy spectrum is shifted with a beam shaping assembly (BSA) surrounding the target. This device is fully designed with the Monte Carlo simulation code MCNPX, with the purpose of maximizing the thermal neutron component of the beam and focusing it on the irradiation area. (Author)

  6. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: An experimental study that supports a potential new application of BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, A.; Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Pozzi, E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Research and Production Reactors, Ezeiza Atomic Center, CNEA, Buenos Aires (Argentina); Nigg, D.W. [Idaho National Laboratory, Idaho Falls, Idaho (United States); Calzetta, O.; Blaumann, H.; Longhino, J. [Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, Rio Negro (Argentina); Nievas, S.I. [Department of Chemistry, CNEA, Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Trivillin, V.A. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina)], E-mail: schwint@cnea.gov.ar

    2009-07-15

    We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na{sub 2}{sup 10}B{sub 10}H{sub 10}) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.

  7. Accelerator-based atomic physics experiments with photon and ion beams

    International Nuclear Information System (INIS)

    Johnson, B.M.; Jones, K.W.; Meron, M.

    1984-01-01

    Accelerator-based atomic physics experiments at Brookhaven presently use heavy-ion beams from the Dual MP Tandem Van de Graaff Accelerator Facility for atomic physics experiments of several types. Work is presently in progress to develop experiments which will use the intense photon beams which will be available in the near future from the ultraviolet (uv) and x-ray rings of the National Synchrotron Light Source (NSLS). Plans are described for experiments at the NSLS and an exciting development in instrumentation for heavy-ion experiments is summarized

  8. Dosimetric performance evaluation regarding proton beam incident angles of a lithium-based AB-BNCT design

    International Nuclear Information System (INIS)

    Lee, Pei-Yi; Jiang, Shiang-Huei; Liu, Yuan-Hao

    2014-01-01

    The 7 Li(p,xn) 7 Be nuclear reaction, based on the low-energy protons, could produce soft neutrons for accelerator-based boron neutron capture therapy (AB-BNCT). Based on the fact that the induced neutron field is relatively divergent, the relationship between the incident angle of proton beam and the neutron beam quality was evaluated in this study. To provide an intense epithermal neutron beam, a beam-shaping assembly (BSA) was designed. And a modified Snyder head phantom was used in the calculations for evaluating the dosimetric performance. From the calculated results, the intensity of epithermal neutrons increased with the increase in proton incident angle. Hence, either the irradiation time or the required proton current can be reduced. When the incident angle of 2.5-MeV proton beam is 120 deg., the required proton current is ∼13.3 mA for an irradiation time of half an hour. The results of this study show that the BSA designs can generate neutron beams with good intensity and penetrability. Using a 20-mA, 2.5-MeV proton beam as the source, the required irradiation time, to induce 60 RBE-Gy of maximum tumour dose, is less than half an hour in any proton beam alignments. On the premise that the dosimetric performances are similar, the intensity of epithermal neutrons can be increased by using non-collinear (e.g. 90 deg., 120 deg.) incident protons. Thus, either the irradiation time or the required proton current can be reduced. The use of 120 deg. BSA model shows the possibility to reduce the required proton current to ∼13.3 mA when the goal of irradiation time is 30 min. The decrease of required proton beam current certainly will make the use of lithium target much easier. In June 2013, a 5-MeV, 30-mA radio frequency quadruple (RFQ) accelerator for BNCT was built at INFN-LNL (Legnaro National Laboratories, Italy), which shows a possibility to build a suitable RFQ accelerator for the authors' design. In addition, a 2.5-MeV, 30-mA Tandem accelerator was

  9. Nuclear engineering aspects of glioma BNCT research in Italy

    International Nuclear Information System (INIS)

    Curzio, G.; Mazzini, M.

    1998-01-01

    A research project on Boron Neutron Capture Therapy (BNCZ) of gliomas has been set up in Italy, with the participation of Departments of Oncology and Mechanical and Nuclear Construction (DCMN) of the University of Pisa, as well as the Neuroscience and Physics Departments of the Universities of Roma. The specific objective of DCMN Research Unit is the study of the physical-engineering aspects related to BNCT. The paper outlines the research lines in progress at DCMN: Monte Carlo calculations of neutron dose distribution for BNCT treatment planning; measurements of neutron fluxes, spectra and doses by neutron detectors specifically set up; design of modifications to the nuclear reactors of ENEA Casaccia Center. In particular, the paper emphasizes the most original contributions on dosimetric aspects, both from informatic and experimental points of view.(author)

  10. Treatment Planning Systems for BNCT Requirements and Peculiarities

    CERN Document Server

    Daquino, G G

    2003-01-01

    The main requirements and peculiarities expected from the BNCT-oriented treatment planning system (TPS) are summarized in this paper. The TPS is a software, which can be integrated or composed by several auxiliary programs. It plays important roles inside the whole treatment planning of the patient's organ in BNCT. However, the main goal is the simulation of the irradiation, in order to obtain the optimal configuration, in terms of neutron spectrum, patient positioning and dose distribution in the tumour and healthy tissues. The presence of neutrons increases the level of complexity, because much more nuclear reactions need to be monitored and properly calculated during the simulation of the patient's treatment. To this purposes several 3D geometry reconstruction techniques, generally based on the CT scanning data, are implemented and Monte Carlo codes are normally used. The TPSs are expected to show also the results (basically doses and fluences) in a proper format, such as isocurves (or isosurfaces) along t...

  11. Measurement and simulation of the TRR BNCT beam parameters

    Energy Technology Data Exchange (ETDEWEB)

    Bavarnegin, Elham [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Department of Physics, University of Guilan, Rasht (Iran, Islamic Republic of); Sadremomtaz, Alireza [Department of Physics, University of Guilan, Rasht (Iran, Islamic Republic of); Khalafi, Hossein [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Kasesaz, Yaser, E-mail: ykasesaz@aeoi.org.ir [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Golshanian, Mohadeseh; Ghods, Hossein; Ezzati, Arsalan; Keyvani, Mehdi; Haddadi, Mohammad [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of)

    2016-09-11

    Recently, the configuration of the Tehran Research Reactor (TRR) thermal column has been modified and a proper thermal neutron beam for preclinical Boron Neutron Capture Therapy (BNCT) has been obtained. In this study, simulations and experimental measurements have been carried out to identify the BNCT beam parameters including the beam uniformity, the distribution of the thermal neutron dose, boron dose, gamma dose in a phantom and also the Therapeutic Gain (TG). To do this, the entire TRR structure including the reactor core, pool, the thermal column and beam tubes have been modeled using MCNPX Monte Carlo code. To measure in-phantom dose distribution a special head phantom has been constructed and foil activation techniques and TLD700 dosimeter have been used. The results show that there is enough uniformity in TRR thermal BNCT beam. TG parameter has the maximum value of 5.7 at the depth of 1 cm from the surface of the phantom, confirming that TRR thermal neutron beam has potential for being used in treatment of superficial brain tumors. For the purpose of a clinical trial, more modifications need to be done at the reactor, as, for example design, and construction of a treatment room at the beam exit which is our plan for future. To date, this beam is usable for biological studies and animal trials. There is a relatively good agreement between simulation and measurement especially within a diameter of 10 cm which is the dimension of usual BNCT beam ports. This relatively good agreement enables a more precise prediction of the irradiation conditions needed for future experiments.

  12. Synthesis and evaluation of boronated folates for BNCT

    International Nuclear Information System (INIS)

    Shukla, S.; Sekido, M.; Guo, W.; Mueller, R.; Sudimack, J.; Lee, R.J.; Tjarks, W.; Adams, D.M.; Barth, R.F.

    2000-01-01

    To study the possible utilization of folic acid as the 10 B carrier for BNCT, folic acid conjugated boron containing liposomes and starburst dendrimers were prepared. In both systems folic acid was used as the recognition part and polyethylene glycol (PEG) as the spacer. In vitro studies were carried out using folate receptor overexpressing 24JK-FBP and KB cells. The results indicated that these boronated folic acid conjugates were incorporated into the tumor cells via receptor-mediated endocytosis. (author)

  13. Optimization of the application of BNCT to undifferentiated thyroid cancer

    International Nuclear Information System (INIS)

    Dagrosa, M.A.; Thomasz, L.; Longhino, J.

    2006-01-01

    The possible increase in BNCT efficacy for undifferentiated thyroid carcinoma (UTC) using BPA plus BOPP and nicotinamide (NA) as a radiosensitizer on the BNCT reaction was analyzed. In these studies nude mice were transplanted with the ARO cells and after 14 days they were treated as follows: 1) Control; 2) NCT (neutrons alone); 3) NCT plus NA (100 mg/kg bw/day for 3 days); 4) BPA (350 mg/kg bw) + neutrons; 5) BPA+ NA+ neutrons; 6) BPA+BOPP (60 mg/kg bw) + neutrons. The flux of hyperthermal neutrons was 2.8 10 8 during 85 min. Neutrons alone or with NA caused some tumor growth delay, while in the BPA, BPA+NA and BPA+BOPP groups a 100% halt of tumor growth was observed. When the initial tumor volume was 50 mm 3 or less a complete cure was found in BPA+NA (2/2); BPA (1/4); BPA+BOPP (7/7). After 90 days of complete regression, recurrence of tumor was observed in 2/2 BPA/NA (2/2) and BPA+BOPP (1/7). Caspase 3 activity was increased in BPA+NA (p<0.05 vs controls). BPA plus NA increased tumor apoptosis but only the combination of BPA+BOPP increased significantly BNCT efficiency. (author)

  14. Medical setup of intraoperative BNCT at JRR-4

    International Nuclear Information System (INIS)

    Akutsu, H.; Yamamoto, T.; Matsumura, A.

    2000-01-01

    Since October 1999, we have been performing clinical trials of intraoperative boron neutron capture therapy (IOBNCT) using a mixed thermal-epithermal beam at the Japan Research Reactor No. 4 (JRR-4). For immediate pre-BNCT care, including administration of a boron compound as well as post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of JRR-4. Following craniotomy in the treatment room, anesthetized patients were transported into the irradiation room for BNCT. The boron concentration in tissue was measured by the PGA and ICP-AES methods. The long-term follow-up was done at the University of Tsukuba Hospital. IOBNCT is a complex clinical procedure, which requires sophisticated operating team and co-medical staffs and also cooperation with physicist team. IOBNCT is a complex clinical procedure requiring a high level of cooperation among the operating team, co-medical staff, and physicists. For the safe and successful performance of IOBNCT, we have made the program including critical pathway and prepared various equipments for IOBNCT. To ensure the safe and successful performance of IOBNCT, we developed a critical pathway for use during the procedure, and prepared various apparatus for IOBNCT. (author)

  15. In vitro biological models in order to study BNCT

    International Nuclear Information System (INIS)

    Dagrosa, Maria A.; Kreimann, Erica L.; Schwint, Amanda E.; Juvenal, Guillermo J.; Pisarev, Mario A.; Farias, Silvia S.; Garavaglia, Ricardo N.; Batistoni, Daniel A.

    1999-01-01

    Undifferentiated thyroid carcinoma (UTC) lacks an effective treatment. Boron neutron capture therapy (BNCT) is based on the selective uptake of 10 B-boronated compounds by some tumours, followed by irradiation with an appropriate neutron beam. The radioactive boron originated ( 11 B) decays releasing 7 Li, gamma rays and alpha particles, and these latter will destroy the tumour. In order to explore the possibility of applying BNCT to UTC we have studied the biodistribution of BPA. In vitro studies: the uptake of p- 10 borophenylalanine (BPA) by the UTC cell line ARO, primary cultures of normal bovine thyroid cells (BT) and human follicular adenoma (FA) thyroid was studied. No difference in BPA uptake was observed between proliferating and quiescent ARO cells. The uptake by quiescent ARO, BT and FA showed that the ARO/BT and ARO/FA ratios were 4 and 5, respectively (p< 0.001). The present experimental results open the possibility of applying BNCT for the treatment of UTC. (author)

  16. Clinical results of BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    Nakagawa, Yoshinobu; Kageji, Teruyoshi; Mizobuchi, Yoshifumi; Kumada, Hiroaki; Nakagawa, Yoshiaki

    2009-01-01

    It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue. However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells. We evaluated the clinical results and courses in patients with malignant glioma under 15 years. Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years. They included 4 patients under 3 years. There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma. All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth. All pontine glioma patients died due to regrowth of the tumor. Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence. BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation. Although it can achieve the local control in the primary site, it cannot prevent CSF dissemination in patients with glioblastoma.

  17. Accelerator-based intense neutron source for materials R ampersand D

    International Nuclear Information System (INIS)

    Jameson, R.A.

    1990-01-01

    Accelerator-based neutron sources for R ampersand D of materials in nuclear energy systems, including fusion reactors, can provide sufficient neutron flux, flux-volume, fluence and other attractive features for many aspects of materials research. The neutron spectrum produced from the D-Li reaction has been judged useful for many basic materials research problems, and to be a satisfactory approximation to that of the fusion process. The technology of high-intensity linear accelerators can readily be applied to provide the deuteron beam for the neutron source. Earlier applications included the Los Alamos Meson Physics Facility and the Fusion Materials Irradiation Test facility prototype. The key features of today's advanced accelerator technology are presented to illustrate the present state-of-the-art in terms of improved understanding of basic physical principles and engineering technique, and to show how these advances can be applied to present demands in a timely manner. These features include how to produce an intense beam current with the high quality required to minimize beam losses along the accelerator and transport system that could cause maintenance difficulties, by controlling the beam emittance through proper choice of the operating frequency, balancing of the forces acting on the beam, and realization in practical hardware. A most interesting aspect for materials researchers is the increased flexibility and opportunities for experimental configurations that a modern accelerator-based source could add to the set of available tools. 8 refs., 5 figs

  18. Calculations of accelerator-based neutron sources characteristics

    International Nuclear Information System (INIS)

    Tertytchnyi, R.G.; Shorin, V.S.

    2000-01-01

    Accelerator-based quasi-monoenergetic neutron sources (T(p,n), D(d;n), T(d;n) and Li (p,n)-reactions) are widely used in experiments on measuring the interaction cross-sections of fast neutrons with nuclei. The present work represents the code for calculation of the yields and spectra of neutrons generated in (p, n)- and ( d; n)-reactions on some targets of light nuclei (D, T; 7 Li). The peculiarities of the stopping processes of charged particles (with incident energy up to 15 MeV) in multilayer and multicomponent targets are taken into account. The code version is made in terms of the 'SOURCE,' a subroutine for the well-known MCNP code. Some calculation results for the most popular accelerator- based neutron sources are given. (authors)

  19. A new method to evaluate neutron spectra for bnct

    International Nuclear Information System (INIS)

    Martin Hernandez, Guido

    2001-01-01

    This paper deals with the development of a method to evaluate neutron spectra for BNCT. Physical dose deposition calculations for different neutron energies, ranging from thermal to fast, were performed. A matrix, containing dose for each energy and position in the beam center line was obtained. MCNP 4B and Snyder's head model were used. A simple computer code containing the matrix calculates the dose for each point in the beam center line depending on the input energy spectrum to be evaluated. The output of this program is the dose distribution in the brain and the dose gain, that is the ratio between dose to tumor and maximum dose to healthy tissue maximum

  20. Fatal carotid blowout syndrome after BNCT for head and neck cancers

    International Nuclear Information System (INIS)

    Aihara, T.; Hiratsuka, J.; Ishikawa, H.; Kumada, H.; Ohnishi, K.; Kamitani, N.; Suzuki, M.; Sakurai, H.; Harada, T.

    2015-01-01

    Boron neutron capture therapy (BNCT) is high linear energy transfer (LET) radiation and tumor-selective radiation that does not cause serious damage to the surrounding normal tissues. BNCT might be effective and safe in patients with inoperable, locally advanced head and neck cancers, even those that recur at previously irradiated sites. However, carotid blowout syndrome (CBS) is a lethal complication resulting from malignant invasion of the carotid artery (CA); thus, the risk of CBS should be carefully assessed in patients with risk factors for CBS after BNCT. Thirty-three patients in our institution who underwent BNCT were analyzed. Two patients developed CBS and experienced widespread skin invasion and recurrence close to the carotid artery after irradiation. Careful attention should be paid to the occurrence of CBS if the tumor is located adjacent to the carotid artery. The presence of skin invasion from recurrent lesions after irradiation is an ominous sign of CBS onset and lethal consequences. - Highlights: • This study is fatal carotid blowout syndrome after BNCT for head and neck cancers. • Thirty-three patients in our institution who underwent BNCT were analyzed. • Two patients (2/33) developed CBS. • The presence of skin invasion from recurrent lesions after irradiation is an ominous sign of CBS. • We must be aware of these signs to perform BNCT safely.

  1. Accelerator-based conversion (ABC) of reactor and weapons plutonium

    International Nuclear Information System (INIS)

    Jensen, R.J.; Trapp, T.J.; Arthur, E.D.; Bowman, C.D.; Davidson, J.W.; Linford, R.K.

    1993-01-01

    An accelerator-based conversion (ABC) system is presented that is capable of rapidly burning plutonium in a low-inventory sub-critical system. The system also returns fission power to the grid and transmutes troublesome long-lived fission products to short lived or stable products. Higher actinides are totally fissioned. The system is suited not only to controlled, rapid burning of excess weapons plutonium, but to the long range application of eliminating or drastically reducing the world total inventory of plutonium. Deployment of the system will require the successful resolution of a broad range of technical issues introduced in the paper

  2. Accelerator-based conversion (ABC) of reactor and weapons plutonium

    Energy Technology Data Exchange (ETDEWEB)

    Jensen, R.J.; Trapp, T.J.; Arthur, E.D.; Bowman, C.D.; Davidson, J.W.; Linford, R.K.

    1993-06-01

    An accelerator-based conversion (ABC) system is presented that is capable of rapidly burning plutonium in a low-inventory sub-critical system. The system also returns fission power to the grid and transmutes troublesome long-lived fission products to short lived or stable products. Higher actinides are totally fissioned. The system is suited not only to controlled, rapid burning of excess weapons plutonium, but to the long range application of eliminating or drastically reducing the world total inventory of plutonium. Deployment of the system will require the successful resolution of a broad range of technical issues introduced in the paper.

  3. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Chadha, M. [Beth Israel Medical Center, NY (United States). Dept. of Radiation Oncology; Coderre, J.A.; Chanana, A.D. [Brookhaven National Lab., Upton, NY (United States)] [and others

    1996-12-31

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT.

  4. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Chadha, M.

    1996-01-01

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT

  5. Summaries on various researches aiming at the closed head BNCT

    International Nuclear Information System (INIS)

    Ono, Koji

    2000-01-01

    As in the boron neutron capture therapy (BNCT) flight of alpha particle formed by reaction of neutron and boron is nearly equal to diameter of cancer cell, when a boron compound accumulates selectively to a cancer cell to be radiated onto the cell by enough amount of neutron beam the alpha particles are irradiated onto the cancer cells nearly selectively. Like this, this is a curing means capable of overcoming a problem undecidable by a paradigm of radiation remedy in the 20th Century, a micro dose amount effect supposing to be a paradigm in the 21st Century, the very (biological) dose concentration into cancer cell is a curing method matching to upgrading on rate of cancer control and improvement on post-cure of the patients without increase of subreaction in every tumors. Here were summarized on characteristic comparison of thermal outer-neutron beams in KUR, JRR-4 and the Peten HFR reactors, development of new boron compounds, effect of BNCT on re-oxygenation of the cancer, and induction of mutation by neutron beam. (G.K.)

  6. Boron dose determination for BNCT using Fricke and EPR dosimetry

    International Nuclear Information System (INIS)

    Wielopolski, L.; Ciesielski, B.

    1995-01-01

    In Boron Neutron Capture Therapy (BNCT) the dominant dose delivered to the tumor is due to α and 7 Li charged particles resulting from a neutron capture by 10 B and is referred to herein as the boron dose. Boron dose is directly attributable to the following two independent factors, one boron concentration and the neutron capture energy dependent cross section of boron, and two the energy spectrum of the neutrons that interact with boron. The neutron energy distribution at a given point is dictated by the incident neutron energy distribution, the depth in tissue, geometrical factors such as beam size and patient's dimensions. To account for these factors can be accommodated by using Monte Carlo theoretical simulations. However, in conventional experimental BNCT dosimetry, e.g., using TLDs or ionization chambers, it is only possible to estimate the boron dose. To overcome some of the limitations in the conventional dosimetry, modifications in ferrous sulfate dosimetry (Fricke) and Electron Paramagnetic Resonance (EPR) dosimetry in alanine, enable to measure specifically boron dose in a mixed gamma neutron radiation fields. The boron dose, in either of the dosimeters, is obtained as a difference between measurements with boronated and unboronated dosimeters. Since boron participates directly in the measurements, the boron dosimetry reflects the true contribution, integral of the neutron energy spectrum with boron cross section, of the boron dose to the total dose. Both methods are well established and used extensively in dosimetry, they are presented briefly here

  7. SUPER-FMIT, an accelerator-based neutron source for fusion components irradiation testing

    International Nuclear Information System (INIS)

    Burke, R.J.; Holmes, J.J.; Johnson, D.L.; Mann, F.M.; Miles, R.R.

    1984-01-01

    The SUPER-FMIT facility is proposed as an advanced accelerator based neutron source for high flux irradiation testing of large-sized fusion reactor components. The facility would require only small extensions to existing accelerator and target technology originally developed for the Fusion Materials Irradiation Test (FMIT) facility. There, neutrons would be produced by a 0.1 ampere beam of 35 MeV deuterons incident upon a liquid lithium target. The volume available for high flux (> 10 14 n/cm 2 -s) testing in SUPER-FMIT would be 14 liters, about a factor of 30 larger than in the FMIT facility. This is because the effective beam current of 35 MeV deuterons on target can be increased by a factor of ten to 1.0 amperes or more. Such a large increase can be accomplished by acceleration of multiple beams of molecular deuterium ions (D 2 +) to 70 MeV in a common accelerator sructure. The availability of multiple beams and large total current allows great variety in the testing that can be done. For example, fluxes greater than 10 16 n/cm 2 -s, multiple simultaneous experiments, and great flexibility in tailoring of spatial distributions of flux and spectra can be achieved

  8. Characteristics of neutron irradiation facility and dose estimation method for neutron capture therapy at Kyoto University research reactor institute

    International Nuclear Information System (INIS)

    Kobayashi, T.; Sakurai, Y.; Kanda, K.

    2001-01-01

    The neutron irradiation characteristics of the Heavy Water Neutron Irradiation Facility (HWNIF) at the Kyoto University Research Reactor Institute (KIJRRI) for boron neutron capture therapy (BNCT), is described. The present method of dose measurement and its evaluation at the KURRI, is explained. Especially, the special feature and noticeable matters were expounded for the BNCT with craniotomy, which has been applied at present only in Japan. (author)

  9. Specific contributions of the Dutch programme {open_quotes}RAS{close_quotes} towards accelerator-based transmutation

    Energy Technology Data Exchange (ETDEWEB)

    Abrahams, K.; Franken, W.M.P.; Bultman, J.H. [Netherlands Energy Research Foundation (ECN), Petten (Netherlands)] [and others

    1995-10-01

    Accelerator-based transmutation is being studied by ECN within its general nuclear waste transmutation programme RAS. In this paper the following contributions are presented: (1) Evaluation of cross sections at intermediate energies, within an international frame given by NEA, (2) Cell calculations on the equilibration of transuranium actinides in thermal molten-salt transmuters, (3) Irradiation facilities at the European research reactor HFR in Petten, which have been constructed with the purpose to demonstrate and investigate the transmutation of waste in a high neutron flux, (4) Studies of accelerator-based neutron generating systems to transmute neptunium and technetium, (5) Comparison of several systems on the basis of criteria for successful nuclear waste-management.

  10. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

    International Nuclear Information System (INIS)

    Nigg, David W.

    2012-01-01

    Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K(nido-7-CH3(CH2)15-7,8-C2B9H11) in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K(nido-7-CH3(CH2)15-7,8-C2B9H11) in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 (ae-B20H17NH3), administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

  11. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

    Energy Technology Data Exchange (ETDEWEB)

    David W. Nigg

    2012-05-01

    Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 [ae-B20H17NH3], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 {+-} 16.1 ppm at 48 h and to 43.9 {+-} 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

  12. SU-E-J-100: Reconstruction of Prompt Gamma Ray Three Dimensional SPECT Image From Boron Neutron Capture Therapy(BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, D; Jung, J; Suh, T [The Catholic University of Korea, College of medicine, Department of biomedical engineering (Korea, Republic of)

    2014-06-01

    Purpose: Purpose of paper is to confirm the feasibility of acquisition of three dimensional single photon emission computed tomography (SPECT) image from boron neutron capture therapy (BNCT) using Monte Carlo simulation. Methods: In case of simulation, the pixelated SPECT detector, collimator and phantom were simulated using Monte Carlo n particle extended (MCNPX) simulation tool. A thermal neutron source (<1 eV) was used to react with the boron uptake region (BUR) in the phantom. Each geometry had a spherical pattern, and three different BURs (A, B and C region, density: 2.08 g/cm3) were located in the middle of the brain phantom. The data from 128 projections for each sorting process were used to achieve image reconstruction. The ordered subset expectation maximization (OSEM) reconstruction algorithm was used to obtain a tomographic image with eight subsets and five iterations. The receiver operating characteristic (ROC) curve analysis was used to evaluate the geometric accuracy of reconstructed image. Results: The OSEM image was compared with the original phantom pattern image. The area under the curve (AUC) was calculated as the gross area under each ROC curve. The three calculated AUC values were 0.738 (A region), 0.623 (B region), and 0.817 (C region). The differences between length of centers of two boron regions and distance of maximum count points were 0.3 cm, 1.6 cm and 1.4 cm. Conclusion: The possibility of extracting a 3D BNCT SPECT image was confirmed using the Monte Carlo simulation and OSEM algorithm. The prospects for obtaining an actual BNCT SPECT image were estimated from the quality of the simulated image and the simulation conditions. When multiple tumor region should be treated using the BNCT, a reasonable model to determine how many useful images can be obtained from the SPECT could be provided to the BNCT facilities. This research was supported by the Leading Foreign Research Institute Recruitment Program through the National Research

  13. Gene transfer-applied BNCT (g-BNCT) for amelanotic melanoma in brain. Further upregulation of 10B uptake by cell modulation

    International Nuclear Information System (INIS)

    Iwakura, M.; Tamaki, N.; Hiratsuka, J.

    2000-01-01

    Our success in eradicating melanoma by single BNCT with BPA led to the next urgent theme, i.e. application of such BNCT for currently uncurable melanoma metastasis in brain. In order to establish 10 B-BPA-BNCT for melanoma in brain, we have investigated the pharmacokinetics of BPA which is most critical factor for successful BNCT, in melanotic and amelanotic and further tyrosinase gene-transfected amelanotic melanoma proliferating in brain having blood-brain-barrier, as compared to melanoma proliferating in skin. We have established three implanted models for melanoma in brain: 1) A1059 cells, amelanotic melanoma, 2) B16B15b cells, melanotic melanoma cells, highly metastatic to brain, and 3) TA1059 cells, with active melanogenesis induced by tyrosinase gene transfection. We would like to report the results of comparative analysis of the BPA uptake ability in these melanoma cells in both brain and skin. Based on these findings, we are further investigating to enhance 10 B-BPA uptake by not only g-BNCT but also by additional melanogenesis upregulating cell modulation. (author)

  14. Successful BNCT for patients with cutaneous and mucosal melanomas. Report of 4 cases

    International Nuclear Information System (INIS)

    Morita, Norimasa; Hiratsuka, Junichi; Kuwabara, Chiaki; Aihara, Teruhito; Harada, Tamotsu; Imajo, Yoshinari; Ono, Koji; Fukuda, Hiroshi; Kumada, Hiroaki

    2006-01-01

    Since 2003 we have conducted BNCT clinical trials on melanomas at the Kyoto University Research Reactor (KUR) and Japan Research Reactor No.4 (JRR-4). We report 4 patients given BNCT for malignant melanomas: 2 with superficial spreading types on the heel, 1 with mucosal melanoma in the nasal cavity, and 1 with a melanoma on the vulva and in the vagina. The two cutaneous melanomas and the nasal cavity mucosal melanoma showed a complete response (CR) by 6 months after BNCT. The residual melanoma showed a partial response (PR) by 3 months after treatment and no regrowth since then. Although two patients experienced normal-tissue damage that exceeded the tolerance level, all the participants were cured within a few months of treatment. BNCT was shown to be a promising treatment for mucosal, as well as for cutaneous, melanomas. (author)

  15. Alpha-amino alcohol of para-boronophenylalanine, BPAol, as a potential boron carrier for BNCT

    International Nuclear Information System (INIS)

    Takagaki, M.; Ono, K.; Masunaga, S.; Kinashi, Y.

    2000-01-01

    α amino alcohol of boronophenylalanine BPAol in which -COOH group is replaced with hydrophilic group of -OH of p-boronophenylalanine (BPA) has been synthesized and its BNCT effect on experimental tumor models have been investigated. Tumor cell killing effect of BPAol on C6 gliosarcoma cells was very high 4.4 times as that of BPA, since it was actively accumulated into tumor cells in 4-5 times as that of BPA. Carboxylic group of BPA might not play as an essential role in uptake of BPA into tumor cells. BPAol-based BNCT strongly inhibited the tumor growth of Green's melanotic melanoma hamsters even under therapeutic dose of BPA-based BNCT. These preliminary findings strongly warrant further extensive pre-clinical study for BPAol as a boron carrier for BNCT. (author)

  16. INEEL BNCT research program. Annual report, January 1, 1996--December 31, 1996

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1997-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1996. Contributions from the individual investigators about their projects are included, specifically, physics: treatment planning software, real-time neutron beam measurement dosimetry, measurement of the Finnish research reactor epithermal neutron spectrum, BNCT accelerator technology; and chemistry: analysis of biological samples and preparation of 10 B enriched decaborane

  17. Physics of epi-thermal boron neutron capture therapy (epi-thermal BNCT).

    Science.gov (United States)

    Seki, Ryoichi; Wakisaka, Yushi; Morimoto, Nami; Takashina, Masaaki; Koizumi, Masahiko; Toki, Hiroshi; Fukuda, Mitsuhiro

    2017-12-01

    The physics of epi-thermal neutrons in the human body is discussed in the effort to clarify the nature of the unique radiologic properties of boron neutron capture therapy (BNCT). This discussion leads to the computational method of Monte Carlo simulation in BNCT. The method is discussed through two examples based on model phantoms. The physics is kept at an introductory level in the discussion in this tutorial review.

  18. Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, H.

    2011-01-01

    The purpose of this study was to compare the radiation dose between long-survivors and non-long-survivors in patients with glioblatoma (GBM) treated with boron neutron capture therapy (BNCT). Among 23 GBM patients treated with BNCT, there were five patients who survived more than three years after diagnosis. The physical and weighted dose of the minimum gross tumor volume (GTV) of long-survivors was much higher than that of non-long survivors with significant statistical differences.

  19. Physics in ;Real Life;: Accelerator-based Research with Undergraduates

    Science.gov (United States)

    Klay, J. L.

    All undergraduates in physics and astronomy should have access to significant research experiences. When given the opportunity to tackle challenging open-ended problems outside the classroom, students build their problem-solving skills in ways that better prepare them for the workplace or future research in graduate school. Accelerator-based research on fundamental nuclear and particle physics can provide a myriad of opportunities for undergraduate involvement in hardware and software development as well as ;big data; analysis. The collaborative nature of large experiments exposes students to scientists of every culture and helps them begin to build their professional network even before they graduate. This paper presents an overview of my experiences - the good, the bad, and the ugly - engaging undergraduates in particle and nuclear physics research at the CERN Large Hadron Collider and the Los Alamos Neutron Science Center.

  20. Very high flux steady state reactor and accelerator based sources

    International Nuclear Information System (INIS)

    Ludewig, H.; Todosow, M.; Simos, N.; Shapiro, S.; Hastings, J.

    2004-01-01

    With the number of steady state neutron sources in the US declining (including the demise of the Bnl HFBR) the remaining intense sources are now in Europe (i.e. reactors - ILL and FMR, accelerator - PSI). The intensity of the undisturbed thermal flux for sources currently in operation ranges from 10 14 n/cm 2 *s to 10 15 n/cm 2 *s. The proposed Advanced Neutron Source (ANS) was to be a high power reactor (about 350 MW) with a projected undisturbed thermal flux of 7*10 15 n/cm 2 *s but never materialized. The objective of the current study is to explore the requirements and implications of two source concepts with an undisturbed flux of 10 16 n/cm 2 *s. The first is a reactor based concept operating at high power density (10 MW/l - 15 MW/l) and a total power of 100 MW - 250 MW, depending on fissile enrichment. The second is an accelerator based concept relying on a 1 GeV - 1.5 GeV proton Linac with a total beam power of 40 MW and a liquid lead-bismuth eutectic target. In the reactor source study, the effects of fissile material enrichment, coolant temperature and pressure drop, and estimates of pressure vessel stress levels will be investigated. The fuel form for the reactor will be different from all other operating source reactors in that it is proposed to use an infiltrated graphitic structure, which has been developed for nuclear thermal propulsion reactor applications. In the accelerator based source the generation of spallation products and their activation levels, and the material damage sustained by the beam window will be investigated. (authors)

  1. Simulation of the BNCT of Brain Tumors Using MCNP Code: Beam Designing and Dose Evaluation

    Directory of Open Access Journals (Sweden)

    Fatemeh Sadat Rasouli

    2012-09-01

    Full Text Available Introduction BNCT is an effective method to destroy brain tumoral cells while sparing the healthy tissues. The recommended flux for epithermal neutrons is 109 n/cm2s, which has the most effectiveness on deep-seated tumors. In this paper, it is indicated that using D-T neutron source and optimizing of Beam Shaping Assembly (BSA leads to treating brain tumors in a reasonable time where all IAEA recommended criteria are met. Materials and Methods The proposed BSA based on a D-T neutron generator consists of a neutron multiplier system, moderators, reflector, and collimator. The simulated Snyder head phantom is used to evaluate dose profiles in tissues due to the irradiation of designed beam. Monte Carlo Code, MCNP-4C, was used in order to perform these calculations.   Results The neutron beam associated with the designed and optimized BSA has an adequate epithermal flux at the beam port and neutron and gamma contaminations are removed as much as possible. Moreover, it was showed that increasing J/Φ, as a measure of beam directionality, leads to improvement of beam performance and survival of healthy tissues surrounding the tumor. Conclusion According to the simulation results, the proposed system based on D-T neutron source, which is suitable for in-hospital installations, satisfies all in-air parameters. Moreover, depth-dose curves investigate proper performance of designed beam in tissues. The results are comparable with the performances of other facilities.

  2. The international dosimetry exchange for BNCT. A basis for pooling and collectively analyzing clinical results

    International Nuclear Information System (INIS)

    Riley, K.J.; Binns, P.J.; Harling, O.K.; Kiger, W.S. III; Seppaelae, T.; Savolainen, S.; Moss, R.; Marek, M.; Rezaei, A.

    2006-01-01

    An international collaboration was organized by the Massachusetts Institute of Technology (MIT) to undertake a dosimetry exchange for the eventual purpose of combining results from various clinical centers that employ different methods for measuring and prescribing absorbed dose in the mixed radiation fields used for neutron capture therapy. Treatment plans calculated at NCT centers in the Czech Republic, Finland, The Netherlands and Sweden were normalized to corresponding measurements performed by the MIT dosimetry group in each beam. More than half of the normalizations for individual absorbed dose components (photon, fast neutron, thermal neutron and boron) determined by comparing MIT measurements to the dose specified in treatment plans from the different centers were statistically significant and ranged from 8 to 400%. Each facility had at least one dose component that would require normalization for the specified doses to be accurately compared. These normalizations establish a technical basis to begin collectively analyzing treatment plans between the European and US centers. Simple but pertinent treatment parameters such as the maximum dose to brain can now be properly compared, once the clinical data is available. This could held to more precisely and quickly determine various dose-response relationships as for example those related to adverse events. Future efforts to determine dose normalization at other centers performing human studies as well as more sophisticated analyses using combined data from several centers should be guided by clearly defined clinical objectives with active participation from clinical BNCT experts. (author)

  3. Organisation and management of the first clinical trial of BNCT in Europe (EORTC Protocol 11961)

    International Nuclear Information System (INIS)

    Sauerwein, W.; Rassow, J.; Hideghety, K.; Sack, H.; Moss, R.; Stecher-Rasmussen, F.; Wolbers, J.G.

    1999-01-01

    Boron Neutron Capture Therapy is based on the ability of the isotope 10 B to capture thermal neutrons and to disintegrate instantaneously producing high LET particles. The only neutron beam available in Europe for such a treatment is based at the European High Flux Reactor HFR at Petten (The Netherlands). The European Commission, owners of the reactor, decided that the potential benefit of the facility should be opened to all European citizens and therefore insisted on a multinational approach to perform the first clinical trial in Europe on BNCT. This precondition had to be respected as well as the national laws and regulations. Together with the Dutch authorities actions were undertaken to overcome the obvious legal problems. Furthermore, the clinical trial at Petten takes place in a nuclear research reactor, which apart from being conducted in a non-hospital environment, is per se known to be dangerous. It was therefore of the utmost importance that special attention is given to safety, beyond normal rules, and to the training of staff. In itself, the trial is an unusual Phase I study, introducing a new drug with a new irradiation modality, with really an unknown dose-effect relationship. This trial must follow optimal procedures, which underscore the quality and qualified manner of performance. (orig.)

  4. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    International Nuclear Information System (INIS)

    Capala, J.; Diaz, A.Z.; Chadha, M.

    1997-01-01

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains

  5. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J. [Brookhaven National Lab., Upton, NY (United States); Diaz, A.Z.; Chadha, M. [Univ. Hospital, State Univ. of New York, NY (United States)] [and others

    1997-12-31

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains.

  6. INEL BNCT Research Program, March/April 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murino screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronopheoylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  7. INEL BNCT Research Program, May/June 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (IBPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  8. INEL BNCT Research Program, September--October 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-12-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotain. carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophonylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  9. INEL BNCT Research Program, September--October 1992

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1992-12-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotain. carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophonylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  10. INEL BNCT research program, July--August 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-10-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  11. INEL BNCT Research Program, January/February 1993

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-04-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  12. TIDBIT - the INEL database of BNCT information and treatment

    International Nuclear Information System (INIS)

    Mancuso, C.A.

    1995-01-01

    The INEL Database of BNCT Information and Treatment (TIDBIT) has been under development for several years. Late in 1993, a new software development team took over the project and did and assessment of the current implementation status, and determined that the user interface was unsatisfactory for the expected users and that the data structures were out of step with the current state of reality. The team evaluated several tools that would improve the user interface to make the system easier to use. Uniface turned out to be the product of choice. During 1994, TIDBIT got its name, underwent a complete change of appearance, had a major overhaul to the data structures that support the application, and system documentation was begun. A prototype of the system was demonstrated in September 1994

  13. INEL BNCT Research Program, January/February 1993

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1993-04-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  14. INEL BNCT Research Program, May/June 1992

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (IBPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  15. Small accelerator-based pulsed cold neutron sources

    International Nuclear Information System (INIS)

    Lanza, Richard C.

    1997-09-01

    Small neutron sources could be used by individual researchers with the convenience of an adequate local facility. Although these sources would produce lower fluxes than the national facilities, for selected applications, the convenience and availability may overcome the limitations on source strength. Such sources might also be useful for preliminary testing of ideas before going to a larger facility. Recent developments in small, high-current pulsed accelerators makes possible such a local source for pulsed cold neutrons.

  16. Accelerator-based intense neutron source for materials R and D

    International Nuclear Information System (INIS)

    Jameson, R.A.

    1990-01-01

    Accelerator-based neutron sources for R and D of materials in nuclear energy systems, including fusion reactors, can provide sufficient neutron flux, flux-volume, fluence and other attractive features for many aspects of materials research. The neutron spectrum produced from the D-Li reaction has been judged useful for many basic materials research problems, and satisfactory as an approximation of the fusion process. A most interesting aspect for materials researchers is the increased flexibility and opportunities for experimental configurations that a modern accelerator-based source could add to the set of available tools. First, of course, is a high flux of neutrons. Four other tools are described: 1. The output energy of the deuteron beam can be varied to provide energy selectivity for the materials researcher. The energy would typically be varied in discrete steps; the number of steps can be adjusted depending on actual needs and costs. 2. The materials sample target chamber could be irradiated by more than one beam, from different angles. This would provide many possibilities for tailoring the flux distribution. 3. Advanced techniques in magnetic optics systems allow the density distribution of the deuteron beam at the target to be tailored. Controlled distributions from Gaussian to uniform to hollow can be provided. This affords further control of the distribution in the target chamber. 4. The accelerator and associated beam transport elements are all essentially electronic systems and, therefore, can be controlled and modulated on a time cycle basis. Therefore, all of the above tools could be varied in possibly complex patterns under computer control; this may open further experimental approaches for studying various rate-dependent effects. These considerations will be described in the context of the Energy Selective Neutron Irradiation Test (ESNIT) facility which is conceived at JAERI. (author)

  17. Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats

    International Nuclear Information System (INIS)

    Trivillin, V.A.; Garabalino, M.A.; Colombo, L.L.

    2013-01-01

    Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats Introduction: Boron Neutron Capture Therapy (BNCT) is based on selective tumor uptake of boron compounds, followed by neutron irradiation. BNCT was proposed for the treatment of unresectable, diffuse lung metastases. The aim of the present study was to perform BNCT studies in an experimental model of lung metastases. Materials and Methods: 3 x 106/0.5 ml colon carcinoma cells (DHD/K12/TRb) were injected iv in syngeneic BDIX rats. Three weeks post-inoculation, rats with diffuse lung metastases were used for in vivo BNCT studies in the RA-3 Nuclear Reactor. Based on previous biodistribution studies and computational dosimetry with Monte Carlo simulation, 2 doses were prescribed, i.e. 4 Gy and 8 Gy minimum absorbed dose to tumor. The animals were assigned to 5 experimental groups (n= 4 to 8) at each dose level: T0 (euthanized pre-treatment), BPA-BNCT, Comb-BNCT (BPA+GB-10), Beam only (background dose) and Sham (same manipulation, no treatment). Boron concentration was measured in a blood sample taken pre-irradiation to verify that the value was in the range established in previous biodistribution studies. The animals were followed clinically for 2 weeks after neutron irradiation and then euthanized to assess the response of tumor and normal lung, macroscopically and histologically. To date we have evaluated the end-point weight of lung (normal lung + metastases) and % lung weight/body weight as an indicator of tumor growth. Results: The statistical analysis (ANOVA) of % lung weight/body weight showed statistically significant differences (p<0.05) between groups T0 (0.79 ± 0.38) and Sham (1.87 ± 0.91). No statistically significant differences were observed between the Beam only groups (at both dose levels) and Sham. Similar and statistically significant tumor control was induced in the groups BPA-BNCT Low dose (LD) (0.56 ± 0.11), BPA-BNCT High dose (HD) (0.80 ± 0.16), Comb-BNCT

  18. A D-D/D-T fusion reaction based neutron generator system for liver tumor BNCT

    International Nuclear Information System (INIS)

    Koivunoro, H.; Lou, T.P.; Leung, K. N.; Reijonen, J.

    2003-01-01

    Boron-neutron capture therapy (BNCT) is an experimental radiation treatment modality used for highly malignant tumor treatments. Prior to irradiation with low energetic neutrons, a 10B compound is located selectively in the tumor cells. The effect of the treatment is based on the high LET radiation released in the 10 B(n,α) 7 Li reaction with thermal neutrons. BNCT has been used experimentally for brain tumor and melanoma treatments. Lately applications of other severe tumor type treatments have been introduced. Results have shown that liver tumors can also be treated by BNCT. At Lawrence Berkeley National Laboratory, various compact neutron generators based on D-D or D-T fusion reactions are being developed. The earlier theoretical studies of the D-D or D-T fusion reaction based neutron generators have shown that the optimal moderator and reflector configuration for brain tumor BNCT can be created. In this work, the applicability of 2.5 MeV neutrons for liver tumor BNCT application was studied. The optimal neutron energy for external liver treatments is not known. Neutron beams of different energies (1eV < E < 100 keV) were simulated and the dose distribution in the liver was calculated with the MCNP simulation code. In order to obtain the optimal neutron energy spectrum with the D-D neutrons, various moderator designs were performed using MCNP simulations. In this article the neutron spectrum and the optimized beam shaping assembly for liver tumor treatments is presented

  19. Observation of Neutron Skyshine from an Accelerator Based Neutron Source

    Energy Technology Data Exchange (ETDEWEB)

    Franklyn, C. B. [Radiation Science Department, Necsa, PO Box 582, Pretoria 0001 (South Africa)

    2011-12-13

    A key feature of neutron based interrogation systems is the need for adequate provision of shielding around the facility. Accelerator facilities adapted for fast neutron generation are not necessarily suitably equipped to ensure complete containment of the vast quantity of neutrons generated, typically >10{sup 11} n{center_dot}s{sup -1}. Simulating the neutron leakage from a facility is not a simple exercise since the energy and directional distribution can only be approximated. Although adequate horizontal, planar shielding provision is made for a neutron generator facility, it is sometimes the case that vertical shielding is minimized, due to structural and economic constraints. It is further justified by assuming the atmosphere above a facility functions as an adequate radiation shield. It has become apparent that multiple neutron scattering within the atmosphere can result in a measurable dose of neutrons reaching ground level some distance from a facility, an effect commonly known as skyshine. This paper describes a neutron detection system developed to monitor neutrons detected several hundred metres from a neutron source due to the effect of skyshine.

  20. Roadmap for the international, accelerator-based neutrino programme

    Energy Technology Data Exchange (ETDEWEB)

    Cao, J. [Beijing, Inst. High Energy Phys. (China); de Gouvêa, A. [Northwestern Univ., Evanston, IL (United States); Duchesneau, D. [CNRS/IN2P3. Univ. Paris (France). Observatoire de Paris. AstroParticule et Cosmologie (APC); Geer, S. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Gomes, R. [Federal University of Goias (Brazil); Kim, S. B. [Seoul National Univ. (Korea, Republic of); Kobayashi, T. [High Energy Accelerator Research Organization (KEK), Tsukuba (Japan); Long, K. [Science and Technology Facilities Council (STFC), Oxford (United Kingdom). Rutherford Appleton Lab. (RAL); Maltoni, M. [Autonomous Univ. of Madrid (Spain); Mezzetto, M. [Univ. of Padua (Italy); Mondal, N. [Tata Inst. of Fundamental Research, Bombay (India); Shiozawa, M. [Univ. of Tokyo (Japan); Sobczyk, J. [Univ. of Wroclaw (Poland); Tanaka, H. A. [TRIUMF, Vancouver, BC (Canada); Wascko, M. [Imperial College, London (United Kingdom); Zeller, G. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States)

    2017-04-26

    In line with its terms of reference the ICFA Neutrino Panel has developed a roadmap for the international, accelerator-based neutrino programme. A "roadmap discussion document" was presented in May 2016 taking into account the peer-group-consultation described in the Panel's initial report. The "roadmap discussion document" was used to solicit feedback from the neutrino community---and more broadly, the particle- and astroparticle-physics communities---and the various stakeholders in the programme. The roadmap, the conclusions and recommendations presented in this document take into account the comments received following the publication of the roadmap discussion document. With its roadmap the Panel documents the approved objectives and milestones of the experiments that are presently in operation or under construction. Approval, construction and exploitation milestones are presented for experiments that are being considered for approval. The timetable proposed by the proponents is presented for experiments that are not yet being considered formally for approval. Based on this information, the evolution of the precision with which the critical parameters governinger the neutrino are known has been evaluated. Branch or decision points have been identified based on the anticipated evolution in precision. The branch or decision points have in turn been used to identify desirable timelines for the neutrino-nucleus cross section and hadro-production measurements that are required to maximise the integrated scientific output of the programme. The branch points have also been used to identify the timeline for the R&D required to take the programme beyond the horizon of the next generation of experiments. The theory and phenomenology programme, including nuclear theory, required to ensure that maximum benefit is derived from the experimental programme is also discussed.

  1. Subpanel on accelerator-based neutrino oscillation experiments

    International Nuclear Information System (INIS)

    1995-09-01

    Neutrinos are among nature's fundamental constituents, and they are also the ones about which we know least. Their role in the universe is widespread, ranging from the radioactive decay of a single atom to the explosions of supernovae and the formation of ordinary matter. Neutrinos might exhibit a striking property that has not yet been observed. Like the back-and-forth swing of a pendulum, neutrinos can oscillate to-and-from among their three types (or flavors) if nature provides certain conditions. These conditions include neutrinos having mass and a property called open-quotes mixing.close quotes The phenomenon is referred to as neutrino oscillations. The questions of the origin of neutrino mass and mixing among the neutrino flavors are unsolved problems for which the Standard Model of particle physics holds few clues. It is likely that the next critical step in answering these questions will result from the experimental observation of neutrino oscillations. The High Energy Physics Advisory Panel (HEPAP) Subpanel on Accelerator-Based Neutrino Oscillation Experiments was charged to review the status and discovery potential of ongoing and proposed accelerator experiments on neutrino oscillations, to evaluate the opportunities for the U.S. in this area of physics, and to recommend a cost-effective plan for pursuing this physics, as appropriate. The complete charge is provided in Appendix A. The Subpanel studied these issues over several months and reviewed all the relevant and available information on the subject. In particular, the Subpanel reviewed the two proposed neutrino oscillation programs at Fermi National Accelerator Laboratory (Fermilab) and at Brookhaven National Laboratory (BNL). The conclusions of this review are enumerated in detail in Chapter 7 of this report. The recommendations given in Chapter 7 are also reproduced in this summary

  2. Effect of different BNCT protocols on DNA synthesis in precancerous and normal tissues in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Heber, Elisa M.; Aromando, Romina; Trivillin, Veronica A.; Itoiz, Maria E.; Kreimann, Erica L.; Schwint, Amanda E.; Nigg, David W.

    2006-01-01

    We previously reported the therapeutic success of different BNCT protocols in the treatment of oral cancer, employing the hamster cheek pouch model. The aim of the present study was to evaluate the effect of these BNCT protocols on DNA synthesis in precancerous and normal tissue in this model and assess the potential lag in the development of second primary tumors in precancerous tissue. The data are relevant to potential control of field cancerized tissue and tolerance of normal tissue. We evaluated DNA synthesis in precancerous and normal pouch tissue 1-30 days post-BNCT mediated by BPA, GB-10 or BPA + GB-10 employing incorporation of bromo-deoxyuridine as an end-point. The BNCT-induced potential lag in the development of second primary tumors in precancerous tissue was monitored. A drastic, statistically significant reduction in DNA synthesis occurred in pacancerous tissue as early as 1 day post-BNCT and was sustained at virtually all time points until 30 days post-BNCT for all protocols. The histological categories evaluated individually within precancerous tissue (dysplasia, hyperplasia and NUMF [no unusual microscopic features]) responded similarly. DNA synthesis in normal tissue treated with BNCT oscillated around the very low pre-treatment values. A BNCT-induced lag in the development of second primary tumors was observed. BNCT induced a drastic fall in DNA synthesis in precancerous tissue that would be associated to the observed lag in the development of second primary tumors. The minimum variations in DNA synthesis in BNCT-treated normal tissue would correlate with the absence of normal tissue radiotoxicity. The present data would contribute to optimize therapeutic efficacy in the treatment of field-cancerized areas. (author)

  3. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    Energy Technology Data Exchange (ETDEWEB)

    Boggio, E. F.; Longhino, J. M. [Centro Atomico Bariloche, Departamento de Fisica de Reactores y Radiaciones / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina); Andres, P. A., E-mail: efboggio@cab.cnea.gov.ar [Centro Atomico Bariloche, Division Proteccion Radiologica / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina)

    2015-10-15

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single {sup 7}LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 ({sup 6}LiF:Mg,Ti with 95.6% {sup 6}Li) and TLD-700 ({sup 7}LiF:Mg,Ti with 99.9% {sup 7}LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom

  4. Subcellular boron and fluorine distributions with SIMS ion microscopy in BNCT and cancer research

    Energy Technology Data Exchange (ETDEWEB)

    Subhash Chandra

    2008-05-30

    The development of a secondary ion mass spectrometry (SIMS) based technique of Ion Microscopy in boron neutron capture therapy (BNCT) was the main goal of this project, so that one can study the subcellular location of boron-10 atoms and their partitioning between the normal and cancerous tissue. This information is fundamental for the screening of boronated drugs appropriate for neutron capture therapy of cancer. Our studies at Cornell concentrated mainly on studies of glioblastoma multiforme (GBM). The early years of the grant were dedicated to the development of cryogenic methods and correlative microscopic approaches so that a reliable subcellular analysis of boron-10 atoms can be made with SIMS. In later years SIMS was applied to animal models and human tissues of GBM for studying the efficacy of potential boronated agents in BNCT. Under this grant the SIMS program at Cornell attained a new level of excellence and collaborative SIMS studies were published with leading BNCT researchers in the U.S.

  5. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    Energy Technology Data Exchange (ETDEWEB)

    Hampel, G.; Grunewald, C.; Schutz, C.; Schmitz, T.; Kratz, J.V. [Nuclear Chemistry, University of Mainz, D-55099 Mainz (Germany); Brochhausen, C.; Kirkpatrick, J. [Department of Pathology, University of Mainz, D-55099 Mainz (Germany); Bortulussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Kudejova, P. [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Appelman, K.; Moss, R. [Joint Research Centre (JRC) of the European Commission, NL-1755 ZG Petten (Netherlands); Bassler, N. [University of Aarhus, Norde Ringade, DK-8000, Aarhus C (Denmark); Blaickner, M.; Ziegner, M. [Molecular Medicine, Health and Environment Department, AIT Austrian Institute of Technology GmbH (Austria); Sharpe, P.; Palmans, H. [National Physical Laboratory, Teddington TW11 0LW, Middlesex (United Kingdom); Otto, G. [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, D-55099 Mainz (Germany)

    2011-07-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed in Pavia (Italy) a few years ago, where patients with liver metastases were treated by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and the treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appears to be an appropriate dosimetry technique. (author)

  6. Radiation shielding design of BNCT treatment room for D-T neutron source.

    Science.gov (United States)

    Pouryavi, Mehdi; Farhad Masoudi, S; Rahmani, Faezeh

    2015-05-01

    Recent studies have shown that D-T neutron generator can be used as a proper neutron source for Boron Neutron Capture Therapy (BNCT) of deep-seated brain tumors. In this paper, radiation shielding calculations have been conducted based on the computational method for designing a BNCT treatment room for a recent proposed D-T neutron source. By using the MCNP-4C code, the geometry of the treatment room has been designed and optimized in such a way that the equivalent dose rate out of the treatment room to be less than 0.5μSv/h for uncontrolled areas. The treatment room contains walls, monitoring window, maze and entrance door. According to the radiation protection viewpoint, dose rate results of out of the proposed room showed that using D-T neutron source for BNCT is safe. Copyright © 2015 Elsevier Ltd. All rights reserved.

  7. BNCT of 3 cases of spontaneous head and neck cancer in feline patients

    Energy Technology Data Exchange (ETDEWEB)

    Rao, M.; Trivillin, V.A.; Heber, E.M.; Angeles Cantarelli, Maria de los; Itoiz, M.E.; Nigg, D.W.; Rebagliati, R.J.; Batistoni, Daniel; Schwint, A.E. E-mail: schwint@cnea.gov.ar

    2004-11-01

    Having demonstrated BPA-BNCT induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of the RA-1 Reactor within a preclinical context. The biodistribution studies showed that, in all three cases evaluated, BPA delivered absolute boron values to tumor in the range that proved therapeutically useful in the experimental model of SCC. BPA-BNCT studies showed no radiotoxic effects, partial tumor control in terms of impaired growth and partial necrosis, an improvement in clinical condition and prolonged survival beyond the terminal condition of the feline patients at the time of recruitment.

  8. Subcellular boron and fluorine distributions with SIMS ion microscopy in BNCT and cancer research

    International Nuclear Information System (INIS)

    Subhash, Chandra

    2008-01-01

    The development of a secondary ion mass spectrometry (SIMS) based technique of Ion Microscopy in boron neutron capture therapy (BNCT) was the main goal of this project, so that one can study the subcellular location of boron-10 atoms and their partitioning between the normal and cancerous tissue. This information is fundamental for the screening of boronated drugs appropriate for neutron capture therapy of cancer. Our studies at Cornell concentrated mainly on studies of glioblastoma multiforme (GBM). The early years of the grant were dedicated to the development of cryogenic methods and correlative microscopic approaches so that a reliable subcellular analysis of boron-10 atoms can be made with SIMS. In later years SIMS was applied to animal models and human tissues of GBM for studying the efficacy of potential boronated agents in BNCT. Under this grant the SIMS program at Cornell attained a new level of excellence and collaborative SIMS studies were published with leading BNCT researchers in the U.S.

  9. Liquid Li based neutron source for BNCT and science application.

    Science.gov (United States)

    Horiike, H; Murata, I; Iida, T; Yoshihashi, S; Hoashi, E; Kato, I; Hashimoto, N; Kuri, S; Oshiro, S

    2015-12-01

    Liquid lithium (Li) is a candidate material for a target of intense neutron source, heat transfer medium in space engines and charges stripper. For a medical application of BNCT, epithermal neutrons with least energetic neutrons and γ-ray are required so as to avoid unnecessary doses to a patient. This is enabled by lithium target irradiated by protons at 2.5 MeV range, with utilizing the threshold reaction of (7)Li(p,n)(7)Be at 1.88 MeV. In the system, protons at 2.5 MeV penetrate into Li layer by 0.25 mm with dissipating heat load near the surface. To handle it, thin film flow of high velocity is important for stable operation. For the proton accelerator, electrostatic type of the Schnkel or the tandem is planned to be employed. Neutrons generated at 0.6 MeV are gently moderated to epithermal energy while suppressing accompanying γ-ray minimum by the dedicated moderator assembly. Copyright © 2015 Elsevier Ltd. All rights reserved.

  10. BNCT clinical trials of skin melanoma patients in Argentina

    International Nuclear Information System (INIS)

    Roth, Berta M.; Bonomi, Marcelo R.; Gonzalez, Sara J.

    2006-01-01

    The clinical outcome of six skin melanoma BNCT irradiations is presented. Three patients (A, B and C), with multiple subcutaneous skin metastases progressed to chemotherapy were infused with ∼14 g/m 2 of boronophenylalanine ( 10 BPA)-fructose and irradiated in the hyperthermal neutron beam of the RA-6 reactor. Patient A received two one fraction irradiations in different areas of the leg, B received one fraction and C was irradiated in three consecutive fields at the calf, heel and foot sole. The maximum prescribed dose to normal skin ranged from 16.5 to 24 Gy-Eq. With a minimum follow-up of 10 months there was a G1 acute epithelitis in A and B and a G3 in C. No late toxicity was observed. Due to the in-field tumor-growth-delay and the absence of severe acute and/or late toxicity observed during the follow-up period, a dose-escalation trial is ongoing. (author)

  11. Conceptual design of 30 MeV magnet system used for BNCT epithermal neutron source

    International Nuclear Information System (INIS)

    Slamet Santosa; Taufik

    2015-01-01

    Conceptual design of 30 MeV Magnet System Used for BNCT Epithermal Neutron Source has been done based on methods of empirical model of basic equation, experiences of 13 MeV cyclotron magnet design and personal communications. In the field of health, cyclotron can be used as an epithermal neutron source for Boron Neutron Capture Therapy (BNCT). The development of cyclotron producing epithermal neutrons for BNCT has been performed at Kyoto University, of which it produces a proton beam current of 1.1 mA with energy of 30 MeV. With some experiences on 13 MeV cyclotron magnet design, to support BNCT research and development we performed the design studies of 30 MeV cyclotron magnet system, which is one of the main components of the cyclotron for deflecting proton beam into circular trajectory and serves as beam focusing. Results of this study are expected to define the parameters of particular cyclotron magnet. The scope of this study includes the study of the parameters component of the 30 MeV cyclotron and magnet initial parameters. The empirical method of basic equation model is then corroborated by a simulation using Superfish software. Based on the results, a 30 MeV cyclotron magnet for BNCT neutron source enables to be realized with the parameters of B 0 = 1.06 T, frequency RF = 64.733938 ≈ 65 MHz, the external radius of 0.73 m, the radius of the polar = 0.85 m, BH = 1.95 T and a gap hill of 4 cm. Because proton beam current that be needed for BNCT application is very large, then in the calculation it is chosen a great focusing axial νz = 0.630361 which can generate B V = 0.44 T. (author)

  12. Might iodomethyl-α-tyrosine be a surrogate for BPA in BNCT?

    International Nuclear Information System (INIS)

    Miura, Michiko; Micca, P.L.; Nawrocky, M.M.; Slatkin, D.N.

    1996-01-01

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with 10 B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that 10 B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing 18 F-fluoroboronophenylaianine [FBPA] as a positron 18 F (T 1/2 = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of 123 I alpha methyltyrosine as a surrogate for BPA in BNCT

  13. Might iodomethyl-{alpha}-tyrosine be a surrogate for BPA in BNCT?

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Micca, P.L.; Nawrocky, M.M.; Slatkin, D.N.

    1996-12-31

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with {sup 10}B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that {sup 10}B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing {sup 18}F-fluoroboronophenylaianine [FBPA] as a positron {sup 18}F (T{sub 1/2} = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of {sup 123}I alpha methyltyrosine as a surrogate for BPA in BNCT.

  14. Primary study for boron neutron capture therapy uses the RSG-GAS beam tube facility

    International Nuclear Information System (INIS)

    Suroso

    2000-01-01

    The minimum epithermal neutron flux as one of the prerequisite of Boron Neutron Capture Therapy (BNCT) is 1.0 x 10 9 n/(cm 2 s) RSG-GAS have 6 beam tube facilities for neutron source, which is one of the beam tube S-2 has a possibility to utilization for BNCT facility. The totally flux neutron measurement in the front of S-2 beam tube is 1.8 x 10 7 n/(cm 2 s). The neutron flux measurement was less than for BNCT minimum prerequisite. Concerning to the flux neutron production in the reactor, which is reach to 2.5 x 10 14 n/(cm 2 s), there for the S-2 beam tube could be used beside collimator modification

  15. A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas

    International Nuclear Information System (INIS)

    Capala, J.; Coderre, J.A.; Chanana, A.D.

    1996-01-01

    Accurate delivery of the prescribed dose during clinical BNCT requires knowledge (or reasonably valid assumptions) about the boron concentrations in tumor and normal tissues. For conversion of physical dose (Gy) into photon-equivalent dose (Gy-Eq), relative biological effectiveness (RBE) and/or compound-adjusted biological effectiveness (CBE) factors are required for each tissue. The BNCT treatment planning software requires input of the following values: the boron concentration in blood and tumor, RBEs in brain, tumor and skin for the high-LET beam components, the CBE factors for brain, tumor, and skin, and the RBE for the gamma component

  16. DOSE EFFECT OF THE 33S(n,α) 30SI REACTION IN BNCT USING THE NEW n_TOF-CERN DATA.

    Science.gov (United States)

    Sabaté-Gilarte, M; Praena, J; Porras, I; Quesada, J M

    2017-09-23

    33S is a stable isotope of sulphur which is being studied as a potential cooperative target for Boron Neutron Capture Therapy (BNCT) in accelerator-based neutron sources because of its large (n,α) cross section in the epithermal neutron energy range. Previous measurements resolved the resonances with a discrepant description of the lowest-lying and strongest one (at 13.5 keV). However, the evaluations of the major databases do not include resonances, except EAF-2010 which shows smaller values in this range than the experimental data. Furthermore, the glaring lack of data below 10 keV down to thermal (25.3 meV) has motivated a new measurement at n_TOF at CERN in order to cover the whole energy range. The inclusion of this new 33S(n,α) cross section in Monte Carlo simulations provides a more accurate estimation of the deposited kerma rate in tissue due to the presence of 33S. The results of those simulations represent the goal of this work. © The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

  17. Towards a new therapy protocol for liver metastases. Effect of boron compounds and BNCT on normal liver regeneration

    International Nuclear Information System (INIS)

    Cardoso, Jorge E.; Heber, Elisa M.; Trivillin, Veronica A.

    2006-01-01

    The Taormina project developed a new method for BNCT treatment of multifocal unresectable liver metastases based on whole liver autograft. The Roffo Institute liver surgeons propose a new technique based on partial liver autograft that would pose less risk to the patient but would require significant healthy liver regeneration following BNCT. The aim of the present study was to assess the effect of BPA, GB-10 (Na 2 10 B 10 H 10 ) and (GB-10 + BPA) and of BNCT mediated by these boron compounds on normal liver regeneration in the Wistar rat. Normal liver regeneration, body weight, hemogram, liver and kidney function were assessed following partial hepatectomy post administration of BPA, GB-10 or (GB-10 + BPA) and post in vivo BNCT at the RA-6 Reactor. These end-points were evaluated 9 days following partial hepatectomy, the time at which complete liver regeneration occurs in untreated controls. The corresponding biodistribution studies were conducted to perform dosimetric calculations. BPA, GB-10 and (GB-10 + PBA) and in vivo BNCT mediated by these boron compounds in dose ranges compatible with therapy did not cause alterations in the outcome of normal liver regeneration, and did not induce alterations in body weight, hemogram, liver or kidney function. The experimental data available to date support the development of a new BNCT protocol for the treatment of liver metastases that requires the regeneration of normal liver past-BNCT. (author)

  18. Abscopal effect of boron neutron capture therapy (BNCT). Proof of principle in an experimental model of colon cancer

    Energy Technology Data Exchange (ETDEWEB)

    Trivillin, Veronica A.; Monti Hughes, Andrea; Schwint, Amanda E. [Comision Nacional de Energia Atomica (CNEA), Department of Radiobiology, B1650KNA San Martin, Provincia Buenos Aires (Argentina); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Pozzi, Emiliano C.C.; Curotto, Paula [Centro Atomico Ezeiza, Comision Nacional de Energia Atomica (CNEA), Department of Research and Production Reactors, Provincia Buenos Aires (Argentina); Colombo, Lucas L. [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Instituto de Oncologia Angel H. Roffo, Ciudad Autonoma de Buenos Aires (Argentina); Thorp, Silvia I.; Farias, Ruben O. [Comision Nacional de Energia Atomica (CNEA), Department of Instrumentation and Control, Provincia Buenos Aires (Argentina); Garabalino, Marcela A. [Comision Nacional de Energia Atomica (CNEA), Department of Radiobiology, B1650KNA San Martin, Provincia Buenos Aires (Argentina); Gonzalez, Sara J. [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Comision Nacional de Energia Atomica (CNEA), Department of Instrumentation and Control, Provincia Buenos Aires (Argentina); Santa Cruz, Gustavo A. [Comision Nacional de Energia Atomica (CNEA), Department of Boron Neutron Capture Therapy, Provincia Buenos Aires (Argentina); Carando, Daniel G. [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Universidad de Buenos Aires, Faculty of Exact and Natural Sciences, Ciudad Autonoma de Buenos Aires (Argentina)

    2017-11-15

    The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 x 10{sup 6} DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue. The remaining group of 14 tumor-bearing rats were left untreated and used as control. Two weeks post-BNCT, 1 x 10{sup 6} DHD/K12/TRb cells were injected subcutaneously in the contralateral left hind flank of each of the 26 BDIX rats. Tumor volume in both legs was measured weekly for 7 weeks to determine response to BNCT in the right leg and to assess a potential influence of BNCT in the right leg on tumor development in the left leg. Within the BNCT group, a statistically significant reduction was observed in contralateral left tumor volume in animals whose right leg tumor responded to BNCT (post-treatment/pre-treatment tumor volume <1) versus animals who failed to respond (post/pre ≥1), i.e., 13 ± 15 vs 271 ± 128 mm{sup 3}. In addition, a statistically significant reduction in contralateral left leg tumor volume was observed in BNCT-responsive animals (post/pre <1) vs untreated animals, i.e., 13 ± 15 vs 254 ± 251 mm{sup 3}. The present study performed in a simple animal model provides proof of principle that the positive response of a tumor to BNCT is capable of inducing an abscopal effect. (orig.)

  19. Abscopal effect of boron neutron capture therapy (BNCT). Proof of principle in an experimental model of colon cancer

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Monti Hughes, Andrea; Schwint, Amanda E.; Pozzi, Emiliano C.C.; Curotto, Paula; Colombo, Lucas L.; Thorp, Silvia I.; Farias, Ruben O.; Garabalino, Marcela A.; Gonzalez, Sara J.; Santa Cruz, Gustavo A.; Carando, Daniel G.

    2017-01-01

    The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 x 10 6 DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue. The remaining group of 14 tumor-bearing rats were left untreated and used as control. Two weeks post-BNCT, 1 x 10 6 DHD/K12/TRb cells were injected subcutaneously in the contralateral left hind flank of each of the 26 BDIX rats. Tumor volume in both legs was measured weekly for 7 weeks to determine response to BNCT in the right leg and to assess a potential influence of BNCT in the right leg on tumor development in the left leg. Within the BNCT group, a statistically significant reduction was observed in contralateral left tumor volume in animals whose right leg tumor responded to BNCT (post-treatment/pre-treatment tumor volume <1) versus animals who failed to respond (post/pre ≥1), i.e., 13 ± 15 vs 271 ± 128 mm 3 . In addition, a statistically significant reduction in contralateral left leg tumor volume was observed in BNCT-responsive animals (post/pre <1) vs untreated animals, i.e., 13 ± 15 vs 254 ± 251 mm 3 . The present study performed in a simple animal model provides proof of principle that the positive response of a tumor to BNCT is capable of inducing an abscopal effect. (orig.)

  20. Radiation Transport Simulation for Boron Neutron Capture Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Ziegner, M.; Blaickner, M. [AIT Austrian Institute of Technology GmbH, Health and Environment Department, Molecular Medicine, Muthgasse 11, 1190 Wien (Austria); Ziegner, M.; Khan, R.; Boeck, H. [Vienna University of Technology, Institute of Atomic and Subatomic Physics, Stadionallee 2, 1020 Wien (Austria); Bortolussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Schmitz, T.; Hampel, G. [Nuclear Chemistry, University of Mainz, Fritz Strassmann Weg 2, 55099 Mainz (Germany)

    2011-07-01

    This work is part of a larger project initiated by the University of Mainz and aiming to use the university's TRIGA reactor to develop a treatment for liver metastases based on Boron Neutron Capture Therapy (BNCT). Diffuse distribution of cancerous cells within the organ makes complete resection difficult and the vicinity to radiosensitive organs impedes external irradiation. Therefore the method of 'autotransplantation', first established at the University of Pavia, is used. The liver is taken out of the body, irradiated in the thermal column of the reactor, therewith purged of metastases and then reimplanted. A highly precise dosimetry system is to be developed by means of measurements at the University of Mainz and computational calculations at the AIT. The stochastic MCNP-5 Monte Carlo-Code, developed by Los Alamos Laboratories, is applied. To verify the calculations of the flux and the absorbed dose in matter a number of measurements are performed irradiating different phantoms and liver sections in a 20cm x 20cm beam tube, which was created by removing graphite blocks from the thermal column of the reactor. The detector material consists of L- {alpha} -alanine pellets which are thought to be the most suitable because of their good tissue equivalence, small size and their wide response range. Another experiment focuses on the determination of the relative biological effectiveness (RBE-factor) of the neutron and photon dose for liver cells. Therefore cell culture plates with the cell medium enriched with {sup 157}Gd and {sup 10}B at different concentrations are irradiated. With regard to the alanine pellets MCNP-5 calculations give stable results. Nevertheless the absorbed dose is underestimated compared to the measurements, a phenomenon already observed in previous works. The cell culture calculations showed the enormous impact of the added isotopes with high thermal neutron cross sections, especially {sup 157}Gd, on the absorbed dose

  1. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: Combined administration of BSH and BPA

    Energy Technology Data Exchange (ETDEWEB)

    D.W. Nigg; William Bauer; Various Others

    2014-06-01

    Sodium mercaptoundecahydro-closo-dodecaborate (BSH) is being investigated clinically for BNCT. We examined the biodistribution of BSH and BPA administered jointly in different proportions in the hamster cheek pouch oral cancer model. The 3 assayed protocols were non-toxic, and showed preferential tumor boron uptake versus precancerous and normal tissue and therapeutic tumor boron concentration values (70–85 ppm). All 3 protocols warrant assessment in BNCT studies to contribute to the knowledge of (BSH+BPA)-BNCT radiobiology for head and neck cancer and optimize therapeutic efficacy.

  2. Tumor blood vessel "normalization" improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    D. W. Nigg

    2012-01-01

    We previously demonstrated the efficacy of BNCT mediated by boronophenylalanine (BPA) to treat tumors in a hamster cheek pouch model of oral cancer with no normal tissue radiotoxicity and moderate, albeit reversible, mucositis in precancerous tissue around treated tumors. It is known that boron targeting of the largest possible proportion of tumor cells contributes to the success of BNCT and that tumor blood vessel normalization improves drug delivery to the tumor. Within this context, the aim of the present study was to evaluate the effect of blood vessel normalization on the therapeutic efficacy and potential radiotoxicity of BNCT in the hamster cheek pouch model of oral cancer.

  3. 2-O-α-glucopytanosyl L-ascorbic acid reduced mutagenicity at HPRT locus of mouse splenocytes following BNCT

    International Nuclear Information System (INIS)

    Kinashi, Yuko; Masunaga, Shin-ichiro; Suzuki, Minoru; Nagata, Kanji; Ono, Koji

    2006-01-01

    In boron neutron capture therapy (BNCT), normal tissue surrounding the tumor cells sometimes take up boron compounds resulting in radiation-induced damage to normal tissue. We have previously reported the evidence for increased the mutagenicity of thermal neutron in the presence of boron. In addition, we described the biological radio-protective effects of the ascorbic acid for mutation induction following BNCT in vitro. Here, we investigated these radio-protective effects of ascorbic acid for mutation induction in mouse splenocytes on HPRT locus following a BNCT study in vivo. (author)

  4. Tumor blood vessel 'normalization' improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer

    International Nuclear Information System (INIS)

    Nigg, D.W.

    2012-01-01

    We previously demonstrated the efficacy of BNCT mediated by boronophenylalanine (BPA) to treat tumors in a hamster cheek pouch model of oral cancer with no normal tissue radiotoxicity and moderate, albeit reversible, mucositis in precancerous tissue around treated tumors. It is known that boron targeting of the largest possible proportion of tumor cells contributes to the success of BNCT and that tumor blood vessel normalization improves drug delivery to the tumor. Within this context, the aim of the present study was to evaluate the effect of blood vessel normalization on the therapeutic efficacy and potential radiotoxicity of BNCT in the hamster cheek pouch model of oral cancer.

  5. "Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Veronica A. Trivillin; Amanda E. Schwint; Emiliano C. C. Pozzi; Maria E. Itoiz; Silvia I. Thorp; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz

    2011-04-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with a thermal or epithermal neutron beam. The minor abundance stable isotope of boron, 10B, interacts with low energy (thermal) neutrons to produce high linear energy transfer (LET) a-particles and 7Li ions. These disintegration products are known to have a high relative biological effectiveness (RBE). Their short range (<10 {micro}m) would limit the damage to cells containing 10B (1,2). Thus, BNCT would target tumor tissue selectively, sparing normal tissue. Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane (BSH) as the 10B carriers, have been performed or are underway in Argentina, Japan, the US and Europe (e.g. 3-8). To date, the clinical results have shown a potential, albeit inconclusive, therapeutic advantage for this technique. Contributory translational studies have been carried out employing a variety of experimental models based on the implantation of tumor cells in normal tissue (e.g. 5).

  6. Clinical results of BNCT for malignant gliomas using BSH and BPA simultaneously

    International Nuclear Information System (INIS)

    Miyatake, Shin-ichi; Kawabata, Shinji; Kajimoto, Yoshinaga

    2006-01-01

    Since 2002 to 2006, we applied BNCT for 41 cases of malignant gliomas. We used 3 different protocols. In each protocol, we used BSH and BPA simultaneously. In protocol 1, BSH 5g/body and BPA 250 mg/kg were used for consecutive 13 cases. Median survival time (MST) of newly diagnosed 4 cases of GB was 23 months after diagnosis. 2 cases were still alive. All cases including recurrent ones showed radiographic improvement. Eight out of 12 cases showed more than 50% mass reduction on images. Major cause of death was CSF dissemination. In protocol 2, BNCT were applied for 4 patients, two times with one to 2 week-interval. MST after BNCT was 13.3 months. In protocol 3, BPA 700 mg/kg were used with 20 to 30 Gy XRT after BNCT. XRT boost was applied especially for deeper part of the tumor. In protocol 3, 6 newly diagnosed GB patients were observed more than 16 months. 3 were dead and 3 were still alive on the preparation of this abstract. MST of these 6 patients was 17.3 months after diagnosis. In each protocol, radiation necrosis was the problem for recurrent cases, while removal of the necrosis prolonged the survival and recovered the neurological deficits. (author)

  7. Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Nigg, David; Calzetta, Osvaldo; Blaumann, Herman; Longhino, Juan; Schwint, Amanda E. E-mail: schwint@cnea.gov.ar

    2004-11-01

    We previously reported biodistribution and pharmacokinetic data for GB-10 (Na{sub 2}{sup 10}B{sub 10}H{sub 10}) and the combined administration of GB-10 and boronophenylalanine (BPA) as boron delivery agents for boron neutron capture therapy (BNCT) in the hamster cheek pouch oral cancer model. The aim of the present study was to assess, for the first time, the response of hamster cheek pouch tumors, precancerous tissue and normal tissue to BNCT mediated by GB-10 and BNCT mediated by GB-10 and BPA administered jointly using the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. GB-10 exerted 75.5% tumor control (partial+complete remission) with no damage to precancerous tissue around tumor or to normal tissue. Thus, GB-10 proved to be a therapeutically efficient boron agent in this model despite the fact that it is not taken up selectively by oral tumor tissue. GB-10 exerted a selective effect on tumor blood vessels leading to significant tumor control with a sparing effect on normal tissue. BNCT mediated by the combined administration of GB-10 and BPA resulted in a reduction in the dose to normal tissue and would thus allow for significant escalation of dose to tumor without exceeding normal tissue tolerance.

  8. Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Nigg, David; Calzetta, Osvaldo; Blaumann, Herman; Longhino, Juan; Schwint, Amanda E.

    2004-01-01

    We previously reported biodistribution and pharmacokinetic data for GB-10 (Na 2 10 B 10 H 10 ) and the combined administration of GB-10 and boronophenylalanine (BPA) as boron delivery agents for boron neutron capture therapy (BNCT) in the hamster cheek pouch oral cancer model. The aim of the present study was to assess, for the first time, the response of hamster cheek pouch tumors, precancerous tissue and normal tissue to BNCT mediated by GB-10 and BNCT mediated by GB-10 and BPA administered jointly using the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. GB-10 exerted 75.5% tumor control (partial+complete remission) with no damage to precancerous tissue around tumor or to normal tissue. Thus, GB-10 proved to be a therapeutically efficient boron agent in this model despite the fact that it is not taken up selectively by oral tumor tissue. GB-10 exerted a selective effect on tumor blood vessels leading to significant tumor control with a sparing effect on normal tissue. BNCT mediated by the combined administration of GB-10 and BPA resulted in a reduction in the dose to normal tissue and would thus allow for significant escalation of dose to tumor without exceeding normal tissue tolerance

  9. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    DEFF Research Database (Denmark)

    Hampel, G.; Grunewald, C.; Schütz, C.

    2011-01-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed at Pavia (Italy) a few ...

  10. Time factor of BSH from intravenous infusion to neutron irradiation for BNCT in patients with glioblastoma

    International Nuclear Information System (INIS)

    Kageji, T.; Nagahiro, S.; Kitamura, K.; Nakagawa, Y.; Hatanaka, H.; Haritz, D.; Grochulla, F.; Haselsberger, K.; Gabel, D.

    2000-01-01

    The present report evaluates the time factor of BSH from infusion to irradiation in patients with glioblastoma as a cooperative study in Europe and Japan. For BNCT with BSH after intravenous infusion, this work confirms that the planned neutron irradiation after intravenous BSH infusion appears to be optimal around 12-19 hours after the infusion. (author)

  11. Azaboranes with hydroxypropyl residues as possible new compounds for use in BNCT

    International Nuclear Information System (INIS)

    Bauer, C.; Gabel, D.; Doefler, U.

    2000-01-01

    The azaboranes of the type RNH 2 B 8 H 11 NHR where R contains a hydroxyl group are possible new compounds for BNCT, because they are water stable and more or less water soluble for physiological transport. These compounds also fulfil the condition of not being toxic. (author)

  12. European Strategy for Accelerator-Based Neutrino Physics

    CERN Document Server

    Bertolucci, Sergio; Cervera, Anselmo; Donini, Andrea; Dracos, Marcos; Duchesneau, Dominique; Dufour, Fanny; Edgecock, Rob; Efthymiopoulos, Ilias; Gschwendtner, Edda; Kudenko, Yury; Long, Ken; Maalampi, Jukka; Mezzetto, Mauro; Pascoli, Silvia; Palladino, Vittorio; Rondio, Ewa; Rubbia, Andre; Rubbia, Carlo; Stahl, Achim; Stanco, Luca; Thomas, Jenny; Wark, David; Wildner, Elena; Zito, Marco

    2012-01-01

    Massive neutrinos reveal physics beyond the Standard Model, which could have deep consequences for our understanding of the Universe. Their study should therefore receive the highest level of priority in the European Strategy. The discovery and study of leptonic CP violation and precision studies of the transitions between neutrino flavours require high intensity, high precision, long baseline accelerator neutrino experiments. The community of European neutrino physicists involved in oscillation experiments is strong enough to support a major neutrino long baseline project in Europe, and has an ambitious, competitive and coherent vision to propose. Following the 2006 European Strategy for Particle Physics (ESPP) recommendations, two complementary design studies have been carried out: LAGUNA/LBNO, focused on deep underground detector sites, and EUROnu, focused on high intensity neutrino facilities. LAGUNA LBNO recommends, as first step, a conventional neutrino beam CN2PY from a CERN SPS North Area Neutrino Fac...

  13. Logic Estimation of the Optimum Source Neutron Energy for BNCT of Brain Tumors

    International Nuclear Information System (INIS)

    Dorrah, M.A.; Gaber, F.A.; Abd Elwahab, M.A.; Kotb, M.A.; Mohammed, M.M.

    2012-01-01

    BNCT is very complicated technique; primarily due to the complexity of element composition of the brain. Moreover; numerous components contributes to the over all radiation dose both to normal brain and to tumor. Simple algebraic summation cannot be applied to these dose components, since each component should at first be weighed by its relative biological effectiveness (RBE) value. Unfortunately, there is no worldwide agreement on these RBE values. For that reason, the parameters required for accurate planning of BNCT of brain tumors located at different depths in brain remained obscure. The most important of these parameters is; the source neutron energy. Thermal neutrons were formerly employed for BNCT, but they failed to prove therapeutic efficacy. Later on; epithermal neutrons were suggested proposing that they would be enough thermalized while transporting in the brain tissues. However; debate aroused regarding the source neutrons energy appropriate for treating brain tumors located at different depths in brain. Again, the insufficient knowledge regarding the RBE values of the different dose components was a major obstacle. A new concept was adopted for estimating the optimum source neutrons energy appropriate for different circumstances of BNCT. Four postulations on the optimum source neutrons energy were worked out, almost entirely independent of the RBE values of the different dose components. Four corresponding condition on the optimum source neutrons energy were deduced. An energy escalation study was carried out investigating 65 different source neutron energies, between 0.01 eV and 13.2 MeV. MCNP4B Monte C arlo neutron transport code was utilized to study the behavior of neutrons in the brain. The deduced four conditions were applied to the results of the 65 steps of the neutron energy escalation study. A source neutron energy range of few electron volts (eV) to about 30 keV was estimated to be the most appropriate for BNCT of brain tumors located at

  14. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

    Energy Technology Data Exchange (ETDEWEB)

    Aiyama, H. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nakai, K., E-mail: knakai@Neurosurg-tsukuba.com [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Yamamoto, T. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyouku (Japan); Kumada, H. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Ishikawa, E. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Isobe, T. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)

    2011-12-15

    We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors. - Highlights: Black-Right-Pointing-Pointer Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor. Black-Right-Pointing-Pointer Two cases with recurrent glioblastoma and anaplastic meningioma. Black-Right-Pointing-Pointer No severe adverse events have been observed using BNCT. Black-Right-Pointing-Pointer BNCT has a possibility of a safe palliative therapy for malignant brain tumors.

  15. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

    International Nuclear Information System (INIS)

    Aiyama, H.; Nakai, K.; Yamamoto, T.; Nariai, T.; Kumada, H.; Ishikawa, E.; Isobe, T.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A.

    2011-01-01

    We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors. - Highlights: ► Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor. ► Two cases with recurrent glioblastoma and anaplastic meningioma. ► No severe adverse events have been observed using BNCT. ► BNCT has a possibility of a safe palliative therapy for malignant brain tumors.

  16. Desain Beam Shaping Assembly (BSA berbasis D-D Neutron Generator 2,45 MeV untuk Uji Fasilitas BNCT

    Directory of Open Access Journals (Sweden)

    Desman P. Gulo

    2015-12-01

    Full Text Available Boron Neutron Capture Therapy (BNCT is one of the cancer treatments that are being developed in nowadays. In order to support BNCT treatment for cancer that exists in underneath skin like breast cancer, the facility needs a generator that is able to produce epithermal neutron. One of the generator that is able to produce neutron is D-D neutron generator with 2.45 MeV energy. Based on the calculation of this paper, we found that the total production of neutron per second (neutron yield from Neutron Generator (NG by PSTA-BATAN Yogyakarta is 2.55×1011 n/s. The energy and flux that we found is in the range of quick neutron. Thus, it needs to be moderated to the level of epithermal neutron which is located in the interval energy of 1 eV to 10 KeV with 109 n/cm2s flux. This number is the recommendation standard from IAEA. Beam Shaping Assembly (BSA is needed in order to moderate the quick neutron to the level of epithermal neutron. One part of BSA that has the responsibility in moderating the quick neutron to epithermal neutron is the moderator. The substance of moderator used in this paper is MgF2 and A1F3. The thickness of moderator has been set in in such a way by using MCNPX software in order to fulfill the standard of IAEA. As the result of optimizing BSA moderator, the data obtain epithermal flux with the total number of 4.64×108 n/cm2/s for both of moderators with the thickness of moderator up to 15 cm. At the end of this research, the number of epithermal flux does not follow the standard of IAEA. This is because the flux neutron that is being produced by NG is relatively small. In conclusion, the NG from PSTA-BATAN Yogyakarta is not ready to be used for the BNCT treatment facility for the underneath skin cancer like breast cancer.

  17. A preliminary inter-centre comparison study for photon, thermal neutron and epithermal neutron responses of two pairs of ionisation chambers used for BNCT

    International Nuclear Information System (INIS)

    Roca, Antoaneta; Liu, Yuan-Hao; Wojnecki, Cecile; Green, Stuart; Nievaart, Sander; Ghani, Zamir; Moss, Ray

    2009-01-01

    The dual ionisation chamber technique is the recommended method for mixed field dosimetry of epithermal neutron beams. This paper presents initial data from an ongoing inter-comparison study involving two identical pairs of ionisation chambers used at the BNCT facilities of Petten, NL and of University of Birmingham, UK. The goal of this study is to evaluate the photon, thermal neutron and epithermal neutron responses of both pairs of TE(TE) (Exradin T2 type) and Mg(Ar) (Exradin M2 type) ionisation chambers in similar experimental conditions. At this stage, the work has been completed for the M2 type chambers and is intended to be completed for the T2 type chambers in the near future.

  18. Boron neutron capture therapy (BNCT) for high-grade gliomas of the brain: a cautionary note

    International Nuclear Information System (INIS)

    Laramore, George E.; Spence, Alexander M.

    1996-01-01

    Purpose/Objective: Boron neutron capture therapy (BNCT) is a method of treating high-grade gliomas of the brain that involves incorporating 10 B into the tumor using appropriate pharmacological agents and then irradiating the tumor with thermal or epithermal neutron beams. To date, over 120 patients have been treated in this manner by Japanese investigators using a thermal neutron beam from a nuclear reactor. Favorable reports on outcome have motivated considerable current research in BNCT. The purpose of this study is to provide an independent analysis of the Japanese data by identifying the subset of patients from the United States who received this treatment in Japan and comparing their outcomes relative to a matched cohort who received conventional therapy in various Radiation Therapy Oncology Group (RTOG) studies. Methods and Materials: The principal referral sources of patients to Japan for BNCT were identified and the names of patients sent for treatment obtained. The treating physicians in Japan were also contacted to see if additional patients from the United States had been treated. Either the patients or their next of kin were contacted, and permission was obtained to retrieve medical records including tumor pathology for central review. Prognostic variables according to an analysis of the RTOG brain tumor database by Curran et al. were determined from these records and used to construct a matched cohort of patients treated conventionally. Results: A total of 14 patients were identified who had traveled to Japan for BNCT treatment between July, 1987 and June, 1994. In the case of one patient (deceased), it was not possible to contact the next of kin. Material was obtained on the other 13 patients and review of the pathology indicated that 1 patient had a central nervous system lymphoma rather than a high-grade glioma. Survival data was analyzed for the other 12 patients on an actuarial basis, and this showed no difference compared to survival data for a

  19. Therapeutic efficacy and toxicity of a single and double application of boron neutron capture therapy (BNCT) in a hamster cheek pouch oral precancer model

    International Nuclear Information System (INIS)

    Monti Hughes, A; Pozzi, E C C; Thorp, S; Garabalino, M A; Farias, R O; Gonzalez, S J; Heber, E M; Itoiz, M E; Aromando, R F; Molinari, A J; Miller, M; Nigg, D W; Curotto, P; Trivillin, V A; Schwint, A E

    2012-01-01

    Tumor development from tissue with potentially malignant disorders (PMD) gives rise to second primary tumors. We previously demonstrated the partial inhibitory effect on tumor development of Boron Neutron Capture Therapy (BNCT) mediated by the boron compounds BPA (boronophenylalanine) and decahydrodecaborate (GB-10) in a hamster pouch oral precancer model. Seeking to optimize BNCT, the aim of the present study was to contribute to the knowledge of BNCT radiobiology for oral precancer and assess new BNCT protocols in terms of inhibition of tumor development and radiotoxicity. Groups of cancerized hamsters were locally exposed to single or double applications (2 weeks apart) of BPA-BNCT or (GB-10 + BPA)-BNCT at a total dose of 8Gy to tissue with PMD; to a single application of BPA-BNCT at 6Gy and to a double application (4 weeks apart) of BPA-BNCT or (BPA + GB-10)-BNCT at a total dose of 10Gy. Cancerized, sham-irradiated hamsters served as controls. Clinical status, tumor development from tissue with PMD and mucositis were followed for 8 months. The marked therapeutic efficacy of single applications of BNCT at 6 and 8Gy were associated to severe radiotoxicity. Dose fractionation into 2 applications reduced mucositis but also reduced therapeutic efficacy, depending on dose and interval between applications. A double application (4 weeks apart) of (GB-10 + BPA)-BNCT at a total dose of 10Gy rendered the best therapeutic advantage, i.e. 63% - 100% inhibition of tumor development with only slight mucositis in 67% of cases. The data reported herein show that issues such as dose levels and dose fractionation, interval between applications, and choice of boron compounds are pivotal to therapeutic advantage and must be tailored for a particular pathology and anatomic site. The present study determined treatment conditions that would contribute to optimize BNCT for precancer and that would warrant cautious assessment in a clinical scenario (author)

  20. Monte Carlo simulations of the cellular S-value, lineal energy and RBE for BNCT

    International Nuclear Information System (INIS)

    Liu Chingsheng; Tung Chuanjong

    2006-01-01

    Due to the non-uniform uptake of boron-containing pharmaceuticals in cells and the short-ranged alpha and lithium particles, microdosimetry provides useful information on the cellular dose and response of boron neutron capture therapy (BNCT). Radiation dose and quality in BNCT may be expressed in terms of the cellular S-value and the lineal energy spectrum. In the present work, Monte Carlo simulations were performed to calculate these microdosimetric parameters for different source-target configurations and sizes in cells. The effective relative biological effectiveness (RBE) of the Tsing Hua Open-pool Reactor (THOR) epithermal neutron beam was evaluated using biological weighting functions that depended on the lineal energy. RBE changes with source-target configurations and sizes were analyzed. (author)

  1. The Phase I/II BNCT Trials at the Brookhaven medical research reactor: Critical considerations

    International Nuclear Information System (INIS)

    Diaz, A.Z.

    2001-01-01

    A phase I/II clinical trial of boronophenylalanine-fructose (BPA-F) mediated boron neutron capture therapy (BNCT) for Glioblastoma Multiforme (GBM) was initiated at Brookhaven National Laboratory (BNL) in 1994. Many critical issues were considered during the design of the first of many sequential dose escalation protocols. These critical issues included patient selection criteria, boron delivery agent, dose limits to the normal brain, dose escalation schemes for both neutron exposure and boron dose, and fractionation. As the clinical protocols progressed and evaluation of the tolerance of the central nervous system (CNS) to BPA-mediated BNCT at the BMRR continued new specifications were adopted. Clinical data reflecting the progression of the protocols will be presented to illustrate the steps taken and the reasons behind their adoption. (author)

  2. Radioprotective agents to reduce BNCT (Boron Neutron Capture Therapy) induced mucositis in the hamster cheek pouch

    International Nuclear Information System (INIS)

    Monti Hughes, A.; Pozzi, E.C.C.; Thorp, S.

    2013-01-01

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of BNCT mediated by boronophenylalanine (BPA) in the hamster cheek pouch oral cancer and pre cancer model. Despite therapeutic efficacy, mucositis induced in premalignant tissue was dose limiting and favored, in some cases, tumor development. In a clinical scenario, oral mucositis limits the dose administered to head and neck tumors. Aim: Our aim was to evaluate the effect of the administration of different radioprotective agents, seeking to reduce BNCT-induced mucositis to acceptable levels in dose-limiting premalignant tissue; without compromising therapeutic effect evaluated as inhibition on tumor development in premalignant tissue; without systemic or local side effects; and without negative effects on the biodistribution of the boron compound used for treatment. Materials and methods: Cancerized hamsters with DMBA (dimethylbenzanthracene) were treated with BPA-BNCT 5 Gy total absorbed dose to premalignant tissue, at the RA-3 Nuclear Reactor, divided into different groups: 1-treated with FLUNIXIN; 2- ATORVASTATIN; 3-THALIDOMIDE; 4-HISTAMINE (two concentrations: Low -1 mg/ml- and High -5 mg/ml-); 5-JNJ7777120; 6-JNJ10191584; 7-SALINE (vehicle). Cancerized animals without any treatment (neither BNCT nor radioprotective therapy) were also analyzed. We followed the animals during one month and evaluated the percentage of animals with unacceptable/severe mucositis, clinical status and percentage of animals with new tumors post treatment. We also performed a preliminary biodistribution study of BPA + Histamine “low” concentration to evaluate the potential effect of the radioprotector on BPA biodistribution. Results: Histamine

  3. Synthesis and in-vivo detection of boronated compounds for use in BNCT

    International Nuclear Information System (INIS)

    Kabalka, G.W.

    1990-04-01

    The primary objective of the DOE Program at the University of Tennessee Biomedical Imaging Center is the development of new technology to detect boron compounds in-vivo. The research focuses on the development of multinuclear magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques for verifying and measuring BNCT agents in-vivo. A small but significant portion of the effort is directed toward the design of boron-containing neutron-capture-therapy agents. The UT -- DOE program is unique in that it has access to two state-of-the-art multinuclear magnetic resonance imaging units housed in the Biomedical Imaging Center at the University of Tennessee Medical Center at Knoxville. Included in this report are two sections describing research accomplishments in multinuclear magnetic resonance imaging and synthesis of potential BNCT agents

  4. On line local measurement of thermal neutron flux on BNCT patient using SPND

    International Nuclear Information System (INIS)

    Miller, M.E.; Sztejnberg Goncalves-Carralves, M.L.; Gonzalez, S.J.

    2006-01-01

    The first on-line neutron flux measurement on a patient using a self-powered neutron detector (SPND) was assessed during the fourth clinical trial of the Boron Neutron Capture Therapy (BNCT) Project carried out at the National Atomic Energy Commission of Argentina (CNEA) and the medical center Angel H. Roffo. The SPND was specially developed and assembled for BNCT by CNEA. Its small size, 1 cm sensible length and 1.9 mm diameter, allowed performing a localized measurement. Since the treated tumors were cutaneous melanomas of nodular type, the SPND was located on the patient's skin. The patient was exposed to three different and consecutive fields and in each of them the SPND was used to measure local thermal neutron fluxes at selected dosimetric reference points. The values of the measured fluxes agreed with the ones estimated by calculation. This trial also demonstrated the usefulness of the SPND for assessing flux on-line. (author)

  5. Design and simulation of an optimized e-linac based neutron source for BNCT research

    International Nuclear Information System (INIS)

    Durisi, E.; Alikaniotis, K.; Borla, O.; Bragato, F.; Costa, M.; Giannini, G.; Monti, V.; Visca, L.; Vivaldo, G.; Zanini, A.

    2015-01-01

    The paper is focused on the study of a novel photo-neutron source for BNCT preclinical research based on medical electron Linacs. Previous studies by the authors already demonstrated the possibility to obtain a mixed thermal and epithermal neutron flux of the order of 10"7 cm"−"2 s"−"1. This paper investigates possible Linac’s modifications and a new photo-converter design to rise the neutron flux above 5 10"7 cm"−"2 s"−"1, also reducing the gamma contamination. - Highlights: • Proposal of a mixed thermal and epithermal (named hyperthermal) neutron source based on medical high energy electron Linac. • Photo-neutron production via Giant Dipole Resonance on high Z materials. • MCNP4B-GN simulations to design the photo-converter geometry maximizing the hyperthermal neutron flux and minimizing the fast neutron and gamma contaminations. Hyperthermal neutron field suitable for BNCT preclinical research.

  6. Four cases of facial melanoma treated by BNCT with 10B-p-boronophenylalanine

    International Nuclear Information System (INIS)

    Fukuda, H.; Mishima, Y.; Hiratsuka, J.; Kobayashi, T.; Karashima, H.; Yoshino, K.; Tsuru, K.; Araki, K.; Ichihashi, M.

    2000-01-01

    We treated four cases of facial melanoma by BNCT with 10 B-paraboronophenylalanine · fructose complex (BPA). The patients received 180 to 200 mg BPA/kg-BW intravenously for 3 to 5 hours. One to two hours after the end of BPA administration, they were irradiated with a thermal neutron beam at the Kyoto University Reactor (KUR). The local control of the tumors was good and complete regression was achieved in all cases. The acute and subacute skin reactions ranged from dry desquamation to erosion and were within tolerable limits. After 2 to 3 months, the skin recovered from damage with slight pigmentation or depigmentation and without serious functional or cosmetic problems. Our results indicate BNCT of facial melanoma is promising not only for tumor cure but also for good QOL of the patients, although surgery is the standard and first choice for the treatment of malignant melanoma. (author)

  7. The Swedish facility for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Skoeld, K.; Capala, J. [Studsvik Medical AB (Sweden); Kierkegaard, J.; Haakansson, R. [Studsvik Nuclear AB (Sweden); Gudowska, I. [Karolinska Institute (Sweden)

    2000-10-01

    A BNCT (Boron Neutron Capture Therapy) facility has been constructed at the R2-0 reactor at Studsvik, Sweden. R2-0 is a 1 MW, open core, pool reactor. The reactor core is suspended on a movable tower and can be positioned anywhere in the pool. The BNCT facility includes two adjacent, parallel filter/moderator configurations and the reactor core is positioned in front of any of them as appropriate. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range and with an extended collimator for convenient patient positioning. The other beam has been designed for radiobiological research and is equipped with a heavy water moderator and a large irradiation cavity with a uniform field of thermal neutrons. (author)

  8. The Swedish facility for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Skoeld, K.; Capala, J.; Kierkegaard, J.; Haakansson, R.; Gudowska, I.

    2000-01-01

    A BNCT (Boron Neutron Capture Therapy) facility has been constructed at the R2-0 reactor at Studsvik, Sweden. R2-0 is a 1 MW, open core, pool reactor. The reactor core is suspended on a movable tower and can be positioned anywhere in the pool. The BNCT facility includes two adjacent, parallel filter/moderator configurations and the reactor core is positioned in front of any of them as appropriate. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range and with an extended collimator for convenient patient positioning. The other beam has been designed for radiobiological research and is equipped with a heavy water moderator and a large irradiation cavity with a uniform field of thermal neutrons. (author)

  9. Treatment optimization of a brain tumor in BNCT by Monte Carlo method

    International Nuclear Information System (INIS)

    Nejat, S.; Binesh, A.; Karimian, A.

    2012-01-01

    Brain cancers are one of the most important diseases. BNCT (Boron Neutron Capture Therapy) is used to brain tumor treatment. In this method the 1 0B (n,α) 7 Li reaction is used. The purpose of this study is absorbed dose evaluation of tumoral and healthy parts of brain. To achieve this aim the brain was simulated by a cylindrical phantom with the dimensions of 20 cm in diameter and height. In BNCT treatment the BSH (Na 2 B 12 H 11 SH) is injected to the human body and absorbed in the healthy and tumoral parts by the ratios of 18 and 65 ppm respectively. So in this research the absorption of BSH in tumoral and healthy parts of brain was considered as the mentioned ratio. Then the neutron with the energy range of 50 eV - 10 keV was exposed to the brain and maximum absorbed dose in healthy and tumoral parts of brain were calculated for a cylindrical tumor with the thickness of about 1 cm which was considered in 5.5 cm depth of brain. This research showed the suitable energy to treat this tumor by BNCT is interval 4 keV- 6keV. The average of dose which is met with healthy and tumor tissue was gained for 6 keV energy of brain 1.18x10 -12 cGy/n and 5.98x10 -12 cGy/n respectively. Maximum of dose which is met with healthy tissue was 4.3 Gy which is much less than standard amount 12.6 Gy. Therefore BNCT method is known as an effective way in the therapy of this kind of tumor. (authors)

  10. Feasibility study on BNCT-SPECT using a CdTe detector

    International Nuclear Information System (INIS)

    Murata, Isao; Mukai, Taiki; Ito, Masao; Miyamaru, Hiroyuki; Yoshida, Shigeo

    2011-01-01

    There is no doubt that boron neutron capture therapy (BNCT) is a promising cancer therapy in the near future. At present, one of the severest problems to solve is monitoring of the treatment effect during neutron irradiation. It is known to be difficult in real time. So far, activation foils, small detectors and so on were used to measure the thermal neutron fluence in a certain place of the tumor. The dose distribution is thus estimated from the measured result and prediction with a transport code. In the present study, 478 keV gamma-rays emitted from the excited state of 7 Li produced by 10 B(n,α) 7 Li reaction are directly measured to realize real time monitoring of the treatment effect of BNCT. In this paper, the result of the feasibility study carried out using a Monte Carlo transport code is summarized. We used CdTe detectors with a quite narrow collimator to obtain a BNCT image keeping good spatial resolution. The intensity of capture gamma-rays of 2223 keV produced by 1 H(n,γ) 2 H reaction is very much higher than that of 478 keV. We thus adjusted the detector efficiency by selecting an appropriate thickness so as to optimize the efficiency ratio between 478 and 2223 keV. From the result of the detector response calculation, in case of 20 mm thick CdTe detector with the collimator of 2 mm in diameter, sufficient net count of ∼1000 for 478 keV in 30 min. was realized. It means an efficient and high-resolution BNCT-SPECT image could be obtained. (author)

  11. A colorimetric determination of boron in biological sample for boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Camillo, M.A.P.; Tomac Junior, U.

    1990-01-01

    The boron neutron capture therapy (BNCT) has shown better prognosis in the treatment of glyemas and gluoblastomas grade III and IV than other therapies. During the treatment the levels of Na 2 10 B 12 H 11 SH must be known in several compartiments of the organism and with this purpose the method of colorimetric determination of boron using curcumine was established. This method is simple, reprodutible and adequate sensitivity for this control. (author) [pt

  12. Hyaluronic acid as a potential boron carrier for BNCT: Preliminary evaluation

    International Nuclear Information System (INIS)

    Zaboronok, A.; Yamamoto, T.; Nakai, K.; Yoshida, F.; Uspenskii, S.; Selyanin, M.; Zelenetskii, A.; Matsumura, Akira

    2015-01-01

    Hyaluronic acid (HA), a nonimmunogenic, biocompatible polymer found in different biological tissues, has the potential to attach to CD44 receptors on the surface of certain cancer cells, where the receptor is overexpressed compared with normal cells. Boron–hyaluronic acid (BHA) was tested for its feasibility as a potential agent for BNCT. BHA with low-viscosity 30 kDa HA could be administered by intravenous injection. The compound showed a certain degree of cytotoxicity and accumulation in C6 rat glioma cells in vitro. Instability of the chelate bonds between boron and HA and/or insufficient specificity of CD44 receptors on C6 cells to BHA could account for the insufficient in vitro accumulation. To ensure the future eligibility of BHA for BNCT experiments, using alternative tumor cell lines and chemically securing the chelate bonds or synthesizing BHA with boron covalently attached to HA might be required. - Highlights: • Hyaluronic acid (HA) is a nonimmunogenic, biocompatible polymer. • Boron–HA (BHA) acid can contain a large number of boron atoms for BNCT. • Active targeting can be realized with CD44 and other HA receptors on tumor cells. • BHA showed a certain degree of toxicity against C6 tumor cells and V79 fibroblasts. • BHA was injected into rats via the tail vein, boron was detected in tumors in vivo.

  13. Construction of voxel head phantom and application to BNCT dose calculation

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Choon Sik; Lee, Choon Ik; Lee, Jai Ki [Hanyang Univ., Seoul (Korea, Republic of)

    2001-06-15

    Voxel head phantom for overcoming the limitation of mathematical phantom in depicting anatomical details was constructed and example dose calculation for BNCT was performed. The repeated structure algorithm of the general purpose Monte Carlo code, MCNP4B was applied for voxel Monte Carlo calculation. Simple binary voxel phantom and combinatorial geometry phantom composed of two materials were constructed for validating the voxel Monte Carlo calculation system. The tomographic images of VHP man provided by NLM(National Library of Medicine) were segmented and indexed to construct voxel head phantom. Comparison od doses for broad parallel gamma and neutron beams in AP and PA directions showed decrease of brain dose due to the attenuation of neutron in eye balls in case of voxel head phantom. The spherical tumor volume with diameter, 5cm was defined in the center of brain for BNCT dose calculation in which accurate 3 dimensional dose calculation is essential. As a result of BNCT dose calculation for downward neutron beam of 10keV and 40keV, the tumor dose is about doubled when boron concentration ratio between the tumor to the normal tissue is 30{mu}g/g to 3 {mu}g/g. This study established the voxel Monte Carlo calculation system and suggested the feasibility of precise dose calculation in therapeutic radiology.

  14. Retrospective review of the clinical BNCT trial at Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    Diaz, A.Z.; Chanana, A.D.; Coderre, J.A.; Ma, R.

    2000-01-01

    The primary objective of the phase I/II dose escalation studies was to evaluate the safety of the boronophenylalanine-fructose (BPA-F) mediated boron neutron capture therapy (BNCT) in subjects with glioblastoma multiforme (GBM). A secondary objective was to retrospectively assess the palliation of GBM by BNCT. Fifty-three subjects with GBM were treated under multiple dose escalation protocols at the Brookhaven Medical Research Reactor (BMRR). Twenty-six subjects were treated using one field, 17 subjects were treated using 2 fields and 10 subjects were treated using 3 fields. BPA-F related toxicity was not observed. The maximum radiation dose to a volume of approximately 1 cc of the normal brain varied from 8.9 to 15.9 gray-equivalent (Gy-Eq). The volume-weighted average radiation dose to normal brain varied from 1.9 to 9.5 Gy-Eq. Six RTOG (Radiation Therapy Oncology Group) grade 3 or 4 toxicities were attributed to BNCT. Four of the 53 subjects are still alive with 3 of them free of recurrent disease with over two years follow-up. The median times to progression and median survival time from diagnosis were 28.4 weeks and 12.8 months respectively. (author)

  15. In vivo tyrosinase mini-gene transfer enhances killing effect of BNCT on amelanotic melanoma

    International Nuclear Information System (INIS)

    Kondoh, H.; Mishima, Y.; Hiratsuka, J.; Iwakura, M.

    2000-01-01

    Using accentuated melanogenesis principally occurring within melanoma cells, we have successfully treated human malignant melanoma (Mm) with 10 B-BPA BNCT. Despite this success, there are still remaining issues for poorly melanogenic Mm and further non-pigment cell tumors. We found the selective accumulation of 10 B-BPA to Mm is primarily due to the complex formation of BPA and melanin-monomers activity synthesized within Mm cells. Then, we succeeded in transferring the tyrosinase gene into amelanotic to substantially produce melanin monomers. These cells has demonstrated increased boron accumulation and enhanced killing effect of BNCT. Further, transfection of TRP-2 (DOPAchrome tautomerase) gene into poorly eumelanotic and slightly phenomelanotic Mm cells in culture cell systems also led to increased BPA accumulation. Thereafter, we studied in vivo gene transfer. We transferred the tyrosinase mini-gene by intra-tumor injection into poorly melanotic Mm proliferating subcutaneously in hamster skin, and performed BNCT. Compared to control tumors, gene-transferred tumors showed increased BPA accumulation leading to enhanced killing effect. (author)

  16. In vivo tyrosinase mini-gene transfer enhances killing effect of BNCT on amelanotic melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Kondoh, H.; Mishima, Y. [Mishima Institute for Dermatological Research, Kobe, Hyogo (Japan); Hiratsuka, J. [Kawasaki Medical School, Dept. of Radiation Oncology, Kurashiki, Okayama (Japan); Iwakura, M. [Kobe Univ. (Japan). School of Medicine

    2000-10-01

    Using accentuated melanogenesis principally occurring within melanoma cells, we have successfully treated human malignant melanoma (Mm) with {sup 10}B-BPA BNCT. Despite this success, there are still remaining issues for poorly melanogenic Mm and further non-pigment cell tumors. We found the selective accumulation of {sup 10}B-BPA to Mm is primarily due to the complex formation of BPA and melanin-monomers activity synthesized within Mm cells. Then, we succeeded in transferring the tyrosinase gene into amelanotic to substantially produce melanin monomers. These cells has demonstrated increased boron accumulation and enhanced killing effect of BNCT. Further, transfection of TRP-2 (DOPAchrome tautomerase) gene into poorly eumelanotic and slightly phenomelanotic Mm cells in culture cell systems also led to increased BPA accumulation. Thereafter, we studied in vivo gene transfer. We transferred the tyrosinase mini-gene by intra-tumor injection into poorly melanotic Mm proliferating subcutaneously in hamster skin, and performed BNCT. Compared to control tumors, gene-transferred tumors showed increased BPA accumulation leading to enhanced killing effect. (author)

  17. Some recent developments in treatment planning software and methodology for BNCT

    International Nuclear Information System (INIS)

    Nigg, D.W.; Wheeler, F.J.; Wessol, D.E.; Wemple, C.A.; Babcock, R.; Capala, J.

    1996-01-01

    Over the past several years/the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape,and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe

  18. Some recent developments in treatment planning software and methodology for BNCT

    International Nuclear Information System (INIS)

    Nigg, D.W.; Wheeler, F.J.; Wessol, D.E.

    1996-01-01

    Over the past several years the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT-rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape, and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe

  19. Monitoring total boron in blood for BNCT by a novel atomic emission method

    International Nuclear Information System (INIS)

    Laakso, J.; Kulvik, M.; Ruokonen, I.; Vaehaetalo, J.; Faerkkilae, M.; Kallio, M.; Zilliacus, R.

    2000-01-01

    In BNCT the duration and timing of the is adjusted by 10 B concentrations in whole blood. Time-frame for determinations is less than 20 minutes. Therefore fast and accurate boron determinations are a prerequisite for BNCT. We present a method based on ICP-AES instrument for whole blood and plasma boron determinations with protein precipitation with trichloroacetic acid as sample pre-treatment and beryllium as an internal standard. The method was compared to established but tedious ICP-mass spectrometric method with wet ashing as a sample pre-treatment. The ICP-AES method is in good agreement (correlation coefficient 0.99) the ICP-MS. Within-day and between-day imprecisions were less than 3,5% CV for whole blood samples. Samples taken during and after BPA-F infusion (290 mg/kg) revealed an uneven distribution between plasma and erythrocytes. The present method is feasible and one of the fastest currently available for BNCT. Our results indicate that BPA-F or its metabolites do not seem to be tightly bound to plasma proteins. It also seems that determination of boron in plasma sample may be preferable than measuring boron in whole blood. (author)

  20. Collaborative Physical and Biological Dosimetry Studies for Neutron Capture Therapy at the RA-1 Research Reactor Facility

    Energy Technology Data Exchange (ETDEWEB)

    David W. Nigg; Amanda E. Schwint; John K. Hartwell; Elisa M. Heber; Veronica Trivillin; Jorge Castillo; Luis Wentzeis; Patrick Sloan; Charles A. Wemple

    2004-10-01

    Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminiscent dosimeters to characterize the BNCT irradiation facility developed at the RA-1 research reactor operated by the Argentine National Atomic Energy Commission in Buenos Aires. Some biological scoping irradiations have also been completed using a small-animal (hamster) oral mucosa tumor model. Results indicate that the RA-1 neutron source produces useful dose rates but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications.

  1. Collaborative Physical and Biological Dosimetry Studies for Neutron Capture Therapy at the RA-1 Research Reactor Facility

    Energy Technology Data Exchange (ETDEWEB)

    Nigg, D.W.; Schwint, A.E.; Hartwell, J.K.; Heber, E.M.; Trivillin, V.; Castillo, J.; Wentzeis, L.; Sloan, P.; Wemple, C.A.

    2004-10-04

    Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminiscent dosimeters to characterize the BNCT irradiation facility developed at the RA-1 research reactor operated by the Argentine National Atomic Energy Commission in Buenos Aires. Some biological scoping irradiations have also been completed using a small-animal (hamster) oral mucosa tumor model. Results indicate that the RA-1 neutron source produces useful dose rates but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications.

  2. Development of cancer therapy facility of HANARO

    Energy Technology Data Exchange (ETDEWEB)

    Jun, Byung Jin; Hwang, S. Y.; Kim, M. J. and others

    2000-04-01

    Facilities of the research and clinical treatments of neutron capture therapy using HANARO are developed, and they are ready to install. They are BNCT irradiation facility and prompt gamma neutron activatiion analysis facility. Since every horizontal neutron facility of HANARO is long and narrow tangential beam tube, it is analysed that sufficient epithermal neutrons for the BNCT cannot be obtained but sufficient thermal neutrons can be obtained by a filter composed of silicon and bismuth single crystals. Since the thermal neutron penetaration increases significantly when the crystals are cooled, a filter cooled by liquid nitrogen is developed. So as to avoid interference with the reactor operation, a water shutter is developed. The irradiation room is designed for the temporary surgical operation as well. Handling tools to remove activated beam port plug and to install water shutter and filter are developed. The basic structure of the irradiation room is already installed and most of other parts are ready to install. Since no free beam port is available for the prompt gamma neutron activation analysis, a method obtaining almost pure thermal neutrons by the vertical diffraction of extra beam for the polarized neutron spectrometer is developed. This method is confirmed by analysis and experiments to give high enough neutron beam. Equipment and devices are provided to install this facility.

  3. Development of cancer therapy facility of HANARO

    International Nuclear Information System (INIS)

    Jun, Byung Jin; Hwang, S. Y.; Kim, M. J. and others

    2000-04-01

    Facilities of the research and clinical treatments of neutron capture therapy using HANARO are developed, and they are ready to install. They are BNCT irradiation facility and prompt gamma neutron activatiion analysis facility. Since every horizontal neutron facility of HANARO is long and narrow tangential beam tube, it is analysed that sufficient epithermal neutrons for the BNCT cannot be obtained but sufficient thermal neutrons can be obtained by a filter composed of silicon and bismuth single crystals. Since the thermal neutron penetaration increases significantly when the crystals are cooled, a filter cooled by liquid nitrogen is developed. So as to avoid interference with the reactor operation, a water shutter is developed. The irradiation room is designed for the temporary surgical operation as well. Handling tools to remove activated beam port plug and to install water shutter and filter are developed. The basic structure of the irradiation room is already installed and most of other parts are ready to install. Since no free beam port is available for the prompt gamma neutron activation analysis, a method obtaining almost pure thermal neutrons by the vertical diffraction of extra beam for the polarized neutron spectrometer is developed. This method is confirmed by analysis and experiments to give high enough neutron beam. Equipment and devices are provided to install this facility

  4. Simple computational modeling for human extracorporeal irradiation using the BNCT facility of the RA-3 Reactor

    International Nuclear Information System (INIS)

    Farias, Ruben; Gonzalez, S.J.; Bellino, A.; Sztenjberg, M.; Pinto, J.; Thorp, Silvia I.; Gadan, M.; Pozzi, Emiliano; Schwint, Amanda E.; Heber, Elisa M.; Trivillin, V.A.; Zarza, Leandro G.; Estryk, Guillermo; Miller, M.; Bortolussi, S.; Soto, M.S.; Nigg, D.W.

    2009-01-01

    We present a simple computational model of the reactor RA-3 developed using Monte Carlo transport code MCNP. The model parameters are adjusted in order to reproduce experimental measured points in air and the source validation is performed in an acrylic phantom. Performance analysis is carried out using computational models of animal extracorporeal irradiation in liver and lung. Analysis is also performed inside a neutron shielded receptacle use for the irradiation of rats with a model of hepatic metastases.The computational model reproduces the experimental behavior in all the analyzed cases with a maximum difference of 10 percent. (author)

  5. PREFACE: 6th Workshop on Infrared Spectroscopy and Microscopy with Accelerator-Based Sources (WIRMS11)

    Science.gov (United States)

    Lupi, Stefano; Perucchi, Andrea

    2012-05-01

    This volume of Journal of Physics: Conference Series is dedicated to a subset of papers related to the work presented at the 6th edition of the international Workshop on Infrared Spectroscopy and Microscopy with Accelerator-Based Sources (WIRMS), held in Trieste, Italy, September 4-8 2011. Previous editions of the conference were held in Porquerolles (France), Lake Tahoe (USA), Rathen (Germany), Awaji (Japan), and Banff (Canada). This edition was organized and chaired by Stefano Lupi (Roma La Sapienza) and co-chaired by Andrea Perucchi (Elettra), with the support of the Italian Synchrotron Light Laboratory ELETTRA, which was honored to host the WIRMS workshop in its tenth anniversary. The 6th WIRMS edition addressed several different topics, ranging from biochemistry to strongly correlated materials, from geology to conservation science, and from forensics to the study of cometary dusts. Representatives from the infrared scientific programs at synchrotron light sources and free-electron-laser facilities. This edition was attended by 88 participants, including representatives from the infrared scientific programs at synchrotron light sources and free-electron-laser facilities, who enjoyed the stimulating scientific presentations, several detailed discussions, and the beautiful weather and scenery of the Trieste gulf. Participants came from 16 different nations and four continents, including many young scientists, six of which were supported by the organizers. There were 45 scientific talks divided in 11 sessions: Facilities, Microspectroscopy (I, II, III), Time-Resolved Spectroscopies, Extreme Conditions, Condensed Matter, Near-Field, Imaging, THz Techniques and High-Resolution Spectroscopy. 37 posters were also presented at two very lively evening poster sessions. We would like to use the opportunity of writing this preface to thank all the participants of the workshop for the very high level of their scientific contribution and for the very friendly atmosphere

  6. A preclinical study of boron neutron capture therapy (BNCT) of spontaneous tumors in cats at RA-6 in Argentina

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Calzetta, Osvaldo A.; Blaumann, Hernan R.; Longhino, J.; Rao, Monica; Cantarelli, Maria de los A.

    2005-01-01

    BNCT is a binary treatment modality that combines irradiation with a thermal or epithermal neutron beam with tumor-seeking, boron containing drugs to produce selective irradiation of tumor tissue. Having demonstrated that BNCT mediated by boronophenylalanine (BPA) induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of RA-1. Having demonstrated partial tumor control with no radio toxic effects, the aim of the present study was to evaluate the effect of BPA-BNCT on tumor and normal tissue in 3 cases of spontaneous SCC in feline patients employing a higher neutron fluence than in the previous study. The present study was performed at RA-6 with the thermalized epithermal neutron beam. All three irradiations were successful. Except for an initial, moderate and reversible mucositis, no significant radio toxic effects were observed in terms of clinical follow-up, histological examination, biochemical analysis and assessment of autopsy material. Partial tumor control was evidenced in terms of growth inhibition and partial necrosis and improvement in the quality of life during the survival period. Optimization of the therapeutic efficacy of BNCT would require improvement in boron tumor targeting and strategies to increase in-depth dose in large tumors. (author)

  7. Microdosimetric measurements in the thermal neutron irradiation facility of LENA reactor

    International Nuclear Information System (INIS)

    Colautti, P.; Moro, D.; Chiriotti, S.; Conte, V.; Evangelista, L.; Altieri, S.; Bortolussi, S.; Protti, N.; Postuma, I.

    2014-01-01

    A twin TEPC with electric-field guard tubes has been constructed to be used to characterize the BNCT field of the irradiation facility of LENA reactor. One of the two mini TEPC was doped with 50 ppm of 10 B in order to simulate the BNC events occurring in BNCT. By properly processing the two microdosimetric spectra, the gamma, neutron and BNC spectral components can be derived with good precision (∼6%). However, direct measurements of 10 B in some doped plastic samples, which were used for constructing the cathode walls, point out the scarce accuracy of the nominal 10 B concentration value. The influence of the Boral ® door, which closes the irradiation channel, has been measured. The gamma dose increases significantly (+51%) when the Boral ® door is closed. The crypt-cell-regeneration weighting function has been used to measure the quality, namely the RBE µ value, of the radiation field in different conditions. The measured RBE µ values are only partially consistent with the RBE values of other BNCT facilities. - Highlights: • A counter with two mini TEPCs, both equipped with electrical-field guard tubes, has been constructed. • The microdosimetric spectrum of the LENA-reactor irradiation vane has been studied. • The radiation-field quality (RBE) assessment confirms that the D n /D tot ratio is not an accurate parameter to characterize the BNCT radiation field

  8. Early phase II study on BNCT in metastatic malignant melanoma using the boron carrier BPA (EORTC protocol 11011)

    International Nuclear Information System (INIS)

    Wittig, Andrea; Sauerwein, Wolfgang; Moss, Raymond

    2006-01-01

    The aim of the trial is to examine the clinical response of metastatic melanoma following BNCT with BPA. The trial contains an optional biodistribution sub-study, which is done if operable metastases are removed prior BNCT. BNCT is applied in 2 fractions at the HFR in Petten. In cases of diffuse brain metastases the whole brain is irradiated homogeneously using 5 irradiation beams from different directions. Up to now 4 patients suffering from multiple brain metastases (more than 20) have been included. In all cases we observed a partial response or no change in the irradiated volume. However, none of the patients survived more than 3 months. The pharmacokinetic of the BPA can be predicted very precisely using a two-compartment model. The treatment can be performed safety. (author)

  9. The use of positron emission tomography in BNCT treatment planning for metastatic malignant melanoma and glioblastoma multiforme

    International Nuclear Information System (INIS)

    Kabalka, G.; Nichols, T.; Smith, G.; Miller, L.; Kahn, M.

    2000-01-01

    Positron emission tomography (PET) evaluations of six glioblastoma multiforme (GBM) and one metastatic melanoma (MM) patient have been carried out utilizing fluorine-18 labeled p-boronophenylalanine. Four of the GBM patients were imaged both prior to and post BNCT. In one GBM patient, biopsy derived boron distribution data compared favorably to the PET derived data. The PET data have been used as input to dosimetry calculations and the results vary from those obtained using current protocols. In addition, PET images of the thorax would indicate that the utility of PET for staging tumors for BNCT may extend beyond the brain. However, higher than anticipated levels of activity in the lungs (as also seen in salivary glands) indicate the more effective BNCT agents will be required. (author)

  10. Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: A recursive partitioning analysis of BNCT patients

    International Nuclear Information System (INIS)

    Nakai, K.; Yamamoto, T.; Aiyama, H.; Takada, T.; Yoshida, F.; Kageji, T.; Kumada, H.; Isobe, T.; Endo, K.; Matsuda, M.; Tsurubuchi, T.; Shibata, Y.; Takano, S.; Mizumoto, M.; Tsuboi, K.; Matsumura, A.

    2011-01-01

    Eight patients to received Boron Neutron Capture Therapy (BNCT) were selected from 33 newly diagnosed glioblastoma patients (NCT(+) group). Serial 42 glioblastoma patients (NCT(−) group) were treated without BNCT. The median OS of the NCT(+) group and NCT (−) group were 24.4 months and 14.9 months. In the high risk patients (RPA class V), the median OS of the NCT(+) group tended to be better than that of NCT(−) group. 50% of BNCT patients were RPA class V. - Highlights: ► We treated 8 patients with boron neutron capture therapy (NCT) for glioblastoma. ► We compare the overall survival between NCT including series and without NCT series. ► The median overall survival of the NCT including series was 24.4 months. ► In the high risk patients, the median OS of NCT including series tended to be better.

  11. The hamster cheek pouch (HCP) as an experimental model of oral cancer for BNCT: biodistribution and pharmacokinetics of BPA

    International Nuclear Information System (INIS)

    Kreimann, E.; Itoiz, M.E.; Dagrosa, A.; Garavaglia, R.; Farias, S.; Batistoni, D.; Schwint, A.E.

    2000-01-01

    We propose and validate the HCP model of oral cancer for BNCT studies. This model serves to explore new applications of the technique, study the biology of BNCT and assess Boron uptake in clinically relevant oral tissues. Tumors are induced by a process that mimics spontaneous malignant transformation instead of by the growth of implanted tumor cells. Syrian hamsters were submitted to tumor induction with a chemical carcinogenesis protocol and then used for biodistribution and pharmacokinetic studies of BPA. The data reveal selective uptake by tumor and, to a lesser degree, by precancerous tissue. Boron concentration in oral tissues and skin was higher than in blood, an issue of clinical relevance given that these tissues may be dose-limiting. Absolute and relative values of Boron concentration would be potentially therapeutic. Boron concentration exhibited a linear relationship with percentage of viable tissue in HCP tumors. The HCP model would provide a novel, contributory approach to BNCT research. (author)

  12. OPTIMIZATION OF A NEUTRON BEAM SHAPING ASSEMBLY DESIGN FOR BNCT AND ITS DOSIMETRY SIMULATION BASED ON MCNPX

    Directory of Open Access Journals (Sweden)

    I Made Ardana

    2017-10-01

    OPTIMASI DESAIN KOLIMATOR NEUTRON UNTUK SISTEM BNCT DAN UJI DOSIMETRINYA MENGGUNAKAN PROGRAM MCNPX. Telah dilakukan penelitian tentang sistem BNCT yang meliputi dua tahapan simulasi dengan menggunakan program MCNPX yaitu uji simulasi untuk optimasi desain kolimator neutron untuk sistem BNCT berbasis Siklotron 30 MeV dan uji simulasi untuk menghitung fluks neutron dan dosimetri radiasi pada kanker sarkoma jaringan lunak pada leher dan kepala. Tujuan simulasi untuk mendapatkan desain kolimator yang paling optimal dalam memoderasi fluks neutron cepat yang dihasilkan dari sistem target berilium sehingga dapat dihasilkan fluks neutron yang sesuai untuk sistem BNCT. Uji optimasi dilakukan dengan cara memvariasikan bahan dan ketebalan masing-masing komponen dalam kolimator seperi reflektor, moderator, filter neutron cepat, filter neutron thermal, filter radiasi gamma dan lubang keluaran. Desain kolimator yang diperoleh dari hasil optimasi tersusun atas moderator berbahan Al dengan ketebalan 39 cm, filter neutron cepat berbahan LiF2 setebal 8,2 cm, dan filter neutron thermal berbahan B4C setebal 0,5 cm. Untuk reflektor, filter radiasi gamma dan lubang keluaran masing-masing menggunakan bahan PbF2, Pb dan Bi. Fluks neutron epithermal yang dihasilkan dari kolimator yang didesain adalah sebesar 2,83 x 109 n/s cm-2 dan telah memenuhi seluruh parameter fluks neutron yang sesuai untuk sistem BNCT. Selanjutnya uji simulasi dosimetri pada kanker sarkoma jaringan lunak pada leher dan kepala dilakukan dengan cara memvariasikan konsentrasi senyawa boron pada model phantom leher manusia (ORNL. Selanjutnya model phantom tersebut diiradiasi dengan fluks neutron yang berasal dari kolimator yang telah didesain sebelumnya. Hasilnya, fluks neutron thermal mencapai nilai tertinggi pada kedalaman 4,8 cm di dalam model phantom leher ORNL dengan laju dosis tertinggi terletak pada area jaringan kanker. Untuk masing-masing variasi konsentrasi senyawa boron pada model phantom leher ORNL supaya

  13. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

    Directory of Open Access Journals (Sweden)

    Ono Koji

    2011-01-01

    Full Text Available Abstract Background Boron neutron capture therapy (BNCT is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10B (sodium borocaptate: BSH delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. Methods We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH, and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution and effectiveness in BNCT therapy in a murine model of multiple liver tumors. Results CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10B concentrations in murine osteosarcoma cells (LM8G5 were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p . In suppressing the spread of tumor cells in mice, BNCT treatment was as

  14. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

    International Nuclear Information System (INIS)

    Fujii, Hitoshi; Tabata, Yasuhiko; Kaneda, Yasufumi; Sawa, Yoshiki; Lee, Chun Man; Matsuyama, Akifumi; Komoda, Hiroshi; Sasai, Masao; Suzuki, Minoru; Asano, Tomoyuki; Doki, Yuichiro; Kirihata, Mitsunori; Ono, Koji

    2011-01-01

    Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10 B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10 B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E) is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10 B (sodium borocaptate: BSH) delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH), and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution) and effectiveness in BNCT therapy in a murine model of multiple liver tumors. CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10 B concentrations in murine osteosarcoma cells (LM8G5) were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p < 0.05). In suppressing the spread of tumor cells in mice, BNCT treatment was as effective with CG-HVJ-E-BSH as with BSH

  15. Dosimetric analysis of BNCT - Boron Neutron Capture Therapy - coupled to 252Cf brachytherapy

    International Nuclear Information System (INIS)

    Brandao, Samia F.; Campos, Tarcisio P.R.

    2009-01-01

    The incidence of brain tumors is increasing in world population; however, the treatments employed in this type of tumor have a high rate of failure and in some cases have been considered palliative, depending on histology and staging of tumor. Its necessary to achieve the control tumor dose without the spread irradiation cause damage in the brain, affecting patient neurological function. Stereotactic radiosurgery is a technique that achieves this; nevertheless, other techniques that can be used on the brain tumor control must be developed, in order to guarantee lower dose on health surroundings tissues other techniques must be developing. The 252 Cf brachytherapy applied to brain tumors has already been suggested, showing promising results in comparison to photon source, since the active source is placed into the tumor, providing greater dose deposition, while more distant regions are spared. BNCT - Boron Neutron Capture Therapy - is another technique that is in developing to brain tumors control, showing theoretical superiority on the rules of conventional treatments, due to a selective irradiation of neoplasics cells, after the patient receives a borate compound infusion and be subjected to a epithermal neutrons beam. This work presents dosimetric studies of the coupling techniques: BNCT with 252 Cf brachytherapy, conducted through computer simulation in MCNP5 code, using a precise and well discretized voxel model of human head, which was incorporated a representative Glioblastoma Multiform tumor. The dosimetric results from MCNP5 code were exported to SISCODES program, which generated isodose curves representing absorbed dose rate in the brain. Isodose curves, neutron fluency, and dose components from BNCT and 252 Cf brachytherapy are presented in this paper. (author)

  16. Co-registration of the BNCT treatment planning images for clinical practice

    International Nuclear Information System (INIS)

    Salli, Eero; Seppaelae, Tiina; Kankaanranta, Leena; Asikainen, Sami; Savolainen, Sauli; Koivunoro, Hanna

    2006-01-01

    We have co-registered MRI, CT and FBPA-PET images for BNCT in clinical practice. Co-registration improves the spatial accuracy of the treatment planning by enabling use of information from all the co-registered modalities. The multimodal co-registration has been implemented as a service product provided by the Imaging Center of Helsinki University Central Hospital to other departments. To increase the accuracy of co-registration and patient positioning in the head area BNCT, a patient-specific fixation mask suitable for PET, MRI and CT was developed. The goal of the fixation mask is to normalize the orientation of the patient's head and neck. Co-registration is performed at the image processing unit by using a rigid body model, mutual-information based algorithms and partly in-house developed software tools. The accuracy of co-registration is verified by comparing the locations of the external skin markers and anatomical landmarks in different modalities. After co-registration, the images are transformed and covered into a format required by the BNCT dose-planning software and set to the dose-planning unit of the hospital. So far co-registration has been done for 22 patients. The co-registration protocol has proved to be reliable and efficient. Some registration errors are seen on some patients in the neck area because the rigid-body model used in co-registration is not fully valid for the brain-neck entity. The registration accuracy in this area could likely be improved by implementing a co-registration procedure utilizing a partly non-rigid body model. (author)

  17. Neutron field characterization in the installation for BNCT study in the IEA-R1 reactor

    International Nuclear Information System (INIS)

    Carneiro Junior, Valdeci

    2008-01-01

    This work aims to characterize the mixed neutron and gamma field, in the sample irradiation position, in a research installation for Boron Neutron Capture Therapy (BNCT), in the IPEN IEA-R1 reactor. The BNCT technique has been studied as a safe and selective option in the treatment of resistant cancerigenous tumors or considered non-curable by the conventional techniques, for example, the Glioblastoma Multiform - a brain cancerigenous tumor. Neutron flux measurements were carried out: thermal, resonance and fast, as well as neutron and gamma rays doses, in the sample position, using activation foils detectors and thermoluminescent dosimeters. For the determination of the neutron spectrum and intensity, a set of different threshold activation foils and gold foils covered and uncovered with cadmium irradiated in the installation was used, analyzed by a high Pure Germanium semiconductor detector, coupled to an electronic system suitable for gamma spectrometry. The results were processed with the SAND-BP code. The doses due to gamma and neutron rays were determined using thermoluminescent dosimeters TLD 400 and TLD 700 sensitive to gamma and TLD 600, sensitive to neutrons. The TLDs were selected and used for obtaining the calibration curves - dosimeter answer versus dose - from each of the TLD three types, which were necessary to calculate the doses due to neutron and gamma, in the sample position. The radiation field, in the sample irradiation position, was characterized flux for thermal neutrons of 1.39.10 8 ± 0,12.10 8 n/cm 2 s the doses due to thermal neutrons are three times higher than those due to gamma radiation and confirm the reproducibility and consistency of the experimental findings obtained. Considering these results, the neutron field and gamma radiation showed to be appropriated for research in BNCT. (author)

  18. Application of HVJ envelope system to boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Nakai, Kei; Kurooka, Masaaki; Kaneda, Yasufumi; Yamamoto, Tetsuya; Matsumura, Akira; Asano, Tomoyuki

    2006-01-01

    Boron Neutron Capture Therapy (BNCT) has been used clinically for the treatment of malignant tumors. Two drugs, p-boronophenylalanine (BPA) and sulfhydral borane (BSH), have been used as boron delivery agents. These drugs seem to be taken up preferentially in solid tumors, but it is uncertain whether therapeutic quantities of boron atoms are taken up by micro-invasive or distant tumor cells. High accumulation and high selective delivery of boron into tumor tissues are the most important requirements to achieve efficient BNCT for malignant tumor. The HVJ envelope (HVJ-E) vector system is a novel fusion-mediated gene delivery system based on inactivated hemagglutinating virus of Japan (HVJ; Sendai virus). Although we developed this vector system for gene transfer, it can also deliver proteins, synthetic oligonucleotides, and drugs. HVJ-liposome, which is liposome fused with HVJ-E, has higher boron trapping efficiency than HVJ-E alone. We report the boron delivery into cultured cells with HVJ-liposome systems. The cellular 10 B concentration after 60 min incubation with HVJ-E containing BSH was 24.9 μg/g cell pellet for BHK-21 cells (baby hamster kidney cells) and 19.4 μg/g cell pellet for SCC VII cells (murine squamous cell carcinoma). These concentrations are higher than that of 60 min incubated cells with BSH containing (100μg 10 B/ml) medium. These results indicate the HVJ-E fused with tumor cell membrane and rapidly delivered boron agents, and that the HVJ-E-mediated delivery system could be applicable to BNCT. Plans are underway to begin neutron radiation experiments in vivo and in vitro. (author)

  19. Requirements for an evaluated nuclear data file for accelerator-based transmutation

    International Nuclear Information System (INIS)

    Koning, A.J.

    1993-06-01

    The importance of intermediate-energy nuclear data files as part of a global calculation scheme for accelerator-based transmutation of radioactive waste systems (for instance with an accelerator-driven subcritical reactor) is discussed. A proposal for three intermediate-energy data libraries for incident neutrons and protons is presented: - a data library from 0 to about 100 MeV (first priority), - a reference data library from 20 to 1500 MeV, - an activation/transmutation library from 0 to about 100 MeV. Furthermore, the proposed ENDF-6 structure of each library is given. The data needs for accelerator-based transmutation are translated in terms of the aforementioned intermediate-energy data libraries. This could be a starting point for an ''International Evaluated Nuclear Data File for Transmutation''. This library could also be of interest for other applications in science and technology. Finally, some conclusions and recommendations concerning future evaluation work are given. (orig.)

  20. Report of the consultant's meeting on applications of accelerator based analysis

    International Nuclear Information System (INIS)

    1998-07-01

    At the present meeting, applications of accelerator based analytical methods, often referred as ion beam analysis (IBA) methods, to the following areas have been discussed: materials (including thin films), Earth sciences (including environmental studies), biology and medicine, art and archaeology (cultural heritage), and other applications (including forensic applications). This report gives brief overview of IBA applications in these areas, with short background about accelerators needed and corresponding analytical techniques

  1. Accelerator-based systems for plutonium destruction and nuclear waste transmutation

    International Nuclear Information System (INIS)

    Arthur, E.D.

    1994-01-01

    Accelerator-base systems are described that can eliminate long-lived nuclear materials. The impact of these systems on global issues relating to plutonium minimization and nuclear waste disposal can be significant. An overview of the components that comprise these systems is given, along with discussion of technology development status and needs. A technology development plan is presented with emphasis on first steps that would demonstrate technical performance

  2. Development of the patient setting system for BNCT at JRR-4

    International Nuclear Information System (INIS)

    Kumada, H.; Yamamoto, K.; Torii, Y.

    2000-01-01

    A new treatment planning software: Computational Dosimetry System (JCDS) is in progress its development for BNCT with epithermal neutron beam in JAERI. Irradiation conditions such as beam angle to a patient are calculated by JCDS. In order to implement these conditions, it is necessary to precisely set the patient to actual irradiation position simulated by JCDS beforehand. Therefore, the Patient Setting System, which accurately and quickly sets the patient to the irradiation position, is being developed with JCDS concurrently. In this report, the current status of the development of JCDS and the Patient Setting System in JAERI will be described. (author)

  3. Ensemble Manifold Rank Preserving for Acceleration-Based Human Activity Recognition.

    Science.gov (United States)

    Tao, Dapeng; Jin, Lianwen; Yuan, Yuan; Xue, Yang

    2016-06-01

    With the rapid development of mobile devices and pervasive computing technologies, acceleration-based human activity recognition, a difficult yet essential problem in mobile apps, has received intensive attention recently. Different acceleration signals for representing different activities or even a same activity have different attributes, which causes troubles in normalizing the signals. We thus cannot directly compare these signals with each other, because they are embedded in a nonmetric space. Therefore, we present a nonmetric scheme that retains discriminative and robust frequency domain information by developing a novel ensemble manifold rank preserving (EMRP) algorithm. EMRP simultaneously considers three aspects: 1) it encodes the local geometry using the ranking order information of intraclass samples distributed on local patches; 2) it keeps the discriminative information by maximizing the margin between samples of different classes; and 3) it finds the optimal linear combination of the alignment matrices to approximate the intrinsic manifold lied in the data. Experiments are conducted on the South China University of Technology naturalistic 3-D acceleration-based activity dataset and the naturalistic mobile-devices based human activity dataset to demonstrate the robustness and effectiveness of the new nonmetric scheme for acceleration-based human activity recognition.

  4. Design and testing of a rotating, cooled device for extra-corporate treatment of liver cancer by BNCT in the epithermal neutron beam at the HFR Petten

    International Nuclear Information System (INIS)

    Moss, Ray; Nievaart, Sander; Pott, Lucien; Wittig, Andrea; Sauerwein, Wolfgang

    2006-01-01

    As part of the joint project on extra-corporal treatment of liver cancer by BNCT between JRC Petten and the University Hospital Essen, a facility has been designed and built to contain the liver during its irradiation treatment at the HFR Petten. The design consists of a rotating spheroid shaped PMMA holder, manufactured to open at the equator and closed by screwing together, surrounded by PMMA and graphite blocks. A validation exercise has been performed regarding both the nuclear conditions and the physical conditions. For the former, activation foil sets of Au, Cu and Mn, were irradiated at positions inside the liver holder filled with water, whilst a second measurement campaign has been performed using gel dosimetry. For the physical test, it is required to operate (rotate) the facility for up to 4 hours and to maintain the liver at approximately 4degC. The latter test was performed using 'cold gun sprays' that inject cold air near the liver holder. Both the nuclear and physical validation tests were performed successfully. (author)

  5. Tumor control induced by Boron Neutron Capture Therapy (BNCT) as a function of dose in an experimental model of liver metastases at 5 weeks follow-up

    International Nuclear Information System (INIS)

    Pozzi, E C C; Trivillin, V A; Colombo, L L; Monti Hughes, A; Thorp, S; Cardoso, J E; Garabalino, M A; Molinari, A J; Heber, E M; Curotto, Paula; Miller, M; Itoiz, M E; Aromando, R F; Nigg, D W; Schwint, A E

    2012-01-01

    BNCT has been proposed for the treatment of multifocal, non-resectable, bilobar colorectal liver metastases that do not respond to chemotherapy. We recently reported that BNCT mediated by boronophenylalanine (BPA) induced significant remission of experimental colorectal tumor nodules in rat liver at 3 weeks follow-up with no contributory liver toxicity (Pozzi et al.,2012). The aim of the present study was to evaluate tumor control and potential liver toxicity of BPA-BNCT at 5 weeks follow-up. Prescribed dose was retrospectively evaluated based on blood boron values, allowing for assessment of response over a range of delivered dose values (author)

  6. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies.

    Science.gov (United States)

    Fujimoto, T; Andoh, T; Sudo, T; Fujita, I; Imabori, M; Moritake, H; Sugimoto, T; Sakuma, Y; Takeuchi, T; Sonobe, H; Epstein, Alan L; Akisue, T; Kirihata, M; Kurosaka, M; Fukumori, Y; Ichikawa, H

    2011-12-01

    Clear cell sarcoma (CCS), a rare malignant tumor with a predilection for young adults, is of poor prognosis. Recently however, boron neutron capture therapy (BNCT) with the use of p-borono-L-phenylalanine (BPA) for malignant melanoma has provided good results. CCS also produces melanin; therefore, the uptake of BPA is the key to the application of BNCT to CCS. We describe, for the first time, the high accumulation of boron in CCS and the CCS tumor-bearing animal model generated for BNCT studies. Copyright © 2011 Elsevier Ltd. All rights reserved.

  7. Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

    Energy Technology Data Exchange (ETDEWEB)

    Bakeine, G.J. [Department of Clinical Medicine and Neurology, Cattinara Hospital, University of Trieste (Italy)], E-mail: jamesbakeine1@yahoo.com; Di Salvo, M. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bortolussi, S.; Stella, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bertolotti, A.; Nano, R. [Department of Animal Biology University of Pavia, Piazza Botta, Pavia (Italy); Clerici, A.; Ferrari, C.; Zonta, C. [Department of Surgery University of Pavia, Piazza Botta, Pavia (Italy); Marchetti, A. [Scientific Research Office, Fondazione San Matteo University Policlinic, Pavia (Italy); Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy)

    2009-07-15

    In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

  8. Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

    International Nuclear Information System (INIS)

    Bakeine, G.J.; Di Salvo, M.; Bortolussi, S.; Stella, S.; Bruschi, P.; Bertolotti, A.; Nano, R.; Clerici, A.; Ferrari, C.; Zonta, C.; Marchetti, A.; Altieri, S.

    2009-01-01

    In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

  9. {sup 124}Sb–Be photo-neutron source for BNCT: Is it possible?

    Energy Technology Data Exchange (ETDEWEB)

    Golshanian, Mohadeseh [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Department of Physics, Shahrood University, Shahrood (Iran, Islamic Republic of); Rajabi, Ali Akbar [Department of Physics, Shahrood University, Shahrood (Iran, Islamic Republic of); Kasesaz, Yaser, E-mail: ykasesaz@aeoi.org.ir [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of)

    2016-11-01

    In this research a computational feasibility study has been done on the use of {sup 124}SbBe photo-neutron source for Boron Neutron Capture Therapy (BNCT) using MCNPX Monte Carlo code. For this purpose, a special beam shaping assembly has been designed to provide an appropriate epithermal neutron beam suitable for BNCT. The final result shows that using 150 kCi of {sup 124}Sb, the epithermal neutron flux at the designed beam exit is 0.23×10{sup 9} (n/cm{sup 2} s). In-phantom dose analysis indicates that treatment time for a brain tumor is about 40 min which is a reasonable time. This high activity {sup 124}Sb could be achieved using three 50 kCi rods of {sup 124}Sb which can be produced in a research reactor. It is clear, that as this activity is several hundred times the activity of a typical cobalt radiotherapy source, issues related to handling, safety and security must be addressed.

  10. Design of thermal neutron beam based on an electron linear accelerator for BNCT.

    Science.gov (United States)

    Zolfaghari, Mona; Sedaghatizadeh, Mahmood

    2016-12-01

    An electron linear accelerator (Linac) can be used for boron neutron capture therapy (BNCT) by producing thermal neutron flux. In this study, we used a Varian 2300 C/D Linac and MCNPX.2.6.0 code to simulate an electron-photoneutron source for use in BNCT. In order to decelerate the produced fast neutrons from the photoneutron source, which optimize the thermal neutron flux, a beam-shaping assembly (BSA) was simulated. After simulations, a thermal neutron flux with sharp peak at the beam exit was obtained in the order of 3.09×10 8 n/cm 2 s and 6.19×10 8 n/cm 2 s for uranium and enriched uranium (10%) as electron-photoneutron sources respectively. Also, in-phantom dose analysis indicates that the simulated thermal neutron beam can be used for treatment of shallow skin melanoma in time of about 85.4 and 43.6min for uranium and enriched uranium (10%) respectively. Copyright © 2016. Published by Elsevier Ltd.

  11. A phase-I clinical trial for cranial BNCT at Harvard-MIT

    International Nuclear Information System (INIS)

    Busse, P.M.; Palmer, M.R.; Harling, O.K.

    2000-01-01

    Phase I trial designed to determine the maximum tolerable dose to normal tissue for cranial BNCT (Boron Neutron Capture Therapy) irradiations was recently completed at Harvard Medical School and MIT. Twenty-two subjects diagnosed with either glioblastoma multiforme or intracranial melanoma were treated between 1996 and 1999. Subjects received either one or two administrations of boronophenylalanine intravenously at doses between 250 and 350 mg/kg body weight, then exposed in one, two or three fields to epithermal neutrons at the MIT Research Reactor in one or two fractions. Over the course of the study, the maximum normal tissue dose target was increased from 8.8 to 14.2 RBE (Relative Biological Effectiveness) Gy in 10% increments. Subjects have been followed clinically and radiographically. Of those patients surviving beyond six months, no MRI (Magnetic Resonance Image) white-matter changes were observed and no long-term complications attributable to BNCT were evident. Tumor responses were observed, particularly with the melanoma subjects. With increasing doses, difficulties arose from long irradiation times (approximately 3 hours) and the emergence of acute reactions in the skin and mucosa. The trial was stopped in May 1999. Future trials will be initiated with the new high intensity, low background fission converter beam at MIT. (author)

  12. The therapeutic ratio in BNCT: Assessment using the Rat 9L gliosarcoma brain tumor and spinal cord models

    International Nuclear Information System (INIS)

    Coderre, J.A.; Micca, P.L.; Nawrocky, M.M.; Fisher, C.D.; Bywaters, A.; Morris, G.M.; Hopewell, J.W.

    1996-01-01

    During any radiation therapy, the therapeutic tumor dose is limited by the tolerance of the surrounding normal tissue within the treatment volume. The short ranges of the products of the 10 B(n,α) 7 Li reaction produced during boron neutron capture therapy (BNCT) present an opportunity to increase the therapeutic ratio (tumor dose/normal tissue dose) to levels unprecedented in photon radiotherapy. The mixed radiation field produced during BNCT comprises radiations with different linear energy transfer (LET) and different relative biological effectiveness (RBE). The short ranges of the two high-LET products of the 'B(n,a)'Li reaction make the microdistribution of the boron relative to target cell nuclei of particular importance. Due to the tissue specific distribution of different boron compounds, the term RBE is inappropriate in defining the biological effectiveness of the 10 B(n,α) 7 Li reaction. To distinguish these differences from true RBEs we have used the term open-quotes compound biological effectivenessclose quotes (CBE) factor. The latter can be defined as the product of the true, geometry-independent, RBE for these particles times a open-quotes boron localization factorclose quotes, which will most likely be different for each particular boron compound. To express the total BNCT dose in a common unit, and to compare BNCT doses with the effects of conventional photon irradiation, multiplicative factors (RBEs and CBEs) are applied to the physical absorbed radiation doses from each high-LET component. The total effective BNCT dose is then expressed as the sum of RBE-corrected physical absorbed doses with the unit Gray-equivalent (Gy-Eq)

  13. Image-guided linear accelerator-based spinal radiosurgery for hemangioblastoma.

    Science.gov (United States)

    Selch, Michael T; Tenn, Steve; Agazaryan, Nzhde; Lee, Steve P; Gorgulho, Alessandra; De Salles, Antonio A F

    2012-01-01

    To retrospectively review the efficacy and safety of image-guided linear accelerator-based radiosurgery for spinal hemangioblastomas. Between August 2004 and September 2010, nine patients with 20 hemangioblastomas underwent spinal radiosurgery. Five patients had von Hipple-Lindau disease. Four patients had multiple tumors. Ten tumors were located in the thoracic spine, eight in the cervical spine, and two in the lumbar spine. Tumor volume varied from 0.08 to 14.4 cc (median 0.72 cc). Maximum tumor dimension varied from 2.5 to 24 mm (median 10.5 mm). Radiosurgery was performed with a dedicated 6 MV linear accelerator equipped with a micro-multileaf collimator. Median peripheral tumor dose and prescription isodose were 12 Gy and 90%, respectively. Image guidance was performed by optical tracking of infrared reflectors, fusion of oblique radiographs with dynamically reconstructed digital radiographs, and automatic patient positioning. Follow-up varied from 14 to 86 months (median 51 months). Kaplan-Meier estimated 4-year overall and solid tumor local control rates were 90% and 95%, respectively. One tumor progressed 12 months after treatment and a new cyst developed 10 months after treatment in another tumor. There has been no clinical or imaging evidence for spinal cord injury. Results of this limited experience indicate linear accelerator-based radiosurgery is safe and effective for spinal cord hemangioblastomas. Longer follow-up is necessary to confirm the durability of tumor control, but these initial results imply linear accelerator-based radiosurgery may represent a therapeutic alternative to surgery for selected patients with spinal hemangioblastomas.

  14. Studies of industrial emissions by accelerator-based techniques: A review of applications at CEDAD

    Science.gov (United States)

    Calcagnile, L.; Quarta, G.

    2012-04-01

    Different research activities are in progress at the Centre for Dating and Diagnostics (CEDAD), University of Salento, in the field of environmental monitoring by exploiting the potentialities given by the different experimental beam lines implemented on the 3 MV Tande-tron accelerator and dedicated to AMS (Accelerator Mass Spectrome-try) radiocarbon dating and IB A (Ion Beam Analysis). An overview of these activities is presented by showing how accelerator-based analytical techniques can be a powerful tool for monitoring the anthropogenic carbon dioxide emissions from industrial sources and for the assessment of the biogenic content in SRF (Solid Recovered Fuel) burned in WTE (Waste to Energy) plants.

  15. Studies of industrial emissions by accelerator-based techniques: A review of applications at CEDAD

    Directory of Open Access Journals (Sweden)

    Calcagnile L.

    2012-04-01

    Full Text Available Different research activities are in progress at the Centre for Dating and Diagnostics (CEDAD, University of Salento, in the field of environmental monitoring by exploiting the potentialities given by the different experimental beam lines implemented on the 3 MV Tande-tron accelerator and dedicated to AMS (Accelerator Mass Spectrome-try radiocarbon dating and IB A (Ion Beam Analysis. An overview of these activities is presented by showing how accelerator-based analytical techniques can be a powerful tool for monitoring the anthropogenic carbon dioxide emissions from industrial sources and for the assessment of the biogenic content in SRF (Solid Recovered Fuel burned in WTE (Waste to Energy plants.

  16. Microwave digestion techniques applied to determination of boron by ICP-AES in BNCT program

    International Nuclear Information System (INIS)

    Farias, Silvia S.; Di Santo, Norberto R.; Garavaglia, Ricardo N.; Pucci, Gladys N.; Batistoni, Daniel A.; Schwint, Amanda E.

    1999-01-01

    Recently, boron neutron capture therapy (BNCT) has merged as an interesting option for the treatment of some kind of tumors where established therapies show no success. A molecular boronated species, enriched in 10 B is administrated to the subject; it localizes in malignant tissues depending the kind of tumor and localization. Therefore, a very important fact in BNCT research is the detection of boron at trace or ultra trace levels precisely and accurately. This is extremely necessary as boronated species do localize in tumoral tissue and also localize in liver, kidney, spleen, skin, membranes. By this way, before testing a boronated species, it is mandatory to determine its biodistribution in a statistically meaning population, that is related with managing of a great number of samples. In the other hand, it is necessary to exactly predict when to begin the irradiation and to determine the magnitude of radiation to obtain the desired radiological dose for a specified mean boron concentration. This involves the determination of boron in whole blood, which is related with boron concentration in the tumor object of treatment. The methodology selected for the analysis of boron in whole blood and tissues must join certain characteristics: it must not be dependant of the chemical form of boron, it has to be fast and capable to determine boron accurately and precisely in a wide range of concentrations. The design and validation of experimental models involving animals in BNCT studies and the determination of boron in blood of animals and subjects upon treatment require reliable analytical procedures to determine boron quantitatively in those biologic materials. Inductively coupled plasma-atomic emission spectrometry (ICP-AES) using pneumatic nebulization is one of the most promising methods for boron analysis, but the sample must be liquid and have low solid concentration. In our case, biological tissues and blood, it is mandatory to mineralize and/or dilute samples

  17. 2.5 MeV CW 4-vane RFQ accelerator design for BNCT applications

    Science.gov (United States)

    Zhu, Xiaowen; Wang, Hu; Lu, Yuanrong; Wang, Zhi; Zhu, Kun; Zou, Yubin; Guo, Zhiyu

    2018-03-01

    Boron Neutron Capture Therapy (BNCT) promises a bright future in cancer therapy for its highly selective destruction of cancer cells, using the 10B +n→7Li +4 He reaction. It offers a more satisfactory therapeutic effect than traditional methods for the treatment of malignant brain tumors, head and neck cancer, melanoma, liver cancer and so on. A CW 4-vane RFQ, operating at 162.5 MHz, provides acceleration of a 20 mA proton beam to 2.5 MeV, bombarding a liquid lithium target for neutron production with a soft neutron energy spectrum. The fast neutron yield is about 1.73×1013 n/s. We preliminarily develop and optimize a beam shaping assembly design for the 7Li(p, n)7Be reaction with a 2.5 MeV proton beam. The epithermal neutron flux simulated at the beam port will reach up to 1 . 575 ×109 n/s/cm2. The beam dynamics design, simulation and benchmark for 2.5 MeV BNCT RFQ have been performed with both ParmteqM (V3.05) and Toutatis, with a transmission efficiency higher than 99.6% at 20 mA. To ease the thermal management in the CW RFQ operation, we adopt a modest inter-vane voltage design (U = 65 kV), though this does increase the accelerator length (reaching 5.2 m). Using the well-developed 3D electromagnetic codes, CST MWS and ANSYS HFSS, we are able to deal with the complexity of the BNCT RFQ, taking the contribution of each component in the RF volume into consideration. This allows us to optimize the longitudinal field distribution in a full-length model. Also, the parametric modeling technique is of great benefit to extensive modifications and simulations. In addition, the resonant frequency tuning of this RFQ is studied, giving the tuning sensitivities of vane channel and wall channel as -16.3 kHz/°C and 12.4 kHz/°C, respectively. Finally, both the multipacting level of this RFQ and multipacting suppressing in the coaxial coupler are investigated.

  18. Comparison of the radiobiological effects of Boron neutron capture therapy (BNCT) and conventional Gamma Radiation

    International Nuclear Information System (INIS)

    Dagrosa, Maria A.; Carpano, Marina; Perona, Marina; Thomasz, Lisa; Juvenal, Guillermo J.; Pisarev, Mario; Pozzi, Emiliano; Thorp, Silvia

    2009-01-01

    BNCT is an experimental radiotherapeutic modality that uses the capacity of the isotope 10 B to capture thermal neutrons leading to the production of 4 He and 7 Li, particles with high linear energy transfer (LET). The aim was to evaluate and compare in vitro the mechanisms of response to the radiation arising of BNCT and conventional gamma therapy. We measured the survival cell fraction as a function of the total physical dose and analyzed the expression of p27/Kip1 and p53 by Western blotting in cells of colon cancer (ARO81-1). Exponentially growing cells were distributed into the following groups: 1) BPA (10 ppm 10 B) + neutrons; 2) BOPP (10 ppm 10 B) + neutrons; 3) neutrons alone; 4) gamma-rays. A control group without irradiation for each treatment was added. The cells were irradiated in the thermal neutron beam of the RA-3 (flux= 7.5 10 9 n/cm 2 sec) or with 60 Co (1Gy/min) during different times in order to obtain total physical dose between 1-5 Gy (±10 %). A decrease in the survival fraction as a function of the physical dose was observed for all the treatments. We also observed that neutrons and neutrons + BOPP did not differ significantly and that BPA was the more effective compound. Protein extracts of irradiated cells (3Gy) were isolated to 24 h and 48 h post radiation exposure. The irradiation with neutrons in presence of 10 BPA or 10 BOPP produced an increase of p53 at 24 h maintain until 48 h. On the contrary, in the groups irradiated with neutrons alone or gamma the peak was observed at 48 hr. The level of expression of p27/Kip1 showed a reduction of this protein in all the groups irradiated with neutrons (neutrons alone or neutrons plus boron compound), being more marked at 24 h. These preliminary results suggest different radiobiological response for high and low let radiation. Future studies will permit establish the role of cell cycle in the tumor radio sensibility to BNCT. (author)

  19. Development of accelerator-based γ-ray-induced positron annihilation spectroscopy technique

    International Nuclear Information System (INIS)

    Selim, F.A.; Wells, D.P.; Harmon, J. F.; Williams, J.

    2005-01-01

    Accelerator-based γ-ray-induced positron annihilation spectroscopy performs positron annihilation spectroscopy by utilizing MeV bremsstrahlung radiation generated from an accelerator (We have named the technique 'accelerator-based γ-ray-induced PAS', even though 'bremsstrahlung' is more correct here than 'γ rays'. The reason for that is to make the name of the technique more general, since PAS may be performed by utilizing MeV γ rays emitted from nuclei through the use of accelerators as described later in this article and as in the case of positron lifetime spectroscopy [F.A. Selim, D.P. Wells, and J.F. Harmon, Rev. Sci. Instrum. 76, 033905 (2005)].) instead of using positrons from radioactive sources or positron beams. MeV γ rays create positrons inside the materials by pair production. The induced positrons annihilate with the material electrons emitting a 511-keV annihilation radiation. Doppler broadening spectroscopy of the 511-keV radiation provides information about open-volume defects and plastic deformation in solids. The high penetration of MeV γ rays allows probing of defects at high depths in thick materials up to several centimeters, which is not possible with most of the current nondestructive techniques. In this article, a detailed description of the technique will be presented, including its benefits and limitations relative to the other nondestructive methods. Its application on the investigation of plastic deformation in thick steel alloys will be shown

  20. Standard Practice for Conducting Irradiations at Accelerator-Based Neutron Sources

    CERN Document Server

    American Society for Testing and Materials. Philadelphia

    1996-01-01

    1.1 This practice covers procedures for irradiations at accelerator-based neutron sources. The discussion focuses on two types of sources, namely nearly monoenergetic 14-MeV neutrons from the deuterium-tritium T(d,n) interaction, and broad spectrum neutrons from stopping deuterium beams in thick beryllium or lithium targets. However, most of the recommendations also apply to other types of accelerator-based sources, including spallation neutron sources (1). Interest in spallation sources has increased recently due to their proposed use for transmutation of fission reactor waste (2). 1.2 Many of the experiments conducted using such neutron sources are intended to simulate irradiation in another neutron spectrum, for example, that from a DT fusion reaction. The word simulation is used here in a broad sense to imply an approximation of the relevant neutron irradiation environment. The degree of conformity can range from poor to nearly exact. In general, the intent of these simulations is to establish the fundam...

  1. Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: a single center experience.

    Science.gov (United States)

    Sager, Omer; Beyzadeoglu, Murat; Dincoglan, Ferrat; Demiral, Selcuk; Uysal, Bora; Gamsiz, Hakan; Oysul, Kaan; Dirican, Bahar; Sirin, Sait

    2013-01-01

    The primary goal of treatment for vestibular schwannoma is to achieve local control without comprimising regional cranial nerve function. Stereotactic radiosurgery has emerged as a viable therapeutic option for vestibular schwannoma. The aim of the study is to report our 15-year single center experience using linear accelerator-based stereotactic radiosurgery in the management of patients with vestibular schwannoma. Between July 1998 and January 2013, 68 patients with unilateral vestibular schwannoma were treated using stereotactic radiosurgery at the Department of Radiation Oncology, Gulhane Military Medical Academy. All patients underwent high-precision stereotactic radiosurgery using a linear accelerator with 6-MV photons. Median follow-up time was 51 months (range, 9-107). Median age was 45 years (range, 20-77). Median dose was 12 Gy (range, 10-13) prescribed to the 85%-95% isodose line encompassing the target volume. Local tumor control in patients with periodic follow-up imaging was 96.1%. Overall hearing preservation rate was 76.5%. Linear accelerator-based stereotactic radiosurgery offers a safe and effective treatment for patients with vestibular schwannoma by providing high local control rates along with improved quality of life through well-preserved hearing function.

  2. JAERI R & D on accelerator-based transmutation under OMEGA program

    Energy Technology Data Exchange (ETDEWEB)

    Takizuka, T.; Nishida, T.; Mizumoto, M. [Japan Atomic Energy Research Institute, Ibaraki-ken (Japan)] [and others

    1995-10-01

    The overview of the Japanese long-term research and development program on nuclide partitioning and transmutation, called {open_quotes}OMEGA,{close_quotes} is presented. Under this national program, major R&D activities are being carried out at JAERI, PNC, and CRIEPI. Accelerator-based transmutation study at JAERI is focused on a dedicated transmutor with a subcritical actinide-fueled subcritical core coupled with a spallation target driven by a high intensity proton accelerator. Two types of system concept, solid system and molten-salt system, are discussed. The solid system consists of sodium-cooled tungsten target and metallic actinide fuel. The molten-salt system is fueled with molten actinide chloride that acts also as a target material. The proposed plant transmutes about 250 kg of minor actinide per year, and generates enough electricity to power its own accelerator. JAERI is proposing the development of an intense proton linear accelerator ETA with 1.5 GeV-10 mA beam for engineering tests of accelerator-based transmutation. Recent achievements in the accelerator development are described.

  3. Tumor development in field-cancerized tissue is inhibited by a double application of Boron neutron capture therapy (BNCT) without exceeding radio-tolerance

    International Nuclear Information System (INIS)

    Monti Hughes, Andrea; Heber, Elisa M.; Itoiz, Maria E.; Molinari, Ana J.; Garabalino, Marcela A.; Trivillin, Veronica A.; Schwint, Amanda E.; Aromando, Romina F.

    2009-01-01

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of a 'single' application of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-1(Na 2 10 B 10 H 10 ) or (GB-10+BPA) to treat hamster cheek pouch tumors with no normal tissue radiotoxicity. Based on these results, we developed a model of precancerous tissue in the hamster cheek pouch for long-term studies. Employing this model we evaluated the long-term potential inhibitory effect on the development of second primary tumors from precancerous tissue and eventual radiotoxicity of a single application of BNCT mediated by BPA, GB-10 or (GB-10+BPA), in the RA-6. The clinical rationale of this study was to search for a BNCT protocol that is therapeutic for tumor, not radio-toxic for the normal tissue that lies in the neutron beam path, and exerts the desired inhibitory effect on the development of second primary tumors, without exceeding the radio-tolerance of precancerous tissue, the dose limiting tissue in this case. Second primary tumors that arise in precancerous tissue (also called locoregional recurrences) are a frequent cause of therapeutic failure in head and neck tumors. Aim: Evaluate the radiotoxicity and inhibitory effect of a 'double' application of the same BNCT protocols that were proved therapeutically successful for tumor and precancerous tissue, with a long term follow up (8 months). A 'double' application of BNCT is a potentially useful strategy for the treatment of tumors, in particular the larger ones, but the cost in terms of side-effects in dose-limiting tissues might preclude its application and requires cautious evaluation. Materials and methods: We performed a double application of 1) BPA-BNCT; 2) (GB

  4. Synthesis of optically active dodecaborate-containing L-amino acids for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Kusaka, Shintaro [Department of Bioscience and Informatics, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai (Japan); Hattori, Yoshihide, E-mail: y0shi_hattori@riast.osakafu-u.ac.jp [Department of Bioscience and Informatics, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai (Japan); Uehara, Kouki; Asano, Tomoyuki [Stella Pharma Corporation, ORIX Kouraibashi Bldg. 5F 3-2-7 Kouraibashi, Chuo-ku, Osaka (Japan); Tanimori, Shinji; Kirihata, Mitsunori [Department of Bioscience and Informatics, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai (Japan)

    2011-12-15

    A convenient and simple synthetic method of dodecaboratethio-L-amino acid, a new class of tumor-seeking boron carrier for BNCT, was accomplished from S-cyanoethylthioundecahydro-closo-dodecaborate (S-cyanoethyl-{sup 10}BSH, [{sup 10}B{sub 12}H{sub 11}]{sup 2-}SCH{sub 2}CH{sub 2}CN) and bromo-L-{alpha}-amino acids by nearly one step S-alkylation. An improved synthesis of S-cyanoethyl-{sup 10}BSH, a key starting compound for S-alkylation, was also performed by Michael addition of {sup 10}BSH with acryronitrile in high yield. Four kinds of new dodecaboratethio-L-amino acids were obtained in optically pure form without the need for any optical resolution.

  5. Study on high speed lithium jet for neutron source of boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Takahashi, Minoru; Kobayashi, Tooru; Zhang, Mingguang; Mak, Michael; Stefanica, Jiri; Dostal, Vaclav; Zhao Wei

    2012-01-01

    The feasibility study of a liquid lithium type proton beam target was performed for the neutron source of the boron neutron capture therapy (BNCT). As the candidates of the liquid lithium target, a thin sheet jet and a thin film flow on a concave wall were chosen, and a lithium flow experiment was conducted to investigate the hydrodynamic stability of the targets. The surfaces of the jets and film flows with a thickness of 0.5 mm and a width of 50 mm were observed by means of photography. It has been found that a stable sheet jet and a stable film flow on a concave wall can be formed up to certain velocities by using a straight nozzle and a curved nozzle with the concave wall, respectively. (author)

  6. Measuring the stopping power of α particles in compact bone for BNCT

    Science.gov (United States)

    Provenzano, L.; Rodríguez, L. M.; Fregenal, D.; Bernardi, G.; Olivares, C.; Altieri, S.; Bortolussi, S.; González, S. J.

    2015-01-01

    The stopping power of α particles in thin films of decalcified sheep femur, in the range of 1.5 to 5.0 MeV incident energy, was measured by transmission of a backscattered beam from a heavy target. Additionally, the film elemental composition was determined by Rutherford Backscattering Spectrometry (RBS). These data will be used to measure boron concentration in thin films of bone using a spectrometry technique developed by the University of Pavia, since the concentration ratio between healthy tissue and tumor is of fundamental importance in Boron Neutron Capture Therapy (BNCT). The present experimental data are compared with numerical simulation results and with tabulated stopping power data of non-decalcified human bone.

  7. Monte Carlo dose calculations for BNCT treatment of diffuse human lung tumours

    International Nuclear Information System (INIS)

    Altieri, S.; Bortolussi, S.; Bruschi, P.

    2006-01-01

    In order to test the possibility to apply BNCT in the core of diffuse lung tumours, dose distribution calculations were made. The simulations were performed with the Monte Carlo code MCNP.4c2, using the male computational phantom Adam, version 07/94. Volumes of interest were voxelized for the tally requests, and results were obtained for tissues with and without Boron. Different collimated neutron sources were tested in order to establish the proper energies, as well as single and multiple beams to maximize neutron flux uniformity inside the target organs. Flux and dose distributions are reported. The use of two opposite epithermal neutron collimated beams insures good levels of dose homogeneity inside the lungs, with a substantially lower radiation dose delivered to surrounding structures. (author)

  8. Neutron therapy coupling brachytherapy and boron neutron capture therapy (BNCT) techniques

    International Nuclear Information System (INIS)

    Chaves, Iara Ferreira.

    1994-12-01

    In the present dissertation, neutron radiation techniques applied into organs of the human body are investigated as oncologic radiation therapy. The proposal treatment consists on connecting two distinct techniques: Boron Neutron Capture Therapy (BNCT) and irradiation by discrete sources of neutrons, through the brachytherapy conception. Biological and radio-dosimetrical aspects of the two techniques are considered. Nuclear aspects are discussed, presenting the nuclear reactions occurred in tumoral region, and describing the forms of evaluating the dose curves. Methods for estimating radiation transmission are reviewed through the solution of the neutron transport equation, Monte Carlo methodology, and simplified analytical calculation based on diffusion equation and numerical integration. The last is computational developed and presented as a quickly way to neutron transport evaluation in homogeneous medium. The computational evaluation of the doses for distinct hypothetical situations is presented, applying the coupled techniques BNTC and brachytherapy as an possible oncologic treatment. (author). 78 refs., 61 figs., 21 tabs

  9. Effects of secondary interactions on the dose calculation in treatments with Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Monteiro, E.

    2004-01-01

    The aimed of this work consists of evaluating the influence of the secondary contributions of dose (thermal neutrons dose, epithermal neutrons dose, fast neutrons dose and photon dose) in treatment planning with BNCT. MCNP4B Code was used to calculate RBE-Gy doses through the irradiation of the modified Snyder head head phantom.A reduction of the therapeutical gain of monoenergetic neutron beans was observed in non invasive treatments, provoked for the predominance of the fast neutron dose component in the skin, showing that the secondary contributions of dose can contribute more in the direction to raise the dose in the fabric healthy that in the tumor, thus reducing the treatment efficiency. (author)

  10. Effective dose evaluation for BNCT treatment in the epithermal neutron beam at THOR

    Energy Technology Data Exchange (ETDEWEB)

    Wang, J.N. [Department of Engineering and System Science, National Tsing Hua University, No. 101, Section 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan (China)] [Division of Health Physics, Institute of Nuclear Energy Research, No. 1000, Wenhua Rd., Jiaan Village, Longtan Township, Taoyuan County 32546, Taiwan (China); Huang, C.K. [Institute of Nuclear Engineering and Science, National Tsing Hua University, No. 101, Section 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan (China); Tsai, W.C. [Department of Engineering and System Science, National Tsing Hua University, No. 101, Section 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan (China); Liu, Y.H. [Nuclear Science and Technol. Develop. Center, National Tsing Hua University, No. 101, Section 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan (China); Jiang, S.H., E-mail: shjiang@mx.nthu.edu.tw [Department of Engineering and System Science, National Tsing Hua University, No. 101, Section 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan (China)] [Institute of Nuclear Engineering and Science, National Tsing Hua University, No. 101, Section 2, Kuang-Fu Rd., Hsinchu 30013, Taiwan (China)

    2011-12-15

    This paper aims to evaluate the effective dose as well as equivalent doses of several organs of an adult hermaphrodite mathematical phantom according to the definition of ICRP Publication 60 for BNCT treatments of brain tumors in the epithermal neutron beam at THOR. The MCNP5 Monte Carlo code was used for the calculation of the average absorbed dose of each organ. The effective doses for a typical brain tumor treatment with a tumor treatment dose of 20 Gy-eq were evaluated to be 0.59 and 0.35 Sv for the LLAT and TOP irradiation geometries, respectively. In addition to the stochastic effect, it was found that it is also likely to produce deterministic effects, such as cataracts and depression of haematopoiesis.

  11. Cell death following BNCT: A theoretical approach based on Monte Carlo simulations

    Energy Technology Data Exchange (ETDEWEB)

    Ballarini, F., E-mail: francesca.ballarini@pv.infn.it [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bakeine, J. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Bortolussi, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bruschi, P. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Cansolino, L.; Clerici, A.M.; Ferrari, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Protti, N.; Stella, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Zonta, A.; Zonta, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Altieri, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy)

    2011-12-15

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called 'lethal aberrations' (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the {sup 10}B(n,{alpha}) {sup 7}Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the {sup 14}N(n,p){sup 14}C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death.

  12. Clinical lessons from the first applications of BNCT on unresectable liver metastases

    Energy Technology Data Exchange (ETDEWEB)

    Zonta, A; Prati, U; Roveda, L; Ferrari, C; Zonta, S; Clerici, Am; Zonta, C; Pinelli, T [Department of Nuclear and Theoretical Physics, University of Pavia and I.N.F.N., Pavia (Italy); Fossati, F [Department of Nuclear and Theoretical Physics, University of Pavia and I.N.F.N., Pavia (Italy); Altieri, S [Department of Nuclear and Theoretical Physics, University of Pavia and I.N.F.N., Pavia (Italy); Bortolussi, S [Department of Nuclear and Theoretical Physics, University of Pavia and I.N.F.N., Pavia (Italy); Bruschi, P [Department of Nuclear and Theoretical Physics, University of Pavia and I.N.F.N., Pavia (Italy); Nano, R [Department of Animal Biology, University of Pavia (Italy); Barni, S [Department of Animal Biology, University of Pavia (Italy); Chiari, P [Department of Animal Biology, University of Pavia (Italy); Mazzini, G [IGM CNR Histochemistry and Cytometry Section, University of Pavia (Italy)

    2006-05-15

    After a long series of studies on the effects of neutron irradiation of 10B loaded neoplastic cells both in culture and in animal experiments, we started the clinical application of BNCT on humans affected by liver metastases of a radically resected colon adenocarcinoma. The procedure we adopted includes a first surgical phase, with hepatectomy; a radiotherapeutic phase, in which the isolated liver, washed and chilled, is extracorporeally irradiated with thermal neutrons; and then a second surgical phase for the reconnection of the liver to the patient. Until now two patients have been subjected to the BNCT treatment. The first one survived 44 months with a good quality of life, and died because of diffuse recurrences of his intestinal tumour. The second patient had the same early perioperative course, but after 33 days a worsening of a dilatative cardiomyopaty, from which he was suffering, determined a cardiac failure and eventually death. This clinical experience, although limited, has shown that extracorporeal neutron irradiation of the liver is a feasible procedure, able to ensure the complete destruction of liver metastases and a possible long lasting survival. In our patients neutron irradiation caused massive cellular necrosis highly specific to tumour cells, whereas normal cells were mostly spared. Nevertheless, the impact of such a traumatic operation on the patient's organism must be taken into account. Finally, we have to be aware that the fight against tumour rarely leads to a complete victory. We now have an innovative weapon which is both powerful and partly unsettled: it must be refined and above all used.

  13. Neutron generator for BNCT based on high current ECR ion source with gyrotron plasma heating.

    Science.gov (United States)

    Skalyga, V; Izotov, I; Golubev, S; Razin, S; Sidorov, A; Maslennikova, A; Volovecky, A; Kalvas, T; Koivisto, H; Tarvainen, O

    2015-12-01

    BNCT development nowadays is constrained by a progress in neutron sources design. Creation of a cheap and compact intense neutron source would significantly simplify trial treatments avoiding use of expensive and complicated nuclear reactors and accelerators. D-D or D-T neutron generator is one of alternative types of such sources for. A so-called high current quasi-gasdynamic ECR ion source with plasma heating by millimeter wave gyrotron radiation is suggested to be used in a scheme of D-D neutron generator in the present work. Ion source of that type was developed in the Institute of Applied Physics of Russian Academy of Sciences (Nizhny Novgorod, Russia). It can produce deuteron ion beams with current density up to 700-800 mA/cm(2). Generation of the neutron flux with density at the level of 7-8·10(10) s(-1) cm(-2) at the target surface could be obtained in case of TiD2 target bombardment with deuteron beam accelerated to 100 keV. Estimations show that it is enough for formation of epithermal neutron flux with density higher than 10(9) s(-1) cm(-2) suitable for BNCT. Important advantage of described approach is absence of Tritium in the scheme. First experiments performed in pulsed regime with 300 mA, 45 kV deuteron beam directed to D2O target demonstrated 10(9) s(-1) neutron flux. This value corresponds to theoretical estimations and proofs prospects of neutron generator development based on high current quasi-gasdynamic ECR ion source. Copyright © 2015 Elsevier Ltd. All rights reserved.

  14. Positron annihilation induced Auger electron spectroscopy and its implementation at accelerator based low energy positron factories

    International Nuclear Information System (INIS)

    Weiss, A.; Koeymen, A.R.; Mehl, D.; Lee, K.H.; Yang Gimo; Jensen, K.

    1991-01-01

    Positron annihilation induced auger electron spectroscopy (PAES) makes use of a beam of low energy positrons to excite Auger transitions by annihilating core electrons. The large secondary electron background usually present in Auger spectra can be eliminated by setting the positron beam energy well below the Auger electron energy. This allows true Auger lineshapes to be obtained. Further, because the positron is localized just outside the surface before it annihilates, PAES is extremely sensitive to the topmost atomic layer. Recent PAES results obtained at the University of Texas at Arlington will be presented. In addition, the use of high resolution energy analyzers with multichannel particle detection schemes to prevent problems due to the high data rates associated with accelerator based positron beams will be discussed. (orig.)

  15. 350 keV accelerator based PGNAA setup to detect nitrogen in bulk samples

    Energy Technology Data Exchange (ETDEWEB)

    Naqvi, A.A., E-mail: aanaqvi@kfupm.edu.sa [Department of Physics and King Fahd University of Petroleum and Minerals, Dhahran (Saudi Arabia); Al-Matouq, Faris A.; Khiari, F.Z.; Gondal, M.A.; Rehman, Khateeb-ur [Department of Physics and King Fahd University of Petroleum and Minerals, Dhahran (Saudi Arabia); Isab, A.A. [Department of Chemistry, King Fahd University of Petroleum and Minerals, Dhahran (Saudi Arabia); Raashid, M.; Dastageer, M.A. [Department of Physics and King Fahd University of Petroleum and Minerals, Dhahran (Saudi Arabia)

    2013-11-21

    Nitrogen concentration was measured in explosive and narcotics proxy material, e.g. anthranilic acid, caffeine, melamine, and urea samples, bulk samples through thermal neutron capture reaction using 350 keV accelerator based prompt gamma ray neutron activation (PGNAA) setup. Intensity of 2.52, 3.53–3.68, 4.51, 5.27–5.30 and 10.38 MeV prompt gamma rays of nitrogen from the bulk samples was measured using a cylindrical 100 mm×100 mm (diameter×height ) BGO detector. Inspite of interference of nitrogen gamma rays from bulk samples with capture prompt gamma rays from BGO detector material, an excellent agreement between the experimental and calculated yields of nitrogen gamma rays has been obtained. This is an indication of the excellent performance of the PGNAA setup for detection of nitrogen in bulk samples.

  16. Review of high energy data and model codes for accelerator-based transmutation

    International Nuclear Information System (INIS)

    Koning, A.J.

    1993-01-01

    After reviewing the most important data needs for accelerator-based transmutation, the present status of the collection of experimental data for high energies is investigated by scanning the two databases NSR and EXFOR for measured cross sections. The most important nuclear theories and some of the associated nuclear model codes that are in use are outlined. Experimental data and simple theories have been used to construct empirical fomulae for the prediction of high-energy cross sections and these parametrizations are listed. A survey is given of the evaluation work that has been done so far, and finally some conclusions and recommendations are presented, with respect to the need of compilation of experimental data. (orig.)

  17. Accelerator based synthesis of hydroxyapatite by MeV ion implantation

    International Nuclear Information System (INIS)

    Rautray, Tapash R.; Narayanan, R.; Kwon, Tae-Yub; Kim, Kyo-Han

    2010-01-01

    Accelerator based MeV ion implantation of Ca 2+ and P 2+ into the titanium substrate to form hydroxyapatite (HA) has been carried out. Calcium hydroxide was formed after heating the calcium implanted titanium in air at 80 o C for 3 h. Upon subsequent annealing for 5 min at 600 o C HA was formed on the surface. Penetration depth of the HA layer in this method is much higher as compared to keV ion implantation. By elemental analysis, Ca/P ratio of the HA was found to be 1.76 which is higher than the ideal 1.67. This higher Ca/P ratio is attributed to the higher penetration depth of the MeV technique used.

  18. 350 keV accelerator based PGNAA setup to detect nitrogen in bulk samples

    International Nuclear Information System (INIS)

    Naqvi, A.A.; Al-Matouq, Faris A.; Khiari, F.Z.; Gondal, M.A.; Rehman, Khateeb-ur; Isab, A.A.; Raashid, M.; Dastageer, M.A.

    2013-01-01

    Nitrogen concentration was measured in explosive and narcotics proxy material, e.g. anthranilic acid, caffeine, melamine, and urea samples, bulk samples through thermal neutron capture reaction using 350 keV accelerator based prompt gamma ray neutron activation (PGNAA) setup. Intensity of 2.52, 3.53–3.68, 4.51, 5.27–5.30 and 10.38 MeV prompt gamma rays of nitrogen from the bulk samples was measured using a cylindrical 100 mm×100 mm (diameter×height ) BGO detector. Inspite of interference of nitrogen gamma rays from bulk samples with capture prompt gamma rays from BGO detector material, an excellent agreement between the experimental and calculated yields of nitrogen gamma rays has been obtained. This is an indication of the excellent performance of the PGNAA setup for detection of nitrogen in bulk samples

  19. 350 keV accelerator based PGNAA setup to detect nitrogen in bulk samples

    Science.gov (United States)

    Naqvi, A. A.; Al-Matouq, Faris A.; Khiari, F. Z.; Gondal, M. A.; Rehman, Khateeb-ur; Isab, A. A.; Raashid, M.; Dastageer, M. A.

    2013-11-01

    Nitrogen concentration was measured in explosive and narcotics proxy material, e.g. anthranilic acid, caffeine, melamine, and urea samples, bulk samples through thermal neutron capture reaction using 350 keV accelerator based prompt gamma ray neutron activation (PGNAA) setup. Intensity of 2.52, 3.53-3.68, 4.51, 5.27-5.30 and 10.38 MeV prompt gamma rays of nitrogen from the bulk samples was measured using a cylindrical 100 mm×100 mm (diameter×height ) BGO detector. Inspite of interference of nitrogen gamma rays from bulk samples with capture prompt gamma rays from BGO detector material, an excellent agreement between the experimental and calculated yields of nitrogen gamma rays has been obtained. This is an indication of the excellent performance of the PGNAA setup for detection of nitrogen in bulk samples.

  20. Artificial neural networks to evaluate the boron concentration decreasing profile in Blood-BPA samples of BNCT patients

    International Nuclear Information System (INIS)

    García-Reiriz, Alejandro; Magallanes, Jorge; Zupan, Jure; Líberman, Sara

    2011-01-01

    For the prediction of decay concentration profiles of the p-boronophenylalanine (BPA) in blood during BNCT treatment, a method is suggested based on Kohonen neural networks. The results of a model trained with the concentration profiles from the literature are described. The prediction of the model was validated by the leave-one-out method. Its robustness shows that it is mostly independent on small variations. The ability to fit retrospective experimental data shows an uncertainty lower than the two compartment model used previously. - Highlights: ► We predicted decaying concentration profiles of BPA in blood during BNCT therapy. ► Is suggested a method based on Kohonen neural networks. ► The results show that it is very robust and mostly independent of small variations. ► It has a better ability to fit retrospective experimental data. ► The model could be progressively improved by adding new data to the training matrix.

  1. Feasibility of sealed D-T neutron generator as neutron source for liver BNCT and its beam shaping assembly.

    Science.gov (United States)

    Liu, Zheng; Li, Gang; Liu, Linmao

    2014-04-01

    This paper involves the feasibility of boron neutron capture therapy (BNCT) for liver tumor with four sealed neutron generators as neutron source. Two generators are placed on each side of the liver. The high energy of these emitted neutrons should be reduced by designing a beam shaping assembly (BSA) to make them useable for BNCT. However, the neutron flux decreases as neutrons pass through different materials of BSA. Therefore, it is essential to find ways to increase the neutron flux. In this paper, the feasibility of using low enrichment uranium as a neutron multiplier is investigated to increase the number of neutrons emitted from D-T neutron generators. The neutron spectrum related to our system has a proper epithermal flux, and the fast and thermal neutron fluxes comply with the IAEA recommended values. Copyright © 2014 Elsevier Ltd. All rights reserved.

  2. Discrimination of various contributions to the absorbed dose in BNCT: Fricke-gel imaging and intercomparison with other experimental results

    Energy Technology Data Exchange (ETDEWEB)

    Gambarini, G. E-mail: grazia.gambarini@mi.infn.it; Agosteo, S.; Marchesi, P.; Nava, E.; Palazzi, P.; Pecci, A.; Rosi, G.; Tinti, R

    2000-11-15

    A method is described for the 3D measurements of absorbed dose in a ferrous sulphate gel phantom, exposed in the thermal column of a nuclear reactor. The method, studied for Boron Neutron Capture Therapy (BNCT) purposes, allows absorbed dose imaging and profiling, with the separation of different contributions coming from different secondary radiations, generated from thermal neutrons. In fact, the biological effectiveness of the different radiations is different. Tests with conventional dosimeters were performed too.

  3. Labelled compounds of interest as antitumour agents. Pt. 4: Deuteration and tritiation of a nitroimidazole-carborane designed for BNCT

    International Nuclear Information System (INIS)

    Scobie, Martin; Bew, S.P.; Threadgill, M.D.

    1994-01-01

    Quenching the anion generated from a 2-(ω-carboranylalkyl)dithiane with 2 H 2 O at -78 o C and at 0 o C introduced deuterium exclusively at C-2 of the carborane. Extension of this model reaction to a bioreductively-targetted carborane allowed the synthesis of 2-[ 2 H]- and 2-[ 3 H]-isotopomers of a nitroimidazole-carborane which is of interest in boron neutron capture therapy (BNCT) of cancer. (author)

  4. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration of the RA-6 nuclear reactor

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, Andrea; Trivillin, Veronica A.; Schwint, Amanda E. [Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Department of Radiobiology, San Martin, Province Buenos Aires (Argentina); National Research Council (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Longhino, Juan; Boggio, Esteban [Bariloche Atomic Center, CNEA, Department of Nuclear Engineering, San Carlos de Bariloche, Province Rio Negro (Argentina); Medina, Vanina A.; Martinel Lamas, Diego J. [National Research Council (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Pontifical Catholic University of Argentina (UCA), Laboratory of Tumoral Biology and Inflammation, School of Medical Sciences, Institute for Biomedical Research (BIOMED CONICET-UCA), Ciudad Autonoma de Buenos Aires (Argentina); Garabalino, Marcela A.; Heber, Elisa M.; Pozzi, Emiliano C.C. [Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Department of Radiobiology, San Martin, Province Buenos Aires (Argentina); Itoiz, Maria E. [Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Department of Radiobiology, San Martin, Province Buenos Aires (Argentina); UBA, Department of Oral Pathology, Faculty of Dentistry, Ciudad Autonoma de Buenos Aires (Argentina); Aromando, Romina F. [UBA, Department of Oral Pathology, Faculty of Dentistry, Ciudad Autonoma de Buenos Aires (Argentina); Nigg, David W. [Idaho National Laboratory, Idaho Falls (United States)

    2017-11-15

    Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We demonstrated, in 2001, the therapeutic effect of BNCT mediated by BPA (boronophenylalanine) in the hamster cheek pouch model of oral cancer, at the RA-6 nuclear reactor. Between 2007 and 2011, the RA-6 was upgraded, leading to an improvement in the performance of the BNCT beam (B2 configuration). Our aim was to evaluate BPA-BNCT radiotoxicity and tumor control in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration. We also evaluated, for the first time in the oral cancer model, the radioprotective effect of histamine against mucositis in precancerous tissue as the dose-limiting tissue. Cancerized pouches were exposed to: BPA-BNCT; BPA-BNCT + histamine; BO: Beam only; BO + histamine; CONTROL: cancerized, no-treatment. BNCT induced severe mucositis, with an incidence that was slightly higher than in ''B1'' experiments (86 vs 67%, respectively). BO induced low/moderate mucositis. Histamine slightly reduced the incidence of severe mucositis induced by BPA-BNCT (75 vs 86%) and prevented mucositis altogether in BO animals. Tumor overall response was significantly higher in BNCT (94-96%) than in control (16%) and BO groups (9-38%), and did not differ significantly from the ''B1'' results (91%). Histamine did not compromise BNCT therapeutic efficacy. BNCT radiotoxicity and therapeutic effect at the B1 and B2 configurations of RA-6 were consistent. Histamine slightly reduced mucositis in precancerous tissue even in this overly aggressive oral cancer model, without compromising tumor control. (orig.)

  5. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration of the RA-6 nuclear reactor

    International Nuclear Information System (INIS)

    Monti Hughes, Andrea; Trivillin, Veronica A.; Schwint, Amanda E.; Longhino, Juan; Boggio, Esteban; Medina, Vanina A.; Martinel Lamas, Diego J.; Garabalino, Marcela A.; Heber, Elisa M.; Pozzi, Emiliano C.C.; Itoiz, Maria E.; Aromando, Romina F.; Nigg, David W.

    2017-01-01

    Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We demonstrated, in 2001, the therapeutic effect of BNCT mediated by BPA (boronophenylalanine) in the hamster cheek pouch model of oral cancer, at the RA-6 nuclear reactor. Between 2007 and 2011, the RA-6 was upgraded, leading to an improvement in the performance of the BNCT beam (B2 configuration). Our aim was to evaluate BPA-BNCT radiotoxicity and tumor control in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration. We also evaluated, for the first time in the oral cancer model, the radioprotective effect of histamine against mucositis in precancerous tissue as the dose-limiting tissue. Cancerized pouches were exposed to: BPA-BNCT; BPA-BNCT + histamine; BO: Beam only; BO + histamine; CONTROL: cancerized, no-treatment. BNCT induced severe mucositis, with an incidence that was slightly higher than in ''B1'' experiments (86 vs 67%, respectively). BO induced low/moderate mucositis. Histamine slightly reduced the incidence of severe mucositis induced by BPA-BNCT (75 vs 86%) and prevented mucositis altogether in BO animals. Tumor overall response was significantly higher in BNCT (94-96%) than in control (16%) and BO groups (9-38%), and did not differ significantly from the ''B1'' results (91%). Histamine did not compromise BNCT therapeutic efficacy. BNCT radiotoxicity and therapeutic effect at the B1 and B2 configurations of RA-6 were consistent. Histamine slightly reduced mucositis in precancerous tissue even in this overly aggressive oral cancer model, without compromising tumor control. (orig.)

  6. Boron neutron capture therapy (BNCT) for glioblastoma multiforme (GBM), using the epithermal neutron beam at the Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    Chadha, Manjeet; Capala, Jacek; Coderre, Jeffrey A.; Elowitz, Eric H.; Joel, Darrel D.; Hungyuan, B. Liu; Slatkin, Daniel N.; Chanana, Arjun D.

    1996-01-01

    Objective: BNCT is a binary treatment modality based on the nuclear reactions that occur when boron ( 10 B) is exposed to thermal neutrons. Preclinical studies have demonstrated the therapeutic efficacy of p-boronophenylalanine (BPA)-based BNCT. The objective of the Phase I/II trial was to evaluate BPA-fructose (BPA-F) as a boron delivery agent for GBM and to study the feasibility and safety of a single-fraction of BNCT. Materials and Methods: The trial design required i) a BPA-F biodistribution study performed at the time of craniotomy; and ii) BNCT within 4 weeks of the craniotomy. From September 94 to July 95, 10 patients with biopsy proven GBM were treated. All but 1 patient underwent a biodistribution study receiving IV BPA-F at the time of craniotomy. Multiple tissue samples and concurrent blood and urine samples were collected for evaluation of the boron concentration and clearance kinetics. For BNCT all patients received 250 mg/kgm of BPA-F (IV infusion over 2 hrs) followed by neutron irradiation. The blood 10 B concentration during irradiation was used to calculate the time of neutron exposure. The 3D treatment planning was done using the BNCT treatment planning software developed at the Idaho National Engineering Laboratory. The BNCT dose is expressed as the sum of the physical dose components corrected for both the RBE and the 10 B localization factor with the unit Gy-Eq. The photon-equivalent dose, where the thermal neutron fluence reaches a maximum, is the peak-dose equivalent. A single-fraction of BNCT was delivered prescribing 10.5 Gy-Eq (9 patients) and 13.8 Gy-Eq (1 patient) as the peak dose-equivalent to the normal brain. The peak dose rate was kept below 27 cGy-Eq/min. Results: Biodistribution data: The maximum blood 10 B concentration was observed at the end of the infusion and scaled as a linear function of the administered dose. The 10 B concentration in the scalp and in the GBM tissue was higher than in blood by 1.5 x and at least 3.5 x

  7. Capability of NIPAM polymer gel in recording dose from the interaction of 10B and thermal neutron in BNCT

    International Nuclear Information System (INIS)

    Khajeali, Azim; Reza Farajollahi, Ali; Kasesaz, Yaser; Khodadadi, Roghayeh; Khalili, Assef; Naseri, Alireza

    2015-01-01

    The capability of N-isopropylacrylamide (NIPAM) polymer gel to record the dose resulting from boron neutron capture reaction in BNCT was determined. In this regard, three compositions of the gel with different concentrations of 10 B were prepared and exposed to gamma radiation and thermal neutrons. Unlike irradiation with gamma rays, the boron-loaded gels irradiated by neutron exhibited sensitivity enhancement compared with the gels without 10 B. It was also found that the neutron sensitivity of the gel increased by the increase of concentration of 10 B. It can be concluded that NIPAM gel might be suitable for the measurement of the absorbed dose enhancement due to 10 B and thermal neutron reaction in BNCT. - Highlights: • Three compositions of NIPAM gel with different concentration of 10 B have been exposed by gamma and thermal neutron. • The vials containing NIPAM gel have been irradiated by an automatic system capable of providing for dose uniformity. • Suitability of NIPAM polymer gel in measuring radiation doses in BNCT has been investigated.

  8. Considerations for boron neutron capture therapy studies; Consideracoes sobre o estudo da BNCT (terapia de captura neutronica por boro)

    Energy Technology Data Exchange (ETDEWEB)

    Faria Gaspar, P de

    1994-12-31

    Radiotherapy is indispensable as a mean to eradicate deeply or infiltrating tumor tissue that can not be removed surgically. Therefore, it is not selective and may also kill the surrounding health tissue. The principle of BNCT (Boron Neutron Capture Therapy) consist in targeting a tumor selectively with a boron-10 compound. This nuclide has a large capture cross section for thermal neutrons and the nuclear reaction and the delivered energy in locus will selective the tumor. Since its initial proposal in 1963 BNCT has made much progress, however it is not used in a routine treatment. In this work it was approached some complex procedures, as the obtention of selective boron compounds, the adequate set up of neutron beams, the biodistribution, the in vivo and in vitro studies, and also human patients treatments. This work provide fundamentals about BNCT to professional of different areas of knowledge since it comprises multidisciplinary study. It includes appendixes for the ones not related to the field for a better comprehension of the many aspects involved. It is also presented a glossary containing technical and basic aspects involved. It is also presented a glossary containing technical and basic terms referred in the work. (author). 174 refs, 1 fig, 12 apps.

  9. Positron emission tomography and [{sup 18}F]BPA: A perspective application to assess tumour extraction of boron in BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Menichetti, L. [Department of PET and Radiopharmaceutical Chemistry, C.N.R. Institute of Clinical Physiology, Pisa (Italy)], E-mail: luca.menichetti@ifc.cnr.it; Cionini, L. [Unit of Radiotherapy, AOUP-University Hospital, Pisa (Italy); Sauerwein, W.A. [Department of Radiation Oncology, University Duisburg-Essen, University Hospital Essen (Germany); Altieri, S. [University of Pavia, Department of Nuclear Physics, Pavia (Italy); Solin, O.; Minn, H. [Turku PET Centre, University of Turku (Finland); Salvadori, P.A. [Department of PET and Radiopharmaceutical Chemistry, C.N.R. Institute of Clinical Physiology, Pisa (Italy)

    2009-07-15

    Positron emission tomography (PET) has become a key imaging tool in clinical practice and biomedical research to quantify and study biochemical processes in vivo. Physiologically active compounds are tagged with positron emitters (e.g. {sup 18}F, {sup 11}C, {sup 124}I) while maintaining their biological properties, and are administered intravenously in tracer amounts (10{sup -9}-10{sup -12} M quantities). The recent physical integration of PET and computed tomography (CT) in hybrid PET/CT scanners allows a combined anatomical and functional imaging: nowadays PET molecular imaging is emerging as powerful pharmacological tool in oncology, neurology and for treatment planning as guidance for radiation therapy. The in vivo pharmacokinetics of boron carrier for BNCT and the quantification of {sup 10}B in living tissue were performed by PET in the late nineties using compartmental models based on PET data. Nowadays PET and PET/CT have been used to address the issue of pharmacokinetic, metabolism and accumulation of BPA in target tissue. The added value of the use of L-[{sup 18}F]FBPA and PET/CT in BNCT is to provide key data on the tumour extraction of {sup 10}B-BPA versus normal tissue and to predict the efficacy of the treatment based on a single-study patient analysis. Due to the complexity of a binary treatment like BNCT, the role of PET/CT is currently to design new criteria for patient enrolment in treatment protocols: the L-[{sup 18}F]BPA/PET methodology could be considered as an important tool in newly designed clinical trials to better estimate the concentration ratio of BPA in the tumour as compared to neighbouring normal tissues. Based on these values for individual patients the decision could be made whether BNCT treatment could be advantageous due to a selective accumulation of BPA in an individual tumour. This approach, applicable in different tumour entities like melanoma, glioblastoma and head and neck malignancies, make this methodology as reliable

  10. 201Tl/99mTc-MIBI SPECT to evaluate therapy effect of BNCT with BSH and BPA for malignant brain tumor

    International Nuclear Information System (INIS)

    Shibata, Yasushi; Katayama, Wataru; Yamamoto, Tetsuya; Nakai, Kei; Endo, Kiyoshi; Matsuda, Masahide; Matsushita, Akira; Matsumura, Akira

    2006-01-01

    201 Tl/ 99m Tc-MIBI SPECT are imaging modalities to evaluate the malignancy and viability of brain tumor. We reviewed these SPECT findings before and after BNCT, and evaluated the usefulness of SPECT. The study includes total 11 patients admitted in our hospital between 1999 and 2005, 8 with glioblastoma, 2 with anaplastic astrocytoma and 2 with anaplastic oligodendroglioma. SPECT was taken with multidetector SPECT at 15 minutes and 3 hours after intravenous injection of Tl 74 MBq or MIBI 740 MBq. Region of interests were set on tumor and contralateral white matter and radioactivity ratios were calculated as Tl, MIBI indexes. For patients with no residual tumor in MRI, Tl/MIBI indexes were low. For patients with large residual tumor the indexes were high. For the patients with recurrent tumor the indexes were very high. Tl/MIBI indexes before BNCT correlated with survival and progression-free period after BNCT. SPECT indexes decreased after BNCT. For 8 patients with recurrent tumor, the indexes increased. Tl and MIBI SPECT are valuable to evaluate malignancy, viability, survival and recurrence of malignant glioma in BNCT. (author)

  11. Evaluation of neutron irradiation fields for BNCT by using absorbed dose in a phantom

    International Nuclear Information System (INIS)

    Aizawa, O.

    1993-01-01

    In a previous paper, the author defined the open-quotes irradiation timeclose quotes as the time of irradiation in which the maximum open-quotes total background doseclose quotes becomes 2,500 RBE-cGy. In this paper, he has modified the definition a little as the time of irradiation in which the maximum open-quotes lμg/g B-10 doseclose quotes becomes 3,000 RBE-cGy, because he assumed that normal tissue contained 1μg/g B-10. Moreover, he has modified the dose criteria for BNCT as follows: The open-quotes eye doseclose quotes, open-quotes total body doseclose quotes and open-quotes except-head doseclose quotes should be less that 200, 100 and 50 RBE-cGy, respectively. He has added one more criterion for BNCT that the thermal neutron fluence at the tumor position should be over 2.5x10 12 n/cm 2 at the open-quotes irradiation timeclose quotes. The distance from the core side to the irradiation port in the open-quotes old configurationclose quotes of the Musashi reactor (TRIGA-II, 100kW) was 160 cm. He is now planning to design an eccentric core and to move the reactor core nearer to the irradiation port, distance between the core side and the irradiation port to be 140, 130 and 120cm. The other assumptions used in this paper are as follows: (1) The B-10 concentrations in tumor are 30 and/or 10μg/g. (2) The depth of the tumor is 5.0 cm to 5.5 cm from the surface. (3) The RBE values used are 1.0 for all gamma rays and 2.3 for B 10 (n,α) reaction products. (4) The RBE values for neutrons are the following three cases: the first case is using 1.6 for all neutrons; the second one is using 3.2 for non-thermal neutrons and 1.6 for thermal neutrons; the third case is using 4.8 for fast neutrons, 3.2 for faster epithermal and epithermal neutrons, and 1.6 for thermal neutrons

  12. Nondestructive elemental analysis of coins using accelerator-based thermal neutrons

    International Nuclear Information System (INIS)

    Khairi, F.Z.; Aksoy, A.; Al-Haddad, M.N.

    2007-01-01

    The accelerator-based thermal-neutrons activation analysis setup at KFUPM has an adequate thermal -neutron flux that can be advantageously used for the elemental analysis of a variety of samples including archeological ones. The thermal neutrons are derived from the moderation of fast neutrons from the D (d, n) He reaction which produces fast 2.5 MeV neutrons. A maximum thermals flux of about 2.5x10 n/m-s was achieved. For the purpose of determining the suitability of the set up for the analysis of contemporary and ancient coins, we carried out a feasibility study by irradiating a selected number of Saudi Arabian coins dating from 1958 to 1987 in the thermal-neutron flux. The induced gamma-ray activities were then counted using a HP-GMX detector coupled to a PC-based data acquisition and analysis system. The elements that were determined in the coins were copper (75%), nickel (around 25%) and manganese (<0.5%). Calibration curves were also established for these elements. The determined concentrations are in agreement with the data published by the Standard Catalogue of World Coins. (author)

  13. Doppler Broadening Analysis of Steel Specimens Using Accelerator Based In Situ Pair Production

    International Nuclear Information System (INIS)

    Makarashvili, V.; Wells, D. P.; Roy, A. K.

    2009-01-01

    Positron Annihilation Spectroscopy (PAS) techniques can be utilized as a sensitive probe of defects in materials. Studying these microscopic defects is very important for a number of industries in order to predict material failure or structural integrity. We have been developing gamma-induced pair-production techniques to produce positrons in thick samples (∼4-40 g/cm 2 , or ∼0.5-5 cm in steel). These techniques are called 'Accelerator-based Gamma-induced Positron Annihilation Spectroscopy'(AG-PAS). We have begun testing the capabilities of this technique for imaging of defect densities in thick structural materials. As a first step, a linear accelerator (LINAC) was employed to produce photon beams by stopping 15 MeV electrons in a 1 mm thick tungsten converter. The accelerator is capable of operating with 30-60 ns pulse width, up to 200 mA peak current at 1 kHz repetition rate. The highly collimated bremsstrahlung beam impinged upon our steel tensile specimens, after traveling through a 1.2 m thick concrete wall. Annihilation radiation was detected by a well-shielded and collimated high-purity germanium detector (HPGe). Conventional Doppler broadening spectrometry (DBS) was performed to determine S, W and T parameters for our samples.

  14. Accelerator-based techniques for the support of senior-level undergraduate physics laboratories

    International Nuclear Information System (INIS)

    Williams, J.R.; Clark, J.C.; Isaacs-Smith, T.

    2001-01-01

    Approximately three years ago, Auburn University replaced its aging Dynamitron accelerator with a new 2MV tandem machine (Pelletron) manufactured by the National Electrostatics Corporation (NEC). This new machine is maintained and operated for the University by Physics Department personnel, and the accelerator supports a wide variety of materials modification/analysis studies. Computer software is available that allows the NEC Pelletron to be operated from a remote location, and an Internet link has been established between the Accelerator Laboratory and the Upper-Level Undergraduate Teaching Laboratory in the Physics Department. Additional software supplied by Canberra Industries has also been used to create a second Internet link that allows live-time data acquisition in the Teaching Laboratory. Our senior-level undergraduates and first-year graduate students perform a number of experiments related to radiation detection and measurement as well as several standard accelerator-based experiments that have been added recently. These laboratory exercises will be described, and the procedures used to establish the Internet links between our Teaching Laboratory and the Accelerator Laboratory will be discussed

  15. Materials considerations for molten salt accelerator-based plutonium conversion systems

    International Nuclear Information System (INIS)

    DiStefano, J.R.; DeVan, J.H.; Keiser, J.R.; Klueh, R.L.; Eatherly, W.P.

    1995-03-01

    Accelerator-driven transmutation technology (ADTT) refers to a concept for a system that uses a blanket assembly driven by a source of neutrons produced when high-energy protons from an accelerator strike a heavy metal target. One application for such a system is called Accelerator-Based Plutonium Conversion, or ABC. Currently, the version of this concept being proposed by the Los Alamos National Laboratory features a liquid lead target material and a blanket fuel of molten fluorides that contain plutonium. Thus, the materials to be used in such a system must have, in addition to adequate mechanical strength, corrosion resistance to molten lead, corrosion resistance to molten fluoride salts, and resistance to radiation damage. In this report the corrosion properties of liquid lead and the LiF-BeF 2 molten salt system are reviewed in the context of candidate materials for the above application. Background information has been drawn from extensive past studies. The system operating temperature, type of protective environment, and oxidation potential of the salt are shown to be critical design considerations. Factors such as the generation of fission products and transmutation of salt components also significantly affect corrosion behavior, and procedures for inhibiting their effects are discussed. In view of the potential for extreme conditions relative to neutron fluxes and energies that can occur in an ADTT, a knowledge of radiation effects is a most important factor. Present information for potential materials selections is summarized

  16. Physical properties of a linear accelerator-based stereotactic installed at national cancer institute

    International Nuclear Information System (INIS)

    Attala, E.M.; Deiab, N.A.; Elawady, R.A.

    2005-01-01

    The purpose of this paper is to present the dosimetry and mechanical accuracy of the first dedicated Siemens PRIMUS M6/6ST linear accelerator-based Stereotactic installed in National Cancer Institute for stereotactic radiosurgery and radiotherapy (SRS/SRT). The data were obtained during the installation, acceptance test procedure, and commissioning of the unit. The Primus M6/6ST has a single 6-MV beam with the same beam characteristics as that of the mother unit, the Siemens. The dosimetric data were taken using pin point ion chamber. The cone sizes vary from 12.5 to 40.0 mm diameter. The mechanical stability of the entire system was verified. The variations in isocenter position with table, gantry, and collimator rotation were found to be < 0.5 mm with a compounded accuracy of < or = 1.0 mm. The beam profiles of all cones in the x and y directions were within +/- 0.5 mm and match with the physical size of the cone. The basic dosimetry parameters such as tissue maximum ratio (TMR), off-axis ratio (OAR) and cone factor needed for patient treatment were evaluated. The mechanical and dosimetric characteristics including dose linearity of this unit are presented and found to be suitable for SRS/SRT. The difficulty in absolute dose measurement for small cone is discussed

  17. Dynamic analysis of an accelerator-based subcritical radioactive waste burning system

    International Nuclear Information System (INIS)

    Woosley, M.L. Jr.; Rydin, R.A.

    1997-01-01

    There has been a recent revival of interest in accelerator-driven subcritical fluid-fueled systems for radioactive waste management. This motivates the need for dynamic analysis of the nuclear kinetics of such systems. A physical description of the Los Alamos Accelerator-Based Conversion (ABC) concept is provided. This system is used as the basis for the kinetic study in this research. The current approach to the dynamic simulation of an accelerator-driven subcritical fluid-fueled system includes four functional blocks: A discrete ordinates model is used to calculate the flux distribution for the source-driven system (DORT); A nodal convection model is used to calculate time-dependent isotope and temperature distributions which impact reactivity (ABCcore); A nodal importance weighting model is used to calculate the reactivity impact of temperature and isotope distributions and to feed this information back to the time-dependent nodal convection model (ABCvip); A transient driver simulates system transients and records simulation data (ABCtrans). Specific transients which have been analyzed with the current modeling system are discussed. These transients include loss-of-flow and loss-of-cooling accidents, xenon and samarium transients, and cold-plug and overfueling events. The results of various transients have uncovered unpredictable behavior, unresolved design issues, and the need for active control. 11 refs., 6 figs., 1 tab

  18. Design of 6 Mev linear accelerator based pulsed thermal neutron source: FLUKA simulation and experiment

    Energy Technology Data Exchange (ETDEWEB)

    Patil, B.J., E-mail: bjp@physics.unipune.ac.in [Department of Physics, University of Pune, Pune 411 007 (India); Chavan, S.T.; Pethe, S.N.; Krishnan, R. [SAMEER, IIT Powai Campus, Mumbai 400 076 (India); Bhoraskar, V.N. [Department of Physics, University of Pune, Pune 411 007 (India); Dhole, S.D., E-mail: sanjay@physics.unipune.ac.in [Department of Physics, University of Pune, Pune 411 007 (India)

    2012-01-15

    The 6 MeV LINAC based pulsed thermal neutron source has been designed for bulk materials analysis. The design was optimized by varying different parameters of the target and materials for each region using FLUKA code. The optimized design of thermal neutron source gives flux of 3 Multiplication-Sign 10{sup 6}ncm{sup -2}s{sup -1} with more than 80% of thermal neutrons and neutron to gamma ratio was 1 Multiplication-Sign 10{sup 4}ncm{sup -2}mR{sup -1}. The results of prototype experiment and simulation are found to be in good agreement with each other. - Highlights: Black-Right-Pointing-Pointer The optimized 6 eV linear accelerator based thermal neutron source using FLUKA simulation. Black-Right-Pointing-Pointer Beryllium as a photonuclear target and reflector, polyethylene as a filter and shield, graphite as a moderator. Black-Right-Pointing-Pointer Optimized pulsed thermal neutron source gives neutron flux of 3 Multiplication-Sign 10{sup 6} n cm{sup -2} s{sup -1}. Black-Right-Pointing-Pointer Results of the prototype experiment were compared with simulations and are found to be in good agreement. Black-Right-Pointing-Pointer This source can effectively be used for the study of bulk material analysis and activation products.

  19. Design study of double-layer beam trajectory accelerator based on the Rhodotron structure

    Energy Technology Data Exchange (ETDEWEB)

    Jabbari, Iraj, E-mail: i_jabbari@ast.ui.ac.ir [Department of Nuclear Engineering, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan 8174673441 (Iran, Islamic Republic of); Poursaleh, Ali Mohammad [Department of Nuclear Engineering, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan 8174673441 (Iran, Islamic Republic of); Central Iran Research Complex, NSTRI, Yazd (Iran, Islamic Republic of); Khalafi, Hossein [Central Iran Research Complex, NSTRI, Yazd (Iran, Islamic Republic of)

    2016-08-21

    In this paper, the conceptual design of a new structure of industrial electron accelerator based on the Rhodotron accelerator is presented and its properties are compared with those of Rhodotron-TT200 accelerator. The main goal of this study was to reduce the power of RF system of accelerator at the same output electron beam energy. The main difference between the new accelerator structure with the Rhodotron accelerator is the length of the coaxial cavity that is equal to the wavelength at the resonant frequency. Also two sets of bending magnets were used around the acceleration cavity in two layers. In the new structure, the beam crosses several times in the coaxial cavity by the bending magnets around the cavity at the first layer and then is transferred to the second layer using the central bending magnet. The acceleration process in the second layer is similar to the first layer. Hence, the energy of the electron beam will be doubled. The electrical power consumption of the RF system and magnet system were calculated and simulated for the new accelerator structure and TT200. Comparing the calculated and simulated results of the TT200 with those of experimental results revealed good agreement. The results showed that the overall electrical power consumption of the new accelerator structure was less than that of the TT200 at the same energy and power of the electron beam. As such, the electrical efficiency of the new structure was improved.

  20. Dosimetric response evaluation of tooth enamel for accelerator-based neutron radiation

    International Nuclear Information System (INIS)

    Khan, R.F.H.; Rink, W.J.; Boreham, D.R.

    2003-01-01

    To study the neutron response of human tooth enamel, a number of experiments with an accelerator-based neutron source have been designed. The neutron beam was produced with the low gamma yield, 7 Li(p,n) 7 Be type thick target, using the 3 MV McMaster K.N. Van de Graaff accelerator. The dosimetry was done using a pre-calibrated snoopy type neutron dosimeter. Neutron irradiation induces a dosimetric signal in the tooth enamel at the same defect site as gamma produced damage with the same g-values (g parallel =1.9973, width 0.4 mT g perpendicular =2.002, width 0.3 mT). The dosimetric signal grows linearly with neutron dose from 6-35 Gy tissue dose. Dosimetric response in two different grain sizes (300-500 μm, and grains <4 mm) has shown increased dosimetric amplitude in the larger grains. Dose build up effect on tooth inside the mouth due to cheek was simulated by placing a 4 mm thick paraffin wax layer between the beam and tooth, but had little effect. These results show that for mean neutron energy of 280 keV, the relative neutron response of the human tooth enamel ranges from 8% to 12% of the equivalent gamma ray response

  1. Materials considerations for molten salt accelerator-based plutonium conversion systems

    International Nuclear Information System (INIS)

    DiStefano, J.R.; DeVan, J.H.; Keiser, J.R.; Klueh, R.L.; Eatherly, W.P.

    1995-02-01

    Accelerator-driven transmutation technology (ADTT) refers to a concept for a system that uses a blanket assembly driven by a source of neutrons produced when high-energy protons from an accelerator strike a heavy metal target. One application for such a system is called Accelerator-Based Plutonium Conversion, or ABC. Currently, the version of this concept being proposed by the Los Alamos National Laboratory features a liquid lead target material and a blanket fuel of molten fluorides that contain plutonium. Thus, the materials to be used in such a system must have, in addition to adequate mechanical strength, corrosion resistance to molten lead, corrosion resistance to molten fluoride salts, and resistance to radiation damage. In this report the corrosion properties of liquid lead and the LiF-BeF 2 molten salt system are reviewed in the context of candidate materials for the above application. Background information has been drawn from extensive past studies. The system operating temperature, type of protective environment, and oxidation potential of the salt are shown to be critical design considerations. Factors such as the generation of fission products and transmutation of salt components also significantly affect corrosion behavior, and procedures for inhibiting their effects are discussed. In view of the potential for extreme conditions relative to neutron fluxes and energies that can occur in an ADTT, a knowledge of radiation effects is a most important factor. Present information for potential materials selections is summarized

  2. Accelerator-based conversion (ABC) of weapons plutonium: Plant layout study and related design issues

    International Nuclear Information System (INIS)

    Cowell, B.S.; Fontana, M.H.; Krakowski, R.A.; Beard, C.A.; Buksa, J.J.; Davidson, J.W.; Sailor, W.C.; Williamson, M.A.

    1995-01-01

    In preparation for and in support of a detailed R and D Plan for the Accelerator-Based Conversion (ABC) of weapons plutonium, an ABC Plant Layout Study was conducted at the level of a pre-conceptual engineering design. The plant layout is based on an adaptation of the Molten-Salt Breeder Reactor (MSBR) detailed conceptual design that was completed in the early 1070s. Although the ABC Plant Layout Study included the Accelerator Equipment as an essential element, the engineering assessment focused primarily on the Target; Primary System (blanket and all systems containing plutonium-bearing fuel salt); the Heat-Removal System (secondary-coolant-salt and supercritical-steam systems); Chemical Processing; Operation and Maintenance; Containment and Safety; and Instrumentation and Control systems. Although constrained primarily to a reflection of an accelerator-driven (subcritical) variant of MSBR system, unique features and added flexibilities of the ABC suggest improved or alternative approaches to each of the above-listed subsystems; these, along with the key technical issues in need of resolution through a detailed R ampersand D plan for ABC are described on the bases of the ''strawman'' or ''point-of-departure'' plant layout that resulted from this study

  3. Acceleration-based methodology to assess the blast mitigation performance of explosive ordnance disposal helmets

    Science.gov (United States)

    Dionne, J. P.; Levine, J.; Makris, A.

    2018-01-01

    To design the next generation of blast mitigation helmets that offer increasing levels of protection against explosive devices, manufacturers must be able to rely on appropriate test methodologies and human surrogates that will differentiate the performance level of various helmet solutions and ensure user safety. Ideally, such test methodologies and associated injury thresholds should be based on widely accepted injury criteria relevant within the context of blast. Unfortunately, even though significant research has taken place over the last decade in the area of blast neurotrauma, there currently exists no agreement in terms of injury mechanisms for blast-induced traumatic brain injury. In absence of such widely accepted test methods and injury criteria, the current study presents a specific blast test methodology focusing on explosive ordnance disposal protective equipment, involving the readily available Hybrid III mannequin, initially developed for the automotive industry. The unlikely applicability of the associated brain injury criteria (based on both linear and rotational head acceleration) is discussed in the context of blast. Test results encompassing a large number of blast configurations and personal protective equipment are presented, emphasizing the possibility to develop useful correlations between blast parameters, such as the scaled distance, and mannequin engineering measurements (head acceleration). Suggestions are put forward for a practical standardized blast testing methodology taking into account limitations in the applicability of acceleration-based injury criteria as well as the inherent variability in blast testing results.

  4. BDTPS The BNCT Treatment Planning System jointly developed at DIMNP and JRC/IE

    CERN Document Server

    Daquino, G G; Mazzini, M; Moss, R; Muzi, L; International Workshop on "Neutron Capture Therapy: State of the art"

    2003-01-01

    The idea to couple the Treatment Planning System (TPS) to the information on the real boron distribution in the patient is the main added value of the new methodology set-up at DIMNP of University of Pisa, in collaboration with the JRC of Petten (NL). The methodology has been implemented in the new TPS, called BDTPS (Boron Distribution Treatment Planning System), which takes into account the actual boron distribution in the patient brain, while the standard TPS assumes a uniform boron distribution, absolutely far from the reality. Nowadays, Positron Emission Tomography (PET) is able to provide this in vivo information. The new TPS, based on the Monte Carlo technique, has been validated comparing the main BNCT parameters (thermal flux, boron dose, etc.) as measured during the irradiation of a special heterogeneous boron phantom (HEBOM), ad hoc designed, as calculated by the BDTPS and by the standard TPS SERA. An evident SERA overestimation of the thermal neutron flux, as well as the boron dose, has been detect...

  5. An automated method for breathing frequency determination for rat lung radiobiology in BNCT

    International Nuclear Information System (INIS)

    Kiger, J.L.; Coderre, J.A.; Kiger, W.S. III

    2006-01-01

    Whole-body plethysmography was used to the measure the breathing rate in rats as a functional indication of radiation-induced lung damage, either weekly or bi-weekly for a period of 180 days following thorax irradiations in a BNCT radiobiology study. A three-minute digital breathing signal was collected in each measurement. Software has been developed to automatically discriminate against large-amplitude noise due to animal movement. After segmenting the signal into consecutive, overlapping and circular blocks, the mean frequency spectrum of the processed signal was calculated using the Fast Fourier Transform (FFT). The breathing rate was defined as the primary frequency of the spectrum and the standard deviation was estimated using the bootstrap method. The mean standard deviation of all measurements in the data set (n=4269) was 2.4%. The improved accuracy with low standard deviation of the measurements ensures good sensitivity and a low threshold for detection of responding animals; breathing rates more than 20% (∼3 σ) above the control mean were considered responding. (author)

  6. Use of linear programming to obtain an optimum, multi-beam treatment plan in BNCT

    International Nuclear Information System (INIS)

    Nievaart, Sander; Moss, Ray; Sauerwein, Wolfgang; Wittig, Andrea

    2006-01-01

    For BNCT of melanoma metastases in the brain, it has been necessary to calculate the dose distributions in the patient for dozens of possible neutron beams and then to combine manually the different beams by individually weighting and adding them. This time consuming approach eventually gave the required treatment plan, which satisfied the prescription dose. However, by linear optimisation with the Simplex method, the optimum weights for a set of beams can be determined mathematically. The objective function to maximise is the minimum averaged physical boron dose in one certain lesion for every set of beams. The maximisation of this objective function is performed under the constraints of certain maximum and minimum dose limits in the organs at risk and lesions respectively and restricting the set of weighted beams to deliver an average total weighted dose of 7 Gy in the brain. After iteration, by using the constraint set for the minimum dose in the lesions as a variable and performed for all combinations of the neutron beams, the optimum beams and weights are found for each treatment. As a preliminary result, the total irradiation time decreased by more than 30%, which is advantageous regarding both the pharmacokinetics of the boron in the patient and patient comfort. (author)

  7. A novel design of beam shaping assembly to use D-T neutron generator for BNCT.

    Science.gov (United States)

    Kasesaz, Yaser; Karimi, Marjan

    2016-12-01

    In order to use 14.1MeV neutrons produced by d-T neutron generators, two special and novel Beam Shaping Assemblies (BSA), including multi-layer and hexagonal lattice have been suggested and the effect of them has been investigated by MCNP4C Monte Carlo code. The results show that the proposed BSA can provide the qualified epithermal neutron beam for BNCT. The final epithermal neutron flux is about 6e9 n/cm2.s. The final proposed BSA has some different advantages: 1) it consists of usual and well-known materials (Pb, Al, Fluental and Cd); 2) it has a simple geometry; 3) it does not need any additional gamma filter; 4) it can provide high flux of epithermal neutrons. As this type of neutron source is under development in the world, it seems that they can be used clinically in a hospital considering the proposed BSA. Copyright © 2016 Elsevier Ltd. All rights reserved.

  8. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

    Energy Technology Data Exchange (ETDEWEB)

    Nariai, Tadashi [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan)], E-mail: nariai.nsrg@tmd.ac.jp; Ishiwata, Kiichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Nakacho, Itabashi-ku, Tokyo (Japan); Kimura, Yuichi [Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba (Japan); Inaji, Motoki; Momose, Toshiya [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan); Yamamoto, Tetsuya; Matsumura, Akira [Department of Neurosurgery, University of Tsukuba, Tennodai, Tsukuba, Igaraki (Japan); Ishii, Kenji [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Nakacho, Itabashi-ku, Tokyo (Japan); Ohno, Kikuo [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan)

    2009-07-15

    Introduction: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes. Methods: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of {sup 18}F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. {sup 11}C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. Result: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other. Conclusion: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

  9. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

    International Nuclear Information System (INIS)

    Nariai, Tadashi; Ishiwata, Kiichi; Kimura, Yuichi; Inaji, Motoki; Momose, Toshiya; Yamamoto, Tetsuya; Matsumura, Akira; Ishii, Kenji; Ohno, Kikuo

    2009-01-01

    Introduction: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes. Methods: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of 18 F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. 11 C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. Result: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other. Conclusion: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

  10. Neutron field characterization in the installation for BNCT study in the IEA-R1 reactor; Caracterizacao do campo de neutrons na instalacao para estudo em BNCT no reator IEA-R1

    Energy Technology Data Exchange (ETDEWEB)

    Carneiro Junior, Valdeci

    2008-07-01

    This work aims to characterize the mixed neutron and gamma field, in the sample irradiation position, in a research installation for Boron Neutron Capture Therapy (BNCT), in the IPEN IEA-R1 reactor. The BNCT technique has been studied as a safe and selective option in the treatment of resistant cancerigenous tumors or considered non-curable by the conventional techniques, for example, the Glioblastoma Multiform - a brain cancerigenous tumor. Neutron flux measurements were carried out: thermal, resonance and fast, as well as neutron and gamma rays doses, in the sample position, using activation foils detectors and thermoluminescent dosimeters. For the determination of the neutron spectrum and intensity, a set of different threshold activation foils and gold foils covered and uncovered with cadmium irradiated in the installation was used, analyzed by a high Pure Germanium semiconductor detector, coupled to an electronic system suitable for gamma spectrometry. The results were processed with the SAND-BP code. The doses due to gamma and neutron rays were determined using thermoluminescent dosimeters TLD 400 and TLD 700 sensitive to gamma and TLD 600, sensitive to neutrons. The TLDs were selected and used for obtaining the calibration curves - dosimeter answer versus dose - from each of the TLD three types, which were necessary to calculate the doses due to neutron and gamma, in the sample position. The radiation field, in the sample irradiation position, was characterized flux for thermal neutrons of 1.39.10{sup 8} {+-} 0,12.10{sup 8} n/cm{sup 2}s the doses due to thermal neutrons are three times higher than those due to gamma radiation and confirm the reproducibility and consistency of the experimental findings obtained. Considering these results, the neutron field and gamma radiation showed to be appropriated for research in BNCT. (author)

  11. Prospect for application of compact accelerator-based neutron source to neutron engineering diffraction

    Energy Technology Data Exchange (ETDEWEB)

    Ikeda, Yoshimasa, E-mail: yoshimasa.ikeda@riken.jp [Center for Advanced Photonics, RIKEN, Wako, Saitama 351-0198 (Japan); Taketani, Atsushi; Takamura, Masato; Sunaga, Hideyuki [Center for Advanced Photonics, RIKEN, Wako, Saitama 351-0198 (Japan); Kumagai, Masayoshi [Faculty of Engineering, Tokyo City University, Setagaya, Tokyo 158-8857 (Japan); Oba, Yojiro [Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494 (Japan); Otake, Yoshie [Center for Advanced Photonics, RIKEN, Wako, Saitama 351-0198 (Japan); Suzuki, Hiroshi [Materials Sciences Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195 (Japan)

    2016-10-11

    A compact accelerator-based neutron source has been lately discussed on engineering applications such as transmission imaging and small angle scattering as well as reflectometry. However, nobody considers using it for neutron diffraction experiment because of its low neutron flux. In this study, therefore, the neutron diffraction experiments are carried out using Riken Accelerator-driven Compact Neutron Source (RANS), to clarify the capability of the compact neutron source for neutron engineering diffraction. The diffraction pattern from a ferritic steel was successfully measured by suitable arrangement of the optical system to reduce the background noise, and it was confirmed that the recognizable diffraction pattern can be measured by a large sampling volume with 10 mm in cubic for an acceptable measurement time, i.e. 10 min. The minimum resolution of the 110 reflection for RANS is approximately 2.5% at 8 μs of the proton pulse width, which is insufficient to perform the strain measurement by neutron diffraction. The moderation time width at the wavelength corresponding to the 110 reflection is estimated to be approximately 30 μs, which is the most dominant factor to determine the resolution. Therefore, refinements of the moderator system to decrease the moderation time by decreasing a thickness of the moderator or by applying the decoupler system or application of the angular dispersive neutron diffraction technique are important to improve the resolution of the diffraction experiment using the compact neutron source. In contrast, the texture evolution due to plastic deformation was successfully observed by measuring a change in the diffraction peak intensity by RANS. Furthermore, the volume fraction of the austenitic phase in the dual phase mock specimen was also successfully evaluated by fitting the diffraction pattern using a Rietveld code. Consequently, RANS has been proved to be capable for neutron engineering diffraction aiming for the easy access

  12. Characterizing a Model of Coronal Heating and Solar Wind Acceleration Based on Wave Turbulence.

    Science.gov (United States)

    Downs, C.; Lionello, R.; Mikic, Z.; Linker, J.; Velli, M.

    2014-12-01

    Understanding the nature of coronal heating and solar wind acceleration is a key goal in solar and heliospheric research. While there have been many theoretical advances in both topics, including suggestions that they may be intimately related, the inherent scale coupling and complexity of these phenomena limits our ability to construct models that test them on a fundamental level for realistic solar conditions. At the same time, there is an ever increasing impetus to improve our spaceweather models, and incorporating treatments for these processes that capture their basic features while remaining tractable is an important goal. With this in mind, I will give an overview of our exploration of a wave-turbulence driven (WTD) model for coronal heating and solar wind acceleration based on low-frequency Alfvénic turbulence. Here we attempt to bridge the gap between theory and practical modeling by exploring this model in 1D HD and multi-dimensional MHD contexts. The key questions that we explore are: What properties must the model possess to be a viable model for coronal heating? What is the influence of the magnetic field topology (open, closed, rapidly expanding)? And can we simultaneously capture coronal heating and solar wind acceleration with such a quasi-steady formulation? Our initial results suggest that a WTD based formulation performs adequately for a variety of solar and heliospheric conditions, while significantly reducing the number of free parameters when compared to empirical heating and solar wind models. The challenges, applications, and future prospects of this type of approach will also be discussed.

  13. Beam shaping assembly of a D-T neutron source for BNCT and its dosimetry simulation in deeply-seated tumor

    Science.gov (United States)

    Faghihi, F.; Khalili, S.

    2013-08-01

    This article involves two aims for BNCT. First case includes a beam shaping assembly estimation for a D-T neutron source to find epi-thermal neutrons which are the goal in the BNCT. Second issue is the percent depth dose calculation in the adult Snyder head phantom. Monte-Carlo simulations and verification of a suggested beam shaping assembly (including internal neutron multiplier, moderator, filter, external neutron multiplier, collimator, and reflector dimensions) for thermalizing a D-T neutron source as well as increasing neutron flux are carried out and our results are given herein. Finally, we have simulated its corresponding doses for treatment planning of a deeply-seated tumor.

  14. Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS.

    Science.gov (United States)

    Andoh, Tooru; Fujimoto, Takuya; Suzuki, Minoru; Sudo, Tamotsu; Sakurai, Yoshinori; Tanaka, Hiroki; Fujita, Ikuo; Fukase, Naomasa; Moritake, Hiroshi; Sugimoto, Tohru; Sakuma, Toshiko; Sasai, Hiroshi; Kawamoto, Teruya; Kirihata, Mitsunori; Fukumori, Yoshinobu; Akisue, Toshihiro; Ono, Koji; Ichikawa, Hideki

    2015-12-01

    Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In the present study, we established a lung metastasis animal model of CCS and investigated the therapeutic effect of boron neutron capture therapy (BNCT) using p-borono-L-phenylalanine (L-BPA). Biodistribution data revealed tumor-selective accumulation of (10)B. Unlike conventional gamma-ray irradiation, BNCT significantly suppressed tumor growth without damaging normal tissues, suggesting that it may be a potential new therapeutic option to treat CCS lung metastases. Copyright © 2015 Elsevier Ltd. All rights reserved.

  15. Intracellular targeting of mercaptoundecahydrododecaborate (BSH) to malignant glioma by transferrin-PEG liposomes for boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Doi, Atsushi; Miyatake, Shin-ichi; Iida, Kyouko

    2006-01-01

    Malignant glioma is one of the most difficult tumor to control with usual therapies. In our institute, we select boron neutron capture therapy (BNCT) as an adjuvant radiation therapy after surgical resection. This therapy requires the selective delivery of high concentration of 10 B to malignant tumor tissue. In this study, we focused on a tumor-targeting 10 B delivery system (BDS) for BNCT that uses transferrin-conjugated polyethylene-glycol liposome encapsulating BSH (TF-PEG liposome-BSH) and compared 10 B uptake of the tumor among BSH, PEG liposome-BSH and TF-PEG liposome-BSH. In vitro, we analyzed 10 B concentration of the cultured human U87Δ glioma cells incubated in medium containing 20 μg 10 B/ml derived from each BDS by inductively coupled plasma atomic emission spectrometry (ICP-AES). In vivo, human U87Δ glioma-bearing nude mice were administered with each BDS (35mg 10 B/kg) intravenously. We analyzed 10 B concentration of tumor, normal brain and blood by ICP-AES. The TF-PEG liposome-BSH showed higher absolute concentration more than the other BDS. Moreover, TF-PEG liposome-BSH decreased 10 B concentration in blood and normal tissue while it maintained high 10 B concentration in tumor tissue for a couple of days. This showed the TF-PEG liposome-BSH caused the selective delivery of high concentration of 10 B to malignant tumor tissue. The TF-PEG liposome-BSH is more potent BDS for BNCT to obtain absolute high 10 B concentration and good contrast between tumor and normal tissue than BSH and PEG liposome-BSH. (author)

  16. Comparative study of the radiobiological effects induced on adherent vs suspended cells by BNCT, neutrons and gamma rays treatments

    International Nuclear Information System (INIS)

    Cansolino, L.; Clerici, A.M.; Zonta, C.; Dionigi, P.; Mazzini, G.; Di Liberto, R.; Altieri, S.; Ballarini, F.; Bortolussi, S.; Carante, M.P.; Ferrari, M.; González, S.J.; Postuma, I.; Protti, N.; Santa Cruz, G.A.; Ferrari, C.

    2015-01-01

    The present work is part of a preclinical in vitro study to assess the efficacy of BNCT applied to liver or lung coloncarcinoma metastases and to limb osteosarcoma. Adherent growing cell lines can be irradiated as adherent to the culture flasks or as cell suspensions, differences in radio-sensitivity of the two modalities of radiation exposure have been investigated. Dose related cell survival and cell cycle perturbation results evidenced that the radiosensitivity of adherent cells is higher than that of the suspended ones.

  17. The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, T., E-mail: tetsu_tsukuba@yahoo.co.jp [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nakai, K. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo (Japan); Kumada, H.; Okumura, T.; Mizumoto, M.; Tsuboi, K. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Zaboronok, A.; Ishikawa, E.; Aiyama, H.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)

    2011-12-15

    The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m{sup 2}) for the treatment of newly diagnosed GBM. BPA uptake is determined by {sup 18}F-BPA-PET and/or {sup 11}C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.

  18. A study of computational dosimetry and boron biodistribution for ex – situ lung BNCT at RA-3 Reactor

    International Nuclear Information System (INIS)

    Garabalino, M.A.; Trivillin, V. A.; Monti Hughes, A.; Pozzi, E.C.C.; Thorp, S.; Curotto, P; Miller, M.; Santa Cruz, G.A.; Saint Martin, G.; Schwint, A.E.; González, S.J.; Farías, R.O; Portu, A.; Ferraris, S.; Santa María, J.; Lange, F.; Bortolussi, S.; Altieri, S.

    2013-01-01

    Within the context of the preclinical ex-situ BNCT Project for the treatment of diffuse lung metastases, we performed boron biodistribution studies in a sheep model and computational dosimetry studies in human lung to evaluate the potential therapeutic efficacy of the proposed technique. Herein we report preliminary data that supports the use of the sheep model as an adequate human surrogate in terms of boron kinetics and uptake in clinically relevant tissues. Furthermore, the estimation of the potential therapeutic efficacy of the proposed treatment in humans, based on boron uptake values in the large animal model, yields promising tumor control probability values even in the most conservative scenario considered. (author)

  19. FMIT: an accelerator-based neutron factory for fusion materials qualification

    International Nuclear Information System (INIS)

    Burke, R.J.; Hagan, J.W.; Trego, A.L.

    1983-01-01

    The Fusion Materials Irradiation Test Facility will provide a unique testing environment for irradiation of structural and special-purpose materials in support of fusion-power systems. The neutron source will be produced by a deuteron-lithium stripping reaction to generate high-energy neutrons to ensure materials damage characteristic of the deuterium-tritium power system. The facility, its testing role, the status, and major aspects of its design and supporting system development are described. Emphasis is given to programmatic elements and features incorporated in the accelerator and other systems to assure that the FMIT runs as a highly reliable fusion materials testing installation

  20. BARC-TIFR Pelletron Linac facility

    International Nuclear Information System (INIS)

    Gore, J.A.; Gupta, A.K.; Saxena, A.

    2017-01-01

    The Pelletron Accelerator, set up as a collaborative project between the Bhabha Atomic Research Centre and the Tata Institute of Fundamental Research, has been serving as the workhorse for the heavy ion accelerator based research in India since its commissioning in December 30, 1988. The facility was augmented with an indigenously developed superconducting Linac booster to enhance the energy of the Pelletron accelerated beams and was fully commissioned on November 28, 2007. The augmented facility is renamed as Pelletron Linac facility (PLF). While the PLF is predominantly utilized by the experimental users from BARC and TIFR, the users include researchers from other research institutions and universities within India and abroad

  1. On isocentre adjustment and quality control in linear accelerator based radiosurgery with circular collimators and room lasers

    Energy Technology Data Exchange (ETDEWEB)

    Treuer, H. [Department of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne (Germany). E-mail: h.treuer at uni-koeln.de; Hoevels, M.; Luyken, K.; Gierich, A.; Sturm, V. [Department of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne (Germany); Kocher, M.; Mueller, R.-P. [Department of Radiotherapy, University of Cologne, Cologne (Germany)

    2000-08-01

    We have developed a densitometric method for measuring the isocentric accuracy and the accuracy of marking the isocentre position for linear accelerator based radiosurgery with circular collimators and room lasers. Isocentric shots are used to determine the accuracy of marking the isocentre position with room lasers and star shots are used to determine the wobble of the gantry and table rotation movement, the effect of gantry sag, the stereotactic collimator alignment, and the minimal distance between gantry and table rotation axes. Since the method is based on densitometric measurements, beam spot stability is implicitly tested. The method developed is also suitable for quality assurance and has proved to be useful in optimizing isocentric accuracy. The method is simple to perform and only requires a film box and film scanner for instrumentation. Thus, the method has the potential to become widely available and may therefore be useful in standardizing the description of linear accelerator based radiosurgical systems. (author)

  2. On isocentre adjustment and quality control in linear accelerator based radiosurgery with circular collimators and room lasers

    International Nuclear Information System (INIS)

    Treuer, H.; Kocher, M.; Mueller, R.-P.

    2000-01-01

    We have developed a densitometric method for measuring the isocentric accuracy and the accuracy of marking the isocentre position for linear accelerator based radiosurgery with circular collimators and room lasers. Isocentric shots are used to determine the accuracy of marking the isocentre position with room lasers and star shots are used to determine the wobble of the gantry and table rotation movement, the effect of gantry sag, the stereotactic collimator alignment, and the minimal distance between gantry and table rotation axes. Since the method is based on densitometric measurements, beam spot stability is implicitly tested. The method developed is also suitable for quality assurance and has proved to be useful in optimizing isocentric accuracy. The method is simple to perform and only requires a film box and film scanner for instrumentation. Thus, the method has the potential to become widely available and may therefore be useful in standardizing the description of linear accelerator based radiosurgical systems. (author)

  3. Investigation of aluminised steel as a barrier to tritium using accelerator-based and hydrogen permeation techniques

    Energy Technology Data Exchange (ETDEWEB)

    Sokhi, R S; Forcey, K S; Ross, D K; Earwaker, L G [Birmingham Univ. (UK). School of Physics and Space Research

    1989-04-01

    Aluminised steel has been proposed as a barrier to tritium permeation in fusion reactors. The properties of these materials as tritium barriers have been studied using accelerator-based techniques and hydrogen permeation methods. The aluminide layers has been characterised by Rutherford backscattering spectroscopy (RBS) and nuclear reaction analysis (NRA) techniques using the 3 MV Dynamitron accelerator based at the School of Physics and Space Research Radiation Centre. The effectiveness of the aluminide layer as a tritium barrier has been measured directly by a conventional permeation apparatus over a range of temperatures. The effect of high temperatures on the structure of the aluminide layer has been examined. Any correlation between the composition of the layer and its effectiveness as a tritium barrier is also discussed. (orig.).

  4. Biodistribution of a new boron compound for BNCT in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Kreimann, Erica L.; Itoiz, Maria E.; Schwint, Amanda E.; Miura, M.; Coderre, J.A.; Garavaglia, Ricardo; Batistoni, Daniel A.

    2000-01-01

    We have proposed and validated the HCP carcinogenesis model of oral cancer, a model that mimics spontaneous malignant transformation, for BNCT research in a separate study. We herein perform a biodistribution study of a lipophilic carborane-containing tetraphenylporphyrin, CuTCPH, in this model. This compound was previously tested in a model of mice bearing subcutaneously transplanted mammary carcinomas. In the present study CuTCPH was administered as a single i.p. injection at a dose of 32 μg/g b.w. (10 μg B/g b.w.) or as 4 i.p. injections over 2 days at a dose of 32 μg/g b.w. per injection. Blood (Bl) and tissue, i.e. tumor (T), precancerous tissue surrounding tumor (P), normal pouch (N), skin, tongue, cheek and palate mucosa, liver, spleen, parotid gland and brain were sampled 3, 6, 12, 24, 48 and 72 hs post-administration in the single dose protocol and 1-4 days after the last injection in the multidose protocol. Boron (B) analysis was performed by ICP-AES. The maximum ratio of B concentration for the single dose protocol was 32.7:1 for T:N and 31.8:1 for T:Bl. The B value in tumor reached a maximum of 43.8 ppm. However, the mean value of 16 ± 14.3 ppm fell short of therapeutically useful levels. The multidose protocol yielded maximum ratios of 53.33:1 for T:N and 3633.3:1 for T:Bl. The maximum absolute B value in tumor reached 106.40 ppm. The mean value in tumor 3 days post-administration was 68.02 ± 25.02. Absolute and relative maximum and average B values markedly exceeded the therapeutic threshold values. (author)

  5. Functional and histological assessment of the radiobiology of normal rat lung in BNCT

    International Nuclear Information System (INIS)

    Kiger, J.L.; Riley, K.J.; Binns, P.J.; Harling, O.K.; Coderre, J.A.; Kiger, W.S. III; Patel, H.

    2006-01-01

    This study investigated the radiobiology and sensitivity of the normal rat lung to Boron Neutron Capture Therapy (BNCT) radiation. Rat thorax irradiations were carried out with x-rays or with neutrons in the presence or absence of p-boronophenylalanine (BPA). Lung damage were assessed functionally with breathing rate measurement up to 180 days after irradiation and then histologically. Breathing rates 20% (∼3 σ) above the control group (sham-irradiated rats) mean were considered as positive responses to lung radiation damage. Though most responding animals demonstrated radiation induced pneumonitis (≤110 days) as well as pulmonary fibrosis (>110 days), some animals receiving neutrons plus BPA showed only the latter. The breathing rate dose response data were fit using probit analysis. The ED 50 values measured for x-rays, neutron beam only, and neutrons plus BPA were 11.5±0.4 Gy, 9.2±0.5 Gy, and 6.7±0.4 Gy, respectively. The biological weighting factors for the neutron beam (n+γ), the thermal neutron dose component, and the 10 B dose component were determined to be 1.2±0.1, 2.2±0.4, and 2.3±0.3, respectively. The histological dose response curves were linear. Consistent with the functional assay, the weighting factors measured histologically were 1.2±0.1 for the thermal neutron beam and 1.9±0.2 for the 10 B dose component. (author)

  6. Linear accelerator-based intensity-modulated total marrow irradiation technique for treatment of hematologic malignancies: a dosimetric feasibility study.

    Science.gov (United States)

    Yeginer, Mete; Roeske, John C; Radosevich, James A; Aydogan, Bulent

    2011-03-15

    To investigate the dosimetric feasibility of linear accelerator-based intensity-modulated total marrow irradiation (IM-TMI) in patients with hematologic malignancies. Linear accelerator-based IM-TMI treatment planning was performed for 9 patients using the Eclipse treatment planning system. The planning target volume (PTV) consisted of all the bones in the body from the head to the mid-femur, except for the forearms and hands. Organs at risk (OAR) to be spared included the lungs, heart, liver, kidneys, brain, eyes, oral cavity, and bowel and were contoured by a physician on the axial computed tomography images. The three-isocenter technique previously developed by our group was used for treatment planning. We developed and used a common dose-volume objective method to reduce the planning time and planner subjectivity in the treatment planning process. A 95% PTV coverage with the 99% of the prescribed dose of 12 Gy was achieved for all nine patients. The average dose reduction in OAR ranged from 19% for the lungs to 68% for the lenses. The common dose-volume objective method decreased the planning time by an average of 35% and reduced the inter- and intra- planner subjectivity. The results from the present study suggest that the linear accelerator-based IM-TMI technique is clinically feasible. We have demonstrated that linear accelerator-based IM-TMI plans with good PTV coverage and improved OAR sparing can be obtained within a clinically reasonable time using the common dose-volume objective method proposed in the present study. Copyright © 2011. Published by Elsevier Inc.

  7. Accelerator-based Single-shot Ultrafast Transmission Electron Microscope with Picosecond Temporal Resolution and Nanometer Spatial Resolution

    OpenAIRE

    Xiang, D.; Fu, F.; Zhang, J.; Huang, X.; Wang, L.; Wang, X.; Wan, W.

    2014-01-01

    We present feasibility study of an accelerator-based ultrafast transmission electron microscope (u-TEM) capable of producing a full field image in a single-shot with simultaneous picosecond temporal resolution and nanometer spatial resolution. We study key physics related to performance of u-TEMs, and discuss major challenges as well as possible solutions for practical realization of u-TEMs. The feasibility of u-TEMs is confirmed through simulations using realistic electron beam parameters. W...

  8. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Brandao, Samia de Freitas, E-mail: samiabrandao@gmail.com [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil). Departamento de Engenharia Nuclear; Campos, Tarcisio Passos Ribeiro de [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil)

    2013-06-15

    Objective: comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and methods: simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results: intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h{sup -1}.p{sup -1}.s, respectively, on the healthy tissue, on the balloon periphery and on the /{sub 1} and /{sub 2} tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h{sup -1}.p{sup -1}.s, respectively on the healthy tissue, on the target tumor and on the /{sub 1} and /{sub 2} infiltration zones. Conclusion: Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones. (author)

  9. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    Directory of Open Access Journals (Sweden)

    Samia de Freitas Brandao

    2013-07-01

    Full Text Available Objective Comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and Methods Simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results Intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h-1.p-1.s, respectively, on the healthy tissue, on the balloon periphery and on the I 1 and I 2 tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h-1.p-1.s, respectively on the healthy tissue, on the target tumor and on the I 1 and I 2 infiltration zones. Conclusion Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones.

  10. Artificial neural networks to evaluate the boron concentration decreasing profile in Blood-BPA samples of BNCT patients

    Energy Technology Data Exchange (ETDEWEB)

    Garcia-Reiriz, Alejandro, E-mail: garciareiriz@gmail.com [Department of Analytical Chemistry, Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Rosario Institute of Chemistry (IQUIR-CONICET), Suipacha 531, Rosario S2002LRK (Argentina); Magallanes, Jorge [Comision Nacional de Energia Atomica, Av. Gral. Paz 1499, San Martin, B1650KNA, Buenos Aires (Argentina); Zupan, Jure [National Institute of Chemistry, Hajdrihova 19, SLO-1000 Ljubljana, Eslovenia (Slovenia); Liberman, Sara [Comision Nacional de Energia Atomica, Av. Gral. Paz 1499, San Martin, B1650KNA, Buenos Aires (Argentina)

    2011-12-15

    For the prediction of decay concentration profiles of the p-boronophenylalanine (BPA) in blood during BNCT treatment, a method is suggested based on Kohonen neural networks. The results of a model trained with the concentration profiles from the literature are described. The prediction of the model was validated by the leave-one-out method. Its robustness shows that it is mostly independent on small variations. The ability to fit retrospective experimental data shows an uncertainty lower than the two compartment model used previously. - Highlights: Black-Right-Pointing-Pointer We predicted decaying concentration profiles of BPA in blood during BNCT therapy. Black-Right-Pointing-Pointer Is suggested a method based on Kohonen neural networks. Black-Right-Pointing-Pointer The results show that it is very robust and mostly independent of small variations. Black-Right-Pointing-Pointer It has a better ability to fit retrospective experimental data. Black-Right-Pointing-Pointer The model could be progressively improved by adding new data to the training matrix.

  11. Optimization of Neutron Spectrum in Northwest Beam Tube of Tehran Research Reactor for BNCT, by MCNP Code

    Energy Technology Data Exchange (ETDEWEB)

    Zamani, M. [National Radiation Protection Department - NRPD, Atomic Energy Organization of Iran - AEOI, Tehran (Iran, Islamic Republic of); End of North Kargar st, Atomic Energy Organization of Iran, P.O. Box: 14155-1339, Tehran (Iran, Islamic Republic of); Kasesaz, Y.; Khalafi, H.; Shayesteh, M. [Radiation Application School, Nuclear Science and Technology Research Institute, AEOI, Tehran (Iran, Islamic Republic of)

    2015-07-01

    In order to gain the neutron spectrum with proper components specification for BNCT, it is necessary to design a Beam Shape Assembling (BSA), include of moderator, collimator, reflector, gamma filter and thermal neutrons filter, in front of the initial radiation beam from the source. According to the result of MCNP4C simulation, the Northwest beam tube has the most optimized neuron flux between three north beam tubes of Tehran Research Reactor (TRR). So, it has been chosen for this purpose. Simulation of the BSA has been done in four above mentioned phases. In each stage, ten best configurations of materials with different length and width were selected as the candidates for the next stage. The last BSA configuration includes of: 78 centimeters of air as an empty space, 40 centimeters of Iron plus 52 centimeters of heavy-water as moderator, 30 centimeters of water or 90 centimeters of Aluminum-Oxide as a reflector, 1 millimeters of lithium (Li) as thermal neutrons filter and finally 3 millimeters of Bismuth (Bi) as a filter of gamma radiation. The result of Calculations shows that if we use this BSA configuration for TRR Northwest beam tube, then the best neutron flux and spectrum will be achieved for BNCT. (authors)

  12. Optimization of Neutron Spectrum in Northwest Beam Tube of Tehran Research Reactor for BNCT, by MCNP Code

    International Nuclear Information System (INIS)

    Zamani, M.; Kasesaz, Y.; Khalafi, H.; Shayesteh, M.

    2015-01-01

    In order to gain the neutron spectrum with proper components specification for BNCT, it is necessary to design a Beam Shape Assembling (BSA), include of moderator, collimator, reflector, gamma filter and thermal neutrons filter, in front of the initial radiation beam from the source. According to the result of MCNP4C simulation, the Northwest beam tube has the most optimized neuron flux between three north beam tubes of Tehran Research Reactor (TRR). So, it has been chosen for this purpose. Simulation of the BSA has been done in four above mentioned phases. In each stage, ten best configurations of materials with different length and width were selected as the candidates for the next stage. The last BSA configuration includes of: 78 centimeters of air as an empty space, 40 centimeters of Iron plus 52 centimeters of heavy-water as moderator, 30 centimeters of water or 90 centimeters of Aluminum-Oxide as a reflector, 1 millimeters of lithium (Li) as thermal neutrons filter and finally 3 millimeters of Bismuth (Bi) as a filter of gamma radiation. The result of Calculations shows that if we use this BSA configuration for TRR Northwest beam tube, then the best neutron flux and spectrum will be achieved for BNCT. (authors)

  13. Stability of high-speed lithium sheet jets for the neutron source in Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Nakagawa, Masamichi; Takahashi, Minoru; Aritomi, Masanori; Kobayashi, Toru

    2014-01-01

    The stability of high-speed liquid lithium sheet jets was analytically studied for the neutron source in Boron Neutron Capture Therapy (BNCT), which makes cancers and tumors curable with cell-level selections and hence high QOL. The object of our research is to realize the thin and high-speed plane sheet jets of liquid lithium in a high-vacuum as an accelerator target. Linear analysis approach is made to the stability on thin plane sheet jets of liquid lithium in a high-vacuum, and then our analytical results were compared with the previous experimental ones. We proved that the waves of surface tension on thin lithium sheet jets in a high-vacuum are of supercritical flows and neutral stable under about 17.4 m/s in flow velocity and that the fast non-dispersive anti-symmetric waves are more significant than the very slow dispersive symmetric waves. We also formulated the equation of shrinking angle in isosceles-triangularly or isosceles-trapezoidal shrinking sheet jets corresponding to the Mach angle of supersonic gas flows. This formula states universally the physical meaning of Weber number of sheet jets on the wave of surface tension in supercritical flows. We obtained satisfactory prospects (making choice of larger flow velocity U and larger thickness of sheet a) to materialize a liquid target of accelerator in BNCT. (author)

  14. Meeting the challenge of homogenous boron targeting of heterogeneous tumors for effective boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Heber, Elisa M.; Trivillin, Veronica A.; Itoiz, Maria E.; Rebagliati, J. Raul; Batistoni, Daniel; Kreimann, Erica L.; Schwint, Amanda E.; Nigg, David W.; Gonzalez, Beatriz N.

    2006-01-01

    BNCT is a tumor cell targeted radiation therapy. Inadequately boron targeted tumor populations jeopardize tumor control. Meeting the to date unresolved challenge of homogeneous targeting of heterogeneous tumors with effective boron carriers would contribute to therapeutic efficacy. The aim of the present study was to evaluate the degree of variation in boron content delivered by boronophenylalanine (BPA), GB-10 (Na 2 10 B 10 H 10 ) and the combined administration of (BPA+GB-10) in different portions of tumor, precancerous tissue around tumor and normal pouch tissue in the hamster cheek pouch oral cancer model. Boron content was evaluated by ICP-AES. The degree of homogeneity in boron targeting was assessed in terms of the coefficient of variation ([S.D./Mean]x100) of boron values. Statistical analysis of the results was performed by one-way ANOVA and the least significant difference test. GB-10 and GB-10 plus BPA achieved respectively a statistically significant 1.8-fold and 3.3-fold increase in targeting homogeneity over BPA. The combined boron compound administration protocol contributes to homogeneous targeting of heterogeneous tumors and would increase therapeutic efficacy of BNCT by exposing all tumor populations to neutron capture reactions in boron. (author)

  15. Boron neutron capture therapy (BNCT). Recent aspect, a change from thermal neutron to epithermal neutron beam and a new protocol

    International Nuclear Information System (INIS)

    Nakagawa, Yoshinobu

    1999-01-01

    Since 1968, One-hundred seventy three patients with glioblastoma (n=81), anaplastic astrocytoma (n=44), low grade astrocytoma (n=16) or other types of tumor (n=32) were treated by boron-neutron capture therapy (BNCT) using a combination of thermal neutron and BSH in 5 reactors (HTR n=13, JRR-3 n=1, MuITR n=98, KUR n=28, JRR-2 n=33). Out of 101 patients with glioma treated by BNCT under the recent protocol, 33 (10 glioblastoma, 14 anaplastic astrocytoma, 9 low grade astrocytoma) patients lived or have lived longer than 3 years. Nine of these 33 lived or have lived longer than 10 years. According to the retrospective analysis, the important factors related to the clinical results were tumor dose radiation dose and maximum radiation dose in thermal brain cortex. The result was not satisfied as it was expected. Then, we decided to introduce mixed beams which contain thermal neutron and epithermal neutron beams. KUR was reconstructed in 1996 and developed to be available to use mixed beams. Following the shutdown of the JRR-2, JRR-4 was renewed for medical use in 1998. Both reactors have capacity to yield thermal neutron beam, epithermal neutron beam and mixed beams. The development of the neutron source lead us to make a new protocol. (author)

  16. Biodistribution study with combined administration of BPA and BSH for BNCT in the hamster cheek pouch oral cancer model

    International Nuclear Information System (INIS)

    Garabalino, M A; Heber, E M; Monti Hughes, A; Pzzi, E C C; Molinari, A J; Niggg, D W; Bauer, W; Trivillin, V A; Schwint, A E

    2012-01-01

    We previously proved the therapeutic potential of the chemically non-selective boron compound decahydrodecaborate (GB-10) as a stand-alone boron carrier for BNCT in the hamster cheek pouch oral cancer model with no toxic effects in normal or precancerous tissue. Although GB-10 is not taken up selectively by oral tumor tissue, selective tumor lethality would result from selective aberrant tumor blood vessel damage. Furthermore, BNCT efficacy was enhanced when GB-10 and boronophenylalanine (BPA) were administered jointly. The fact that sodium mercaptoundecahydro-closo-dodecaborate (BSH) is being investigated clinically as a stand-alone boron agent for BNCT of brain tumors and in combination with BPA for recurrent head and neck malignancies makes it a particularly interesting boron compound to explore. Based on the working hypothesis that BSH would conceivably behave similarly to GB-10 in oral cancer, we previously performed biodistribution studies with BSH alone in the hamster cheek pouch oral cancer model. The aim of the present study was to perform biodistribution studies of BSH + BPA administered jointly in the hamster cheek pouch oral cancer model as a starting point to contribute to the knowledge of (BSH+BPA)-BNCT radiobiology and optimize therapeutic efficacy. The right cheek pouch of Syrian hamsters was subjected to topical administration of a carcinogen twice a week for 12 weeks. Once the exophytic tumors, i.e. squamous cell carcinomas, had developed, the animals were used for biodistribution studies with BSH + BPA. Three administration protocols with different proportions of each of the compounds were assessed: 1. BSH, 50 mg 10 B/kg, iv + BPA, 15.5 mg 10 B/kg, ip; 2. BSH, 34.5 mg 10 B/kg, iv + BPA, 31 mg 10 B/kg, ip; 3. BSH, 20 mg 10 B/kg, iv + BPA, 46.5 mg 10 B/kg, ip. Groups of animals were euthanized 4 h after the administration of BSH and 3 h after the administration of BPA. Samples of blood, tumor, precancerous and normal pouch and other tissues with

  17. Rhodium self-powered neutron detector as a suitable on-line thermal neutron flux monitor in BNCT treatments.

    Science.gov (United States)

    Miller, Marcelo E; Sztejnberg, Manuel L; González, Sara J; Thorp, Silvia I; Longhino, Juan M; Estryk, Guillermo

    2011-12-01

    A rhodium self-powered neutron detector (Rh SPND) has been specifically developed by the Comisión Nacional de Energía Atómica (CNEA) of Argentina to measure locally and in real time thermal neutron fluxes in patients treated with boron neutron capture therapy (BNCT). In this work, the thermal and epithermal neutron response of the Rh SPND was evaluated by studying the detector response to two different reactor spectra. In addition, during clinical trials of the BNCT Project of the CNEA, on-line neutron flux measurements using the specially designed detector were assessed. The first calibration of the detector was done with the well-thermalized neutron spectrum of the CNEA RA-3 reactor thermal column. For this purpose, the reactor spectrum was approximated by a Maxwell-Boltzmann distribution in the thermal energy range. The second calibration was done at different positions along the central axis of a water-filled cylindrical phantom, placed in the mixed thermal-epithermal neutron beam of CNEA RA-6 reactor. In this latter case, the RA-6 neutron spectrum had been well characterized by both calculation and measurement, and it presented some marked differences with the ideal spectrum considered for SPND calibrations at RA-3. In addition, the RA-6 neutron spectrum varied with depth in the water phantom and thus the percentage of the epithermal contribution to the total neutron flux changed at each measurement location. Local (one point-position) and global (several points-positions) and thermal and mixed-field thermal neutron sensitivities were determined from these measurements. Thermal neutron flux was also measured during BNCT clinical trials within the irradiation fields incident on the patients. In order to achieve this, the detector was placed on patient's skin at dosimetric reference points for each one of the fields. System stability was adequate for this kind of measurement. Local mixed-field thermal neutron sensitivities and global thermal and mixed

  18. Rhodium self-powered neutron detector as a suitable on-line thermal neutron flux monitor in BNCT treatments

    Energy Technology Data Exchange (ETDEWEB)

    Miller, Marcelo E.; Sztejnberg, Manuel L.; Gonzalez, Sara J.; Thorp, Silvia I.; Longhino, Juan M.; Estryk, Guillermo [Comision Nacional de Energia Atomica, Av. del Libertador 8250, Ciudad de Buenos Aires 1429 (Argentina); Comision Nacional de Energia Atomica, Av. del Libertador 8250, Ciudad de Buenos Aires 1429, Argentina and CONICET, Av. Rivadavia 1917, Ciudad de Buenos Aires 1033 (Argentina); Comision Nacional de Energia Atomica, Av. del Libertador 8250, Ciudad de Buenos Aires 1429 (Argentina)

    2011-12-15

    Purpose: A rhodium self-powered neutron detector (Rh SPND) has been specifically developed by the Comision Nacional de Energia Atomica (CNEA) of Argentina to measure locally and in real time thermal neutron fluxes in patients treated with boron neutron capture therapy (BNCT). In this work, the thermal and epithermal neutron response of the Rh SPND was evaluated by studying the detector response to two different reactor spectra. In addition, during clinical trials of the BNCT Project of the CNEA, on-line neutron flux measurements using the specially designed detector were assessed. Methods: The first calibration of the detector was done with the well-thermalized neutron spectrum of the CNEA RA-3 reactor thermal column. For this purpose, the reactor spectrum was approximated by a Maxwell-Boltzmann distribution in the thermal energy range. The second calibration was done at different positions along the central axis of a water-filled cylindrical phantom, placed in the mixed thermal-epithermal neutron beam of CNEA RA-6 reactor. In this latter case, the RA-6 neutron spectrum had been well characterized by both calculation and measurement, and it presented some marked differences with the ideal spectrum considered for SPND calibrations at RA-3. In addition, the RA-6 neutron spectrum varied with depth in the water phantom and thus the percentage of the epithermal contribution to the total neutron flux changed at each measurement location. Local (one point-position) and global (several points-positions) and thermal and mixed-field thermal neutron sensitivities were determined from these measurements. Thermal neutron flux was also measured during BNCT clinical trials within the irradiation fields incident on the patients. In order to achieve this, the detector was placed on patient's skin at dosimetric reference points for each one of the fields. System stability was adequate for this kind of measurement. Results: Local mixed-field thermal neutron sensitivities and

  19. Rhodium self-powered neutron detector as a suitable on-line thermal neutron flux monitor in BNCT treatments

    International Nuclear Information System (INIS)

    Miller, Marcelo E.; Sztejnberg, Manuel L.; Gonzalez, Sara J.; Thorp, Silvia I.; Longhino, Juan M.; Estryk, Guillermo

    2011-01-01

    Purpose: A rhodium self-powered neutron detector (Rh SPND) has been specifically developed by the Comision Nacional de Energia Atomica (CNEA) of Argentina to measure locally and in real time thermal neutron fluxes in patients treated with boron neutron capture therapy (BNCT). In this work, the thermal and epithermal neutron response of the Rh SPND was evaluated by studying the detector response to two different reactor spectra. In addition, during clinical trials of the BNCT Project of the CNEA, on-line neutron flux measurements using the specially designed detector were assessed. Methods: The first calibration of the detector was done with the well-thermalized neutron spectrum of the CNEA RA-3 reactor thermal column. For this purpose, the reactor spectrum was approximated by a Maxwell-Boltzmann distribution in the thermal energy range. The second calibration was done at different positions along the central axis of a water-filled cylindrical phantom, placed in the mixed thermal-epithermal neutron beam of CNEA RA-6 reactor. In this latter case, the RA-6 neutron spectrum had been well characterized by both calculation and measurement, and it presented some marked differences with the ideal spectrum considered for SPND calibrations at RA-3. In addition, the RA-6 neutron spectrum varied with depth in the water phantom and thus the percentage of the epithermal contribution to the total neutron flux changed at each measurement location. Local (one point-position) and global (several points-positions) and thermal and mixed-field thermal neutron sensitivities were determined from these measurements. Thermal neutron flux was also measured during BNCT clinical trials within the irradiation fields incident on the patients. In order to achieve this, the detector was placed on patient's skin at dosimetric reference points for each one of the fields. System stability was adequate for this kind of measurement. Results: Local mixed-field thermal neutron sensitivities and global

  20. Reliability Considerations for the Operation of Large Accelerator User Facilities

    CERN Document Server

    Willeke, F.J.

    2016-01-01

    The lecture provides an overview of considerations relevant for achieving highly reliable operation of accelerator based user facilities. The article starts with an overview of statistical reliability formalism which is followed by high reliability design considerations with examples. The article closes with operational aspects of high reliability such as preventive maintenance and spares inventory.

  1. Impact of accelerator-based analytical techniques on the knowledge and conservation of cultural heritage

    International Nuclear Information System (INIS)

    Dran, Jean Claude

    2001-01-01

    A large set of modern analytical techniques is currently applied to get a better insight on art and archaeological objects as well as to contribute to their conservation and restoration. Because of the precious and sometimes unique character of the works, non-destructive techniques and even those requiring no (or only minute) sampling, are preferred. From this standpoint, ion beam analysis (IBA) constitutes one of the best choices, since it combines quite good analytical performance and non-destructiveness. For over 10 years, an IBA facility has been installed in the Research Laboratory of the Museums of France. Until now it is the only facility of this kind entirely devoted to the study of cultural heritage. A special set-up, namely an external beam line, has been developed which permits the in-air analysis of large or fragile works of art without sampling. This facility is used for both short investigations at the request of museum curators and extensive research works in art history and archaeology. Numerous examples will be given to highlight the impact of this tool on cultural heritage. (author)

  2. Microwave digestion techniques applied to determination of boron by ICP-AES in BNCT program; Digestion de matrices biologicas asistida por microondas para el analisis espectrometrico de boro en BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Farias, Silvia S; Di Santo, Norberto R; Garavaglia, Ricardo N; Pucci, Gladys N; Batistoni, Daniel A [Comision Nacional de Energia Atomica, General San Martin (Argentina). Dept. de Quimica; Schwint, Amanda E [Comision Nacional de Energia Atomica, General San Martin (Argentina). Dept. de Radiobiologia

    1999-07-01

    Recently, boron neutron capture therapy (BNCT) has merged as an interesting option for the treatment of some kind of tumors where established therapies show no success. A molecular boronated species, enriched in {sup 10}B is administrated to the subject; it localizes in malignant tissues depending the kind of tumor and localization. Therefore, a very important fact in BNCT research is the detection of boron at trace or ultra trace levels precisely and accurately. This is extremely necessary as boronated species do localize in tumoral tissue and also localize in liver, kidney, spleen, skin, membranes. By this way, before testing a boronated species, it is mandatory to determine its biodistribution in a statistically meaning population, that is related with managing of a great number of samples. In the other hand, it is necessary to exactly predict when to begin the irradiation and to determine the magnitude of radiation to obtain the desired radiological dose for a specified mean boron concentration. This involves the determination of boron in whole blood, which is related with boron concentration in the tumor object of treatment. The methodology selected for the analysis of boron in whole blood and tissues must join certain characteristics: it must not be dependant of the chemical form of boron, it has to be fast and capable to determine boron accurately and precisely in a wide range of concentrations. The design and validation of experimental models involving animals in BNCT studies and the determination of boron in blood of animals and subjects upon treatment require reliable analytical procedures to determine boron quantitatively in those biologic materials. Inductively coupled plasma-atomic emission spectrometry (ICP-AES) using pneumatic nebulization is one of the most promising methods for boron analysis, but the sample must be liquid and have low solid concentration. In our case, biological tissues and blood, it is mandatory to mineralize and/or dilute

  3. Accelerator based production of fissile nuclides, threshold uranium price and perspectives

    International Nuclear Information System (INIS)

    Djordjevic, D.; Knapp, V.

    1988-01-01

    Accelerator breeder system characteristics are considered in this work. One such system which produces fissile nuclides can supply several thermal reactors with fissile fuel, so this system becomes analogous to an uranium enrichment facility with difference that fissile nuclides are produced by conversion of U-238 rather than by separation from natural uranium. This concept, with other long-term perspective for fission technology on the basis of development only one simpler technology. The influence of basic system characteristics on threshold uranium price is examined. Conditions for economically acceptable production are established. (author)

  4. Report of the workshop on accelerator-based atomic and molecular science

    International Nuclear Information System (INIS)

    Meyerhof, W.E.

    1981-01-01

    This Workshop, held in New London, NH on July 27-30, 1980, had a registration of 43, representing an estimated one-third of all principal investigators in the United States in this research subfield. The workshop was organized into 5 working groups for the purpose of (1) identifying some vital physics problems which experimental and theoretical atomic and molecular science can address with current and projected techniques; (2) establishing facilities and equipment needs required to realize solutions to these problems; (3) formulating suggestions for a coherent national policy concerning this discipline; (4) assessing and projecting the manpower situation; and (5) evaluating the relations of this interdisciplinary science to other fields. Recommedations deal with equipment and operating costs for small accelerator laboratories, especially at universities; instrumentation of ion beam lines dedicated to atomic and molecular science at some large accelerators; development of low-velocity, high charge-state ion sources; synchrotron light sources; improvement or replacement of tandem van de Graaff accelerators; high-energy beam lines for atomic physics; the needs for postdoctoral support in this subfield; new accelerator development; need for representatives from atomic and molecular science on program committees for large national accelerator facilities; and the contributions the field can make to applied physics problems

  5. First evaluation of the biologic effectiveness factors of boron neutron capture therapy (BNCT) in a human colon carcinoma cell line.

    Science.gov (United States)

    Dagrosa, Maria Alejandra; Crivello, Martín; Perona, Marina; Thorp, Silvia; Santa Cruz, Gustavo Alberto; Pozzi, Emiliano; Casal, Mariana; Thomasz, Lisa; Cabrini, Romulo; Kahl, Steven; Juvenal, Guillermo Juan; Pisarev, Mario Alberto

    2011-01-01

    DNA lesions produced by boron neutron capture therapy (BNCT) and those produced by gamma radiation in a colon carcinoma cell line were analyzed. We have also derived the relative biologic effectiveness factor (RBE) of the neutron beam of the RA-3- Argentine nuclear reactor, and the compound biologic effectiveness (CBE) values for p-boronophenylalanine ((10)BPA) and for 2,4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ((10)BOPP). Exponentially growing human colon carcinoma cells (ARO81-1) were distributed into the following groups: (1) BPA (10 ppm (10)B) + neutrons, (2) BOPP (10 ppm (10)B) + neutrons, (3) neutrons alone, and (4) gamma rays ((60)Co source at 1 Gy/min dose-rate). Different irradiation times were used to obtain total absorbed doses between 0.3 and 5 Gy (±10%) (thermal neutrons flux = 7.5 10(9) n/cm(2) sec). The frequency of micronucleated binucleated cells and the number of micronuclei per micronucleated binucleated cells showed a dose-dependent increase until approximately 2 Gy. The response to gamma rays was significantly lower than the response to the other treatments (p irradiations with neutrons alone and neutrons + BOPP showed curves that did not differ significantly from, and showed less DNA damage than, irradiation with neutrons + BPA. A decrease in the surviving fraction measured by 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromide (MTT) assay as a function of the absorbed dose was observed for all the treatments. The RBE and CBE factors calculated from cytokinesis block micronucleus (CBMN) and MTT assays were, respectively, the following: beam RBE: 4.4 ± 1.1 and 2.4 ± 0.6; CBE for BOPP: 8.0 ± 2.2 and 2.0 ± 1; CBE for BPA: 19.6 ± 3.7 and 3.5 ± 1.3. BNCT and gamma irradiations showed different genotoxic patterns. To our knowledge, these values represent the first experimental ones obtained for the RA-3 in a biologic model and could be useful for future experimental studies for the application of BNCT to colon carcinoma

  6. Deuteron nuclear data for the design of accelerator-based neutron sources: Measurement, model analysis, evaluation, and application

    Science.gov (United States)

    Watanabe, Yukinobu; Kin, Tadahiro; Araki, Shouhei; Nakayama, Shinsuke; Iwamoto, Osamu

    2017-09-01

    A comprehensive research program on deuteron nuclear data motivated by development of accelerator-based neutron sources is being executed. It is composed of measurements of neutron and gamma-ray yields and production cross sections, modelling of deuteron-induced reactions and code development, nuclear data evaluation and benchmark test, and its application to medical radioisotopes production. The goal of this program is to develop a state-of-the-art deuteron nuclear data library up to 200 MeV which will be useful for the design of future (d,xn) neutron sources. The current status and future plan are reviewed.

  7. Accelerator-based single-shot ultrafast transmission electron microscope with picosecond temporal resolution and nanometer spatial resolution

    Science.gov (United States)

    Xiang, D.; Fu, F.; Zhang, J.; Huang, X.; Wang, L.; Wang, X.; Wan, W.

    2014-09-01

    We present feasibility study of an accelerator-based ultrafast transmission electron microscope (u-TEM) capable of producing a full field image in a single-shot with simultaneous picosecond temporal resolution and nanometer spatial resolution. We study key physics related to performance of u-TEMs and discuss major challenges as well as possible solutions for practical realization of u-TEMs. The feasibility of u-TEMs is confirmed through simulations using realistic electron beam parameters. We anticipate that u-TEMs with a product of temporal and spatial resolution beyond 10-19 ms will open up new opportunities in probing matter at ultrafast temporal and ultrasmall spatial scales.

  8. Depth-dose evaluation for lung and pancreas cancer treatment by BNCT using an epithermal neutron beam

    International Nuclear Information System (INIS)

    Matsumoto, Tetsuo; Fukushima, Yuji

    2000-01-01

    The depth-dose distributions were evaluated for possible treatment of both lung and pancreas cancers using an epithermal neutron beam. The MCNP calculations showed that physical dose in tumors were 6 and 7 Gy/h, respectively, for lung and pancreas, attaining an epithermal neutron flux of 5x10 8 ncm -2 s -1 . The boron concentrations were assumed at 100 ppm and 30 ppm, respectively, for lung and pancreas tumors and normal tissues contains 1/10 tumor concentrations. The dose ratios of tumor to normal tissue were 2.5 and 2.4, respectively, for lung and pancreas. The dose evaluation suggests that BNCT could be applied for both lung and pancreas cancer treatment. (author)

  9. BNCT of intracerebral melanoma. Enhanced survival and cure following Cereport mediated opening of the blood-brain barrier

    International Nuclear Information System (INIS)

    Barth, R.F.; Yang, W.; Bartus, R.T.; Rotaru, J.H.; Ferketich, A.K.; Moeschberger, M.L.; Nawrocky, M.M.; Coderre, J.A.

    2000-01-01

    Cereport is a bradykinin analogue that produces a transient, pharmacologically mediated opening of the blood-brain barrier (BBB). The present study was designed to determine if Cereport could enhance the delivery of BPA and the efficacy of BNCT in nude rats bearing intracerebral implants of the human MRA 27 melanoma. Animals that received intracarotid (i.c.) injection of Cereport and i.c. BPA had a mean survival time of 115 d compared to 82 d without Cereport, 42 d for i.v. BPA with Cereport and 31 d for irradiated controls. The combination of i.c. Cereport and BPA produced a 400% increase in the life span with 35% long-term survivors (>180 d). (author)

  10. RTNS-II fusion materials irradiation facility

    International Nuclear Information System (INIS)

    Heikkinen, D.W.; Tuckerman, D.B.; Davis, J.C.; Massoletti, D.J.; Short, D.W.

    1986-01-01

    The Rotating Target Neutron Source (RTNS-II) facility provides an intense source of 14-MeV neutrons for the fusion energy programs of Japan and the United States. Each of the two identical accelerator-based neutron sources is capable of providing source strengths in excess of 3 x 10 13 n/s using deuteron beam currents up to 150 mA. The present status of the facility, as well as the various upgrade options, will be described in detail

  11. John Adams Lecture | Accelerator-Based Neutrino Physics: Past, Present and Future by Kenneth Long | 8 December

    CERN Multimedia

    2014-01-01

    John Adams Lecture: Accelerator-Based Neutrino Physics: Past, Present and Future by Dr. Kenneth Long (Imperial College London & STFC).   Monday, 8 December 2014 from 2 p.m. to 4 p.m. at CERN ( 503-1-001 - Council Chamber ) Abstract: The study of the neutrino is the study of physics beyond the Standard Model. We now know that the neutrinos have mass and that neutrino mixing occurs causing neutrino flavour to oscillate as neutrinos propagate through space and time. Further, some measurements can be interpreted as hints for new particles known as sterile neutrinos. The measured values of the mixing parameters make it possible that the matter-antimatter (CP) symmetry may be violated through the mixing process. The consequences of observing CP-invariance violation in neutrinos would be profound. To discover CP-invariance violation will require measurements of exquisite precision. Accelerator-based neutrino sources are central to the future programme and advances in technique are required ...

  12. Measurement of the 33S(n,α) cross-section at n_TOF(CERN): Applications to BNCT

    Science.gov (United States)

    Sabaté-Gilarte, Marta; Praena, Javier; Porras, Ignacio; Quesada, José Manuel; Mastinu, Pierfrancesco

    2016-01-01

    Aim The main purpose of this work is to present a new (n,α) cross-section measurement for a stable isotope of sulfur, 33S, in order to solve existing discrepancies. Background 33S has been studied as a cooperating target for Boron Neutron Capture Therapy (BNCT) because of its large (n,α) cross-section in the epithermal neutron energy range, the most suitable one for BNCT. Although the most important evaluated databases, such as ENDF, do not show any resonances in the cross-section, experimental measurements which provided data from 10 keV to 1 MeV showed that the lowest-lying and strongest resonance of 33S(n,α) cross-section occurs at 13.5 keV. Nevertheless, the set of resonance parameters that describe such resonance shows important discrepancies (more than a factor of 2) between them. Materials and methods A new measurement of the 33S(n,α)30Si reaction cross-section was proposed to the ISOLDE and Neutron Time-of-Flight Experiments Committee of CERN. It was performed at n_TOF(CERN) in 2012 using MicroMegas detectors. Results In this work, we will present a brief overview of the experiment as well as preliminary results of the data analysis in the neutron energy range from thermal to 100 keV. These results will be taken into account to calculate the kerma-fluence factors corresponding to 33S in addition to 10B and those of a standard four-component ICRU tissue. Conclusions MCNP simulations of the deposited dose, including our experimental data, shows an important kerma rate enhancement at the surface of the tissue, mainly due to the presence of 33S. PMID:26933393

  13. Measurement of the (33)S(n,α) cross-section at n_TOF(CERN): Applications to BNCT.

    Science.gov (United States)

    Sabaté-Gilarte, Marta; Praena, Javier; Porras, Ignacio; Quesada, José Manuel; Mastinu, Pierfrancesco

    2016-01-01

    The main purpose of this work is to present a new (n,α) cross-section measurement for a stable isotope of sulfur, (33)S, in order to solve existing discrepancies. (33)S has been studied as a cooperating target for Boron Neutron Capture Therapy (BNCT) because of its large (n,α) cross-section in the epithermal neutron energy range, the most suitable one for BNCT. Although the most important evaluated databases, such as ENDF, do not show any resonances in the cross-section, experimental measurements which provided data from 10 keV to 1 MeV showed that the lowest-lying and strongest resonance of (33)S(n,α) cross-section occurs at 13.5 keV. Nevertheless, the set of resonance parameters that describe such resonance shows important discrepancies (more than a factor of 2) between them. A new measurement of the (33)S(n,α)(30)Si reaction cross-section was proposed to the ISOLDE and Neutron Time-of-Flight Experiments Committee of CERN. It was performed at n_TOF(CERN) in 2012 using MicroMegas detectors. In this work, we will present a brief overview of the experiment as well as preliminary results of the data analysis in the neutron energy range from thermal to 100 keV. These results will be taken into account to calculate the kerma-fluence factors corresponding to (33)S in addition to (10)B and those of a standard four-component ICRU tissue. MCNP simulations of the deposited dose, including our experimental data, shows an important kerma rate enhancement at the surface of the tissue, mainly due to the presence of (33)S.

  14. A sensitivity study on neutron flux variation due to 10B concentration in dose calculation for BNCT

    International Nuclear Information System (INIS)

    Jung, Sang Hoon

    2006-02-01

    The effects of inclusion of 10 B concentration on neutron flux and dose in dose calculation were studied. In order to provide the quantitative effects of inclusion of 10 B concentrations on depressions of neutron and photon flux and dose, the fluxes and doses with voxel head phantoms for various 10 B concentrations homogeneously distributed were calculated by using MCNPX simulations. A lithium target system and beam shaping assembly, which have been developed at the Hanyang University, were used as epithermal neutron beam. The calculation results show that the neutron flux at the center of the head phantom decreases by approximately 5.4% per 10 ppm of 10 B concentration in comparison with the neutron flux in the case of boron-free. It was also observed that the tissue dose at the center of the head phantom is depressed by approximately 4.7% per 10 ppm of the 10 B concentration and the tumor dose by approximately 5.3% per 10 ppm. According to depth of tumors, it was observed that the depressions of the doses in the tumors are ranged in 3.7 ∼ 9.2%. The dose calculations in the case of boron-free show that it is overestimated in comparison with the dose calculations in the cases of the inclusion of 10 B concentrations for the normal tissue and the tumors. Therefore, in dose calculation for BNCT, the depressions of neutron flux and dose should be considered. The results in this study are available to setting up the depression ratios which can be used for converting neutron and gamma fluxes and doses in phantom with boron free into the fluxes and doses in phantom with inclusion of 10 B concentrations in treatment. It is expected that the depression ratios is practicable to dose evaluation for BNCT

  15. Studies for the application of Boron neutron capture therapy (BNCT) to the treatment of differentiated thyroid cancer (CDT)

    International Nuclear Information System (INIS)

    Carpano, Marina; Thomasz, Lisa; Perona, Marina; Juvenal, Guillermo J.; Pisarev, Mario; Dagrosa, Maria A.; Nievas, Susana I.; Pozzi, Emiliano; Thorp, Silvia

    2009-01-01

    Boron neutron capture therapy (BNCT) is a high linear energy transfer (LET) radiotherapy for cancer, which it is based on the nuclear reaction that occurs when boron-10 that it is a non radioactive isotope of the natural elemental boron, is irradiated with low energy thermal neutrons to produce an alpha particle and a nucleus of lithium-7. Both particles have a range smaller than the diameter of a cell causing cell tumor death without significant damage to the surrounding normal tissues. In previous studies we have shown that BNCT can be a possibility for the treatment of undifferentiated thyroid cancer (UTC). However, more than 80 % of patients with thyroid neoplasm present differentiated carcinoma (CDT). These carcinomas are treated by surgery followed by therapy with 131 I and mostly these forms are well controlled. But in some patients recurrence of the tumor is observed. BNCT can be an alternative for these patients in who the tumor lost the capacity to concentrate iodide. The aim of these studies was to evaluate the possibility of treating differentiated thyroid cancer by BNCT. Materials and Methods: The human cell lines of follicular (WRO) and papillary carcinomas (TPC-1) were grown in RPMI and modified DMEM medium respectively. Both supplemented with 10 % of SFB. The cell line of thyroid rat, FRTL-5, used as control normal, was cultured in DMEM/F12. The uptakes of 125 I and p-borophenylalanine BPA (6.93mM) were studied. The intracellular boron concentration was measured by inductively coupled plasma optical emission spectroscopy (ICP-OES) at 2 hr post incubation. The NIH strain of male nude mice, aged 6 to 8 weeks and weighing 20 to 25 g were implanted (s.c) in the back right flank with different concentrations of tumor cells. The size of the tumors was measured with a caliper twice or three times a week and the volume was calculated according the following formulae: A 2 x B/2 (were A is the width and B is the length). To evaluate the BPA uptake, animals

  16. SU-E-T-124: Anthropomorphic Phantoms for Confirmation of Linear Accelerator Based Small Animal Irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Perks, J; Benedict, S [UC Davis Cancer Center, Sacramento, CA (United States); Lucero, S [UC Davis, Davis, CA (United States)

    2015-06-15

    Purpose: To document the support of radiobiological small animal research by a modern radiation oncology facility. This study confirms that a standard, human use linear accelerator can cover the range of experiments called for by researchers performing animal irradiation. A number of representative, anthropomorphic murine phantoms were made. The phantoms confirmed the small field photon and electron beams dosimetry validated the use of the linear accelerator for rodents. Methods: Laser scanning a model, CAD design and 3D printing produced the phantoms. The phantoms were weighed and CT scanned to judge their compatibility to real animals. Phantoms were produced to specifically mimic lung, gut, brain, and othotopic lesion irradiations. Each phantom was irradiated with the same protocol as prescribed to the live animals. Delivered dose was measured with small field ion chambers, MOS/FETs or TLDs. Results: The density of the phantom material compared to density range across the real mice showed that the printed material would yield sufficiently accurate measurements when irradiated. The whole body, lung and gut irradiations were measured within 2% of prescribed doses with A1SL ion chamber. MOSFET measurements of electron irradiations for the orthotopic lesions allowed refinement of the measured small field output factor to better than 2% and validated the immunology experiment of irradiating one lesion and sparing another. Conclusion: Linacs are still useful tools in small animal bio-radiation research. This work demonstrated a strong role for the clinical accelerator in small animal research, facilitating standard whole body dosing as well as conformal treatments down to 1cm field. The accuracy of measured dose, was always within 5%. The electron irradiations of the phantom brain and flank tumors needed adjustment; the anthropomorphic phantoms allowed refinement of the initial output factor measurements for these fields which were made in a large block of solid water.

  17. Linear Accelerator-Based Radiosurgery Alone for Arteriovenous Malformation: More Than 12 Years of Observation

    Energy Technology Data Exchange (ETDEWEB)

    Matsuo, Takayuki, E-mail: takayuki@nagasaki-u.ac.jp; Kamada, Kensaku; Izumo, Tsuyoshi; Hayashi, Nobuyuki; Nagata, Izumi

    2014-07-01

    Purpose: Although radiosurgery is an accepted treatment method for intracranial arteriovenous malformations (AVMs), its long-term therapeutic effects have not been sufficiently evaluated, and many reports of long-term observations are from gamma-knife facilities. Furthermore, there are few reported results of treatment using only linear accelerator (LINAC)-based radiosurgery (LBRS). Methods and Materials: Over a period of more than 12 years, we followed the long-term results of LBRS treatment performed in 51 AVM patients. Results: The actuarial obliteration rates, after a single radiosurgery session, at 3, 5, 10, and 15 years were 46.9%, 54.0%, 64.4%, and 68.0%, respectively; when subsequent radiosurgeries were included, the rates were 46.9%, 61.3%, 74.2%, and 90.3%, respectively. Obliteration rates were significantly related to target volumes ≥4 cm{sup 3}, marginal doses ≥12 Gy, Spetzler-Martin grades (1 vs other), and AVM scores ≥1.5; multivariate analyses revealed a significant difference for target volumes ≥4 cm{sup 3}. The postprocedural actuarial symptomatic radiation injury rates, after a single radiation surgery session, at 5, 10, and 15 years were 12.3%, 16.8%, and 19.1%, respectively. Volumes ≥4 cm{sup 3}, location (lobular or other), AVM scores ≥1.5, and the number of radiosurgery were related to radiation injury incidence; multivariate analyses revealed significant differences associated with volumes ≥4 cm{sup 3} and location (lobular or other). Conclusions: Positive results can be obtained with LBRS when performed with a target volume ≤4 cm{sup 3}, an AVM score ≤1.5, and ≥12 Gy radiation. Bleeding and radiation injuries may appear even 10 years after treatment, necessitating long-term observation.

  18. Fractionated BNCT for locally recurrent head and neck cancer: Experience from a phase I/II clinical trial at Tsing Hua Open-Pool Reactor

    International Nuclear Information System (INIS)

    Wang, Ling-Wei; Chen, Yi-Wei; Ho, Ching-Yin; Hsueh Liu, Yen-Wan; Chou, Fong-In; Liu, Yuan-Hao; Liu, Hong-Ming; Peir, Jinn-Jer; Jiang, Shiang-Huei; Chang, Chi-Wei; Liu, Ching-Sheng; Wang, Shyh-Jen; Chu, Pen-Yuan; Yen, Sang-Hue

    2014-01-01

    To introduce our experience of treating locally and regionally recurrent head and neck cancer patients with BNCT at Tsing Hua Open-Pool Reactor in Taiwan, 12 patients (M/F=10/2, median age 55.5 Y/O) were enrolled and 11 received two fractions of treatment. Fractionated BNCT at 30-day interval with adaptive planning according to changed T/N ratios was feasible, effective and safe for selected recurrent head and neck cancer in this trial. - Highlights: • We treated 12 patients with recurrent Head and Neck (H and N) cancer after radical surgery and radiotherapy since 2010. • Four complete response (CR) and 3 partial response (PR) were found. Total response rate was 58%. • Two patients had local control longer than one year. • No grade 4 or higher toxicity was noted for both acute and chronic effects

  19. A micro-PET/CT approach using O-(2-[{sup 18}F]fluoroethyl)-L-tyrosine in an experimental animal model of F98 glioma for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Menichetti, L., E-mail: luca.menichetti@ifc.cnr.it [CNR Institute of Clinical Physiology, Pisa (Italy); Petroni, D.; Panetta, D. [CNR Institute of Clinical Physiology, Pisa (Italy); Burchielli, S. [Fondazione CNR/Regione Toscana G. Monasterio, Pisa (Italy); Bortolussi, Silva [Dept. Theoretical and Nuclear Physics, University of Pavia, Pavia (Italy); Matteucci, M. [Scuola Superiore Sant' Anna, Pisa (Italy); Pascali, G.; Del Turco, S. [CNR Institute of Clinical Physiology, Pisa (Italy); Del Guerra, A. [Department of Physics, University of Pisa, Pisa (Italy); Altieri, S. [Dept. Theoretical and Nuclear Physics, University of Pavia, Pavia (Italy); Salvadori, P.A. [CNR Institute of Clinical Physiology, Pisa (Italy)

    2011-12-15

    The present study focuses on a micro-PET/CT application to be used for experimental Boron Neutron Capture Therapy (BNCT), which integrates, in the same frame, micro-CT derived anatomy and PET radiotracer distribution. Preliminary results have demonstrated that {sup 18}F-fluoroethyl-tyrosine (FET)/PET allows the identification of the extent of cerebral lesions in F98 tumor bearing rat. Neutron autoradiography and {alpha}-spectrometry on axial tissues slices confirmed the tumor localization and extraction, after the administration of fructose-boronophenylalanine (BPA). Therefore, FET-PET approach can be used to assess the transport, the net influx, and the accumulation of FET, as an aromatic amino acid analog of BPA, in experimental animal model. Coregistered micro-CT images allowed the accurate morphological localization of the radiotracer distribution and its potential use for experimental BNCT.

  20. Design and characterization of a novel neutron shield for BNCT in an experimental model of oral cancer in the hamster cheek pouch at RA-3

    International Nuclear Information System (INIS)

    Pozzi, E.C.C.; Curotto, P.; Monti Hughes, A.; Nigg, D.W.; Schwint, A.E.; Trivillin, V.A.; Thorp, S.I.

    2013-01-01

    Our research group at the Radiation Pathology Division of the Department of Radiobiology (National Atomic Energy Commission) has previously demonstrated the therapeutic efficacy of different BNCT protocols to treat oral cancer in an experimental hamster cheek pouch model. In particular, to perform studies in this experimental model at the thermal facility constructed at RA-3, we designed and constructed a shielding device for thermal neutrons, to be able to expose the cheek pouch while minimizing the dose to the rest of the body. This device allowed for the irradiation of one animal at a time. Given the usage rate of the device, the aim of the present study was to design and construct an optimized version of the existing shielding device that would allow for the simultaneous irradiation of 2 animals at the thermal facility of RA-3. Taking into account the characteristics of the neutron source and preliminary biological assays, we designed the shielding device for the body of the animal, i.e. a rectangular shaped box with double acrylic walls. The space between the walls contains a continuous filling of 6Li 2 CO 3 (95% enriched in 6Li), approximately 6 mm thick. Two small windows interrupt the shield at one end of the box through which the right pouch of each hamster is everted out onto an external acrylic shelf for exposure to the neutron flux. The characterization of the shielding device showed that the neutron flux was equivalent at both irradiation positions confirming that we were able to design and construct a new shielding device that allows for the irradiation of 2 animals at the same time at the thermal facility of RA-3. This new version of the shielding device will reduce the number of interventions of the reactor operators, reducing occupational exposure to radiation and will make the procedure more efficient for researchers. In addition, we addressed the generation of tritium as a product of the capture reaction in lithium. It was considered as a

  1. Beam shaping assembly of a D–T neutron source for BNCT and its dosimetry simulation in deeply-seated tumor

    International Nuclear Information System (INIS)

    Faghihi, F.; Khalili, S.

    2013-01-01

    This article involves two aims for BNCT. First case includes a beam shaping assembly estimation for a D–T neutron source to find epi-thermal neutrons which are the goal in the BNCT. Second issue is the percent depth dose calculation in the adult Snyder head phantom. Monte-Carlo simulations and verification of a suggested beam shaping assembly (including internal neutron multiplier, moderator, filter, external neutron multiplier, collimator, and reflector dimensions) for thermalizing a D–T neutron source as well as increasing neutron flux are carried out and our results are given herein. Finally, we have simulated its corresponding doses for treatment planning of a deeply-seated tumor. - Highlights: ► An assembly for the D–T neutron source including many regions is given herein. ► Dosimetry simulations in the Snyder head phantom for a deeply-seated tumor are carried out. ► Brief literatures conclusions on the recent BNCT studies are presented herein

  2. Selective enhancement of boron accumulation with boron-entrapped water-in-oil-water emulsion in VX-2 rabbit hepatic cancer model for BNCT

    International Nuclear Information System (INIS)

    Yanagie, Hironobu; Higashi, Shushi; Ikushima, Ichiro

    2006-01-01

    Tumor cell destruction in boron neutron-capture therapy (BNCT) is due to the nuclear reaction between 10 B and thermal neutrons. It is necessary for effective BNCT therapy to accumulate 10 B atoms in the tumor cells without affecting adjacent healthy cells. Water-in-oil-water (WOW) emulsion was used as the carrier of anti-cancer agents on arterial injections in clinical cancer treatment. In this study, we prepared 10 BSH entrapped WOW emulsion for selective arterial infusion for the treatment of hepatocellular carcinoma. WOW emulsion was administrated by arterial injections via proper hepatic artery. The anti-tumor activity of the emulsion was compared with 10 BSH-Lipiodol mix emulsion or 10 BSH solutions on VX-2 rabbit hepatic tumor models. The 10 B concentrations in VX-2 tumor on delivery with WOW emulsion was superior to those by conventional lipiodol mix emulsion. Electro-microscopic figures of WOW emulsion delineated the accumulation of fat droplets of WOW emulsion in the tumor site, but there was no accumulation of fat droplets in lipiodol emulsion. These results indicate that 10 B entrapped WOW emulsion is most useful carrier for arterial delivery of boron agents on BNCT to cancer. (author)

  3. The results of a non-linear mathematical model for the kinetics of 10B after BPA-F infusion in BNCT

    International Nuclear Information System (INIS)

    Ryynaenen, P.; Savolainen, S.; Hiismaeki, P.; Kangasmaeki, A.

    2001-01-01

    The aim of this study was to create a model for the kinetics of 10 B in glioma patients after p-boronophenylalanine fructose complex (BPA-F) infusion in order to predict the 10 B concentration in blood during the neutron irradiations in BNCT. The more specific aim was to create a flexible model that would work with variable infusion duration and variable amounts of infused BRA, by forehand carrying out only 1 to 2 kinetic studies per different trials. Previously used bi-exponential fitting and open compartmental model are capable, but, however, heavy kinetic studies are needed before they are reliable enough. A model probe with a memory effect based on phenomenological findings was created. The model development was based on the data from 10 glioblastoma multiforme patients from the Brookhaven National Laboratory BNCT trials. These patients received i.v. 290 mg BPA/kg body weight as a fructose complex during two hours. Blood samples were collected during and after the infusion. The accuracy of the model was verified with distinctive fitting of 10 new glioma patient data from the Finnish BNCT-trials. The 10 B- concentration in whole blood samples was determined by ICP-AES method. In the study it is concluded that the constructed non-linear model is flexible and capable in describing the kinetics of 10 B concentration in blood after a single infusion of BPA-F. (author)

  4. Evaluation of moderator assemblies for use in an accelerator-based neutron source for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Woollard, J.E.; Blue, T.E.; Gupta, N.; Gahbauer, R.A.

    1998-01-01

    The neutron fields produced by several moderator assemblies were evaluated using both in-phantom and in-air neutron field assessment parameters. The parameters were used to determine the best moderator assembly, from among those evaluated, for use in the accelerator-based neutron source for boron neutron capture therapy. For a 10-mA proton beam current and the specified treatment parameters, a moderator assembly consisting of a BeO moderator and a Li 2 CO 3 reflector was found to be the best moderator assembly whether the comparison was based on in-phantom or in-air neutron field assessment parameters. However, the parameters were discordant regarding the moderator thickness. The in-phantom neutron field assessment parameters predict 20 cm of BeO as the best moderator thickness, whereas the in-air neutron field assessment parameters predict 25 cm of BeO as the best moderator thickness

  5. Accelerator-based analytical technique in the evaluation of some Nigeria's natural minerals: Fluorite, tourmaline and topaz

    Energy Technology Data Exchange (ETDEWEB)

    Olabanji, S.O. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), viale dell' Universita 2, 35020 Legnaro, Padova (Italy)]. E-mail: skayode2002@yahoo.co.uk; Ige, O.A. [Natural History Museum, Obafemi Awolowo University, Ile-Ife (Nigeria); Mazzoli, C. [Dipartimento di Mineralogia e Petrologia, Universita di Padova, 35100 Padova (Italy); Ceccato, D. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), viale dell' Universita 2, 35020 Legnaro, Padova (Italy); Dipartimento di Fisica, Universita di Padova, via Marzolo 8, 35100 Padova (Italy); Akintunde, J.A. [CERD, Obafemi Awolowo University, Ile-Ife (Nigeria); De Poli, M. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), viale dell' Universita 2, 35020 Legnaro, Padova (Italy); Moschini, G. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), viale dell' Universita 2, 35020 Legnaro, Padova (Italy); Dipartimento di Fisica, Universita di Padova, via Marzolo 8, 35100 Padova (Italy)

    2005-10-15

    For the first time, the complementary accelerator-based analytical technique of PIXE and electron microprobe analysis (EMPA) were employed for the characterization of some Nigeria's natural minerals namely fluorite, tourmaline and topaz. These minerals occur in different areas in Nigeria. The minerals are mainly used as gemstones and for other scientific and technological applications and therefore are very important. There is need to characterize them to know the quality of these gemstones and update the geochemical data on them geared towards useful applications. PIXE analysis was carried out using the 1.8 MeV collimated proton beam from the 2.5 MV AN 2000 Van de Graaff accelerator at INFN, LNL, Legnaro, Padova, Italy. The novel results which show many elements at different concentrations in these minerals are presented and discussed.

  6. The role of accelerator-based systems for optimal elimination of plutonium to minimize global proliferation risks

    International Nuclear Information System (INIS)

    Liebert, W.; Glaser, A.; Pistner, C.

    1997-01-01

    The new proliferation dangers associated with plutonium coming out of the dismantlement of nuclear warheads and the fact that nearly all mixtures of plutonium isotopes are weapon-usable highlight the need for a sustainable disposition option. This paper gives an overview on existing military as well as civilian plutonium stocks worldwide and estimates their future development. An assessment of pros and cons of disposition options discussed so far shows that only the capability of an accelerator-based system to eliminate the plutonium virtually completely makes it attractive from the non-proliferator's point of view. We propose a set of criteria to guide the development of an appropriate system. Special attention is directed on overall proliferation resistance and safety aspects without being compromised by power generation. 17 refs., 1 fig., 1 tab

  7. An in situ accelerator-based diagnostic for plasma-material interactions science on magnetic fusion devices.

    Science.gov (United States)

    Hartwig, Zachary S; Barnard, Harold S; Lanza, Richard C; Sorbom, Brandon N; Stahle, Peter W; Whyte, Dennis G

    2013-12-01

    This paper presents a novel particle accelerator-based diagnostic that nondestructively measures the evolution of material surface compositions inside magnetic fusion devices. The diagnostic's purpose is to contribute to an integrated understanding of plasma-material interactions in magnetic fusion, which is severely hindered by a dearth of in situ material surface diagnosis. The diagnostic aims to remotely generate isotopic concentration maps on a plasma shot-to-shot timescale that cover a large fraction of the plasma-facing surface inside of a magnetic fusion device without the need for vacuum breaks or physical access to the material surfaces. Our instrument uses a compact (~1 m), high-current (~1 milliamp) radio-frequency quadrupole accelerator to inject 0.9 MeV deuterons into the Alcator C-Mod tokamak at MIT. We control the tokamak magnetic fields--in between plasma shots--to steer the deuterons to material surfaces where the deuterons cause high-Q nuclear reactions with low-Z isotopes ~5 μm into the material. The induced neutrons and gamma rays are measured with scintillation detectors; energy spectra analysis provides quantitative reconstruction of surface compositions. An overview of the diagnostic technique, known as accelerator-based in situ materials surveillance (AIMS), and the first AIMS diagnostic on the Alcator C-Mod tokamak is given. Experimental validation is shown to demonstrate that an optimized deuteron beam is injected into the tokamak, that low-Z isotopes such as deuterium and boron can be quantified on the material surfaces, and that magnetic steering provides access to different measurement locations. The first AIMS analysis, which measures the relative change in deuterium at a single surface location at the end of the Alcator C-Mod FY2012 plasma campaign, is also presented.

  8. National Biomedical Tracer Facility. Project definition study

    Energy Technology Data Exchange (ETDEWEB)

    Schafer, R.

    1995-02-14

    We request a $25 million government-guaranteed, interest-free loan to be repaid over a 30-year period for construction and initial operations of a cyclotron-based National Biomedical Tracer Facility (NBTF) in North Central Texas. The NBTF will be co-located with a linear accelerator-based commercial radioisotope production facility, funded by the private sector at approximately $28 million. In addition, research radioisotope production by the NBTF will be coordinated through an association with an existing U.S. nuclear reactor center that will produce research and commercial radioisotopes through neutron reactions. The combined facilities will provide the full range of technology for radioisotope production and research: fast neutrons, thermal neutrons, and particle beams (H{sup -}, H{sup +}, and D{sup +}). The proposed NBTF facility includes an 80 MeV, 1 mA H{sup -} cyclotron that will produce proton-induced (neutron deficient) research isotopes.

  9. National Biomedical Tracer Facility. Project definition study

    International Nuclear Information System (INIS)

    Schafer, R.

    1995-01-01

    We request a $25 million government-guaranteed, interest-free loan to be repaid over a 30-year period for construction and initial operations of a cyclotron-based National Biomedical Tracer Facility (NBTF) in North Central Texas. The NBTF will be co-located with a linear accelerator-based commercial radioisotope production facility, funded by the private sector at approximately $28 million. In addition, research radioisotope production by the NBTF will be coordinated through an association with an existing U.S. nuclear reactor center that will produce research and commercial radioisotopes through neutron reactions. The combined facilities will provide the full range of technology for radioisotope production and research: fast neutrons, thermal neutrons, and particle beams (H - , H + , and D + ). The proposed NBTF facility includes an 80 MeV, 1 mA H - cyclotron that will produce proton-induced (neutron deficient) research isotopes

  10. Facilities & Leadership

    Data.gov (United States)

    Department of Veterans Affairs — The facilities web service provides VA facility information. The VA facilities locator is a feature that is available across the enterprise, on any webpage, for the...

  11. Biochemistry Facility

    Data.gov (United States)

    Federal Laboratory Consortium — The Biochemistry Facility provides expert services and consultation in biochemical enzyme assays and protein purification. The facility currently features 1) Liquid...

  12. Use of the Power Burst Facility for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Crocker, J.G.; Griebenow, M.L.; Leatham, J.

    1990-01-01

    A program is under development at the Idaho National Engineering Laboratory (INEL) that involves using the Power Burst Facility (PBF) for research into boron neutron capture therapy (BNCT). BNCT utilizes the ionizing energy from boron-neutron capture to stop reproduction of or destroy cells in cancerous tissue in a two-step process. The first step is to selectively concentrate a boron isotope within the tumor cell, that when activated by neutron capture emits highly ionizing, short range particles. The second step involves activation of the isotope only in the vicinity of the tumor with a narrow neutron beam. The ( 10 B[n, 4 He] 7 Li) reaction with thermal neutrons produces fission products with track lengths approximately equal to a cell diameter. The INEL program includes the modification of the PBF by the addition of a filter and treatment area. The filter will down-scatter high energy neutrons into the epithermal range and remove thermal neutrons and excessively damaging gamma components. The intense source of epithermal neutrons from PBF is considered necessary to achieve optimum therapy for deep-seated tumors with minimum damage to surface tissue. THe neutron filter conceptualized for PBF utilizes aluminum and heavy water to down-scatter neutrons into the proper energy range. Bismuth will be used for gamma shielding and cadmium will remove the thermal neutron contaminant from the beam. The INEL program leads to human clinical trials at PBF which are intended to prove that brain tumors can be successfully treated through noninvasive techniques. Further research into BNCT at PBF for other cancer types is also anticipated

  13. Dosimetric characterization of hypofractionated Gamma Knife radiosurgery of large or complex brain tumors versus linear accelerator-based treatments.

    Science.gov (United States)

    Dong, Peng; Pérez-Andújar, Angélica; Pinnaduwage, Dilini; Braunstein, Steve; Theodosopoulos, Philip; McDermott, Michael; Sneed, Penny; Ma, Lijun

    2016-12-01

    OBJECTIVE Noninvasive Gamma Knife (GK) platforms, such as the relocatable frame and on-board imaging, have enabled hypofractionated GK radiosurgery of large or complex brain lesions. This study aimed to characterize the dosimetric quality of such treatments against linear accelerator-based delivery systems that include the CyberKnife (CK) and volumetric modulated arc therapy (VMAT). METHODS Ten patients treated with VMAT at the authors' institution for large brain tumors (> 3 cm in maximum diameter) were selected for the study. The median prescription dose was 25 Gy (range 20-30 Gy) in 5 fractions. The median planning target volume (PTV) was 9.57 cm 3 (range 1.94-24.81 cm 3 ). Treatment planning was performed using Eclipse External Beam Planning V11 for VMAT on the Varian TrueBeam system, Multiplan V4.5 for the CyberKnife VSI System, and Leksell GammaPlan V10.2 for the Gamma Knife Perfexion system. The percentage of the PTV receiving at least the prescription dose was normalized to be identical across all platforms for individual cases. The prescription isodose value for the PTV, conformity index, Paddick gradient index, mean and maximum doses for organs at risk, and normal brain dose at variable isodose volumes ranging from the 5-Gy isodose volume (V5) to the 15-Gy isodose volume (V15) were compared for all of the cases. RESULTS The mean Paddick gradient index was 2.6 ± 0.2, 3.2 ± 0.5, and 4.3 ± 1.0 for GK, CK, and VMAT, respectively (p 0.06). The average prescription isodose values were 52% (range 47%-69%), 60% (range 46%-68%), and 88% (range 70%-94%) for GK, CK, and VMAT, respectively, thus producing significant variations in dose hot spots among the 3 platforms. Furthermore, the mean V5 values for GK and CK were similar (p > 0.79) at 71.9 ± 36.2 cm 3 and 73.3 ± 31.8 cm 3 , respectively, both of which were statistically lower (p linear accelerator-based treatments. Such a result supports the use of a large number of isocenters or confocal beams for the

  14. Dance Facilities.

    Science.gov (United States)

    Ashton, Dudley, Ed.; Irey, Charlotte, Ed.

    This booklet represents an effort to assist teachers and administrators in the professional planning of dance facilities and equipment. Three chapters present the history of dance facilities, provide recommended dance facilities and equipment, and offer some adaptations of dance facilities and equipment, for elementary, secondary and college level…

  15. The BNCT resistant fraction of cancer cells. An in vitro morphologic and cytofluorimetric study on a rat coloncarcinoma cell line

    International Nuclear Information System (INIS)

    Ferrari, C.; Clerici, A.M.; Mazzini, G.

    2006-01-01

    Given the high efficacy of the BNCT treatment, recurrences reasonably depends on the failure of a cell fraction to uptake and retain adequate levels of boronated compounds. Aim of this study is to identify, quantify and characterize the resistant cell fraction relative to the delivered boron concentration. Experiments were performed on the DHD/K12/TRb line by means of cytofluorimetric DNA analysis, plating efficiency and morphologic observations. Cells were incubated with p-boronophenylalanine (BPA) concentrations ranging from 10 to 40 ppm for 18 h. Following neutron exposure, cells were reseeded for subsequent morphologic observations, counting and DNA analysis. Samples of irradiated cells not BPA enriched and non-irradiated cells with and without boron were compared with them. After 24 hs there were no differences among the four conditions, in terms of number of recovered cells, morphology and cell cycle distribution. Starting from 48 hs and up to 7 days BPA irradiated cells showed growth in dimensions, important cell number reduction and multiclonal DNA profile worsening with time. After 9 days normally sized cell clones appeared confirming the presence of a resistant cell fraction able to restore the original cell population after 21 days. The incidence of surviving cells turned out to be in the range 0,026-0,05%. (author)

  16. Application of 10BSH entrapped transferrin-PEG-liposome to boron neutron-capture therapy (BNCT) for solid tumor

    International Nuclear Information System (INIS)

    Maruyama, K.; Ishida, O.; Iwatsuru, M.; Yanagie, H.; Eriguchi, M.; Kobayashi, H.

    2000-01-01

    The successful treatment of cancer by BNCT requires the selective concentration of 10 B within malignant tumor cells. Intracellular targeting ability and cytotoxic effects of 10 B entrapped TF-PEG-liposomes, in which TF is covalently linked to the distal terminal of PEG chains on the external surface of PEG-liposomes, were examined in Colon 26 tumor-bearing mice. TF-PEG-liposomes readily bound to tumor cells in vivo, and were internalized by receptor-mediated endocytosis. 10 B-PEG-liposomes and 10 B-TF-PEG-liposomes showed prolonged residence time in the circulation and low RES uptake in tumor-bearing mice, resulting in enhanced extravasation of the liposomes into the solid tumor tissue and reached high level of 10 B content in tumor. After thermal neutron irradiation of mice injected with 10 B-PEG-liposomes or 10 B-TF-PEG-liposome, tumor growth was suppressed relative to controls. These results suggest that intravenous injection of 10 B TF-PEG-liposome can increase the intracellular retention of 10 B atoms, which were introduced by receptor mediated endocytosis after binding, causing tumor growth suppression in vivo upon thermal neutron irradiation. (author)

  17. An optimum source neutron spectrum and holder shape for extra-corporal treatment of liver cancer by BNCT

    International Nuclear Information System (INIS)

    Nievaart, Sander; Moss, Ray; Sauerwein, Wolfgang; Malago, Massimo; Kloosterman, Jan Leen; Hagen, Tim van der; Dam, Hugo van

    2006-01-01

    In extra-corporal treatment of liver cancer by BNCT, it is desired to have an as homogeneous as possible thermal neutron field throughout the organ. Previous work has shown that when using an epithermal neutron beam, the shape of the holder in which the liver is placed is the critical factor. This study develops the notion further as to what is the optimum neutron spectrum to perform such treatments. In the design calculations, when using Monte Carlo techniques, it is shown that when the expected contributions of the source neutrons in every part of the liver is calculated, a linear optimization scheme such as the Simplex method results in a mix of thermal and epithermal source neutrons to get the highest homogeneity for the thermal neutron field. This optimisation method is demonstrated in 3 holder shapes: cuboid, cylindrical and spherical with each 3 volumes of 2, 4 and 6 litres. A 10 cm thick cuboid model, irradiated from both sides gives the highest homogeneity. The spherical (rotating) holder has the lowest homogeneity but the highest contribution of every source neutron to the thermal neutrons in the liver. This can be advantageous when using a relatively small sized neutron beam with a low strength. (author)

  18. A conceptual design of neutron tumor therapy reactor facility with a YAYOI based fast neutron source reactor

    International Nuclear Information System (INIS)

    Wakabayashi, Hiroaki; An, Shigehiro.

    1983-01-01

    Fast neutron is known as one of useful radiations for radiation therapy of tumors. Boron neutron capture therapy (BNCT) of tumors which makes use of 10 B(n, α) 7 Li reaction of 10 B compounds selectively attached to tumor cells with thermal and intermediate neutrons is another way of neutron based radiation therapy which is, above all, attractive enough to kill tumor cells selectively sparing normal tissue. In Japan, BNCT has already been applied and leaned to be effective. After more than a decade operational experiences and the specific experiments designed for therapeutical purposes, in this paper, a conceptual design of a special neutron therapy reactor facility based on YAYOI - fast neutron source reactor of Nuclear Engineering Research Laboratory, Faculty of Engineering, the University of Tokyo - modified to provide an upward beam of fast and intermediate neutrons is presented. Emphasis is placed on the in-house nature of facility and on the coordinating capability of biological and physical researches as well as maintenances of the facility. (author)

  19. Radioprotective agents to reduce BNCT (Boron Neutron Capture Therapy) induced mucositis in the hamster cheek pouch; Agentes radioprotectores para reducir la mucositis inducida por la terapia por captura neutrónica en boro (BNCT) en la bolsa de la mejilla del hámster

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, A. [Dpto. de Radiobiología, Gerencia de Química Nuclear y Ciencias de la Salud, GAATEN, Comisión Nacional de Energía Atómica (CNEA) (Argentina); Pozzi, E. C.C. [Gerencia de Reactores de Investigación y Producción, GAATEN, CNEA (Argentina); Thorp, S., E-mail: andrea.monti@cnea.gov.ar [Sub-Gerencia Instrumentación y Control, GAEN, CNEA(Argentina)

    2013-07-01

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of BNCT mediated by boronophenylalanine (BPA) in the hamster cheek pouch oral cancer and pre cancer model. Despite therapeutic efficacy, mucositis induced in premalignant tissue was dose limiting and favored, in some cases, tumor development. In a clinical scenario, oral mucositis limits the dose administered to head and neck tumors. Aim: Our aim was to evaluate the effect of the administration of different radioprotective agents, seeking to reduce BNCT-induced mucositis to acceptable levels in dose-limiting premalignant tissue; without compromising therapeutic effect evaluated as inhibition on tumor development in premalignant tissue; without systemic or local side effects; and without negative effects on the biodistribution of the boron compound used for treatment. Materials and methods: Cancerized hamsters with DMBA (dimethylbenzanthracene) were treated with BPA-BNCT 5 Gy total absorbed dose to premalignant tissue, at the RA-3 Nuclear Reactor, divided into different groups: 1-treated with FLUNIXIN; 2- ATORVASTATIN; 3-THALIDOMIDE; 4-HISTAMINE (two concentrations: Low -1 mg/ml- and High -5 mg/ml-); 5-JNJ7777120; 6-JNJ10191584; 7-SALINE (vehicle). Cancerized animals without any treatment (neither BNCT nor radioprotective therapy) were also analyzed. We followed the animals during one month and evaluated the percentage of animals with unacceptable/severe mucositis, clinical status and percentage of animals with new tumors post treatment. We also performed a preliminary biodistribution study of BPA + Histamine “low” concentration to evaluate the potential effect of the radioprotector on BPA biodistribution. Results: Histamine

  20. Electron energy and electron trajectories in an inverse free-electron laser accelerator based on a novel electrostatic wiggler

    Science.gov (United States)

    Nikrah, M.; Jafari, S.

    2016-06-01

    We expand here a theory of a high-gradient laser-excited electron accelerator based on an inverse free-electron laser (inverse-FEL), but with innovations in the structure and design. The electrostatic wiggler used in our scheme, namely termed the Paul wiggler, is generated by segmented cylindrical electrodes with applied oscillatory voltages {{V}\\text{osc}}(t) over {{90}\\circ} segments. The inverse-FEL interaction can be described by the equations that govern the electron motion in the combined fields of both the laser pulse and Paul wiggler field. A numerical study of electron energy and electron trajectories has been made using the fourth-order Runge-Kutta method. The results indicate that the electron attains a considerable energy at short distances in this device. It is found that if the electron has got sufficient suitable wiggler amplitude intensities, it can not only gain higher energy in longer distances, but also can retain it even after the passing of the laser pulse. In addition, the results reveal that the electron energy gains different peaks for different initial axial velocities, so that a suitable small initial axial velocity of e-beam produces substantially high energy gain. With regard to the transverse confinement of the electron beam in a Paul wiggler, there is no applied axial guide magnetic field in this device.

  1. Accelerator-based analytical technique in the study of some anti-diabetic medicinal plants of Nigeria

    International Nuclear Information System (INIS)

    Olabanji, S.O.; Omobuwajo, O.R.; Ceccato, D.; Adebajo, A.C.; Buoso, M.C.; Moschini, G.

    2008-01-01

    Diabetes mellitus, a clinical syndrome characterized by hyperglycemia due to deficiency of insulin, is a disease involving the endocrine pancreas and causes considerable morbidity and mortality in the world. In Nigeria, many plants, especially those implicated in herbal recipes for the treatment of diabetes, have not been screened for their elemental constituents while information on phytochemistry of some of them is not available. There is therefore the need to document these constituents as some of these plants are becoming increasingly important as herbal drugs or food additives. The accelerator-based technique PIXE, using the 1.8 MeV collimated proton beam from the 2.5 MV AN 2000 Van de Graaff accelerator at INFN, LNL, Legnaro (Padova) Italy, was employed in the determination of the elemental constituents of these anti-diabetic medicinal plants. Leaves of Gardenia ternifolia, Caesalpina pulcherrima, Solemostenon monostachys, whole plant of Momordica charantia and leaf and stem bark of Hunteria umbellata could be taken as vegetables, neutraceuticals, food additives and supplements in the management of diabetes. However, Hexabolus monopetalus root should be used under prescription

  2. Accelerator-based analytical technique in the study of some anti-diabetic medicinal plants of Nigeria

    Energy Technology Data Exchange (ETDEWEB)

    Olabanji, S.O. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), I-35020 Legnaro, Padova (Italy)], E-mail: skayode2002@yahoo.co.uk; Omobuwajo, O.R. [Department of Pharmacognosy, Obafemi Awolowo University, Ile-Ife (Nigeria); Ceccato, D. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), I-35020 Legnaro, Padova (Italy); Dipartmento di Fisica, Universita di Padova, Padova (Italy); Adebajo, A.C. [Department of Pharmacognosy, Obafemi Awolowo University, Ile-Ife (Nigeria); Buoso, M.C. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), I-35020 Legnaro, Padova (Italy); Moschini, G. [Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali di Legnaro (LNL), I-35020 Legnaro, Padova (Italy); Dipartmento di Fisica, Universita di Padova, Padova (Italy)

    2008-05-15

    Diabetes mellitus, a clinical syndrome characterized by hyperglycemia due to deficiency of insulin, is a disease involving the endocrine pancreas and causes considerable morbidity and mortality in the world. In Nigeria, many plants, especially those implicated in herbal recipes for the treatment of diabetes, have not been screened for their elemental constituents while information on phytochemistry of some of them is not available. There is therefore the need to document these constituents as some of these plants are becoming increasingly important as herbal drugs or food additives. The accelerator-based technique PIXE, using the 1.8 MeV collimated proton beam from the 2.5 MV AN 2000 Van de Graaff accelerator at INFN, LNL, Legnaro (Padova) Italy, was employed in the determination of the elemental constituents of these anti-diabetic medicinal plants. Leaves of Gardenia ternifolia, Caesalpina pulcherrima, Solemostenon monostachys, whole plant of Momordica charantia and leaf and stem bark of Hunteria umbellata could be taken as vegetables, neutraceuticals, food additives and supplements in the management of diabetes. However, Hexabolus monopetalus root should be used under prescription.

  3. Work in the field of BNCT using the Portuguese Research Reactor

    International Nuclear Information System (INIS)

    Goncalves, I.C.; Ramalho, A.G.; Goncalves, I.F.; Salgado, J.; Pertusa, J.; Irles, A.; Mascarenhas, F.; Castro, M.; Valle, F.; Toscano Rico, J.; Alcober, V.

    1999-01-01

    The goal of this work is to pursue the research activity in BNC and the installation of a therapy facility in the position presently occupied by the thermal column. With these objectives the experimental studies in mice and cells are continuing while improvements in the facilities are created or prepared. For this effect: (1) the installation of lead shield in the vertical access of the thermal column, which resulted in an enhancement of the Φ th to D γ ratio, was performed, (2) the adaptation of a beam tube to deliver a dominantly thermal or epithermal beam in two possible beam openings in being done and (3) Monte Carlo calculations aiming at the optimization of the conditions for the therapy installation are in progress. (author)

  4. The international fusion materials irradiation facility

    International Nuclear Information System (INIS)

    Shannon, T.E.; Cozzani, F.; Crandall, D.H.; Wiffen, F.W.; Katsuta, H.; Kondo, T.; Teplyakov, V.; Zavialsky, L.

    1994-01-01

    It is widely agreed that the development of materials for fusion systems requires a high flux, 14 MeV neutron source. The European Union, Japan, Russia and the US have initiated the conceptual design of such a facility. This activity, under the International Energy Agency (IEA) Fusion Materials Agreement, will develop the design for an accelerator-based D-Li system. The first organizational meeting was held in June 1994. This paper describes the system to be studied and the approach to be followed to complete the conceptual design by early 1997

  5. An advanced fusion neutron source facility

    International Nuclear Information System (INIS)

    Smith, D.L.

    1992-01-01

    Accelerator-based 14-MeV-neutron sources based on modifications of the original Fusion Materials Irradiation Facility are currently under consideration for investigating the effects of high-fluence high-energy neutron irradiation on fusion-reactor materials. One such concept for a D-Li neutron source is based on recent advances in accelerator technology associated with the Continuous Wave Deuterium Demonstrator accelerator under construction at Argonne National Laboratory, associated superconducting technology, and advances in liquid-metal technology. In this paper a summary of conceptual design aspects based on improvements in technologies is presented

  6. L-DOPA Preloading Increases the Uptake of Borophenylalanine in C6 Glioma Rat Model: A New Strategy to Improve BNCT Efficacy

    International Nuclear Information System (INIS)

    Capuani, Silvia; Gili, Tommaso; Bozzali, Marco; Russo, Salvatore; Porcari, Paola; Cametti, Cesare; D'Amore, Emanuela; Colasanti, Marco; Venturini, Giorgio; Maraviglia, Bruno; Lazzarino, Giuseppe; Pastore, Francesco S.

    2008-01-01

    Purpose: Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on 10 B(n,α) 7 Li reaction, for the treatment of malignant gliomas. One of the main limitations for BNCT effectiveness is the insufficient intake of 10 B nuclei in the tumor cells. This work was aimed at investigating the use of L-DOPA as a putative enhancer for 10 B-drug 4-dihydroxy-borylphenylalanine (BPA) uptake in the C6-glioma model. The investigation was first performed in vitro and then extended to the animal model. Methods and Materials: BPA accumulation in C6-glioma cells was assessed using radiowave dielectric spectroscopy, with and without L-DOPA preloading. Two L-DOPA incubation times (2 and 4 hours) were investigated, and the corresponding effects on BPA accumulation were quantified. C6-glioma cells were also implanted in the brain of 32 rats, and tumor growth was monitored by magnetic resonance imaging. Rats were assigned to two experimental branches: (1) BPA administration; (2) BPA administration after pretreatment with L-DOPA. All animals were sacrificed, and assessments of BPA concentrations in tumor tissue, normal brain, and blood samples were performed using high-performance liquid chromatography. Results: L-DOPA preloading induced a massive increase of BPA concentration in C6-glioma cells only after a 4-hour incubation. In the animal model, L-DOPA pretreatment produced a significantly higher accumulation of BPA in tumor tissue but not in normal brain and blood samples. Conclusions: This study suggests the potential use of L-DOPA as enhancer for BPA accumulation in malignant gliomas eligible for BNCT. L-DOPA preloading effect is discussed in terms of membrane transport mechanisms

  7. In-phantom dosimetry using the 13C(d,n)14N reaction for BNCT (boron neutron capture therapy)

    International Nuclear Information System (INIS)

    Burlon, Alejandro; Kreiner, Andres J.; White, S.; Blackburn, B.; Gierga, David; Yanch, Jacquelyn C.

    2000-01-01

    The use of the 13 C(d,n) 14 N reaction at E d =1.5 MeV for accelerator-based boron neutron capture therapy is investigated. The 13 C(d,n) 14 N reaction presents the advantages of carbon as a target material and its large cross section. The deuteron beam was produced by a tandem accelerator at MIT's Laboratory for Accelerator Beam Applications. The resulting neutron spectra were evaluated in terms of RBE-dose rates at different depths inside a water-filled brain phantom using a heavy water moderator and lead reflector assembly. All results were simulated using the code MCNP. (author)

  8. Bystander effect-induced mutagenicity in HPRT locus of CHO cells following BNCT neutron irradiation: Characteristics of point mutations by sequence analysis

    Energy Technology Data Exchange (ETDEWEB)

    Kinashi, Yuko [Research Reactor Institute, Kyoto University, Kumatori-cho, Sennan-gun, Osaka (Japan)], E-mail: kinashi@rri.kyoto-u.ac.jp; Suzuki, Minoru; Masunaga, Shinichiro; Ono, Koji [Research Reactor Institute, Kyoto University, Kumatori-cho, Sennan-gun, Osaka (Japan)

    2009-07-15

    To investigate bystander mutagenic effects induced by alpha particles during boron neutron capture therapy (BNCT), we mixed cells that were electroporated with borocaptate sodium (BSH), which led to the accumulation of {sup 10}B inside the cells, with cells that did not contain the boron compound. BSH-containing cells were irradiated with {alpha} particles produced by the {sup 10}B(n,{alpha}){sup 7}Li reaction, whereas cells without boron were only affected by the {sup 1}H(n,{gamma}){sup 2}H and {sup 14}N(n,{rho}){sup 14}C reactions. The frequency of mutations induced in the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus was examined in Chinese hamster ovary (CHO) cells irradiated with neutrons (Kyoto University Research Reactor: 5 MW). Neutron irradiation of 1:1 mixtures of cells with and without BSH resulted in a survival fraction of 0.1, and the cells that did not contain BSH made up 99.4% of the surviving cell population. Using multiplex polymerase chain reactions (PCRs), molecular structural analysis indicated that most of the mutations induced by the bystander effect were point mutations and that the frequencies of total and partial deletions induced by the bystander effect were lower than those resulting from the {alpha} particles produced by the {sup 10}B(n,{alpha}){sup 7}Li reaction or the neutron beam from the {sup 1}H(n,{gamma}){sup 2}H and {sup 14}N(n,{rho}){sup 14}C reactions. The types of point mutations induced by the BNCT bystander effect were analyzed by cloning and sequencing methods. These mutations were comprised of 65.5% base substitutions, 27.5% deletions, and 7.0% insertions. Sequence analysis of base substitutions showed that transversions and transitions occurred in 64.7% and 35.3% of cases, respectively. G:C{yields}T:A transversion induced by 8-oxo-guanine in DNA occurred in 5.9% of base substitution mutants in the BNCT bystander group. The characteristic mutations seen in this group, induced by BNCT {alpha} particles

  9. Sodium borocaptate (BSH) for Boron Neutron Capture Therapy (BNCT) in the hamster cheek pouch oral cancer model: boron biodistribution at 9 post administration time-points

    International Nuclear Information System (INIS)

    Garabalino, M.A.; Heber, E.M.; Monti, Hughes A.; Molinari, A.J.; Pozzi, E.C.C.; Trivillin, V.A.; Schwint, Amanda E.

    2011-01-01

    The therapeutic success of Boron Neutron Capture Therapy (BNCT) depends centrally on boron concentration in tumor and healthy tissue. We previously demonstrated the therapeutic efficacy of boronophenylalanine (BPA) and sodium decahydrodecaborate (GB-10) as boron carriers for BNCT in the hamster cheek pouch oral cancer model. Given the clinical relevance of sodium mercaptoundecahydro-closo-dodecaborate (BSH) as a boron carrier, the aim of the present study was to expand the ongoing BSH biodistribution studies in the hamster cheek pouch oral cancer model. In particular, we studied 3 additional post-administration time-points and increased the sample size corresponding to the time-points evaluated previously, to select more accurately the post-administration time at which neutron irradiation would potentially confer the greatest therapeutic advantage. BSH was dissolved in saline solution in anaerobic conditions to avoid the formation of the dimer BSSB and its oxides which are toxic. The solution was injected intravenously at a dose of 50 mg 10 B/kg (88 mg BSH / kg). Different groups of animals were killed humanely at 7, 8, and 10 h after administration of BSH. The sample size corresponding to the time-points 3, 4, 6, 9 and 12 h was increased. Samples of blood, tumor, precancerous tissue, normal pouch tissue, cheek mucosa, parotid gland, palate, skin, tongue, spinal cord marrow, brain, liver, kidney, spleen and lung were processed for boron measurement by Optic Emission Spectroscopy (ICP-OES). Boron concentration in tumor peaked to 24-34 ppm, 3-10 h post-administration of BSH, with a spread in values that resembled that previously reported in other experimental models and human subjects. The boron concentration ratios tumor/normal pouch tissue and tumor/blood ranged from 1.3 to 1.8. No selective tumor uptake was observed at any of the time points evaluated. The times post-administration of BSH that would be therapeutically most useful would be 5, 7 and 9 h. The

  10. Waste Facilities

    Data.gov (United States)

    Vermont Center for Geographic Information — This dataset was developed from the Vermont DEC's list of certified solid waste facilities. It includes facility name, contact information, and the materials...

  11. Health Facilities

    Science.gov (United States)

    Health facilities are places that provide health care. They include hospitals, clinics, outpatient care centers, and specialized care centers, ... psychiatric care centers. When you choose a health facility, you might want to consider How close it ...

  12. Fabrication Facilities

    Data.gov (United States)

    Federal Laboratory Consortium — The Fabrication Facilities are a direct result of years of testing support. Through years of experience, the three fabrication facilities (Fort Hood, Fort Lewis, and...

  13. Factors Predictive of Symptomatic Radiation Injury After Linear Accelerator-Based Stereotactic Radiosurgery for Intracerebral Arteriovenous Malformations

    Energy Technology Data Exchange (ETDEWEB)

    Herbert, Christopher, E-mail: cherbert@bccancer.bc.ca [Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC (Canada); Moiseenko, Vitali [Department of Medical Physics, British Columbia Cancer Agency, Vancouver, BC (Canada); McKenzie, Michael [Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC (Canada); Redekop, Gary [Division of Neurosurgery, Vancouver General Hospital, University of British Columbia, Vancouver, BC (Canada); Hsu, Fred [Department of Radiation Oncology, British Columbia Cancer Agency, Abbotsford, BC (Canada); Gete, Ermias; Gill, Brad; Lee, Richard; Luchka, Kurt [Department of Medical Physics, British Columbia Cancer Agency, Vancouver, BC (Canada); Haw, Charles [Division of Neurosurgery, Vancouver General Hospital, University of British Columbia, Vancouver, BC (Canada); Lee, Andrew [Department of Neurosurgery, Royal Columbian Hospital, New Westminster, BC (Canada); Toyota, Brian [Division of Neurosurgery, Vancouver General Hospital, University of British Columbia, Vancouver, BC (Canada); Martin, Montgomery [Department of Medical Imaging, British Columbia Cancer Agency, Vancouver, BC (Canada)

    2012-07-01

    Purpose: To investigate predictive factors in the development of symptomatic radiation injury after treatment with linear accelerator-based stereotactic radiosurgery for intracerebral arteriovenous malformations and relate the findings to the conclusions drawn by Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC). Methods and Materials: Archived plans for 73 patients who were treated at the British Columbia Cancer Agency were studied. Actuarial estimates of freedom from radiation injury were calculated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards models were used for analysis of incidence of radiation injury. Log-rank test was used to search for dosimetric parameters associated with freedom from radiation injury. Results: Symptomatic radiation injury was exhibited by 14 of 73 patients (19.2%). Actuarial rate of symptomatic radiation injury was 23.0% at 4 years. Most patients (78.5%) had mild to moderate deficits according to Common Terminology Criteria for Adverse Events, version 4.0. On univariate analysis, lesion volume and diameter, dose to isocenter, and a V{sub x} for doses {>=}8 Gy showed statistical significance. Only lesion diameter showed statistical significance (p < 0.05) in a multivariate model. According to the log-rank test, AVM volumes >5 cm{sup 3} and diameters >30 mm were significantly associated with the risk of radiation injury (p < 0.01). The V{sub 12} also showed strong association with the incidence of radiation injury. Actuarial incidence of radiation injury was 16.8% if V{sub 12} was <28 cm{sup 3} and 53.2% if >28 cm{sup 3} (log-rank test, p = 0.001). Conclusions: This study confirms that the risk of developing symptomatic radiation injury after radiosurgery is related to lesion diameter and volume and irradiated volume. Results suggest a higher tolerance than proposed by QUANTEC. The widely differing findings reported in the literature, however, raise considerable uncertainties.

  14. Boron in nuclear medicine: New synthetic approaches to PET, SPECT, and BNCT agents

    International Nuclear Information System (INIS)

    Kabalka, G.W.

    1989-10-01

    The primary objective of the DOE Nuclear Medicine Program at The University of Tennessee is the creation of new methods for introducing short-lived isotopes into agents for use in PET and SPECT. A small, but significant portion of our effort is directed toward the design of boron-containing neutron therapy agents. The uniqueness of the UT program is its focus on the design of new chemistry (molecular architecture) and technology as opposed to the application of known reactions to the synthesis of specific radiopharmaceuticals, the new technology is then utilized in nuclear medicine research at the UT Biomedical Imaging Center and in collaboration with colleagues at other DOE facilities (Brookhaven National Laboratory, Oak Ridge National Laboratory, Los Alamos National Laboratory, and Oak Ridge Associated Universities)

  15. Comparison of BNCT and GdNCT efficacy in treatment of canine cancer

    Energy Technology Data Exchange (ETDEWEB)

    Mitin, V.N. [Russian Cancer Research Center of the RAMS, Kashirskoe shosse, 24, 115478 Moscow (Russian Federation); Kulakov, V.N.; Khokhlov, V.F.; Sheino, I.N. [State Research Center Institute of Biophysics, Zhivopisnaya ul., 46, 123182 Moscow (Russian Federation); Arnopolskaya, A.M. [Russian Cancer Research Center of the RAMS, Kashirskoe shosse, 24, 115478 Moscow (Russian Federation)], E-mail: ariana_777@inbox.ru; Kozlovskaya, N.G. [Russian Cancer Research Center of the RAMS, Kashirskoe shosse, 24, 115478 Moscow (Russian Federation); Zaitsev, K.N.; Portnov, A.A. [Moscow Engineering Physics Institute, Kashirskoe shosse, 31, 115409 Moscow (Russian Federation)

    2009-07-15

    In this study efficacy of antineoplastic action of gadolinium NCT and boron NCT in cases of canine melanoma and osteosarcoma was compared. Canine spontaneous tumors, such as melanoma and osteosarcoma, have clinical common features with human malignancies, so these tumors in dogs can be considered as clinical model of human melanoma and osteosarcoma. The study has been carried out on 33 dogs with oral cavity melanoma and 9 dogs with osteosarcoma. Dogs with spontaneous melanoma of oral cavity and osteosarcoma of extremities were selected by the results of clinical examination. Irradiation was carried out at the NCT facility of the IRT MEPhI reactor. Neutron irradiation without boron or gadolinium was chosen as a control method to evaluate the efficacy of NCT.

  16. Comparison of BNCT and GdNCT efficacy in treatment of canine cancer

    International Nuclear Information System (INIS)

    Mitin, V.N.; Kulakov, V.N.; Khokhlov, V.F.; Sheino, I.N.; Arnopolskaya, A.M.; Kozlovskaya, N.G.; Zaitsev, K.N.; Portnov, A.A.

    2009-01-01

    In this study efficacy of antineoplastic action of gadolinium NCT and boron NCT in cases of canine melanoma and osteosarcoma was compared. Canine spontaneous tumors, such as melanoma and osteosarcoma, have clinical common features with human malignancies, so these tumors in dogs can be considered as clinical model of human melanoma and osteosarcoma. The study has been carried out on 33 dogs with oral cavity melanoma and 9 dogs with osteosarcoma. Dogs with spontaneous melanoma of oral cavity and osteosarcoma of extremities were selected by the results of clinical examination. Irradiation was carried out at the NCT facility of the IRT MEPhI reactor. Neutron irradiation without boron or gadolinium was chosen as a control method to evaluate the efficacy of NCT.

  17. Boron in nuclear medicine: New synthetic approaches to PET, SPECT, and BNCT agents

    International Nuclear Information System (INIS)

    Kabalka, G.W.

    1991-09-01

    The primary objective of the DOE Nuclear Medicine Program at The University of Tennessee is the creation of new methods for introducing short-lived isotopes into agents for use in computerized tomography. A portion of the research effort is directed toward the development of new synthetic methods for the preparation of boron-containing neutron therapy agents. The uniqueness of the UT program is its focus on the design of new chemistry and technology as opposed to the application of known reactions to the synthesis of specific radiopharmaceuticals. The versatile organic boron reagents are utilized in most of the new chemistry. This new technology is then used in nuclear medicine research at the UT Biomedical Imaging Center and in collaborative research programs with colleagues at other DOE facilities. An important goal of the DOE Nuclear Medicine Program at UT is to provide training for students (predoctoral and postdoctoral) in the scientific aspects of nuclear medicine. 83 refs., 12 figs

  18. RADIATION DOSIMETRY IN THE BNCT PATIENT TREATMENT ROOM AT THE BMRR.

    Energy Technology Data Exchange (ETDEWEB)

    HOLDEN, N.E.; RECINIELLO, R.N.; HU, J.-P.

    2005-05-08

    The Medical Research Reactor at the Brookhaven National Laboratory (BMRR) was a heterogeneous, tank type, light water cooled and moderated, graphite reflected reactor, which was operated on demand at a power level up to 3 mega-watts (MW) for medical and biological research [1]. The reactor first went critical on March 15, 1959, with 17 fresh fuel elements (2.52 kg uranium-235 in a total of 2.7 kg uranium) in the center core. The BMRR had two treatment rooms on opposite sides of the core. It had a predominately thermal neutron beam in the Thermal Neutron Irradiation Facility (TNE) on the west side of the core. By early 1990, a redesigned beam line had a predominately epithermal neutron beam in the Epithermal Neutron Irradiation Facility (ENIF) on the east side of the core [2]. The ENP was approximately 11 feet by 21 feet in size with its focal point consisting of a bismuth plate mounted in the wall adjacent to the reactor shield about 36 inches above the floor. The beam originated at a shutter constructed of 0.75 inch steel filled with concrete and weighing {approx}21 tons. Access to the ENIF was through a pair of hand operated steel shielding doors, each 42 inches wide, 84 inches high and 5 inches thick. The inner door had a 4-inch thick layer of paraffin on the side facing the reactor. The doors 5000 pounds weighed each. Additional shielding material had been added to the entire beam port at reactor wall within the ENIF. The shielding material consisted of 2-inch thick polyethylene sheets, which were impregnated with 95%-enriched {sup 6}Li in lithium carbonate (Li{sub 2}CO{sub 3}). The shielding sheets around the port face were designed to allow the insertion of a variety of different beam collimators.

  19. Design and optimization of a beam-shaping assembly (BSA) for BNCT based on a neutron generator located at CEADEN, Havana, Cuba

    International Nuclear Information System (INIS)

    Padilla Cabal, F.; Martin, G; Abrahantes, A.

    2007-01-01

    A monoenergetic neutron beam simulation study is carried out to determine the most suitable neutron energy for treatment of shallow and deep-seated brain tumors in the context of Boron Neutron Capture Therapy (BNCT). Two figures-of-merit, i.e. the absorbed dose for healthy tissue and the absorbed tumor dose at a given depth in the brain are used to measure the neutron beam quality. Also irradiation time, therapeutic gain and the power generated in the target are utilized as beam assessment parameters. Moderators, reflectors and delimiters are designed and optimized to moderate the high-energy neutrons from the fusion reactions 2 H(d;n) 3 He and 3 H(d;n) 4 He down to a suitable energy spectrum. Metallic uranium and manganese are successfully tested for fast-to-epithermal neutron moderation as well as Fluental TM for the neutron spectrum shifting. A semispherical target is proposed in order to dissipate twice the amount of power generated in the target, and decrease all the dimensions of the BSA. The cooling system of the target is also included in the calculations. Calculations are performed using the MCNP code. After the optimization of our beam-shaper a study of the dose distribution in the head had been made. The therapeutic gain is increased in 9% while the current required for one hour treatment is decreased in comparison with the trading prototypes of NG used for BNCT. (Author)

  20. Design and optimization of a beam-shaping assembly (BSA) for BNCT based on a neutron generator located at CEADEN, Havana, Cuba

    International Nuclear Information System (INIS)

    Padilla Cabal, F.; Martin, G.; Abrahantes, A.

    2007-01-01

    A monoenergetic neutron beam simulation study is carried out to determine the most suitable neutron energy for treatment of shallow and deep-seated brain tumors in the context of Boron Neutron Capture Therapy (BNCT). Two figures-of-merit, i.e. the absorbed dose for healthy tissue and the absorbed tumor dose at a given depth in the brain are used to measure the neutron beam quality. Also irradiation time, therapeutic gain and the power generated in the target are utilized as beam assessment parameters. Moderators, reflectors and delimiters are designed and optimized to moderate the high-energy neutrons from the fusion reactions 2 H(d;n) 3 He and 3 H(d;n) 4 Hedown to a suitable energy spectrum. Metallic uranium and manganese are successfully tested for fast-to-epithermal neutron moderation as well as Fluental TM for the neutron spectrum shifting. A semi spherical target is proposed in order to dissipate twice the amount of power generated in the target, and decrease all the dimensions of the BSA. The cooling system of the target is also included in the calculations. Calculations are performed using the MCNP code. After the optimization of our beam-shaper a study of the dose distribution in the head had been made. The therapeutic gain is increased in 9% while the current required for one hour treatment is decreased in comparison with the trading prototypes of NG used for BNCT. (Author)

  1. Linear accelerator-based stereotactic radiosurgery for brainstem metastases: the Dana-Farber/Brigham and Women's Cancer Center experience.

    Science.gov (United States)

    Kelly, Paul J; Lin, Yijie Brittany; Yu, Alvin Y C; Ropper, Alexander E; Nguyen, Paul L; Marcus, Karen J; Hacker, Fred L; Weiss, Stephanie E

    2011-09-01

    To review the safety and efficacy of linear accelerator-based stereotactic radiosurgery (SRS) for brainstem metastases. We reviewed all patients with brain metastases treated with SRS at DF/BWCC from 2001 to 2009 to identify patients who had SRS to a single brainstem metastasis. Overall survival and freedom-from-local failure rates were calculated from the date of SRS using the Kaplan-Meier method. Prognostic factors were evaluated using the log-rank test and Cox proportional hazards model. A total of 24 consecutive patients with brainstem metastases had SRS. At the time of SRS, 21/24 had metastatic lesions elsewhere within the brain. 23/24 had undergone prior WBRT. Primary diagnoses included eight NSCLC, eight breast cancer, three melanoma, three renal cell carcinoma and two others. Median dose was 13 Gy (range, 8-16). One patient had fractionated SRS 5 Gy ×5. Median target volume was 0.2 cc (range, 0.02-2.39). The median age was 57 years (range, 42-92). Follow-up information was available in 22/24 cases. At the time of analysis, 18/22 patients (82%) had died. The median overall survival time was 5.3 months (range, 0.8-21.1 months). The only prognostic factor that trended toward statistical significance for overall survival was the absence of synchronous brain metastasis at the time of SRS; 1-year overall survival was 31% with versus 67% without synchronous brain metastasis (log rank P = 0.11). Non-significant factors included primary tumor histology and status of extracranial disease (progressing vs. stable/absent). Local failure occurred in 4/22 cases (18%). Actuarial freedom from local failure for all cases was 78.6% at 1 year. RTOG grade 3 toxicities were recorded in two patients (ataxia, confusion). Linac-based SRS for small volume brainstem metastases using a median dose of 13 Gy is associated with acceptable local control and low morbidity.

  2. Practical considerations of linear accelerator-based frameless extracranial radiosurgery for treatment of occipital neuralgia for nonsurgical candidates.

    Science.gov (United States)

    Denton, Travis R; Shields, Lisa B E; Howe, Jonathan N; Shanks, Todd S; Spalding, Aaron C

    2017-07-01

    Occipital neuralgia generally responds to medical or invasive procedures. Repeated invasive procedures generate increasing complications and are often contraindicated. Stereotactic radiosurgery (SRS) has not been reported as a treatment option largely due to the extracranial nature of the target as opposed to the similar, more established trigeminal neuralgia. A dedicated phantom study was conducted to determine the optimum imaging studies, fusion matrices, and treatment planning parameters to target the C2 dorsal root ganglion which forms the occipital nerve. The conditions created from the phantom were applied to a patient with medically and surgically refractory occipital neuralgia. A dose of 80 Gy in one fraction was prescribed to the C2 occipital dorsal root ganglion. The phantom study resulted in a treatment achieved with an average translational magnitude of correction of 1.35 mm with an acceptable tolerance of 0.5 mm and an average rotational magnitude of correction of 0.4° with an acceptable tolerance of 1.0°. For the patient, the spinal cord was 12.0 mm at its closest distance to the isocenter and received a maximum dose of 3.36 Gy, a dose to 0.35 cc of 1.84 Gy, and a dose to 1.2 cc of 0.79 Gy. The brain maximum dose was 2.20 Gy. Treatment time was 59 min for 18, 323 MUs. Imaging was performed prior to each arc delivery resulting in 21 imaging sessions. The average deviation magnitude requiring a positional or rotational correction was 0.96 ± 0.25 mm, 0.8 ± 0.41°, whereas the average deviation magnitude deemed within tolerance was 0.41 ± 0.12 mm, 0.57 ± 0.28°. Dedicated quality assurance of the treatment planning and delivery is necessary for safe and accurate SRS to the cervical spine dorsal root ganglion. With additional prospective study, linear accelerator-based frameless radiosurgery can provide an accurate, noninvasive alternative for treating occipital neuralgia where an invasive procedure is contraindicated. © 2017

  3. Animal facilities

    International Nuclear Information System (INIS)

    Fritz, T.E.; Angerman, J.M.; Keenan, W.G.; Linsley, J.G.; Poole, C.M.; Sallese, A.; Simkins, R.C.; Tolle, D.

    1981-01-01

    The animal facilities in the Division are described. They consist of kennels, animal rooms, service areas, and technical areas (examining rooms, operating rooms, pathology labs, x-ray rooms, and 60 Co exposure facilities). The computer support facility is also described. The advent of the Conversational Monitor System at Argonne has launched a new effort to set up conversational computing and graphics software for users. The existing LS-11 data acquisition systems have been further enhanced and expanded. The divisional radiation facilities include a number of gamma, neutron, and x-ray radiation sources with accompanying areas for related equipment. There are five 60 Co irradiation facilities; a research reactor, Janus, is a source for fission-spectrum neutrons; two other neutron sources in the Chicago area are also available to the staff for cell biology studies. The electron microscope facilities are also described

  4. Three dimensional measurements of absorbed dose in BNCT by Fricke-gel imaging

    International Nuclear Information System (INIS)

    Gambarini, G.; Agosteo, S.; Marchesi, P.; Nava, E.; Palazzi, P.; Pecci, A.; Rosa, R.; Rosi, G.; Tinti, R.

    2001-01-01

    A method has been studied for absorbed dose imaging and profiling in a phantom exposed to thermal or epithermal neutron fields, also discriminating between various contributions to the absorbed dose. The proposed technique is based on optical imaging of FriXy-gel phantoms, which are proper tissue-equivalent phantoms acting as continuous dosimeters. Convenient modifications in phantom composition allow, from differential measurements, the discrimination of various contributions to the absorbed dose. The dosimetry technique is based on a chemical dosimeter incorporated in a tissue-equivalent gel (Agarose). The chemical dosimeter is a ferrous sulphate solution (which is the main component of the standard Fricke dosimeter) added with a metal ion indicator (Xylenol Orange). The absorbed dose is measured by analysing the variation of gel optical absorption in the visible spectrum, imaged by means of a CCD camera provided with a suitable filter. The technique validity has been tested by irradiating and analysing phantoms in the thermal facility of the fast research reactor TAPIRO (ENEA, Casaccia, Italy). In a cylindrical phantom simulating a head, we have imaged the therapy dose from thermal neutron reactions with 10 B and the dose in healthy tissue not containing boron. In tissue without boron, we have discriminated between the two main contributions to the absorbed dose, which comes from the 1 H(n,γ) 2 H and 14 N(n,p) 14 C reactions. The comparison with the results of other experimental techniques and of simulations reveals that the technique is very promising. A method for the discrimination of fast neutron contribution to the absorbed dose, still in an experimental stage, is proposed too. (author)

  5. Fate of the chemical warfare agent O-ethyl S-2-diisopropylaminoethyl methylphosphonothiolate (VX) on soil following accelerant-based fire and liquid decontamination.

    Science.gov (United States)

    Gravett, M R; Hopkins, F B; Self, A J; Webb, A J; Timperley, C M; Riches, J R

    2014-08-01

    In the event of alleged use of organophosphorus nerve agents, all kinds of environmental samples can be received for analysis. These might include decontaminated and charred matter collected from the site of a suspected chemical attack. In other scenarios, such matter might be sampled to confirm the site of a chemical weapon test or clandestine laboratory decontaminated and burned to prevent discovery. To provide an analytical capability for these contingencies, we present a preliminary investigation of the effect of accelerant-based fire and liquid decontamination on soil contaminated with the nerve agent O-ethyl S-2-diisopropylaminoethyl methylphosphonothiolate (VX). The objectives were (a) to determine if VX or its degradation products were detectable in soil after an accelerant-based fire promoted by aviation fuel, including following decontamination with Decontamination Solution 2 (DS2) or aqueous sodium hypochlorite, (b) to develop analytical methods to support forensic analysis of accelerant-soaked, decontaminated and charred soil and (c) to inform the design of future experiments of this type to improve analytical fidelity. Our results show for the first time that modern analytical techniques can be used to identify residual VX and its degradation products in contaminated soil after an accelerant-based fire and after chemical decontamination and then fire. Comparison of the gas chromatography-mass spectrometry (GC-MS) profiles of VX and its impurities/degradation products from contaminated burnt soil, and burnt soil spiked with VX, indicated that the fire resulted in the production of diethyl methylphosphonate and O,S-diethyl methylphosphonothiolate (by an unknown mechanism). Other products identified were indicative of chemical decontamination, and some of these provided evidence of the decontaminant used, for example, ethyl 2-methoxyethyl methylphosphonate and bis(2-methoxyethyl) methylphosphonate following decontamination with DS2. Sample preparation

  6. Facilities Programming.

    Science.gov (United States)

    Bullis, Robert V.

    1992-01-01

    A procedure for physical facilities management written 17 years ago is still worth following today. Each of the steps outlined for planning, organizing, directing, controlling, and evaluating must be accomplished if school facilities are to be properly planned and constructed. However, lessons have been learned about energy consumption and proper…

  7. Nuclear facilities

    International Nuclear Information System (INIS)

    Anon.

    2000-01-01

    Here is given the decree (2000-1065) of the 25. of October 2000 reporting the publication of the convention between the Government of the French Republic and the CERN concerning the safety of the LHC (Large Hadron Collider) and the SPS (Proton Supersynchrotron) facilities, signed in Geneva on July 11, 2000. By this convention, the CERN undertakes to ensure the safety of the LHC and SPS facilities and those of the operations of the LEP decommissioning. The French legislation and regulations on basic nuclear facilities (concerning more particularly the protection against ionizing radiations, the protection of the environment and the safety of facilities) and those which could be decided later on apply to the LHC, SPS and auxiliary facilities. (O.M.)

  8. Joint Assessment of ETRR-2 Research Reactor Operations Program, Capabilities, and Facilities

    International Nuclear Information System (INIS)

    Bissani, M; O'Kelly, D S

    2006-01-01

    A joint assessment meeting was conducted at the Egyptian Atomic Energy Agency (EAEA) followed by a tour of Egyptian Second Research Reactor (ETRR-2) on March 22 and 23, 2006. The purpose of the visit was to evaluate the capabilities of the new research reactor and its operations under Action Sheet 4 between the U.S. DOE and the EAEA, ''Research Reactor Operation'', and Action Sheet 6, ''Technical assistance in The Production of Radioisotopes''. Preliminary Recommendations of the joint assessment are as follows: (1) ETRR-2 utilization should be increased by encouraging frequent and sustained operations. This can be accomplished in part by (a) Improving the supply-chain management for fresh reactor fuel and alleviating the perception that the existing fuel inventory should be conserved due to unreliable fuel supply; and (b) Promulgating a policy for sample irradiation priority that encourages the use of the reactor and does not leave the decision of when to operate entirely at the discretion of reactor operations staff. (2) Each experimental facility in operation or built for a single purpose should be reevaluated to focus on those that most meet the goals of the EAEA strategic business plan. Temporary or long-term elimination of some experimental programs might be necessary to provide more focused utilization. There may be instances of emerging reactor applications for which no experimental facility is yet designed or envisioned. In some cases, an experimental facility may have a more beneficial use than the purpose for which it was originally designed. For example, (a) An effective Boron Neutron Capture Therapy (BNCT) program requires nearby high quality medical facilities. These facilities are not available and are unlikely to be constructed near the Inshas site. Further, the BNCT facility is not correctly designed for advanced research and therapy programs using epithermal neutrons. (b) The ETRR-2 is frequently operated to provide color-enhanced gemstones but is

  9. Experimental Studies of Boronophenylalanine ({sup 10}BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

    Energy Technology Data Exchange (ETDEWEB)

    Carpano, Marina; Perona, Marina; Rodriguez, Carla [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); Nievas, Susana; Olivera, Maria; Santa Cruz, Gustavo A. [Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín (Argentina); Brandizzi, Daniel; Cabrini, Romulo [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); School of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Pisarev, Mario [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Department of Human Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires (Argentina); Juvenal, Guillermo Juan [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Dagrosa, Maria Alejandra, E-mail: dagrosa@cnea.gov.ar [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina)

    2015-10-01

    Purpose: Patients with the same histopathologic diagnosis